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ABSTRACT 
 
As survival in Cystic Fibrosis (CF) has improved dramatically, Cystic Fibrosis Related 
Diabetes (CFRD) has now come to the forefront, with an increasing prevalence. 
CFRD is associated with worse pulmonary function, under nutrition and an increase 
in early mortality. The pathophysiology of CFRD is complex and not fully 
understood, with CFRD unlike other types of diabetes. 
In CF, gastric emptying and motility are likely to be altered, changing the way in 
which nutrients are presented to the gut compared to normal individuals. Then, the 
relative progressive insulinopaenia that occurs in CF may result in diurnal changes 
in glucose and other nutrient handling, and abnormalities in the small intestine may 
alter incretin secretion and associated pancreatic enzymes. 
The aim of this thesis was to enhance understanding of the physiology and 
regulation of gastric emptying, glucose handling and pancreatic hormones in CF 
individuals.  
A series of experiments involving 10 healthy volunteers and 20 CF patients are 
presented in this thesis. Firstly, gastric emptying was measured using a novel easy 
technique and the responses compared to healthy control subjects, throughout the 
day. Secondly, glucose handling and secretory patterns of insulin, c-peptide, 
glucagon, incretin hormones (GLP1 and GIP) and pancreatic polypeptide (PYY) 
throughout the day were compared. 
The main conclusions that can be drawn from this thesis are: (1) There is delayed 
gastric emptying throughout the day in CF subjects (2) The novel and inexpensive 
bedside technique used in this study, provides a simple method of assessing gastric 
emptying (3) The mixed meal is more physiological in CF (4) In CF subjects without 
frank diabetes, there is deficient glucose handling with differences in the afternoon 
and testing in the evening deserving more attention (5) The quantity of insulin 
secreted is similar in CF and healthy subjects with an insulin lag in CF subjects and 
glucagon does not appear to contribute to elevated blood sugars (6) Insulin 
sensitivity is highest in the afternoon and appears to play a significant part in 
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improving glucose handling in the afternoon (7) b cells take longer in in the evening 
to produce insulin, a concept I refer to as ‘pancreatic fatigue’ (8) There is no 
difference in GLP1 or GIP secretion following a mixed-meal, but GIP hypersecretion 
exists early in the response to the OGTT in the CF group (9) CF subjects have lower 
PYY levels likely to be secondary to existing pancreatic insufficiency. 
Areas of potential future research based on this thesis are also outlined. 
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1.1 Diabetes 
1.1.1 History of Diabetes 
The earliest recorded descriptions of ‘Diabetes’ date back to around 1550 BC. The term 
Diabetes is derived from the Greek word for ‘Siphon’ and ‘Mellitus’ or sweet was a subsequent 
addition to the term to distinguish it from another polyuric condition ‘Diabetes Insipidus’, in 
which urine was tasteless. 
Diabetes was linked to hyperglycaemia and defects in glucose metabolism for many centuries 
and the first linking of diabetes to the internal secretion of the pancreas was by Minkowski 
and Von Mering in 1890. 
A major landmark was the discovery of islet cells by Paul Langerhans in 1869 and 
subsequently the most significant development with relation to Diabetes Mellitus was in 1921: 
the discovery of insulin by Banting and Best [1]. Eventually Frederick Sanger in 1955 identified 
the insulin sequence and the treatment of diabetes mellitus was revolutionised [2]. Following 
on from this discovery, over the last six decades there have been major developments in the 
understanding of the aetiology, types, classification and management of diabetes with the 
development of more refined forms of insulin and oral agents. 
However, the management of diabetes is still a challenge for most physicians. 
1.1.2 Diagnosis of diabetes 
Since 1965 the World Health Organisation (WHO) has published guidance and criteria for 
the diagnosis and classification of diabetes. In 1965, a fasting blood sugar (glucose) value ≥7.2 
mmol/L was used for diagnosis [3]. Subsequent revisions were made over the next three 
decades. In 1979, the National Diabetes Data Group, proposed new criteria and introduced 
the terms ‘Non-Insulin Dependent Diabetes Mellitus’ (NIDDM) and ‘Insulin Dependent 
Diabetes Mellitus’ (IDDM) to distinguish the two main types of diabetes and also included 
the term ‘Impaired Glucose Tolerance’ (IGT) [4]. 
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The American Diabetes Association (ADA), in 1997, revised the criteria for diagnosis to a new 
lower threshold for fasting blood glucose of 7 mmol/L and introduced a new category 
‘Impaired Fasting Glucose’ (IFG) for those with fasting glucose values between 6 and 6.9 
mmol/L [5]. 
Although similar, there are small differences between the WHO and ADA criteria. The ADA 
consider a cut-off value of 5.6 mmol/L for IFG based on studies on Pima Indians and other 
ethnic groups [6] and the WHO cut-off value remains at ≥6.1 mmol/L. The WHO 
recommendations are based upon diagnostic criteria being able to distinguish a group with 
significantly increased premature mortality and increased risk of microvascular and 
cardiovascular complications. 
1.1.3 Diagnostic tests to define glycaemic status 
The WHO recommends that venous plasma glucose be the standard for measuring and 
reporting. 
Oral Glucose Tolerance Test (OGTT): There is considerable debate about the role of the 
OGTT in the diagnosis and classification of diabetes. A number of studies have reported that 
fasting plasma glucose and 2-hour post-glucose plasma glucose do not identify the same 
people as having diabetes. Using only fasting plasma glucose criteria will fail to diagnose 
approximately 30% of people with diabetes [7]. There are documented increased rates of 
mortality and worse outcomes in relation to diabetes diagnosed on the basis of the 2-hour 
plasma glucose result. The Hoorn study [8] showed that all cause cardiovascular mortality 
over a 8 year follow-up was significantly elevated in those with a 2 hour plasma glucose ≥11.1 
mmol/L but not in those with a fasting plasma glucose ≥7 mmol/L. The 2-hour plasma 
glucose is also important for microvascular complications with an increased incidence of 
retinopathy [9] in newly diagnosed diabetics with 2-hour values ≥11.1 mmol/L and even in 
those with a fasting value ≥7 mmol/L. Hence the recommendation by the WHO that the 
OGTT is an important test and is the only means of identifying people with IGT and is an 
important exclusion test in asymptomatic people. The WHO recommends that the OGTT be 
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used, with fasting glucose values between 6.1 and 6.9 mmol/L to determine glucose tolerance 
status. Figure 1-1 on page 4 shows the diagnostic values for diabetes mellitus. 
The test is recommended by the WHO [10] and although the ADA acknowledges the OGTT 
as a valid diagnostic test, in clinical practice it is inconvenient, costly and poorly reproducible 
[11]. 
Glycated Haemoglobin (HbA1c): HbA1c was identified in 1969 as an unusual haemoglobin in 
patients with diabetes [12] and subsequently numerous studies correlating HbA1c to glucose 
measurements suggested it could be used as an objective measure of glycaemic control. 
Since the 1980s HbA1c has been widely used in clinical practice and reflects average plasma 
glucose over the previous 8 – 12 weeks [13]. It soon became the preferred test for assessing 
glycaemic control in diabetics as it could be performed any time in the day and did not 
require any special preparation or fasting. In addition, the HbA1c measure bypassed the 
problem of variability of daily glucose levels. The WHO, after initially rejecting the test, 
revised its guidance to include this as a diagnostic test. An HbA1c value of 6.5% (48 IFCC) is 
recommended as the cut off point for diagnosing diabetes.  
 
Figure 1-1: Diagnostic criteria for diabetes 
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1.1.4 Classification of diabetes 
The first classification of diabetes was by the WHO in 1980. This has then been modified over 
the last three decades. Since 1998, a new classification based on collaboration between the 
WHO and ADA groups have been in use [6, 11]. Diabetes is classified into four major groups – 
Type 1, Type 2, gestational and other types of diabetes (Table 1-1) and their main differences 
are shown in Figure 1-2.  
Type 1 and Type 2 diabetes are briefly discussed below. 
Table 1-1: The classification of diabetes 
Type 1 (beta cell destruction, usually leading to absolute insulin deficiency) 
• Autoimmune 
• Idiopathic 
Type 2 (may range from predominantly insulin resistance with relative insulin 
deficiency to a predominantly secretory defect with or without insulin resistance) 
Other specific types 
• Genetic defects of beta cell function 
• Genetic defects in insulin action 
• Diseases of the exocrine pancreas 
• Endocrinopathies 
• Drug or chemical induced 
• Infections 
• Immune-mediated diseases 
• Other genetic syndromes sometimes associated with diabetes 
Gestational diabetes 
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Figure 1-2: Differences in types of diabetes 
From Diabetic Med. 15: 539-553 (1998) 
 
Type 1 Diabetes (TIDM) 
T1DM usually diagnosed in children and young adults is a chronic autoimmune disease in 
which destruction or damage of β cells in the islets of Langerhans results in insulin deficiency 
and hyperglycaemia. Autoimmunity is the predominant mechanism of T1DM, but may not be 
its primary cause. T1DM precipitates in genetically susceptible individuals, very likely 
because of an environmental trigger. 
The many types of insulin replacement available have dramatically increased the quality of 
life of T1DM patients and insulin remains the major treatment in the short and long term. 
Type 2 Diabetes (T2DM) 
T2DM is a chronic metabolic disorder with steadily increasing worldwide prevalence. As a 
result, it has become an epidemic in some countries with the number of people affected 
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expected to double in the next decade due to increases in an ageing population. A number of 
lifestyle factors are known to be important to its development - physical inactivity, sedentary 
lifestyles, cigarette smoking and excess alcohol consumption [14]. There is a strong genetic 
association, where having first-degree relatives with T2DM significantly increases the risk of 
developing the condition. Concordance among monozygotic twins is close to 100%, and 
about 25% of those affected have a diabetic family history [15].  
T2DM is characterized by insulin insensitivity as a result of insulin resistance, declining 
insulin production, and eventual pancreatic b cell failure [16, 17]. This leads to decreases in 
glucose transport into liver, muscle, and fat cells, and increases in breakdown of fat with 
hyperglycaemia. Moreover, the involvement of impaired a cell function has also been 
recognized in the pathophysiology of T2DM [18]. 
1.1.5 Complications of diabetes 
The complications of diabetes involve different organ systems and may be found at the time 
of diagnosis of diabetes, or many years after the onset of diabetes. Many complications are 
secondary to persistently elevated levels of blood glucose. These complications can broadly 
be divided into acute and chronic (See Table 1-2 on page 8) and are discussed below. 
Acute complications 
Acute complications occur as a result of an absolute or relative lack of insulin that lead to 
changes in glucose metabolism [19]. These can broadly be divided into those associated with 
hypoglycaemia and hyperglycaemia. Acute complications of hyperglycaemia include diabetic 
keto-acidosis seen in Type 1 diabetics and non-ketotic hyper-osmolar coma (HONK) seen 
mainly in Type 2 diabetics. HONK is characterised by very high blood sugars, dehydration 
and shock. Both conditions need managing rapidly and aggressively with fluid and insulin 
therapy.  
Hypoglycaemia, most often an acute complication secondary to glucose lowering drug 
therapy (insulin or oral hypoglycaemic agents) is also common. 
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Chronic complications 
Long-term exposure to hyperglycaemia results in significant end-organ damage, classified in 
two categories – microvascular and macrovascular damage. In the general population, 
diabetes is the leading cause of blindness (retinopathy), end-stage renal disease 
(nephropathy) and small nerve damage (neuropathy). The cause of this end-organ damage 
involves several mechanisms leading to the accumulation of advanced glycation end-
products [20]. These complications are often progressive and irreversible. However, increased 
awareness and advances in our understanding of the pathogenesis of diabetes has allowed 
earlier detection and interventions to slow the progression of diabetic complications. 
Table 1-2: Complications of diabetes 
Acute 
Diabetic ketoacidosis 
Hyperosmolar hyperglycaemic non-ketotic coma 
Hypoglycaemia 
Chronic 
Macrovascular 
Coronary disease 
Cerebrovascular disease 
Peripheral vascular 
disease  
Microvascular 
Retinopathy 
Nephropathy 
Neuropathy 
Autonomic 
Somatic 
 
Pulmonopathy (described later) 
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1.1.6 Factors affecting glucose handling 
In the fasted and postprandial states, factors which affect rates of glucose entry into the 
circulation are more important for maintaining normal glucose homeostasis than those that 
affect the rate of removal of glucose from the circulation. The liver is responsible for 
glycogenolysis and some gluconeogenesis. Postprandially,  almost all endogenous glucose 
release is via gluconeogenesis [21] - the liver and kidney contributing approximately 8 and 2 
μmol/kg/min, respectively; Of the total glucose released into the circulation (10 
μmol/kg/min)  the brain, splanchnic tissue, muscle, adipose tissue, and blood cells account 
for approximately 5, 2, 1.5, 0.5, and 0.5 μmol/kg/min of glucose uptake (See Figure 1-3). 
The regulation of glucose entry into the circulation is complex, being influenced by 
hormones, the sympathetic nervous system, and meal composition and substrates (i.e., free 
fatty acid concentrations and availability of gluconeogenic precursors). Of these, insulin and 
glucagon are most important both in fasting and postprandial states. Incretins that form the 
entero-insular axis contribute by altering gastric emptying, insulin and glucagon secretion. 
These hormones are discussed individually in subsequent sections of this review.  
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Figure 1-3: Glucose utilization and production in the post-absorptive state 
From: Gerich J.E. Normal Glucose Homeostasis. In: Poretsky L, editor. Principles of Diabetes 
Mellitus: Springer; 2010 [21]  
2 Normal Glucose Homeostasis 27
Liver 10.0
Kidney
8.0
Muscle
Brain
2.0
5.0
1.5
0.5
0.5
2.0
Adipose Tissue
and Skin
Blood CellsSplanchnic Organs
Fig. 2.2 Glucose utilization and production in the postabsorptive state. The liver and kidney contribute approximately 8.0 and
2.0 µmol/kg/min, respectively; top, the total release of glucose into the circulation (10 µmol/kg/min); the brain, splanchnic tissue,
muscle, adipose tissue, and blood cells account for approximately 5.0, 2.0, 1.5, 0.5, and 0.5 µmol/kg/min, respectively. This figure
was published in Endocrinology Volume 1 edited by LJ DeGroot and JL Jameson, chapter entitled “Hypoglycemia” authored by
John Gerich, p. 923. Copyright © Elsevier 2001. Used with permission
Table 2.5 Glucose disposal in the postabsorptive state
Rate (µmol/kg/min) % of total
Overall 10 100
Oxidation ∼7 ∼70
Glycolysis ∼3 ∼30
Tissues
Brain 5 ∼50
Skeletal muscle 2 ∼20
Splanchnic organs 1 ∼10
Kidney 1 ∼10
Adipose tissue 0.5 ∼5
Blood cells 0.5 ∼5
Glucose uptake by brain, blood cells, renal medulla, and splanchnic tissue occurs largely independent of
insulin, and plasma insulin concentrations are low in the postabsorptive state (<10 µU/ml). Under these condi-
tions, amount of glucose removed from the circulation is determined almost exclusively by tissue demands, the
mass action effect of the plasma glucose concentration per se, and the number and characteristics of the glucose
transporters in specific tissue rather than by insulin. Insulin may be viewed as playing a permissive role, while
counterregulatory hormones that antagonize the action of insulin (e.g., cortisol, growth hormone, epinephrine,
and thyroid hormones) can be viewed as modulating the sensitivity of tissue to the effect of insulin on tissue
glucose uptake and utilization.4,8
Prolonged Fasting
With prolongation of fasting, plasma insulin levels decrease while those of glucagon, catecholamines, growth
hormone, and cortisol increase (Table 2.6). Consequently, plasma FFA, glycerol, and the ketone bodies – products
of FFA oxidation (beta hydroxybutyrate) – increase. Since hepatic glycogen stores become depleted by 60 h,
virtually all of the glucose release at this time is due to gluconeogenesis. Initially, hepatic gluconeogenesis
decreases while renal gluconeogenesis increases, with an overall result of a decrease in overall glucose release
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1.1.7 Management of diabetes 
The importance of tight glycaemic control in the management of diabetes has been firmly 
established and classed into the following categories [Adapted from Management of diabetes, 
Quick Reference Guide 2010, (SIGN) Scottish Intercollegiate Guidelines Network]. 
Ø Lifestyle	management	
o access	to	structured	education	programmes	
o smoking	cessation	
o weight	loss	
o self-monitoring	of	blood	glucose	
Ø Systematic	screening	for	diabetic	retinal	disease		
Ø Assess	risk	of	developing	a	foot	ulcer	
Ø Psychosocial	factors	
o regular	assessment	of	a	broad	range	of	psychological	and	behavioural	problems	(e.g.	anxiety,	depression	and	eating	disorders)	
Ø Management	of	Type	1	diabetes	
o either	regular	human	or	rapid-acting	insulin	analogues		
o basal	 insulin	analogues	are	recommended	 in	adults	with	 type	1	diabetes	who	experience	severe	or	nocturnal	hypoglycaemia	
o tailored	insulin	regime	
o optimisation	of	glycaemic	control	towards	a	normal	level		
Ø Management	of	Type	2	Diabetes	(Pharmacological)	
o HbA1c	target	of	7.0%	(53	mmol/mol)	
o Consideration	of	oral	hypoglycaemic	agents	
o DPP-4	inhibitors	may	be	used	to	improve	blood	glucose	control	
o GLP1	 agonists	 (such	 as	 exenatide	 or	 liraglutide)	 may	 be	 used	 to	 improve	glycaemic	control	in	obese	adults	
o When	commencing	insulin	therapy,	bedtime	basal	insulin	is	recommended	with	dosage	titration	against	morning	(fasting)	glucose	
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1.2 Cystic fibrosis related diabetes (CFRD) 
The first recognition of cystic fibrosis related diabetes (CFRD) as a unique entity was in 1955 
[22] and since then its association with a number of comorbidities and increased mortality 
has been well described. As survival in CF has improved dramatically over the last 50 years, 
CFRD has now come to the forefront. The median age of onset of CFRD is 20 years [23-25] 
with females more susceptible, tending to develop CFRD at a younger age [24, 26]. With 
newer diagnostic methods, CFRD can be present in about 20% of CF adolescents and up to 
50% of adults [27] and is associated with increasing age, worse pulmonary function, under 
nutrition, liver dysfunction and steroid use [28, 29]. 
CFRD shares features of both Type 1 (occurs in young people and associated with insulin 
insufficiency) and Type 2 (mild insulin resistance present and ketosis is rare) diabetes. Unlike 
those with T1DM, those with CFRD do not develop a complete absence of insulin secretion 
and there is some retention of basal insulin secretion [30]. However, few CF patients have 
truly normal glucose metabolism. The differences between CFRD and the most common 
types of diabetes – Type 1 and 2 are shown in Table 1-3 (page 13). The presence of CFRD is 
associated with an increase in early mortality of up to six fold [31] and importantly weight 
and lung function decline have been shown to precede diagnosis of CFRD by standard 
criteria [32]. Insulin treatment confers a short-term benefit and in the long-term enhances 
nutritional status and pulmonary function, on average delaying decline in FEV1 by 34 months 
[33].  
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Table 1-3: Differences between Type 1, Type 2 and CF related diabetes 
 Type 1 DM Type 2 DM CFRD 
Onset Acute Insidious Insidious 
Peak age of onset Children and 
adolescents 
Adults 18-24 years 
Antibody presence Yes No Probably No 
Insulin secretion Eventually absent Decreased Severely decreased 
but not absent 
Insulin sensitivity Somewhat decreased Severely decreased Somewhat 
decreased 
Treatment Insulin Diet, oral 
medications, insulin 
Insulin 
Microvascular 
complications 
Yes Yes Increasing 
incidence 
Macrovascular 
complications 
Yes Yes No 
Cause of death Cardiovascular 
disease and 
nephropathy 
Cardiovascular 
disease 
Pulmonary disease 
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1.2.1 Pathophysiology of diabetes in CF 
The pathophysiology of CFRD is complex and not fully understood.   
Autopsy findings have demonstrated pancreatic fibrosis and atrophy with a 50% reduction in 
pancreatic islet mass [34] and progressive β cell loss is thought to cause abnormal glucose 
handling [35, 36]. There is delayed insulin secretion following a glucose load in people with 
CF when compared to normal matched controls [37] and an impairment in glucagon release 
(discussed in the subsequent chapter). The role of insulin sensitivity is unclear, as is that 
of insulin resistance that is not thought be the primary pathology. However, not all those 
with pancreatic insufficiency develop CFRD and a genetic predisposition might exist [38].  
The role of CFTR in the pancreas is still unclear. Discordant observations have been made 
about the presence of CFTR in the pancreas. Strong et al [39] and later Rolon et al [40] found 
no apparent expression of CFTR protein in the islets of Langerhans of CF patients, whereas 
Polychronakos [41] found the highest level of CFTR expressed in these islets. However, this 
could be due to a reflection in the sensitivity of the methods used to localise CFTR in the 
human pancreas. 
Genetics: While abnormal chloride channel function induced by CFTR mutations is 
necessary for CFRD to develop, the twin and sibling study by Blackman [42] involving 1366 
individuals at 109 centres, from which were derived 68 monozygous twin pairs, 23 dizygous 
twin pairs, and 588 sibling pairs, all with CF showed that genetic modifiers are the primary 
cause of diabetes in CF subjects. Data from the UK CF registry of 8,029 individuals, 
demonstrated CFTR class I and II mutations increase the risk of diabetes independent of 
other risk factors [43].  
Histopathology: It is believed that  CFRD results from a combination of chronic pancreatic 
inflammation and loss of the islet cells, pancreatic duct obstruction leading to interstitial 
oedema and ischaemic changes of the endocrine pancreas [29, 44, 45]. The  islet cells are 
initially preserved but destroyed by fibrous fatty tissue over time and this could explain why 
CFRD is more common later in life [46]. 
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Comparisons can be made with non-CF obese T2DM subjects where a 63% decrease in β cell 
mass was observed, compared with an obese non-diabetic group [47]. In the same study, a 
40% decrease in β cell mass was observed in those with impaired fasting glucose. It is 
established [48] that a 50% pancreatectomy in humans causes loss of normal glucose 
regulation and the degree of β cell loss observed in post-mortem studies in T2DM is 
sufficient to account for at least some part of hyperglycaemia. The degree of cell death and 
islet cell dysfunction are only marginally associated [49] adding to the difficulty in 
identifying a single causative process and this is even more pertinent in the CF condition. 
1.2.2 Complications associated with CFRD 
The most serious acute complication of CFRD is hypoglycaemia. Hypoglycaemia not 
requiring assistance from another individual is common even in CF patients without CFRD. 
It can occur in the fasting state, where it may reflect malnutrition and/or increased energy 
needs due to inflammation and infection, and postprandially, where it is related to delayed 
and discordant insulin secretion [50]. In those with CFRD, hypoglycaemia can occur as in any 
patient on insulin therapy, although severe hypoglycaemia may be less common in CF [51] 
probably secondary to an inadequate glucagon response to hypoglycaemia, a brisk 
catecholamine response and normal hypoglycemia awareness [52]. 
Chronic complications of CFRD include microvascular disease that typically does not appear 
to become clinically apparent until individuals have had the disease for at least 5 years and 
have developed fasting hyperglycaemia [53-55]. Renal failure due solely to diabetes is 
uncommon in CF, but the reported incidence of microalbuminuria is 4 – 21% in individuals 
with CFRD [53-55]. Tight glycaemic control and treatment of microalbuminuria with ACE 
inhibitors or angiotensin receptor blockers combined with optimal control of hypertension 
are thought to delay progression of microvascular damage in CFRD as in T1DM and T2DM. 
Diabetic retinopathy occurs in 10 – 23% of patients with CFRD but diabetic neuropathy does 
not seem to occur commonly in CFRD [53, 54]. Current data suggest the severity of this 
microvascular complication may be less in CFRD [53], but gastroparesis is common in CF 
patients both with and without CFRD. It is thought CFRD aggravates gastroparesis.  
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However, this has been difficult to determine [53] due to complexities in assessment. Also, 
gastroparesis may make good glycaemic control difficult to achieve in those with CFRD. 
Hypertension is not uncommon in adult CF patients, particularly after transplantation [54] 
and although atherosclerotic vascular disease has not been described in CF, hypertension is a 
known risk factor for diabetic kidney disease. Hyperlipidaemia is rare in CF but may occur, 
especially after transplantation or in pancreatic-sufficient individuals. 
1.2.3 Glucose handling and its impact on the lungs 
Significant morbidity and mortality associated with CFRD usually occurs before diabetic 
retinopathy develops (unlike in T1DM and T2DM). The most important organ in CF is the 
lung and diabetes can harm the lung, at levels far below the current diabetic biochemical 
thresholds: a process described as ‘pulmonopathy’ [56]. It has been argued that 
hyperglycaemic thresholds based on specific features of pulmonary function decline would 
be of greater relevance to those with CF than any based on the statistics for developing 
microvascular disease as in T1DM. Diagnostic criteria based on lung function therefore need 
to be developed in order to decide on the level of plasma glucose that should be the cut-off in 
a screening programme [56]. 
Diabetes can affect the lung in a number of ways – an increase in infections, reduced gas 
diffusion and increased lung stiffness resulting in an increased effort of breathing.  
Non-CF subjects with impaired glucose handling at diabetic thresholds have been shown to 
have higher morbidity and mortality from pulmonary infection than those with normal blood 
glucose levels [57-59]. There is loss of lung elasticity and recoil in diabetics and a greater rate 
of decline in lung function with age compared with non-diabetic subjects. As a result, the 
lungs become stiffer and harder to inflate and deflate resulting in a decrease in FEV1 and FVC. 
The diffusion capacity (DLCO; diffusion of carbon monoxide from the alveoli, across the 
epithelium and into the blood) is slightly reduced, probably owing to thickening in the 
alveolar epithelium and the pulmonary capillary basal lamina. Changes have been seen in 
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arterioles and capillaries of the lung, which are similar to those in the diabetic kidney, 
although less marked [60].  
There are a number of mechanisms by which increases in glucose levels within airway 
secretions contribute to increased frequency and severity of pulmonary infection [61]. The air 
spaces are lined with a thin layer of fluid which normally contains little or no glucose [62], 
but the level can be increased by both hyperglycaemia and inflammation, both of which 
occur in CF. This presence of glucose increases proliferation of colonising and infective 
microorganisms with increased virulence. It may also foster virulence [61] leading to altered 
immune proteins and impairment of epithelial cell function [62]. Hence, the optimisation of 
glycaemic control and maintenance of normal glucose concentrations in the airways is a 
significant factor in protecting patients with CF from acute and chronic microbial infection.  
In CF, we are now well aware of the deterioration in pulmonary function in those with CFRD 
[28, 63, 64]. Reductions in FEV1 and FVC in those with CFRD and IGT have been noted [65]. 
It is also well established that this decline is seen from at least two to six years prior to 
diabetes being diagnosed using the standard OGTT [25, 32].  
In following up 343 CF patients, Schaedel et al [66] demonstrated declines in pulmonary 
function, even before the classical definition of diabetes mellitus was achieved and an 
associated faster decline in those with diabetes, but this was seen only in those over 15 years 
of age. In their studied population, all those with diabetes had pancreatic insufficiency 
raising the possibility that the mechanism of glucose intolerance is via under nutrition, 
leading to poor lung function.  
Brennan et al [67] studied breath condensates in healthy volunteers (n = 23),  CF patients  
with (n = 10) and without (n = 10) CFRD, and non-CF diabetic subjects (n = 17). In their study, 
glucose levels in breath condensates were low in healthy volunteers, but raised in other 
groups. However, the levels were higher in those with CF (both with and without CFRD) than 
in the non-CF diabetic group. The highest levels were seen in those with CFRD suggesting 
airway glucose is raised by both hyperglycaemia and inflammation.  
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More recently, measures of sputum glucose in 88 CF patients with and without CFRD were 
studied [68]. Interestingly, the sputum glucose measurement was highest in subjects with 
normal glucose tolerance, suggesting the dynamics of glycaemic control, sputum glucose and 
pulmonary infections are more complex than previously thought.  
In a review of CF related diabetes studies, Milla et al [63] noted the cause-and-effect 
relationship between insulin deficiency and decline in health, but most studies were 
retrospective, making it difficult to determine whether glucose intolerance accelerated 
decline or whether sicker patients were more likely to get diabetes. 
Subsequently, they carried out a prospective study [63] over 4 years of 152 CF patients and 
divided them into three groups based on the OGTT: NGT (45%), IGT (39%) and CFRD 
without fasting hyperglycaemia (16%). Over the follow-up period lung function declined in 
those with IGT and CFRD without fasting hyperglycaemia, but not in those with baseline 
NGT. They also demonstrated an association between baseline insulin production and lung 
function decline, with the highest decline in those with lower baseline insulin. However, 
insulin levels did not correlate with glucose groups, suggesting in part a direct relationship 
between insulin and lung function perhaps due to the catabolic effect of insulin deficiency 
[63] and hence is probably why insulin supplementation slows declines in lung function [33].  
The lung is the organ most at risk with CF and hyperglycaemia has several adverse effects on 
the lung occurring early and one of the earliest manifestations of hyperglycaemia might be 
weight loss. With damage occurring early and glucose levels well below the threshold for the 
usual definition of diabetes by current criteria, there is a need to screen and intervene at an 
earlier stage, making the choice of a screening test important.  
1.2.4 Screening and diagnosing CFRD 
The diagnosis of CFRD can be difficult to detect biochemically and clinically. The classical 
symptoms of ‘polyuria, polydipsia and poor weight gain’ have been reported to occur in only 
33% of patients with CFRD [23]. Therefore, the diagnosis of CFRD purely on the basis of 
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symptoms would fail to recognize the vast majority of diabetics.  Hence the inclusion of a 
diabetic test in the CF annual screen has been advocated.  
Several screening tests have been used to screen for CFRD: 50-g glucose challenge test, 75-g 
OGTT, OGTT 60-minute glucose level, continuous glucose monitoring (CGM), fasting 
plasma glucose, HbA1C, serial capillary blood glucose monitoring and combinations of these 
tests.  
Fasting blood glucose (FPG) is insensitive, as fasting hyperglycaemia occurs late in CFRD 
[23, 69, 70] thereby making this a poor test to diagnose CFRD. A raised FPG may detect only 
16% of cases [23], however it is still one of the screening tests recommended CFRD by the 
ADA [71] . 
Random blood glucose elevations tend to occur across the spectrum of CFRD but a single 
elevated recording is of no value in CF. 
Glycosylated haemoglobin (HbA1C) reflects blood glucose levels over the preceding 2-3 
months and a level ≥ 6.5 % is the globally accepted standard [72] to diagnose T2DM due to 
the association with the prevalence of diabetic retinopathy above this level.  An 
elevated HbA1C is suggestive of CFRD but again is a late occurrence and levels are often 
spuriously low in those with CF [23]: hence, reliance on this as a screening test will miss a 
significant number of diabetics [73] and cannot be used as a reliable test to diagnose CFRD. 
There are two possible reasons why the HbA1C is a late occurrence in individuals with CF. 
Firstly, the initial step of glycation of Hb is a non-enzymatic reversible reaction, and 
therefore requires prolonged hyperglycaemia for Hb to get irreversibly glycated (the HbA1C) 
and therefore not high in CF until late in CFRD. Moreover, rebound hypoglycaemia common 
in CF will reverse any glycation initially.  Secondly, the increased red cell turnover in CF 
might be responsible for a lesser time for Hb to become glycated. 
Fructosamine, a glycated serum protein measured in conditions where hormonal changes 
cause greater short-term fluctuation in glucose concentrations (e.g. pregnancy) reflects blood 
glucose levels over a short period of two to three weeks. It has been demonstrated that 
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neither HbA1c nor fructosamine correlate with mean blood glucose levels in CF [74], thereby 
providing limited value. 
Postprandial glucose monitoring is a more accurate reflection of changes on a day-to-day 
basis. It is easy to carry out and if performed serially and correctly is a valuable screening test 
[75]. 
OGTT: Current, UK CF Trust [76] and ADA [77] guidelines  on the management of diabetes 
recommend an OGTT to diagnose CFRD.   The values of an OGTT test indicating normal and 
abnormal glucose tolerance (NGT <7.8, IGT ≥7.8 - <11.1 and diabetes ≥11.1mmol/L at 120-
minutes) are drawn from a non-CF diabetic population who are geno-typically different. The 
existing diagnostic criteria for diabetes were based on the WHO criteria and the risk of 
developing micro-vascular complications in T2DM [78] rather than CF specific outcomes.  In 
T2DM an OGTT involves only baseline and 120-minute values but in CF the 120-minute value 
fails to discriminate between healthy controls and those with CF [75]. The earliest glycaemic 
abnormality associated with clinical decline in CF is not known and it is common practice to 
carry out sampling at 30-minute intervals between baseline and 120-minutes, but the value of 
each time point is not yet established. 
In impaired glucose-tolerant and T2DM patients the  OGTT glucose values at 60-minutes is 
thought to be a good indicator for decreased insulin sensitivity and secretion for the 
prediction of future T2DM than the 120-minute value [79]. The importance of the 60-minute 
value has also been suggested in CF - in studies of 89 paediatric CF patients [80] and 240 
adult CF patients [81], where the higher 60-minute value was associated with worse 
pulmonary function. This higher 60-minute value has also been associated with a higher 
future risk of CFRD occurrence and patients increased their BMI following early insulin 
introduction [82, 83]. 
OGTTs are labour intensive, time-consuming and cause discomfort due to repeated 
sampling. In the CF population, glucose tolerance is often variable and a single OGTT based 
on guidelines may be misleading. Decline in weight and lung function tend to precede the 
diagnosis of CRFD by current criteria by months to years [84-86]. The OGTT has poor 
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sensitivity and specificity in the diagnosis of CFRD [87] questioning the applicability of this 
as a screening test in CF. 
Continuous Glucose Monitoring (CGM) has recently emerged as a useful validated tool to 
screen for CFRD [75, 88-90]. CGM was developed for monitoring glucose control in those 
with T1DM and uses a tiny subcutaneous filament probe that records interstitial fluid glucose 
levels every 5-minutes generating a detailed profile over a course of three to five days of usual 
diet and activity. It provides profiles of glucose handling at any time of the day or night and 
is particularly useful in CF, as the CF diet frequently exceeds the carbohydrate load of a 
standard OGTT. A study of 17 children with CF and 14 controls demonstrated that CGM is a 
useful tool in detecting early glucose derangements in those with CF. Importantly, CGM was 
the stronger predictor of the development of CFRD in a 2.5 year follow up period, when 
compared to an OGTT [91]. CGM time ≥ 4.5% of glucose values ≥ 7.8 mmol/L is associated 
with declining weight and lung function in the preceding 12 months [69] and is perhaps the 
most useful test of glucose handling in CF. 
There is a need for a new accurate screening tool appropriate for individuals with CF that can 
alert a CF physician to commence insulin to prevent clinical deterioration. 
 
1.2.5 Treatment of CFRD 
Nutrition: A high calorie, high fat diet is recommended in CF patients [92]. There is no 
evidence to support reductions in carbohydrate load in patients with CFRD or to avoid high 
glycaemic index foods as this might reduce the total energy intake and impair nutritional 
status in those individuals with CF. 
Oral hypoglycaemic agents: Sulphonylurea derivatives act by increasing insulin secretion, 
but progressive destruction of β cells make this treatment of limited value and there is an 
associated high incidence of hypoglycaemia [93], hence not recommended for use in CF. 
Insulin resistance is not a major factor in CF and agents that primarily work by reducing 
insulin resistance are not adequately effective. Drugs such as metformin tend to cause 
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significant side effects such as nausea, diarrhoea and abdominal discomfort and most 
patients with CF do not tolerate these side effects [64].  
Insulin treatment: Currently, insulin is the only treatment recommended in the 
management of CFRD. The choice and regime of insulin depends on the individual needs of 
the patient. A basal bolus regime provides the required background insulin and a continuous 
anabolic effect. Short acting insulin helps control post-prandial hyperglycaemia and allows 
for variable eating patterns [94]. Patients on overnight feeds might require more insulin at 
night.  
1.2.6 Benefits of insulin in CF 
Patients with CFRD are insulin insufficient, and insulin is the only recommended treatment. 
Those with CF on insulin therapy who achieve glycaemic control demonstrate improvements 
in weight, fat free mass, pulmonary function and survival [27, 83]. 
Insulin improves lung function after decline resulting from the pre-diabetic condition in 
patients with CF [95]. Previous data from 42 patients from this CF unit [33] has shown that 
prior to treatment, over a period of 5 years, the annual rate of change in FEV1 was -3.2%, FVC 
-2.5%, and BMI -0.07%. Three months following commencement of insulin treatment, there 
were significant improvements in all parameters, that were maintained at 1 year for FEV1 
(55.1%; p <0.002), 2 years for FVC (72.1%; p<0.01) and 3 years for BMI (20.4%; p < 0.002). After 
3 months, FEV1 declined at a rate similar to that before treatment (-3.2 vs. -3.1% per year; 
p=0.77), such that the mean FEV1 after treatment returned to pre-treatment baseline values at 
34 months, suggesting, insulin enhances the nutritional state and temporarily improves 
pulmonary function in CFRD patients, on average delaying the decline in FEV1 by 34 months. 
The subsequent chapter discusses pancreatic endocrine cell function and its assessment in 
CF. 
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1.3 Pancreatic endocrine cell function 
The pancreas is responsible for the release of several hormones contributing to carbohydrate 
metabolism and glucose handling. The pancreatic islets of Langerhans secrete glucagon (α 
cells), insulin (β cells), somatostatin (D cells) and pancreatic polypeptide (F or D cells) that 
modulate insulin and glucagon secretion, and are all polypeptides. Insulin is only secreted by 
β cells whereas the other hormones are also secreted by gastrointestinal mucosa and 
somatostatin is also found in the brain. Insulin (and c-peptide), glucagon and pancreatic 
polypeptide (PYY) are discussed in greater detail below.  
1.3.1 Insulin and C-peptide 
Insulin is synthesized in β cells in the form of pre-proinsulin the precursor, and the gene for 
the same is located on chromosome 11. Within a-minute after synthesis, pre-proinsulin is 
discharged into the space of the rough endoplasmic reticulum where it is cleaved into 
proinsulin by proteolytic enzymes. Proinsulin with a C (connecting) chain linking A and B 
chains is then transported by microvesicles to the Golgi apparatus. Proinsulin is released in 
vesicles and the conversion of proinsulin to insulin continues in maturing granules through 
the action of pro-hormone-convertase 2 and 3 and carboxy-peptidase-H. In the conversion 
process, a C-peptide chain is removed from the proinsulin molecule producing the disulfide-
connected A and B chains that are insulin [96, 97]. Maturing granules are translocated with 
the help of microtubules and microﬁlaments. A normal healthy β cell, maintains in excess of 
10,000 granules, but not all granules are functionally equivalent. Roughly 1,000 granules are 
attached to the plasma membrane, and some of these are in a readily releasable pool. Only a 
small proportion of total insulin is released even under maximal stimulatory conditions [98]. 
These granules are dynamic structures and around 10% granules turn over every hour during 
active secretion. Granule formation and turnover are precisely controlled processes and 
involve regulation and expression of multiple genes. 
C-peptide reflects insulin synthesis and low levels of C-peptide are seen when insufficient 
insulin is produced by β cells or when production is suppressed. 
 24 
 
Insulin secretion is pulsatile and regulated by a variety of stimulatory and inhibitory factors, 
most related to glucose metabolism and effects of cAMP. Insulin secretion is stimulated by 
high blood glucose levels and reduced when blood glucose is low. Other stimulatory factors 
include several amino acids, intestinal hormones and acetylcholine (reflecting 
parasympathetic stimulation). Once in circulation, insulin is degraded within-minutes in the 
liver and kidneys. Insulin binds with specific membrane receptors found in almost all cells, 
forming an insulin-receptor complex taken into the cell by endocytosis. The insulin-receptor, 
a tetramer, is made up of two alpha and two beta glycoprotein subunits. The β subunit is a 
protein kinase that catalyzes phosphorylation of proteins, an activity resulting in change in 
the number of "transporters". The insulin-receptor complex enters lysosomes where it is 
cleaved, the hormone internalized and the receptor recycled. Increased circulating levels of 
insulin reduce the number of receptors and decreased insulin levels up-regulate the number 
of receptors. The number of receptors per cell is increased in starvation and decreased in 
conditions such as obesity and acromegaly; receptor affinity is decreased by excess 
glucocorticoid. 
There are several actions of insulin:  
• Facilitation of glucose transport through membranes (adipose and muscle cells) 
• Stimulation of the enzyme system for conversion of glucose to glycogen (liver and 
muscle cells)  
• Decreases the rate of gluconeogenesis (liver and muscle cells) 
• Regulation of lipogenesis (liver and adipose cells)  
• Promotion of protein synthesis and growth (general effect) 
Diabetes results from the failure of β cells to produce or increase insulin secretion in 
response to an increasing demand for insulin from peripheral tissue.  
The normal physiological release of insulin following ingestion of a meal is the rapid release 
of preformed insulin from storage granules within β cells. This occurs in 2 phases, the first 
within 2 - 5-minutes of a glucose load being ingested and continues for 10 to 15-minutes. This 
"first phase" of insulin secretion promotes peripheral utilization of nutrient load, suppresses 
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hepatic glucose production and limits postprandial elevation of glucose. The remaining 
secretion is post-prandial. The second phase of prandial secretion follows and is sustained 
until normoglycaemia is restored. In non-diabetic individuals, approximately 50% of total 
daily insulin is secreted during basal periods. It is well recognized in T2DM that decreased 
first-phase insulin secretion is an early marker of β cell dysfunction, appearing long before 
significant changes in absolute glucose concentrations are apparent [99, 100]. This is also true 
in patients with CF and there is impairment in first phase of insulin release in response to 
glucose and this has been demonstrated even in non-diabetic CF patients [37, 101, 102] in part 
contraindicating the hypothesis that reduced β cell mass is solely responsible for the 
development of CFRD. These points to other possible mechanisms that might contribute to 
the development of CFRD such as the role of peripheral insulin sensitivity or altered β cell 
function. 
1.3.2 Insulin sensitivity and resistance 
Studies using gold standard hyper-insulinaemic clamp techniques to directly assess insulin 
sensitivity have demonstrated conflicting results. Cucinotta et al [102] could not demonstrate 
reduced sensitivity in diabetic CF patients, whereas,  Ahmad et al [103] demonstrated 
increased sensitivity in CF subjects compared to controls. However, in this study subjects 
were not stratified according to their glucose tolerance. In contrast, Bergman [104], Lanng 
[105] and Holl [37] reported significant reductions in insulin sensitivity in those with IGT, 
while CF subjects with NGT did not differ from healthy controls. Data from my CF unit [101] 
demonstrated no differences in insulin sensitivity or resistance among three CF groups (NGT, 
IGT and CFRD) confirming the co-existence of altered secretory kinetics and delayed peak 
insulin concentration. A number of studies have shown no significant changes in insulin 
resistance in those with CF [45, 102, 103, 105-108] suggesting glucose intolerance is 
characterized by qualitative and quantitative defects in insulin secretion and not insulin 
resistance. 
Therefore, in the long term, early identification of β cell defects need to be identified to 
prevent clinical decline in CF.  
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1.3.3 Measuring β cell function 
The hyperinsulinaemic ⁄ euglycaemic glucose clamp method is the widely-accepted gold 
standard to evaluate insulin sensitivity. However, its use of an unphysiological dose of 
insulin, variations in test methodology, cost and complexity limit its role in clinical practice 
[109, 110]. To circumvent this, a variety of methods of deriving surrogate measures of insulin 
sensitivity and secretion from non-invasive methods such as the OGTT have been developed 
to calculate both insulin sensitivity and pancreatic β cell function in basal and dynamic 
states. These methods correlate well with clamp techniques and are accepted as providing 
reliable estimates of insulin sensitivity and β cell function and perform reasonably well for 
discrimination between groups and individuals with differing levels of insulin secretion, 
sensitivity and resistance [110-113]. 
Methods such as the updated homeostatic model assessment (HOMA2) estimates insulin 
sensitivity and β cell function using fasting glucose and insulin levels [114, 115]. This method, 
developed in 1985 and subsequently computerised [116] and updated in 1996, is used to 
measure pancreatic β cell function and insulin resistance [114] from paired glucose and 
insulin concentrations in basal states. This model is used in numerous studies, has been well 
validated and is available as a computer spread sheet application 
(http://www.dtu.ox.ac.uk/homa/) known as the HOMA Calculator© (The University of Oxford 
2004). The model is based on non-linear equations and mathematical assessments of 
interaction between the above two variables. HOMA2 has been widely used in normal and 
diabetic patients, including those with CF. 
Stumvoll and colleagues developed indices that allow simultaneous estimation of insulin 
sensitivity and β cell function in dynamic states using glucose and insulin values during an 
OGTT [117, 118]. First and second phase insulin secretion is calculated using the Stumvoll 
equation (1283 + 1.829 x Ins30- 138:7 x  Gluc30 + 3:772 _x Ins0) validated using the euglycaemic 
hyperinsulinaemic clamp [117]. 
Another index, the Matsuda Index [111] had been designed to indicate values which are 
comparable to rates of disappearance of plasma glucose measured by insulin clamp methods. 
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Retnakaran et al [119] demonstrated a hyperbolic relationship between the Matsuda index of 
insulin sensitivity and the ratio of the total areas under the curve (AUC) for insulin and 
glucose (AUC ins/glu) over 120-minutes derived from OGTT data in subjects with normal and 
impaired glucose tolerance referred to as the Disposition Index (DI) [ΔI0–30/ΔG0–30 and 
1/fasting insulin]. In prospective studies, the DI declines well before glucose levels rise into 
the diabetic range: a low DI is an early marker of inadequate β cell compensation and 
predicts development of future diabetes above and beyond fasting and 2-hour glucose levels 
over 10 years [120]. Within CF, the only study [121] evaluating β cell function measured by DI 
showed DI to be reduced compared to non-CF controls. The DI was reduced even in those CF 
subjects with NGT and decreased further in those with CFRD. It remains to be seen whether 
DI proves to be a predictor of the development of CFRD in larger studies enabling 
identification of CF patients who are at particularly high risk, allowing early interventions 
aimed to delay or prevent CFRD. 
1.3.4 Oral mixed meal tolerance test (MMT):  
The patho-physiology of diabetes has usually been studied using the OGTT, but this is un-
physiological and may not necessarily give information that is relevant to responses to meals. 
Dietary constituents other than glucose affect insulin secretion. The addition of protein, 
amino acids or fat to carbohydrate is known to enhance insulin secretion; hence the 
administration of a standard mixed meal is considered a more physiological test for 
evaluating subjects both at the time of diagnosis and follow-up and has been proposed for 
clinical practice [122]. 
A near normal incremental plasma glucose pattern and more rapid insulin response to a 
standard breakfast have been reported in mild diabetics [123]. 
The MMT is commonly used to assess residual insulin secretion. Randomized studies [124] 
comparing the MMT with a Glucagon Stimulation Test (GST) showed the MMT was more 
sensitive of residual β cell function, the peak C-peptide response being signiﬁcantly higher 
compared to the GST, an effect likely to be due to the inherently greater response to 
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combined stimuli of a mixed-meal. Repeat testing also demonstrated the MMT was more 
reproducible. Therefore, the standardized MMT is the preferred test to assess β cell function. 
Various types and formulations of mixed meals have been used. One study [125] used a mixed 
meal consisting of 15 g Weetabix, 100 g skimmed milk, 250 mL pineapple juice, 50 g white 
meat chicken, 60 g whole meal bread and 10 g polyunsaturated margarine (75 g 
carbohydrates; total, 500 Cal; calorie contribution: 55% carbohydrate, 30% fat, and 15% 
protein) to study pancreatic ß cell responsiveness. Subjects were required to consume the 
meal within 10-minutes. Another study [122], comparing an OGTT and mixed meal, used a 
standard mixed meal whose composition was similar to a continental breakfast. The meal 
consisted of 125 g fruit juice, 75 g ham and 80g white bread (590 kcal, 44% carbohydrates, 
41% lipids and 15% proteins) with sampling times comparable to an OGTT.  
1.3.5 Glucagon 
Glucagon is synthesized and secreted by the pancreatic islet α cells. Variation in blood 
glucose levels cause changes in glucagon secretion. This is achieved directly at the level of α 
cells via adequate glucose sensing, and the rate of exocytosis of glucagon-containing 
granules. Glucagon release is also regulated by systemic, extrinsic factors to the islet and 
mediated by the autonomic nervous system [126]. Glucagon levels are highest in venous 
drainage of the pancreas and hepatic portal vein with the liver being the principle target. The 
glucagon receptor (GlcaR) is highly specific and abundantly expressed by hepatocytes. 
Hepatic clearance of glucagon is 20-30% of portal content, with the kidney contributing to a 
major portion of glucagon removal.  
Abnormalities of glucagon secretion are encountered in diabetic patients. Insufficient 
secretion in response to hypoglycaemia underlies disorders of counter-regulation in long-
term T1DM subjects. The almost complete loss of β cells profoundly alters islet architecture 
but is not accompanied by changes in α cell mass [127]. It is widely recognized that T2DM 
patients show elevated plasma glucagon levels relative to their high glucose levels [128, 129]. 
Excessive glucagon secretion, with background insulin insufficiency and resistance, causes 
fasting hyperglycaemia by promoting glucose production in the liver. Insufficient and 
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delayed inhibition of glucagon secretion after meals contributes to postprandial 
hyperglycaemia. Owing to decreases in β cell mass, the α to β cell ratio is increased in many, 
though not all T2DM subjects, but the α cell mass is similar to that of non-diabetic subjects 
[130]. 
In both T1DM and T2DM there is impaired glucagon suppression after glucose ingestion [131, 
132]. This is an important factor contributing to failed suppression of hepatic glucose release 
after meal ingestion [133, 134].  
There are a number of studies demonstrating elevated fasting glucagon levels in those with 
IGT [134-136] suggesting that there is early α and β cell dysfunction in pre-diabetic states. 
This is pertinent in CF where early detection of α and β cell dysfunction is important. 
Within CF, the evidence has been limited and conflicting. Fasting levels of glucagon have 
been found to be normal in patients with CF. In one of the first studies in CF looking at 
glucagon and insulin responses [137] in 17 children with CF and in 9 control children, 
glucagon responses did not parallel those of insulin. Glucagon output varied in CF children 
and there was diminished insulin secretion in the CF group, but diminished secretion was 
only noted when some insulin secretion was preserved. Subsequently, Lanng at al [36] 
demonstrated glucagon suppression decreases along with decreasing glucose tolerance. Lippe 
[138] and Moran [52] demonstrated normal fasting glucagon levels in CF patients, but these 
subjects were not able to appropriately increase glucagon secretion in response to arginine, 
consistent with reduced α cell mass leading to a blunted glucagon response. 
1.3.6 Pancreatic polypeptide (PYY) 
PYY is a 36–amino acid peptide produced by pancreatic F cells located in the Islets of 
Langerhans. It can be measured in plasma by radio-immuno assay (RIA), has a basal level of 
10-30 pM and exhibits a rapid increase after food ingestion peaking at 15-30 min followed by a 
lower sustained phase that lasts 4-5 hours in humans [139-141], with the vagus nerve as the 
main stimulator of secretion [142]. Intravenous infusions of amino-acids, glucose, or lipids do 
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not significantly alter circulating PYY levels, indicating the possible contribution of an 
entero-PYY axis.  
PYY has effects on GI motility, metabolism and food intake. In the gastrointestinal tract, PYY 
inhibits gastric emptying rate, pancreatic exocrine secretion, and gallbladder motility [143], 
and in contrast to its central effects, intraperitoneal administration of PYY decreases food 
intake and increases energy expenditure [144]. Decreased postprandial secretion of PYY has 
been observed in individuals with morbid obesity [145], whereas subjects with anorexia 
nervosa are characterized by an exaggerated postprandial release of PYY [146, 147]. In 
humans, PYY inhibits gastric emptying of solid food and delays postprandial rises in plasma 
glucose and insulin [148]. PYY is suggested to have a physiological role in the pancreatic 
postprandial counter regulation of gastric emptying and insulin secretion. 
Raised plasma PYY levels have been reported in both maturity onset and juvenile diabetes 
[141] where hyperplasia of F cells is seen [149]. 
Within CF, early studies demonstrated absent PYY secretory responses to protein-stimulated 
meals in those with exocrine pancreatic insufficiency, suggesting defects in the PYY secretory 
mechanism [150]. PYY measurements in response to secretin may be a convenient and useful 
means of following the course of pancreatic disease in a chronic illness such as CF and 
abnormal PYY secretion might be considered an indirect index of pancreatic damage in CF 
[151]. Subsequently, Moran et al [52] showed peak PYY responses to hypoglycaemia 
distinguished CF patients with and without exocrine insufficiency. Those with exocrine 
disease had reduced F cell function suggesting exocrine disease causes some endocrine 
dysfunction in CF or that a common pathogenic process simultaneously and independently 
impairs exocrine and endocrine function. 
Within CF, no studies exist looking at early derangements of PYY secretion, its role in 
glucose handling and its repose to stimuli in the CF population. 
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1.3.7 Incretins 
La Barre in 1932 was the first to refer to the term ‘incretin’: an extract from upper gut mucosa 
that produced hypoglycaemia but did not alter exocrine secretion. Since then significant 
progress on the incretin concept has been made. John C Brown in 1971 isolated a peptide 
from intestinal mucosa and exogenous administration of this peptide inhibited gastric 
secretion in dogs and was called Gastric Inhibitory Peptide (GIP) [152]. This was subsequently 
found to have insulinotropic properties and was called glucose-dependent insulinotropic 
peptide [153]. The two main incretins are discussed below in more detail. 
Incretins are hormones released from the gut into the blood stream in response to ingestion 
of food and modulate the insulin secretory response to products within nutrients in food. 
Insulin secretory responses to incretins, called the incretin effect, accounts for two-thirds of 
the insulin response to an oral glucose load and is due to potentiating effects of gut-derived 
hormones [154]. The incretins GLP1 and GIP released post-prandially have been shown to be 
modulators of glucose homeostasis and play a major role in insulin secretion [155]. Moreover, 
responses vary according to glucose tolerance status and may differ depending on the nature 
of the stimulus.  
GIP and GLP1, the two incretin hormones have a number of similarities and differences [156] 
and these are outlined in Figure 1-4 below. 
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Figure 1-4: Actions of incretin hormones 
Reproduced from: Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: 
Similarities and differences. Journal of diabetes investigation. 2010 Apr 22;1(1-2):8-23. 
 
1.3.7.1 The incretin effect 
The incretin effect is the β cell secretory response to factors other than glucose. This is 
represented by differences in response of plasma insulin, C-peptide or insulin secretion rate, 
measured during oral glucose ingestion versus isoglycaemic intravenous glucose infusions 
(See Figure 1-5 below). 
In healthy subjects, the incretin effect accounts for up to 70% of the total amount of insulin 
released in response to an oral glucose load. This amplification of glucose induced insulin 
secretion is the result of actions of incretins which potentiate glucose induced insulin 
secretion and, therefore, play an essential role in the regulation of glucose homeostasis - in 
particular, postprandial glucose levels. It is known that the incretin effect is severely impaired 
or absent in patients with T2DM and this has fuelled interest in the development of therapies 
that target the incretin system. 
as incretins25–29. Furthermore, deficiency of dipeptidyl pepti-
dase-4 (DDP-4), which cleaves the two NH2-terminal amino
acids of GIP and GLP-1 in plasma and inactivates their insuli-
notropic activities30,31, enhances insulin secretion in response to
oral glucose challenge consistently with their function as incre-
tins32. GIP and GLP-1 thus share common properties as incre-
tins, but they also possess different biological characteristics
(Figure 2). Here, we summariz similarities and difference in
the processes of the secretion and metabolism of GIP and
GLP-1, their insulinotropic actions on pancreatic b cells, and
their non-insulinotropic effects.
SECRETION AND METABOLISM OF GIP AND GLP-1
Because GIP and GLP-1 rapidly undergo proteolytic degradation
catalyzed by DPP-430,31, not onl intact but also total (i.e. inta t
plus DPP-4-metabolized) forms of GIP and GLP-1 must be mea-
sured to study their secretion and processing in vivo (Figure 3).
However, immunoassays for GIP and GLP-1 levels, especially
those used to measure their intact forms in plasma, require
specific antibodies and are not widely available33. Furthermore,
because carboxyl-terminal arginine of GLP-1 is susceptible to
amidation, GLP-1 occurs in both non-amidated GLP-1(7–37)
and amidated GLP-1(7–36)amide, both of which show similar in-
sulinotropic effects and metabolism in humans34. Although most
of the GLP-1 secreted from the gut is amidated in humans35,
careful c siderations are required when measuring t e levels of
GLP-1 because some antibodies only recognize amidated GLP-1.
GIP secretion from K cells is enhanced in response to ingestion
of meals or glucos 36. A series of studies using the antib dy R65,
which recognizes both intact GIP(1–42) and DPP-4-processed
GIP(3–42), shows that plasma levels of total GIP at fasting are
5–20 pM in healthy Caucasians36, indicating basal secretion in
healthy Caucasians. These levels f tot l GIP reach 50–100 pM
within 30 min in response to ingestion of 75-gram glucose in
healthy Caucasians, whereas those of total GIP reach
100–150 pM within 60 min in response to ingestion of mixed
Figure 1 | The glucose-dependent insulinotropic polypepide (GIP) gene is localized on human chromosome 17q21.3–q22 and comprises 6 exons.
Proteolytic processing of preproGIP generates GIP that is secreted from K cells. The proglucagon gene is localized on human chromosome 2q36–
q37 and comprises 6 exons. In the intestine, proteolytic processing of proglucagon generates glucagon-like peptide (GLP)-1 and GLP-2, whereas
glucagon is produced in the pancreas.
Figure 2 | Pancreatic and exopancreatic function of glucose-dependent insulinotropic polypepide (GIP) and glucagon-like peptide (GLP)-1. GIP acts
directly on the endocrine pancreas, bone, fat, gastrointestinal (GI) tract and brain. GLP-1 acts directly on the endocrine pancreas, gastrointestinal tract,
heart and brain.
ª 2010 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd Journal of Diabetes Investigation Volume 1 Issue 1/2 February/April 2010 9
Similarities and differences of GIP and GLP-1
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Plasma glucose after an oral glucose load (50 g/400 ml) and during "isoglycaemic" intravenous 
glucose infusion 
Figure 1-5: The incretin effect 
From: Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-
insulin-dependent) diabetes. Diabetologia. 1986 Jan;29(1):46-52.   
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1.3.7.2 Glucose-dependent insulotropic peptide (GIP) 
GIP is a single 42-amino acid peptide structurally like secretin, glucagon and vasoactive 
intestinal peptide. It is synthesized and released in response to nutrients from entero-
endocrine (K) cells mainly in the duodenum and jejunum. GIP is glucose dependent and 
exerts its effects following a glucose load - ensuring prompt insulin mediated glucose uptake 
into tissues. 
In the fasted state, GIP levels are low compared to levels after a meal and this release is 
stimulated by food ingestion containing glucose or fat [153, 157]. GIP exerts its effect by 
binding to specific receptors (GIPR) on β cells and facilitates secretion of insulin via 
activation of proximal signal transduction pathways. GIPR activation leads to membrane 
depolarization and increases in intracellular Ca2+ concentration leading to a direct effect on 
insulin exocytosis. In addition to potentiating the release of insulin from β cells, GIP 
replenishes insulin in β cells by increasing insulin gene transcription and biosynthesis, and 
enhances the glucose-sensing system by increasing expression of components of β cell 
glucose sensors. GIP also affects fat metabolism in adipocytes by enhancing insulin-
stimulated incorporation of fatty acids into triglycerides and modulates fatty acid synthesis 
[158]. 
GIP synergizes with glucose, causing more insulin to be released from β cells both in vivo and 
in vitro, and the amount of insulin released from β cells is proportional to rates of glucose 
metabolism [159], determined by plasma membrane glucose transporters, enzymes 
responsible for glucose metabolism and their activity [160]. There is some evidence indicating 
GIP acts synergistically with glucose as a growth- and anti-apoptotic factor by protecting β 
cells from cell death induced by various stimuli and serum or glucose deprivation [161, 162], 
providing another mechanism by which GIP promotes long-term accommodation of β cell 
function to changing nutritional status. 
Ingestion of oral fat alone without any carbohydrate induces GIP secretion, but is insufficient 
to stimulate insulin at fasting glucose concentrations, indicating the effects of GIP on insulin 
release do not occur if plasma levels of glucose are also not concurrently increasing [163]. 
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The GIP response to a mixed meal was found to be  186% larger than that elicited by an oral 
glucose load [164] thereby suggesting the role of these hormones in the breakdown of a meal. 
GIP secretion in response to oral glucose ingestion or different test meals has been quantified 
in many studies. In humans, fasting plasma total GIP, assayed from peripheral venous blood 
collection, is approximately 9 - 11pM and peak plasma concentrations are 50 - 120pM, 
achieved after eating, dependent upon the health status of the individual, and the quantity 
and quality of food consumed [165]. Once released, GIP is degraded very quickly by the 
enzyme di-peptidyl-peptidase-4 (DPP4), which is bound to lymphocytes and endothelial cells 
in blood vessels of gut and liver. The elimination rates of GIP are similar in subjects with type 
2 diabetes and those without [166]; hence, more rapid degradation and elimination of GIP is 
unlikely to be a factor in defective insulinotropic effects seen in T2DM. 
In T2DM, concentrations of GIP have been found to be normal or increased [165], however 
the insulinotropic effect is diminished. T2DM is characterised by a severely impaired or 
absent GIP insulinotropic effect [167] that most likely results in worsening insulin secretion. 
Recent studies suggest that hyperglycaemia alters physiological responses by down-
regulating GIPR expression / activity [168, 169].  
However, it seems unlikely that T2DM results from deficient GIP secretion. One explanation 
for using DPP4 inhibitors such as Gliptins in T2DM is that they lead to “normalisation” of 
incretin levels that are supposedly reduced compared with non-diabetic subjects [170]. 
However, it is far from certain that incretin secretion is reduced in T2DM. Based on OGTT 
and MMT data, GIP secretion and fasting levels seem to be increased, in both impaired and 
diabetic states [164, 171] whereas the insulinotropic effect is almost totally lost. Although 
different radio-immunoassays have been used over the years, most studies seem to agree that 
secretion of GIP is normal or even higher in patients with T2DM compared with healthy 
control subjects [166, 172-175]. 
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1.3.7.3 Glucagon-like peptide 1 (GLP1) 
In 1985, another peptide - GLP1 was found to be insulinotropic and was the second incretin to 
be identified. GLP1 is produced in entero-endocrine L cells that are scattered among 
enterocytes throughout the small bowel and ascending colon, most in distal parts of the 
intestine, where they are secreted into the bloodstream in response to nutrient ingestion 
[176, 177]. Potential mechanisms of stimulation include upper gut signals such as stimulation 
of the autonomic nervous system [178-180], neurotransmitters such as Acetylcholine (Ach) 
[181] and gastrin-releasing-peptide [180], suggesting intramural enteric nervous system 
involvement in mediating release of GLP1 when appropriate nutrients enter the duodenum or 
upper jejunum. 
In addition, GLP1 inhibits gastric emptying, decreases food intake [182], inhibits glucagon 
secretion [183] and slows the rate of glucose production [184]. Again, GLP1 has been shown to 
protect b cells from apoptosis [185] and continuous GLP1 treatment in T2DM has been shown 
to normalise blood sugar, improve b cell function, and restore first-phase insulin secretion 
and glucose competence to b cells [186, 187]. Hence, GLP1 receptors have become therapeutic 
targets for the treatment of T2DM.  
GLP1 levels reach maximum secretion 17 to 20-minutes after oral glucose administration and 
60 to 90-minutes after a mixed meal, followed by a slow decline toward fasting levels. Typical 
basal (fasting) levels of bioactive GLP1, measured from peripheral veins, are in the range of 5 
to 10 pM and increase by 2- to 3-fold after meal ingestion, depending on  size and 
composition of meal [188].  
GLP1 is one of the most potent substances known to stimulate glucose-dependent insulin 
secretion and, like GIP, its stimulatory activity is exerted via binding to its receptor on β cells. 
This binding result in activation of adenylyl cyclase with consequent production of cAMP, 
subsequent activation of Protein Kinase A (PKA) and cAMP-binding proteins (also known as 
Epac), which lead to inhibition of K+ ATP channels, elevation of intracellular Ca2+ levels, 
increases in mitochondrial ATP synthesis, and enhanced exocytosis of insulin from insulin-
secretory vesicles.  
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Data from the large Baltimore Longitudinal Study of Aging showed GLP1 secretion is not 
deficient in either the fasting state or after oral glucose ingestion in glucose-impaired or 
diabetic subjects not taking any drugs affecting glucose homeostasis. Vollmer et al. [164] 
found a trend toward higher plasma GLP1 levels in 17 well-controlled subjects with T2DM 
after a mixed meal. In their study, the mean HbA1c level was 6.8%, and as HbA1c is a measure 
used in clinical practice to monitor long-term blood glucose control in diabetes management 
(levels <7% indicate good control), it is evident that T2DM develops in the setting of normal 
incretin secretion. Hence, reduced secretion cannot be justified as causing the disease. Older 
studies, using patients with worse metabolic control, on multiple drugs and suffering from 
diabetes for longer times, have found impairments in GLP1 secretion [165, 189] and so chronic 
hyperglycaemia and its metabolic consequences may be the cause of slightly impaired GLP1 
secretion seen in previous studies. The study by Toft-Neilsen et al [189] reported an increase 
in total GLP1 in 33 healthy participants and 54 T2DM subjects after 60-minutes and in the 
second hour, peak GLP1 levels were maintained in healthy participants, but returned to lower 
levels in the T2DM group. Overall, this reflected a 53% reduction in integrated GLP1 
concentrations in T2DM patients, relative to healthy controls. Based on this, it has been 
implied that slightly reduced GLP1 concentrations after a meal in those with impaired oral 
glucose tolerance and more severely impaired GLP1 secretion in T2DM may translate into a 
progressive loss of the ability to secrete GLP1 with advancing T2DM as part of disease 
progression [190]. 
In addition, in T2DM, insulin secretion is typically reduced just after ingestion of glucose or a 
meal (referred to as defective early-phase insulin secretion), but studies showing deficient 
GLP1 secretion found reductions in secretion at 60 to 150 min, which is well after early-phase 
insulin secretion has occurred and at a time where there is actually exaggerated insulin 
secretion; therefore, defective insulin secretion did not coincide in time with defective GLP1 
secretion, so one cannot postulate cause and effect [165]. With relation to GLP1 and insulin, it 
seems possible to conclude that abnormalities of incretin secretion are unlikely to be a 
primary pathogenic factor in the development of T2DM and are instead a consequence of the 
diabetic state [191-193]. It is also clear that the incretin effect of GLP1 in T2DM is better 
preserved, in contrast to that of GIP [194], because an infusion of GLP1 in T2DM so as to 
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reach pharmacologic concentrations in plasma can normalize fasting [195-197] and 
postprandial [196-198] glucose concentrations, resulting from increases of glucose-stimulated 
insulin secretion, decrease of glucagon secretion and slowing of gastric emptying [195, 199, 
200]. Continuous intravenous infusion of GLP1 also lowers postprandial plasma glucose levels 
in subjects with type 1 diabetes by delaying gastric emptying [199]. These effects of GLP1 have 
been consistently shown in a number of human studies [194, 201, 202]. In particular, 
continuous subcutaneous infusions of GLP1 for 6 weeks in T2DM subjects was associated with 
significant reductions in both fasting and post-prandial blood glucose as well as HbA1c with a 
slight decrease of body weight [187]. Prolonging the GLP1 infusion for 3 months in patients 
with T2DM resulted in restoration of first-phase insulin secretion as well as an improvement 
of late-phase secretion during a glucose clamp, but no significant change in body weight and 
plasma glucagon levels were noted [203]. In another study, repeated i.v. infusions of GLP1 
normalized fasting blood glucose in patients with T2DM [204]. Thus, there has been 
considerable interest in an incretin-based therapeutic approach for treating T2DM. However, 
continuous GLP1 infusion or repeated GLP1 injections are impractical and expensive ways to 
lower blood glucose and so the above strategies have been developed. 
1.3.7.4 Incretins in Cystic Fibrosis 
The role of incretins in CF has received limited attention. Lanng et al [36], observed normal 
basal GLP1 and GIP levels across the spectrum of glucose tolerance in CF but GIP hyper-
secretion during an OGTT was found in adults without CFRD [205].  
More recently Kuo et al [206] described impaired GLP1 and GIP secretions in five adults with 
CF without CFRD: however, their study subjects’ glucose tolerance and peak insulin secretion 
were not well characterised.  
In another study in CF patients, Anzeneder et al reported no differences in GLP1 or insulin 
responses to OGTT in adults with CF and NGT, IGT, and in newly diagnosed CFRD compared 
to healthy controls [207]. The authors evaluated responses to an oral glucose load and not a 
mixed meal, so possible impairments in fat and protein stimulated incretin secretion would 
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not have been detected. In addition, they combined pancreatic exocrine sufficient and 
insufficient subjects in the analyses. 
We now know that pancreatic enzyme replacement improves glucose excursion and GLP1 
secretion in response to a mixed meal [206] and this was studied in greater detail recently 
[208] where, although pancreatic enzyme supplementation restored GLP1 and GIP secretion, 
the latter was still not normalized in the adult group. This perhaps suggests suboptimal 
mixing of enzymes and nutrients in the most proximal small intestine, from which most of 
GIP is derived. 
In summary, the evidence relating to GLP1 and GIP secretion is limited and conflicting in CF, 
probably reflecting methodological inconsistencies in the studies described above. Moreover, 
the variation in incretin secretion through the day and its effect on blood glucose has not 
been studied in CF. 
Thus, in CF more work needs to be done to assess those with normal glucose tolerance.  
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1.4 Diurnal Variation in glucose handling 
In humans, the phenomenon of diurnal variation in glucose tolerance is well known with 
glucose intolerance increasing throughout the day, and also as the pancreas ages [209-215]. It 
has been suggested that impaired glucose tolerance in the afternoon or "afternoon diabetes" 
is an early sign or a forerunner of frank diabetes mellitus [216] and in the general population, 
a reduced glucose tolerance in the evening appears to reflect both decreases in insulin 
sensitivity and insulin secretion [217]. 
Early morning rises in fasting glucose levels and insulin requirements known as the ‘dawn 
phenomenon’ have been seen in patients with diabetes [218] and in some patients with non-
diabetes [219, 220]. Nocturnal elevations in growth hormone and early morning increases in 
cortisol secretion have been explored as contributors to this phenomenon [221-223]. 
However, a number of studies have shown that blood glucose levels in response to a mixed 
meal are markedly higher in the late afternoon or evening compared to morning and both 
the size of responses and diurnal variation are more pronounced when the meal has a high 
carbohydrate content [224, 225]. This could be partially mediated by circadian variations in 
circulating concentrations of cortisol, a counter-regulatory hormone [226]. Furthermore, it 
has been postulated that if testing was carried out in the afternoon using current oral glucose 
tolerance test (OGTT) criteria for the diagnosis, half of all cases of undiagnosed diabetes 
would be captured [227] and this may be important in CF. 
It is possible to attribute the loss of glucose tolerance to a diminished pancreatic response to 
a glycaemic stimulus. Freinkel et al [228] observed a diurnal variation in plasma insulin levels 
during periods of total fasting, with mean levels in the morning exceeding those in the 
afternoon. Lambert and Hoet [229] also noted a diurnal pattern in insulin levels. They found 
high levels during the night, even though daytime meals were presumably stimulating insulin 
release from the pancreas. It is possible that insulin liberated post-prandially in the morning 
conserves a certain activity at the moment of the next meal, and still intervenes in 
maintaining glucose homeostasis. Later in the day, however, glucose homeostasis would 
necessitate a new synthesis of insulin. 
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1.4.1 Diurnal variation in CF 
Within the CF population, screening later in the day might be able to identify CFRD earlier. 
Moreover, the caloric intake in those with CF is observed to be greater later in the day 
compared to the general population [230].  
Using classical testing methods, 40% of adults will have severe enough glucose intolerance in 
the morning to be labelled with CFRD. However, it is not known what happens to glucose 
tolerance and pancreatic β cell function in CF patients through the day. 
The current diagnostic criteria for diabetes are based on plasma glucose levels recorded in 
the morning after an overnight fast of at least 8 hours. However, in the CF population, many 
patients are seen late in the morning, are in an uncertain duration of fasting, are encouraged 
to eat regularly, tend to be anorexic in the morning and usually have their largest meal later 
in the day - thereby making the early morning assessment of blood glucose un-physiological. 
It is unclear whether the current diagnostic criteria for diabetes in CF (a single point test in 
the morning) can be applied uniformly to all patients and especially those who are tested for 
diabetes at other times of the day. 
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1.5 Gastric Motility and Glucose Handling 
Gastric emptying is central to post-prandial glycaemic control [231, 232]. In healthy 
individuals, gastric emptying accounts for around a third of the variation in the peak glucose 
response after an oral glucose load [233]. A number of factors might influence the rate of 
gastric emptying, including meal composition and volume, posture, illness, glycaemia and 
medications.  
Factors that promote gastric emptying 
• Gastric volume: Increased food volume in the stomach promotes increased emptying 
and antral distension stimulates vasovagal excitatory reflexes leading to increased 
antral pump activity. 
• Liquid vs solid food: Clear fluids are emptied rapidly, usually half within 30-minutes. 
Solids stay in the stomach longer. 
• Types of food:  Protein empties fastest, followed by carbohydrates. Fats take longest 
to empty. 
• Hormonal factors: Gastrin has mild to moderate stimulatory effects on motor 
functions in the body of the stomach. This enhances activity of the pyloric pump. In 
addition, motilin released by epithelium of the small intestine enhances the strength 
of the migrating motor complex which is a peristaltic wave that begins within the 
oesophagus and travels thru the whole gut every 60-90 min during the inter-digestive 
period. 
• Neural: Parasympathetic innervation via the vagus nerve stimulates motility as does 
the local myenteric reflex. 
• Drugs:   Prokinetics such as domperidone, cisapride, erythromycin and 
metoclopramide promote gastric motility. 	
Factors that inhibit gastric emptying 
• Duodenal distension results in inhibitory enterogastic reflexes that slow or even stop 
stomach emptying if the volume of chyme in the duodenum becomes too much. 
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• Osmolarity of chime:  Iso-osmotic gastric contents empty faster than hyper or hypo-
osmotic contents due to feedback inhibition produced by duodenal chemoreceptors. 
• Types of food: Fat and protein breakdown products in the small intestine inhibit 
gastric emptying. 
• Acid: pH of chyme in the small intestine of < 3.5-4 activates reflexes to inhibit 
stomach emptying until duodenal chyme can be neutralized by pancreatic and other 
secretions. 
• Temperature: Cold liquids (40C) empty more slowly. 
• Hormones: Cholecystokinin released from the duodenum in response to breakdown 
products of fat and protein digestion, blocks the stimulatory effects of gastrin on 
antral smooth muscle. Secretin released from the duodenum in response to acid has a 
direct inhibitory effect on gastric smooth muscle. Other hormones that decrease 
emptying are somatostatin, vasoactive intestinal peptide (VIP) and gastric inhibitory 
peptide (GIP). 
• Neural: Sympathetic nerves via the celiac plexus inhibits motility. 
• Physiological factors:  Pregnancy, anxiety and pain. 
• Disease states such as diabetes mellitus (autonomic neuropathy), post-operative 
bowel surgery with resultant ileus and high intra-abdominal pressure. 
• Drugs such as opioids 
Disordered gastrointestinal motor and sensory function occur frequently in diabetes mellitus 
and has substantial implications for the morbidity and effective management of patients with 
diabetes. 
Gastric emptying is abnormally delayed in 30–50% of patients with T1DM or T2DM leading to 
potential consequences of gastrointestinal symptoms, impaired nutrition, poor glycaemic 
control, and delayed absorption [234]. This abnormal motility in humans has traditionally 
been attributed to irreversible autonomic neuropathy, but the association between delayed 
gastric emptying and the presence of cardiovascular autonomic neuropathy is relatively poor 
[235]. However, acute changes in blood glucose concentration — both hyper- and 
hypoglycaemia — have a marked, reversible, effect on gut motility [234]. 
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1.5.1 Gastric Motility in CF 
Gastric motility within CF has received little attention. 
Variables of relevance to CF are pancreatic enzyme supplementation, glycaemia and the high 
fat/high energy diet prescribed for these individuals.  Gastric emptying is itself influenced by 
acute changes in blood glucose concentrations, with hyperglycaemia delaying gastric 
emptying, which in turn slows the absorption of ingested carbohydrate and reduces the 
propensity for further hyperglycaemia [236]. 
Only a limited number of studies have evaluated gastric emptying in CF, with inconsistent 
results, attributable to differences in subject characteristics, meal composition, use of 
pancreatic enzymes and the methodology used to measure gastric emptying.  The results 
have been conflicting with Collins [237] and Kuo [206] reporting rapid emptying, Pauwels 
[238] reporting delayed emptying, or gastric emptying being no different from healthy 
control subjects [239-241]. A delayed or rapid gastric emptying rate (GER) in patients with CF 
can have important clinical consequences.  
In addition, circadian changes in glucose handling are well described in the normal 
population [209, 212, 213, 217] and gastric emptying, which is in turn slowed by 
hyperglycaemia [242] may influence these changes. However there have been no studies of 
circadian changes in gastric emptying in CF subjects, a group with poor glucose handling. 
Hence, there is a need to explore gastric motility in CF and the effects this might have on 
glucose handling and CFRD.  
1.5.2 Assessment of Gastric motility 
Several different methods have been used to evaluate gastric emptying in adults. 
Oesophageal manometry, intubation and epigastric impedance are invasive tests and need 
specialised equipment. They also need sedation or anaesthesia and hence are poor tests to 
study dynamic changes. Barium contrast studies are not practical due to the large amounts of 
radiation and the effect of gravity. More recently paracetamol absorption studies, looking at 
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plasma paracetamol levels after ingestion of a fixed amount of the drug have been used. 
Although good in assessing gastric motility in type 1 and 2 diabetics, it is not a good test in CF 
due to co-existing liver disease. The gold standard test is scintigraphy, a nuclear medicine 
scan wherein, the subjects consume radio-tracer labelled food and images are taken every 
few-minutes for upto 4 hours. Subjects need to remain in a fixed position for the duration of 
the study. Hence, none of these tests are practicable for daily use and there is need for a safe 
non-invasive method that is easy to use and has practical applications. 
Assessment of gastric emptying using this ultrasound method is safe, easy to use and requires 
a standard ultrasound transducer and gives real time results. This method has been 
standardized by determining gastric antral cross-sectional area in a single section of the 
stomach [243]. The gastric antrum is considered to be the most reliable and reproducible 
portion of the stomach demonstrating a ‘distinct’ sonographic appearance when empty and 
after a meal, when visualised with a curvilinear probe.  
The advantage of trans-abdominal ultrasonography is the ability to measure several 
parameters of gastric motor function. Serial changes in antral cross-sectional area provide an 
index of gastric emptying. Gastric emptying is considered complete when the antral area 
returns to the fasting baseline level. 
This method of assessment has been validated against barium studies [244] and the gold 
standard test – scintigraphy [245, 246]. In a non-CF population, this method has been used to 
demonstrate delayed gastric emptying following the ingestion of fat before a carbohydrate 
meal and the increased postprandial rise in glucose, insulin and GIP, in T2DM. Within CF, 
gastric ultrasound to evaluate emptying has been used in the paediatric population [247] to 
demonstrate gastric dysmotility and compare the benefits of H2 blockers to those of pro-
kinetic agents.  
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1.6 Indications for current research 
This literature review has demonstrated that CFRD is unlike other types of diabetes for 
several pertinent reasons: 
1. Gastric emptying and motility are likely to be altered in the condition, changing the 
way in which nutrients presented to the gut compared to normal individuals.  
 
2. The relative progressive insulinopaenia that occurs in CF over time may result in 
diurnal changes in glucose and other nutrient handling that has not previously been 
explained. 
 
3. Abnormalities	 in	 the	 small	 intestine	 due	 to	 the	 condition	may	 alter	 the	 secretion	 of	incretins	and	the	associated	pancreatic	enzymes	compared	to	non-CF	individuals. 
 
1.7 Aims and objectives 
The aims and objectives of this study are: 
1. Measure gastric emptying using a novel easy technique in CF and compare responses 
to healthy control subjects, throughout the day. 
 
2. Determine whether ‘pancreatic fatigue’ contributes to a delayed insulin release and 
peak that is seen in patients with cystic fibrosis. 
 
3. Explore glucose handling in CF and characterise the secretory pattern of insulin, c-
peptide, glucagon, GIP and GLP1 and PYY throughout the day. 
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1.8 Hypothesis 
The hypotheses this study aims to test are as follows: 
1. Insulin	 sensitivity	 and	gastric	motility	are	altered	 in	CF	 and	 this	 is	 influenced	by	 the	type	of	meal.			2. Relative	gradual	insulinopenia	in	CF,	results	in	pancreatic	fatigue	throughout	the	day.			3. The	 entero-insular	 axis	 is	 intact	 and	 altered	 glucose	 handling	 is	 due	 to	 a	 beta	 cell	defect.	
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2 Subjects, Materials and Methods 
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2.1 Ethical approval 
R&D approval was obtained from the sponsor of the study (Liverpool Heart and Chest 
Hospital, UK.). 
Ethical approval was obtained from the National Research Ethics Service (NRES Committee 
North West - Greater Manchester East) on 18 June 2012 [(REC reference 11/NW/0552); 
[Appendix 3]. 
2.2 Subjects 
Ten (5 males, 5 females) healthy volunteers and 20 CF (17 males, 3 females) patients from the 
large (n=281) [See Figure 2-1 on page 51] regional adult unit in Liverpool, UK (281 patients) 
were recruited. CF subjects were recruited in the outpatient department during their usual 
CF clinic review. Control subjects were recruited through a poster advertisement in the 
hospital. No subjects needed to be withdrawn from the study or requested withdrawal before 
completion of the study protocol.  
2.2.1 Inclusion criteria 
CF subjects 
• Male or female with a confirmed diagnosis of CF defined by 
o Clinical features consistent with a diagnosis of CF AND 
o Sweat chloride ≥60mmol/L by pilocarpine ionotophoresis; OR 
o Genotypic confirmation of CFTR mutation 
• Aged 18 – 50 years  
• Outpatients from the regional adult unit in Liverpool  
• Clinically stable over the preceding 4 weeks i.e. no indication for iv antibiotics, steroids 
or hospital admissions 
• Haemoglobin value >10g/dl at their last CF annual screen 
• Subjects known to be pancreatic insufficient as documented in their clinical record 
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Control subjects 
• Male or female without a known diagnosis of CF  
• Aged 18 – 50 years  
• Clinically stable over the preceding 4 weeks  
• Haemoglobin value ≥10g/dl (done on the morning of visit 1) 
 
2.2.2 Exclusion criteria 
• Subjects with known diabetes or on glucose lowering medications (insulin, oral 
hypoglycaemic agents) 
• On-going acute illness 
• Long-term oral steroids or on steroids at the time of the test 
• Pregnant or intention to become pregnant 
• Those on immunosuppressive treatment  
• History of, or planned organ transplant  
• Known clinically significant abnormal findings on haematology or clinical chemistry 
• Subjects known to have significant CF related liver disease as documented in their 
clinical record 
• Subjects with documented or suspected, clinically significant, alcohol or drug abuse. The 
determination of clinical significance was determined by the investigator 
• History of malignant disease 
• Any serious or active medical or psychiatric illness, which in the opinion of the 
investigator, would interfere with subject treatment, assessment, or compliance with the 
protocol 
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2.2.3 Subject selection 
 
Figure 2-1: Subject selection 
 
 52 
 
2.2.4 Demographic data 
I recruited 10 control subjects (5 males and 5 females) and 20 CF subjects [See Table 2-1 below 
and Appendix 1]. Of the CF subjects, four were diabetic and one had IGT based on the OGTT, 
one subject with NGT was subsequently found to be pancreatic sufficient and one subject 
was found to have significant liver disease (See CONSORT Flow diagram - Figure 2-1 on page 
51). These subjects were excluded from the analysis.  
The analysis includes 10 control subjects (age range 23 – 41 years) and 13 CF subjects (age 
range 18 – 38 years). Their characteristics are shown in Table 2-2 below.  
The 13 CF subjects had a FEV1 of 80 ± 16 (% predicted) and a FVC of 95 ± 15 (% predicted).   
Table 2-1: Subject distribution 
 
n M F 
Controls 10 5 5 
CF-NGT 14 12 2 
CF-IGT 1 1 0 
CFRD 5 4 1 
Table 2-2: Subject characteristics 
 
Age 
(yrs) 
Weight 
(kg) 
Height 
(m) 
BMI 
(kg/m2) 
HbA1c 
(IFCC) 
Controls 29.7 ± 4.8 70.9 ± 10.8 1.7 ± 0.1 24.3 ± 3.4 34.2 ± 3.1 
CF 25.9 ± 5.5 71.8 ± 7.3 1.7 ± 0.1 23.9 ± 2.1 37.6 ± 3.8 
Control subjects (n=10); CF subjects (n=13). [Mean ± SD]  
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2.3 Consent 
All subjects provided written consent in triplicate in accordance with Good Clinical Practice 
(GCP). [See appendix for approved REC documents]. 
2.4 Power calculation 
This work was preliminary and exploratory and hence no statistical power analysis was 
carried out. Based on previous studies in other populations it was recognized that large 
cohort sizes would be necessary to detect weak associations.   
I initially set out to undertake a study of 12 CF patients as a realistic and pragmatic target for 
recruitment from the existing population at the CF centre. Moreover, this patient number 
would make the study feasible considering funding, time and effort. 
Following the University Advisory Panel meeting in May 2012, it was suggested that the CF 
subjects be increased to 20 to make the study more powerful and this amendment to the 
protocol was approved by the NHS REC committee. 
2.5 Statistical analysis 
Data were collated on a spreadsheet (MS Excel 2010) and analysed using StatsDirect® version 
3.1.14®. Data were analysed for distribution using the Shapiro-Wilk test. For normally 
distributed data, comparisons between groups were carried out with an independent t-test 
and differences within groups with a paired t-test. For non-normally distributed data, 
comparisons between groups were carried out with a Mann-Whitney test and differences 
within groups with Wilcoxon's Signed Ranks Test. Differences over time were examined 
using repeated analysis of variance (ANOVA). Significant F-tests were followed by Bonferroni 
adjusted pairwise comparisons. Statistical significance was accepted at the 5% level and 
results presented as means ± standard deviation (SD) in all data tables. All figures in the 
results chapters with charts represent the mean ± confidence interval (CI) and one half of 
each error bar has been omitted for clarity (unless otherwise stated).  
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2.6 Study protocol 
See Figure 2-2 on page 56.  
Subjects consenting and fulfilling the inclusion criteria were recruited and entered into a 
database with full details of demographics, anthropometry (height and weight) and baseline 
spirometry (FEV1, FVC).  
On 2 occasions, following an overnight fast of at least 12 hours, subjects underwent a 
standard OGTT at 0800 hrs and then within a week, a MMT at 0800, 1300 and 1800 hours.  
Part 1 (OGTT – Liquid meal) – Visit 1 
Subjects were asked to take any routine medication at least 1 hour prior to the start of the test 
(0800 hrs).  
Subjects then consumed 113 mL Polycal® (Nutricia Clinical, UK) made up with extra water to 
a total volume of 200mL. This was the routine OGTT (liquid meal) providing subjects 75g of 
CHO. 
Part 2: (MMTT - Mixed meal) – Visit 2 
This was carried out within a week of the initial test and after a 12 hour overnight fast. As in 
visit 1, the subject took any routine medication at least 1 hour prior to the start of (each) test.  
The mixed meal (see Table 2-4 on page 58) was consumed by the fasted subject within 10-
minutes. All the tests as in part 1 were carried out. 
Following completion of the first MMT at 1000 hrs, a second MMT was carried out after three 
hours (1300 hrs), followed by a third MMT after another 3 hours (1800 hrs). Subjects 
remained fasted between meals.  
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On each occasion, blood was drawn and ultrasound measurements performed as in Part 1. 
These timings were chosen to physiologically match the time most individuals have their 
meals. The study was considered complete at the collection of the last blood sample and 
recording of the gastric antral diameters at 120-minutes after the completion of the third 
meal. 
Prior to both visit 1 and 2 the following were obtained prior to the commencement of the 
study 
• Written consent (visit 1) 
• Inclusion and exclusion criteria reviewed  
• Medical history reviewed 
• Medications and concomitant medications reviewed 
• BMI 
• Routine physical examination 
• Vital signs: blood pressure, heart rate, respiratory rate, oxygen saturation (SpO2) 
• Blood samples for FBC (visit 1) 
• Asked overnight fasting period (minimum 12 hours required) 
For each part of the experiment, blood samples were collected at 0 (baseline), 30, 60, 90 and 
120-minutes. Gastric motility, using ultrasound, was measured as outlined above at 15, 30, 60, 
90 and 120-minutes. This part of the study was considered complete at the collection of the 
last blood sample and recording gastric antral diameters at 120-minutes (See Experiment 1). 
At visit 1, the above was carried out once and at visit 2, was carried out thrice.  
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Figure 2-2: Study protocol  
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Table 2-3: Schedule of tests 
 
  
  
Time Points (mins) 0 15 30 60 90 120 
Visit 1 
0800 – 1000 
hrs 
Blood collection x 
 
x x x x 
Ultrasound study x x x x x x 
 
Visit 2 
0800 – 1000 
hrs 
Blood collection x 
 
x x x x 
Ultrasound study x x x x x x 
1300 – 1500 
hrs 
Blood collection x 
 
x x x x 
Ultrasound study x x x x x x 
1800 – 2000 
hrs 
Blood collection x 
 
x x x x 
Ultrasound study x x x x x x 
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2.7 Mixed meal composition 
A standardized mixed meal (see Table 2-4) consisting of carbohydrate, lipids and protein was 
formulated. Each meal resembled a standard continental breakfast and provided the subject 
741.07 kcal. The components of the mixed meal were determined using the nutrient analysis 
software system Microdiet® (Downlee Systems Ltd, UK).  
The meal provided nutrients that are shown in Table 2-5.  
Table 2-4: Composition of meal administered 
Food name Quantity 
White bread, sliced 2 (72 g) 
Unsmoked standard ham (Tesco®) 75 g 
Margarine (soft, polyunsaturated) 2 (14 g) 
Orange juice (sweetened) 1 (150 g) 
Cheddar cheese slice (Tesco®) 1 (45 g) 
Digestive biscuits, plain 30 g 
Total 386 g 
Table 2-5: Nutrients in meal 
Nutrient Amount (g) Nutrient Amount (g) 
Water 231.03 Total Monounsaturates 12.27 
Total Nitrogen 5.54 Total polyunsaturates 6.8 
Protein 34.13 Non-starch polysaccharides 2.03 
Carbohydrate 73.75 Total sugars 26.51 
Sodium 1.79 Total saturates 15.12 
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2.8 Blood sample collection 
A cannula (20 or 22 G) was inserted in the ante-cubital fossa or the forearm. Blood was 
collected using BD vacutainer® tubes (See Table 2-6 below) from the cannula after discarding 
the first 3 ml. Following collection of each sample, the cannula was flushed with 5 mls of 
0.9% Sodium Chloride. 
Blood samples were separated immediately by centrifugation at 3000 rpm for 10-minutes at 4 
oC. Aliquots of serum and plasma were stored at -80°C until analysis in batches at the end of 
the study.  
In summary, the various tests carried out through the study are outlined in Table 2-3 on page 
57  and the summary of the protocol outlined in Figure 2-2 on page 56. 
Table 2-6: Blood tubes used for sample collection 
Test Tube 
Plasma glucose Potassium oxalate/ sodium fluoride tube 
Serum biochemistry Clot activator and gel for serum separation 
Full blood count Liquid K3EDTA 
Gut and pancreatic cell hormones Spray-coated K2EDTA 
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2.9 Laboratory methods 
Analyses of all samples were carried out at the listed below (Table 2-7) and the methods 
employed detailed in the relevant chapters.  
Table 2-7: Sample analysis location 
Test Laboratory 
• Glucose Clinical Biochemistry, Royal Liverpool University 
Hospital, Liverpool L7 8XP, UK. 
• Insulin 
• C-peptide 
Clinical laboratory, Liverpool Heart and Chest 
Hospital, Thomas Drive, Liverpool L14 3PE, UK. 
• Glucagon 
• GIP 
• GLP1 
• Pancreatic polypeptide (PYY) 
Clinical biochemistry laboratory, Department of 
Genomics of Common Disease, Hammersmith 
Hospital, Imperial College London, Burlington-Danes 
Building, Du Cane Road, London, W12 0NN, UK. [Dr 
Paul Bech] 
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3 Experiment 1: The evaluation of gastric emptying 
in Cystic Fibrosis using bedside ultrasonography 
 
3.1  Assessment of gastric motility 
Ultrasound measurements were performed in real time using a 3.5-MHz abdominal 
transducer probe [243] connected to a M-TURBO Ultrasound machine® (Sonosite, 
Washington , United States). 
I was trained and competency assessed by an expert ultra-sonographer (Dr Hilary 
Fewins MBBS, FRCR, Consultant Radiologist, Liverpool Heart and Chest Hospital), prior to 
the start of this study. 
Measuring GER using this method involved marking of the gastric antrum (See Figure 3-1 on 
page 62) by identifying the liver and the aorta: once these landmarks are identified, the 
gastric antrum comes into view and when located, 2 perpendicular diameters (D1 and D2) 
were measured and the mean of 3 consecutive recordings taken at each time point. 
The antral cross-sectional area determined using the formula 
A (Antrum) = π x (D1 mean x D2 mean) / 4 
was obtained 15-minutes after ingestion of the meal (liquid / mixed), as the stomach is largest 
at 15-minutes, allowing for gastric accommodation.  
From this, the emptying rate was obtained by determining the % change from 15-minutes to 
any time point 
GER = [1-(A area x mins / A area 15 min)] x 100 
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A GER of > 45% at 60-minutes (GER60) for a liquid meal and  > 63% at 90-minutes (GER90) for 
the mixed meal [243] is considered normal.  
 
 
Figure 3-1:  Identification of gastric antrum 
The figure illustrates the calculation of gastric volume by identifying the landmarks of the (L) 
Liver and (Ao) Aorta and measuring the perpendicular diameters (A, B) of the gastric antrum. 
This image is that of control subject 4 after the liquid meal (OGTT) at 15 minutes. 
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3.2 Results 
Ten control and 13 CF subjects underwent ultrasonographic assessment of GER. It was not 
possible to reliably identify the gastric antrum in 1 CF subject, so data are reported for the 
remaining 12.  
 
3.2.1 Oral Glucose Tolerance Test (liquid meal) 
See Table 3-1 on page 64 and Figure 3-2 on page 65  
A. Controls	
These had a mean gastric emptying at 60-minutes (GER60) of 51 %, which is within the 
normal range. None had delayed gastric emptying. Individual data are given in the appendix 
(Appendix 2 on page IV). 
B. Cystic	Fibrosis	
These had a mean GER60 of 46%, which is also within the normal range. However, 5 (42%) 
subjects had delayed gastric emptying. Individual data are given in the appendix (Appendix 2 
on page IV). 
C. Controls	v	Cystic	Fibrosis	
CF subjects had a lower baseline GER (GER30), but this did not achieve statistical significance 
compared to controls (p=0.07). However, GER worsened over time, becoming significant at 
GER90 (p=0.001) and GER120 (p=0.003). Individual data are given in the appendix (Appendix 2 
on page IV). 
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Table 3-1: GER following the OGTT 
 
GER (%) 
 
30 mins 60 mins 90 mins 120 mins 
Controls 37 ± 4 51 ± 8 69 ± 4 74 ± 3 
CF 31 ± 10 46 ± 10 56 ± 10 64 ± 10 
p 0.07 0.22 0.001 0.003 
Comparison of gastric emptying rate (GER%) of a liquid meal (OGTT) over 120 minutes 
between control (n=10) and CF (n=12) subjects (mean ± SD). Statistical comparisons between 
groups were carried out using the Mann-Whitney U test.  
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(Top panel): Comparison of gastric emptying rate (GER%) of a liquid meal (OGTT) over 120 
minutes between control (n=10) and CF (n=12) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual GER% over 120 minutes, following the liquid meal. [ Controls  x  
CF] 
Figure 3-2: GER: Response to the OGTT  
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3.2.2 Mixed Meal Test 1 (solid meal)  
See Table 3-2 on page 66 and Figure 3-3 on page 67  
A. Controls	
These had a mean gastric emptying at 90-minutes (GER90) of 72%, which is within the 
normal range. None had delayed gastric emptying. Individual data are given in the appendix 
(Appendix 2 on page IV). 
B. Cystic	Fibrosis	
These had a mean GER90 of 56%, which is below the normal range; only 2 had normal 
emptying. Individual data are given in the appendix (Appendix 2 on page IV). 
C. Controls	v	Cystic	Fibrosis	
There was no difference at GER30 (CF 33% vs controls 39%, p=0.12), but GER in CF worsened 
over time, becoming significant at GER60 (CF 44% vs controls 53%, p=0.01) until GER120 (64% 
vs 79%, respectively, p=0.0003). Individual data are given in the appendix (Appendix 2 on 
page IV). 
Table 3-2: GER following the MMT 
 
GER (%) 
 
30 mins 60 mins 90 mins 120 mins 
Controls 39 ± 6 53 ± 7 72 ± 3 79 ± 2 
CF 33 ± 10 44 ± 9 56 ± 9 64 ± 10 
p 0.12 0.01 0.002 0.0003 
Comparison of gastric emptying rate (GER%) of a mixed meal (MMT) over 120 minutes between 
control (n=10) and CF (n=12) subjects (mean ± SD). Statistical comparisons between groups 
were carried out using the Mann-Whitney U test.  
 
p=0.0
7 
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(Top panel): Comparison of gastric emptying rate (GER%) of a mixed meal (mean ± CI) over 120 
minutes between control (n=10) and CF (n=12) subjects. (Bottom panel): Comparison of the 
individual GER% over 120 minutes, following the mixed meal (MMT). [ Controls  x  CF]. 
Figure 3-3: GER - Response to the MMT 
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3.2.3 Comparison between the OGTT and MMT 
See Table 3-3 on page 68 and Figure 3-4 on page 69 
I then compared the differences in gastric motility in both groups in response to the OGTT 
and the MMT1. 
A. Controls	
Control subjects had normal emptying for both the liquid (GER60) and the mixed meal 
(GER90) until 90-minutes. The GER30, GER60 and GER90 were no different between the liquid 
and mixed meals. However, the GER120 was higher after the MMT compared to the OGTT 
(p<0.0001).  
B. Cystic	Fibrosis	
There were no differences between individual time points in the group between the 2 studies. 
However, CF subjects had decreased gastric emptying following the MMT compared to the 
OGTT (Fisher’s exact test, p = 0.049). 
Table 3-3: GER - Comparison between the OGTT and MMT 
  
GER (%) 
  
30 mins 60 mins 90 mins 120 mins 
Controls 
OGTT 37 ± 4 51 ± 8 69 ± 4 74 ± 3 
MMT 39 ± 6 53 ± 7 72 ± 3 79 ± 2 
p 0.38 0.47 0.08 <0.0001 
      
CF 
OGTT 31 ± 10 46 ± 10 56 ± 10 64 ±1 0 
MMT 33 ± 10 44 ± 9 56 ± 9 64 ± 10 
p 0.36 0.47 0.68 0.93 
Comparison of gastric emptying rate (GER%) of a liquid (OGTT) and mixed (MMT) meal over 
120 minutes in control (n=10) and CF (n=12) subjects (mean ± SD). Statistical comparisons 
between tests were carried out using the Wilcoxon signed-rank test. 
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Comparison of the individual gastric emptying rate (GER%) over 120 minutes, following the 
liquid meal (OGTT) and mixed meal (MMT) in control (n=10, upper panel) and CF subjects 
(n=12, bottom panel [ OGTT x  MMT]. 
 Figure 3-4: GER - Comparison between OGTT and MMT 
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3.2.4 Diurnal Studies (MMT 2 and MMT 3) 
 See Table 3-4 and Figure 3-5 on page 72  
A. Controls	
In the afternoon (MMT2), control subjects had gastric emptying [GER90] of 70%, which is 
within the normal range.  
In the evening (MMT3), control subjects had the same emptying (GER90) of 70%. Again, none 
had delayed gastric emptying. Individual data are given in the appendix (Appendix 2 on page 
IV). 
B. Cystic	Fibrosis	
In CF subjects, the GER90 in the afternoon (MMT2) was 58%, again indicating reduced 
emptying. Only 1 subject had normal emptying at this time. In the evening (MMT3) GER90 
was 59%, indicating reduced emptying in the evening too. Two subjects had normal 
emptying at this time.  
C. Controls	v	Cystic	fibrosis	
When the 2 groups were compared in the afternoon (MMT2), CF subjects showed no 
difference in the GER30 (CF 31% vs controls 36%, p=0.20), but lower GER60 (CF 43% vs 
controls 54%, p=0.003) and lower GER120 (CF 67% vs controls 77%, p=0.0003) compared to 
control subjects. 
When the 2 groups were compared in the evening (MMT3) CF subjects now had lower GER30 
(CF 26% vs controls 35 %, p=0.003), lower GER60 (CF 43% vs controls 50%, p=0.02) and lower 
GER120 (CF 71% vs controls 76%, p=0.001) compared to control subjects. 
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Diurnal changes 
I then compared the incremental changes in GER through the day and evaluated the changes 
in GER at 30 (GER30), 60 (GER60), 90 (GER90) and 120 (GER120) minutes in both groups (See 
Figure 3-5 on page 72 and Table 3-4 on page 72).  
A. Controls	
When assessed for changes during the day, there was no difference in GER90 throughout the 
day (p=0.07) in control subjects. There was also no difference throughout the day for the 
GER30 (p=0.37) and GER60 (p=0.28). GER120 appeared to worsen throughout the day (p=0.04), 
but the post-hoc statistical tests were not significant for specific times of the day.  
B. Cystic	Fibrosis	
In CF subjects, although there was no difference in GER90 throughout the day (p=0.33), GER30 
worsened (p=0.02) with GER30 lower in the evening (MMT3) (26%) compared to the morning 
(MMT1) (33 %) [p=0.01]. There was no difference in GER60 (p=0.97), but conversely GER120 
appeared to improve throughout the day (p=0.03). The evening GER120 (MMT3) (71%) 
although higher than the corresponding time in the morning (MMT1) (64%), was statistically 
not significant (p=0.036) on the post-hoc test.  
 
3.2.5 Repeatability of tests (GER %) 
Since control subjects had gastric motility assessed on several occasions, I used this group to 
evaluate repeatability of the measures. An ANOVA comparing GER30 in the morning, 
afternoon and evening studies (MMT1, MMT2, MMT3: Appendix 2) showed good similarity [F 
(variance ratio) = 0.84, p=0.44] indicating that the method was repeatable. 
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Table 3-4: GER through the day 
 
Morning Afternoon Evening 
 
Control CF p Control CF p Control CF p 
30 mins 39 ± 6 33 ± 10 0.12 36 ± 9 31 ± 6 0.2 35 ± 6 26 ± 7* 0.003 
60 mins 53 ± 7 44 ± 9 0.01 54 ± 9 43 ± 7 0.003 50 ± 4 43 ± 8 0.02 
90 mins 72 ± 3 56 ± 9 <0.0001 70 ± 2 58 ± 5 <0.0001 70 ± 2 59 ± 4 <0.0001 
120 mins 79 ± 2 64 ± 10 0.0003 77 ± 3 67 ± 7 0.0003 76 ± 4# 71 ± 3£ 0.001 
Comparison between gastric emptying rates (GER%) over 120 minutes, following the mixed 
meal in the morning, afternoon and evening (Mean ± SD). Statistical comparisons between 
control (n=10) and CF (n=12) subjects at each time point were carried out using the Mann-
Whitney U test and a repeated measures ANOVA was performed to study differences within the 
group through the day. [Comparison to morning: *p=0.02; £ p=0.03; #p=0.02] 
 
Figure 3-5: GER through the day 
Comparison of GER of a mixed meal (mean ± SEM) over 120 minutes between control (n=10) 
and CF (n=12) subjects in the morning, afternoon and evening. 
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3.3 Discussion 
This gastric emptying ultrasound technique is inexpensive, the equipment is widely available 
and moreover it can be carried out at the bedside. The use of a 3.5-MHz abdominal 
transducer probe to measure the antral cross-sectional area and volume allows gastric 
emptying to be assessed in real time and this can be applied to both liquid and mixed meals.  
The technique has been shown to be accurate with good intra- and inter-observer agreement 
[243]: I was trained and had a competency assessment carried out by a validated experienced 
ultrasound radiologist. In this experiment, I was able to reliably measure GER in 22 of 23 
subjects (96%).  
Although my experiment did not seek to evaluate reproducibility and repeatability, four 
complete studies for each subject were carried out on two different days, three of which were 
performed on the second day. ANOVA of these duplicated tests gave a variance ratio (F) of 
0.84 (p=0.44), indicating an acceptable level of repeatability. 
With regards to reproducibly, I had initially set out to compare the GER30 in the morning on 
the 2 separate days. However, since the volumes of substance used to make up the OGTT and 
MMT were different, stomach distension was dissimilar such that comparison was not 
possible. Furthermore, it was not possible to blind the study given the nature of the 
experimental subjects. 
This is the first study to use ultrasound to assess gastric emptying in the adult CF population.  
Using this method, I have shown that healthy control subjects have normal gastric emptying 
for both liquid and mixed meals after an overnight fast, in keeping with previous literature 
using ultrasound to evaluate GER [248]. 
However, for the first time I have shown that although adult CF subjects without known 
CFRD have a normal antral size, following an overnight fast they have delayed gastric 
emptying for both liquid and mixed meals.  
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Only one previous study has evaluated GER throughout the day in normal subjects. Goo et al 
[249] measured GER in 16 healthy males at 8am and 8pm on separate occasions (2 – 21 days 
apart), and showed that GER in the evening was greater for solids but not liquids when 
compared to the morning. My results partly concur with this, since my normal subjects had 
normal GER for both solids and liquids throughout the day, but at 120-minutes the emptying 
in the evening appeared reduced compared to the morning,  although this was not 
statistically significant on the post-hoc analysis, possibly due to the small sample size of my 
study. However, these two studies are not comparable – unlike the work of Goo, my subjects 
were studied on the same day with fasting between each meal, and the constituents of the 
meals used were different. 
In my study cohort, although the mean gastric emptying rate in response to a liquid meal was 
normal, 5 CF subjects (42%) had decreased gastric emptying at 60-minutes. These 5 subjects 
also had reduced emptying of a mixed meal. I explored possible reasons as to why these 
individual subjects responded differently. I reviewed the possible factors that might have 
reduced gastric emptying in these subjects. On review of their medications, 3 subjects were 
on a PPI (1 Omeprazole and 2 Lansoprazole). The other factors that might affect gastric 
emptying were controlled by the nature of the experiment – all subjects had the same volume 
and type of meal at room temperature, none reported any significant pain or anxiety and all 
subjects had their usual dose of pancreatic supplements. 
There have been no previous studies of gastric emptying in adult CF patients throughout the 
day. I have shown that not only do CF individuals without known CFRD have delayed gastric 
emptying in the morning, but this delay continues throughout the day. Additionally, I have 
shown that more CF subjects have decreased gastric emptying in response to a mixed meal 
compared to a liquid meal, demonstrating that the mixed meal test is the more physiological 
test in CF individuals.  
Gastric emptying is a complex process influenced by gastric contents and volume, hormonal 
actions, and vagal activity. A number of studies have also demonstrated that pre-existing 
hyperglycaemia slows gastric emptying in healthy humans [232], Type 1 [250-252] and Type 2 
diabetics [231]: I chose CF individuals without known CFRD to minimise this and also 
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prevent the possibility of occult gastroparesis due to diabetic-related autonomic neuropathy. 
Similarly, by using the same carefully measured constituents in each experiment I sought to 
control for differences in food composition and volume. Nevertheless, these CF subjects still 
had a delay in gastric emptying: the experiments in subsequent chapters aim to explore 
dynamic glucose handling and the influence of incretins and other hormones following both 
physiological (MMT) and non-physiological (OGTT) nutrient loads that might influence 
gastric emptying. 
Furthermore, gastric ultrasound may also be useful in the clinical setting, by providing a 
simple cheap non-invasive way of assessing gastric emptying, for example to aid the 
prescription of pro-kinetic agents used as an adjunct to improving nutrition in gastroparesis 
or preventing reflux and potential micro-aspiration.  
In summary, this is the first study to use ultrasound to assess gastric motility in the adult CF 
population and demonstrates delayed gastric emptying throughout the day in CF subjects, 
compared to matched controls, for both liquid and mixed meals. Moreover, this study shows 
that this novel inexpensive bedside technique provides a simple method of assessing GER in 
CF and will have a role in the clinical setting. 
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4 Experiment 2: Glucose handling in CF and its 
diurnal variation 
4.1 Insulin and C-peptide assay 
Insulin and c-peptide assays employed sandwich based techniques and c-peptide assays were 
based on the principle of competitive binding, using commercial kits [DRG® Insulin ELISA 
(EIA-2935); DRG® C-Peptide ELISA (EIA-1293)].  
The dynamic measuring ranges of the assays were 1.76 - 100 μIU/ml for insulin and 0.06 – 
16ng/ml for c-peptide. Actual mean within and between batch precision levels (% CV) were 
5.77 and 14.44 % for Insulin and 6.41 and 7.07 % for c-peptide. 
All ELISA assays employed absorbance based detection systems at 450nm, measured on a 
Wallac Victor 2 plate reader.  
4.2 Glucagon assay 
Glucagon was measured using established in-house (Hammersmith Hospital) RIAs [253, 254]. 
All samples were assayed in duplicate. Glucagon was purchased from Bachem Ltd 
(Switzerland). All other reagents and materials were supplied by Sigma (Poole, Dorset, UK). 
The glucagon labels were prepared by Professor M. Ghatei (Professor of Regulatory Peptides, 
Metabolic Medicine, Faculty of Medicine, Imperial College) who iodinated the peptide using 
the iodogen method [255] and this was purified by reverse-phase HPLC.  
Assays were performed in veronal buffer (1 litre distilled water containing 10.3g sodium 
barbitone, 0.3g sodium azide), at pH 8.0 with 0.3% BSA (VWR International, UK). Standard 
curves were prepared in assay buffer of 0.5 pmol/ml, added in duplicate at volumes of 1, 2, 3, 
5, 10, 15, 20, 30, 50 and 100 μl.  
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The glucagon antibody (RCS5) was raised in rabbits against the C-terminal of glucagon and is 
therefore specific for pancreatic glucagon. In this assay, the antibody was used at a dilution of 
1:50000.  
Experimental samples of 50 μl, 100 μl glucagon antibody solution and 100 μl of glucagon label 
solution were used and all tubes were buffered to a total volume of 700 μl with assay buffer. 
The assays were incubated for 96 hours at 4oC. Free peptide was separated from bound using 
charcoal adsorption. To each tube, 4 mg of charcoal, suspended in 0.06 M phosphate buffer 
with gelatine was added immediately prior to centrifugation. The samples were then 
centrifuged at 1500 rpm at 4o C, for 20-minutes. Bound and free label were separated and 
both the pellet and supernatant counted for 180 seconds in a γ-counter (Model NE1600, 
Thermo Electron Corporation). Plasma glucagon concentration in the samples were 
calculated using a non-linear plot (RIA Software, Thermo Electron Corporation) and results 
calculated in terms of the standard. 
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4.3 Results 
As outlined in the subject demographics and selection, subjects with a 120-minute value >11.1 
mmol/L were excluded from analysis. Data are reported on 10 controls and 13 CF subjects.  
4.3.1 Oral Glucose Tolerance Test (liquid meal) 
4.3.1.1 Glucose:  
See Table 4-1 below and Figure 4-1 on page 79 
A. Controls	
In response to the OGTT, control subjects had normal baseline (4.52 ± 0.44 mmol/L) and 120-
minute (4.59 ± 1.48 mmol/L) glucose levels.  
B. Cystic	Fibrosis	
CF subjects had normal baseline (4.61 ± 0.46 mmol/L) and 120-minute (5.06 ± 1.13 mmol/L) 
glucose levels. 
C. Controls	v	Cystic	Fibrosis	
Compared to healthy controls, in response to the OGTT, CF subjects had higher 30 (p=0.01), 
60 (p=0.03) and 90 (p=0.008)-minute glucose levels. 
Table 4-1: Glucose levels following the OGTT 
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 4.52 ± 0.44 6.64 ± 1.54 6.31 ± 2.45 4.54 ± 1.52 4.59 ± 1.48 
CF 4.61 ± 0.46 8.56 ± 1.68 8.90 ± 2.75 7.09 ± 2.37 5.06 ± 1.13 
p 0.65 0.01 0.03 0.008 0.39 
Comparison of glucose (mmol/L) levels following a liquid meal (OGTT) over 120 minutes 
between control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between 
groups were carried out using the independent t-test.  
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(Top panel): Comparison of glucose (mmol/L) levels following a liquid meal (OGTT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual glucose levels over 120 minutes, following the liquid meal (OGTT). 
[ Controls  x  CF]. 
Figure 4-1: Plasma glucose responses to the OGTT 
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4.3.1.2 Insulin 
See Table 4-2 on page 80 and Figure 4-2 on page 81 
A. Controls	
All control subjects had baseline insulin levels within the normal range (< 25 μIU/mL). 
However, at 120-minutes 4 control subjects had low insulin levels (normal range 16 - 166 μIU 
/L).  
B. Cystic	Fibrosis	
All CF subjects had baseline insulin levels within the normal range (< 25 μIU/mL), but at 120-
minutes, 7 CF subjects had low insulin levels. 
C. Controls	v	Cystic	Fibrosis	
When the 2 groups were compared, there was no difference in the baseline, 60, 90 and 120-
minute values, but the mean 30-minute insulin level was lower in CF subjects (p=0.02).  
Table 4-2: Insulin levels following the OGTT 
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 9.20 ± 6.55 55.82 ± 26.77 55.25 ± 29.65 43.16 ± 29.21 35.69 ± 27.15 
CF 7.57 ± 2.35 30.52 ± 21.90 41.96 ± 24.90 36.46 ± 20.95 19.43 ± 9.90 
p 0.47 0.02 0.26 0.53 0.1 
Comparison of insulin (μIU/mL) levels following a liquid meal (OGTT) over 120 minutes 
between control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between 
groups were carried out using the independent t-test.  
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(Top panel): Comparison of insulin (μIU/mL) following a liquid meal (OGTT) over 120 minutes 
between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): Comparison of the 
individual insulin levels over 120 minutes, following the liquid meal (OGTT). [ Controls  x  CF]. 
Figure 4-2: Plasma insulin responses to the OGTT 
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4.3.1.3 C-peptide 
 See Table 4-3 below and Figure 4-3 on page 83  
A. Controls	
As a group, controls had normal C-peptide levels at baseline (4.38 ± 2.25 ng/mL) and at 120-
minutes (8.43 ± 2.31). One subject had a high fasting c-peptide level (normal range 0.8 - 5.1 
ng/mL)  
B. Cystic	Fibrosis	
As a group, CF subjects had normal C-peptide levels at baseline (2.61 ± 2.03) and at 120-
minutes (7.64 ± 2.67), but one subject had a high fasting c-peptide level.  
C. Controls	v	Cystic	Fibrosis	
Compared to healthy controls, CF subjects had lower 30 (p=0.02) and 60-minute (p=0.04) c-
peptide levels (Table 4-3), and had lower baseline values although this did not reach 
statistical significance (p=0.06).  
 
Table 4-3: C-peptide levels following the OGTT 
 
Baseline 30 mins 60 mins 90 mins 120 mins 
Controls 4.4 ± 2.2 8.9 ± 3.0 11.4 ± 2.8 7.9 ± 2.8 8.4 ± 2.3 
CF 2.6 ± 2.0 5.2 ± 3.5 8.0 ± 4.7 11.7 ± 8.5 7.6 ± 2.7 
p 0.06 0.02 0.04 0.22 0.29 
Comparison of c-peptide (ng/mL) levels following a liquid meal (OGTT) over 120 minutes 
between control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between 
groups were carried out using the independent t-test.  
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(Top panel): Comparison of c-peptide (ng/mL) levels following a liquid meal (OGTT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual c-peptide levels over 120 minutes, following the liquid meal 
(OGTT). [ Controls  x  CF] 
Figure 4-3: C-peptide responses to the OGTT 
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4.3.1.4 Glucagon 
See Table 4-4 below and Figure 4-4 on page 85 
A. Controls	
Glucagon analysis was not possible due to insufficient sampling for 1 control subject (subject 
6) at baseline, 60, 90 and 120-minutes and another subject (subject 10) at 120-minutes. Data 
are reported for the remaining samples. Glucagon levels at baseline in healthy control 
subjects were 20.1 ± 7.9 pmol/L and at 120-minutes were 15.3 ± 5.1 pmol/L. 5 control subjects 
had glucagon levels above the normal range (Normal < 17.2 pmol/L). 
B. Cystic	Fibrosis	
Glucagon levels at baseline were 11.0 ± 3.4 pmol/L and at 120-minutes 8.8 ± 4.3 pmol/L. 3 
subjects had levels below the lower limit of detection (<5 pmol/L) – subject 1 (60-minutes), 
subject 12 (baseline, 90 and 120-minutes) and subject 18 (60-minutes).  No CF subject had 
glucagon levels above the normal range (< 17.2 pmol/L).  
C. Controls	v	Cystic	Fibrosis	
When the 2 groups were compared, CF subjects had lower glucagon levels at all-time points. 
 Table 4-4: Glucagon responses to the OGTT 
 
Baseline 30 mins 60 mins 90 mins 120 mins 
Controls 20.1 ± 7.9 16.3 ± 5.5 15.4 ± 6.3 19.1 ± 8.3 15.3 ± 5.1 
CF 11.0 ± 3.4 10.6 ± 3.8 9.5 ± 2.5 8.9 ± 4.0 8.8 ± 4.3 
p 0.009 0.008 0.02 0.006 0.007 
Comparison of glucagon (pmol/L) levels following a liquid meal (OGTT) over 120 minutes 
between control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between 
groups were carried out using the Mann-Whitney U test. 
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Comparison of glucagon (pmol/L) levels following a liquid meal (OGTT) over 120 minutes 
between control (n=10) and CF (n=13) subjects (mean ± CI).  
Figure 4-4: Glucagon responses to the OGTT 
  
0
5
10
15
20
25
0	mins 30	mins 60	mins 90	mins 120	mins
pm
ol
/L
Glucagon	response	to	the	OGTT
ControlsCF
 86 
 
4.3.1.5 Time to peak response 
See Table 4-5 below and Figure 4-5 on page 86  
I then calculated the time to peak levels for insulin, c-peptide and glucagon following the 
OGTT and compared the differences between control and CF subjects.  
A. Controls	
Control subjects took 54 ± 24 minutes to peak insulin level, 60 ± 24 minutes to peak c-
peptide level and 45 ± 47minutes to peak glucagon level.  
B. Cystic	Fibrosis	
CF subjects took 65 ± 21 minutes to peak insulin level, 79 ± 23 minutes to peak c-peptide level 
and 24 ± 32minutes to peak glucagon level.  
C. Controls	v	Cystic	Fibrosis	
When the 2 groups were compared, there were no differences in the time for insulin and 
glucagon to peak, but the time to c-peptide peak was longer in CF subjects (p=0.02). 
Table 4-5: Time to reach a peak level following the OGTT 
 
Insulin C-peptide Glucagon 
Controls 54 ± 24 60 ± 24 45 ± 47 
CF 65 ± 21 79 ± 23 24 ± 32 
p 0.14 0.02 0.37 
Comparison between control and CF subjects in the time (minutes) to reach a peak response for 
insulin, c-peptide and glucagon following the liquid meal (OGTT). [Mean ± SD] 
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Comparison between control and CF subjects in the time (minutes) to reach a peak response for 
insulin, c-peptide and glucagon following the liquid meal (OGTT). [Mean ± SEM] 
Figure 4-5: Time to peak response (OGTT) 
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4.3.1.6 Incremental changes in response to the OGTT 
See Table 4-6 on page 89 
I calculated the incremental and total response to the OGTT by evaluating the initial 
response at 30-minutes (AUC30) and the total response at 120-minutes (AUC120). 
A. Glucose	
CF subjects had higher Glucose AUC30 [controls: 166 ± 28, CF: 198 ± 29; p=0.02] and a higher 
AUC120 [controls: 661 ± 170, CF: 882 ± 179; p= 0.007]. 
B. Insulin	
The insulin AUC30 was lower in CF subjects [controls: 975 ± 465, CF: 606 ± 356; p=0.04]. 
However, there was no statistical difference in the total insulin produced (AUC120). 
C. C-peptide	
The c-peptide AUC30 [controls: 194 ± 75, CF: 116 ± 76; p=0.02;] was lower in CF subjects, but 
there was no difference in the AUC120. 
D. Glucagon	
With regards to glucagon, the CF group had lower AUC30 [controls: 556 ± 152, CF: 332 ± 78; 
p=0.002] and AUC120 between the 2 groups [controls: 2004 ± 597, CF: 1201 ± 204; p=0.006]. 
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Table 4-6: Incremental and total responses to the OGTT 
  Glucose 
(mmol/L) 
Insulin 
(μIU/mL) 
C-peptide 
(ng/mL) 
Glucagon 
(pmol/L) 
AUC30 Controls 166 ± 28 975 ± 465 194 ± 75 556 ± 152 
CF 198 ± 29 606 ± 356 116 ± 76 332 ± 78 
p 0.02 0.04 0.02 0.002 
      
AUC120 Controls 662 ± 170 4945 ± 1699 1044 ± 242 2004 ± 597 
CF 882 ± 179 3743 ± 1610 900 ± 433 1201 ± 204 
p 0.007 0.1 0.35 0.006 
Comparison of the initial (AUC30) and total (AUC120) glucose (mmol/L), insulin (μIU/mL), c-
peptide (ng/mL) and glucagon (pmol/L) levels following a liquid meal (OGTT) between control 
(n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between groups were 
carried out using the independent t-test for glucose and c-peptide and the Mann-Whitney U 
test for insulin and glucagon.  
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4.3.1.7 Summary of OGTT Results 
A. Glucose	
Ø Although baseline and 120-minute levels were normal, CF subjects had higher 
blood glucose levels throughout the study. 
 
B. Insulin	
Ø Although	insulin	production	in	the	CF	subjects	overall	compared	with	the	controls,	early	insulin	production	was	deficient.	
Ø A	number	of	CF	and	control	subjects	had	low	insulin	levels	at	the	end	of	the	study.		
C. C-peptide	
Ø CF	subjects	had	lower	early	levels	and	the	time	to	reach	a	peak	c-peptide	level	was	delayed.		
D. Glucagon	
Ø CF	subjects	had	lower	levels	at	all	time-points.		
Ø A	number	of	controls	had	high	glucagon	levels.	
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4.3.2 Mixed Meal Test 1 (solid meal) 
 
4.3.2.1 Glucose 
See Table 4-7 below and Figure 4-6 on page 92.  
A. Controls	
The control group had normal baseline (4.6 ± 0.4 mmol/L) and 120-minute (4.6 ± 1.2) glucose 
levels, and all subjects had normal values (<7.8 mmol/L) at 120-minutes. 
B. Cystic	Fibrosis	
Similarly, the CF group had normal baseline (4.8 ± 0.1 mmol/L) and 120-minute (5.4 ± 0.2) 
values, and all subjects had normal values (<7.8 mmol/L) at 120-minutes. 
C. Controls	v	Cystic	Fibrosis	
Compared to the control group, CF subjects had higher 30 (p=0.004), 60 (p<0.0001) and 90 
(p=0.01)-minute glucose levels. At 120-minutes CF subjects had higher levels, although this 
did not reach statistical significance (p=0.06). 
Table 4-7: Glucose levels following the MMT 
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 4.61 ± 0.42 5.43 ± 1.68 4.17 ± 1.65 4.60 ± 0.89 4.58 ± 1.17 
CF 4.78 ± 0.13 7.53 ± 0.39 7.57 ± 0.46 6.02 ± 0.39 5.43 ± 0.24 
p 0.37 0.004 <0.0001 0.01 0.06 
Comparison of glucose (mmol/L) levels following a mixed meal (MMT) over 120 minutes 
between control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between 
groups were carried out using the independent t-test.  
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(Top panel): Comparison of glucose (mmol/L) levels following a mixed meal (MMT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual glucose levels over 120 minutes, following the mixed meal (MMT). 
[ Controls  x  CF] 
Figure 4-6: Glucose responses following the MMT 
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4.3.2.2 Insulin 
See Table 4-8 on page 93 and Figure 4-7 on page 94 
All control subjects had baseline insulin levels within the normal range (< 25 μIU/mL), (8.45 
± 4.75), and although the group were within the normal range (16 - 166 µU/mL) at 120-
minutes (29.72 ± 23.24 µU/mL) 3 subjects had low insulin levels.  
A. Cystic	Fibrosis	
Similarly, all CF subjects had baseline insulin levels within the normal range (7.75 ± 2.85) and 
although the group were within the normal range at 120-minutes (19.82 ± 8.49 µU/mL), 6 
subjects had low insulin levels. 
B. Controls	v	Cystic	Fibrosis	
When the 2 groups were compared, CF subjects had lower insulin levels at 30-minutes 
(p=0.01), but there was no difference at baseline levels or other times of the MMT.  
Table 4-8: Insulin levels following the MMT 
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 8.45 ± 4.75 54.92 ± 29.61 35.31 ± 21.44 39.09 ± 20.97 29.72 ± 23.24 
CF 7.75 ± 2.85 24.67 ± 13.56 32.43 ± 19.12 31.18 ± 29.23 19.82 ± 8.49 
p 0.66 0.01 0.73 0.48 0.11 
Comparison of insulin (μIU/mL) levels following a mixed meal (MMT) over 120 minutes 
between control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between 
groups were carried out using the Mann-Whitney U test.  
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(Top panel): Comparison of insulin (μIU/mL) levels following a mixed meal (MMT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual insulin levels over 120 minutes, following the mixed meal (MMT). 
[ Controls  x  CF] 
Figure 4-7: Insulin levels following the MMT 
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4.3.2.3 C-peptide 
See summary data Table 4-9 on page 95 and Figure 4-8 on page 96 
A. 	Controls	
The group had normal C-peptide levels at baseline (3.9 ± 2.4) and 120-minutes (7.2 ± 2.4 
ng/mL), but 2 subjects had high baseline levels and 1 a low baseline level. (normal range 0.8-
5.1 ng/mL).   
B. Cystic	Fibrosis	
The group had normal C-peptide levels at baseline (2.5 ± 1.7) and 120-minutes (5.6 ± 3.6 
ng/mL), but 1 subject had a high and 1 a low baseline level (normal range 0.8-5.1 ng/mL).   
C. Controls	v	Cystic	Fibrosis	
There was no statistical difference between the 2 groups at any time point. At 30 minutes, CF 
subjects had lower levels; however, this difference did not achieve statistical significance. 
Table 4-9: C-peptide levels following the MMT 
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 3.89 ± 2.38 7.61 ± 4.42 7.24 ± 3.72 7.95 ± 2.36 7.14 ± 2.44 
CF 2.45 ± 1.71 4.88 ± 1.97 6.63 ± 3.43 7.35 ± 4.45 5.58 ± 3.56 
p 0.1 0.07 0.48 0.62 0.19 
Comparison of c-peptide (ng/mL) levels following a mixed meal (MMT) over 120 minutes 
between control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between 
groups were carried out using the independent t-test.  
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(Top panel): Comparison of c-peptide (ng/mL) levels following a mixed meal (MMT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual c-peptide levels over 120 minutes, following the mixed meal 
(MMT). [ Controls  x  CF] 
 
Figure 4-8: C-peptide responses following the MMT 
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4.3.2.4 Glucagon 
See Table 4-10 on page 98 and Figure 4-9 on page 99  
A. Controls	
Insufficient samples were available for glucagon analysis in subject 6 at baseline and 30-
minutes, and for subject 10 at baseline, 60- and 120-minutes. Data are therefore reported for 
the remaining samples.  
In this group glucagon levels at baseline (15.2 ± 4.8 pmol/L) and 120-minutes (21.2 ± 3.8 
pmol/L) were within the normal range (< 17.2 pmol/L), but 2 subjects had baseline levels 
above the normal range. 
B. Cystic	Fibrosis	
Insufficient samples were available for glucagon analysis in subject 16 at baseline and in 
subject 13 at 90-minutes: data are reported for the remaining samples. 
As a group baseline and 120-minutes levels were within the normal range (11.4 ± 5.1 pmol/L 
and 15.5 ± 9.3 pmol/L respectively), but 2 subjects had levels below the lower limit of 
detection (<5 pmol/L) – (one at 30- and 60-minutes and another at 90-minutes). One subject 
had a glucagon level above the normal range (Normal < 17.2 pmol/L). 
C. Controls	v	Cystic	Fibrosis	
When the 2 groups were compared, there was no statistical difference in baseline (p=0.1) or 
120-minute  (p=0.06) levels, but CF subjects at 60-minutes had lower levels (p=0.01).  
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Table 4-10: Glucagon levels following the MMT 
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 15.2 ± 4.8 17.2 ± 9.7 21.0 ± 7.6 18.1 ± 7.6 21.2 ± 3.8 
CF 11.4 ± 5.1 13.8 ± 4.0 12.6 ± 5.8 14.4 ± 6.6 15.5 ± 9.3 
p 0.1 0.35 0.01 0.23 0.06 
Comparison of glucagon (pmol/L) levels following a mixed meal (MMT) over 120 minutes 
between control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between 
groups were carried out using the Mann-Whitney U test.  
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(Top panel): Comparison of glucagon (pmol/L) levels following a mixed meal (MMT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual glucagon levels over 120 minutes, following the mixed meal 
(MMT). [ Controls  x  CF] 
Figure 4-9: Glucagon responses following the MMT 
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4.3.2.5 Time to peak response 
See Table 4-11 below and Figure 4-10 on page 101 
As with the OGTT, I calculated the time for insulin, c-peptide and glucagon to reach a peak 
level, following the MMT and compared the differences between control and CF subjects. 
A. Controls	
Control subjects took 53 ± 27 minutes to peak insulin level, 60 ± 32 minutes to peak c-peptide 
level and 63 ± 52 minutes to peak glucagon level.  
B. Cystic	Fibrosis	
CF subjects took 68 ± 29 minutes to peak insulin level, 83 ± 27 minutes to peak c-peptide 
level and 86 ± 44 minutes to peak glucagon level.  
C. Controls	v	Cystic	Fibrosis	
When the two groups were compared there was no difference in the time to reach peak levels 
for insulin, c-peptide and glucagon. 
Table 4-11: Time to reach a peak level following the MMT 
 
Insulin C-peptide Glucagon 
Controls 53 ± 27 60 ± 32 63 ± 52 
CF 68 ± 29 83 ± 27 86 ± 44 
p 0.11 0.17 0.23 
Comparison between control and CF subjects in the time (minutes) to reach a peak response for 
insulin, c-peptide and glucagon following the liquid meal (OGTT). [Mean ± SD] 
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Comparison between control and CF subjects in the time (minutes) to reach a peak response for 
insulin, c-peptide and glucagon following the liquid meal (OGTT). [Mean ± SEM] 
Figure 4-10: Time to reach a peak level following the MMT 
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4.3.2.6 Incremental changes in response to the MMT 
See Table 4-12 on page 103 
I measured the incremental and total responses to the MMT in the morning for glucose, 
insulin, c-peptide and glucagon and compared the 2 groups.    
A. Controls	
The initial response (AUC30) for glucose was 151 ± 29 mmol/L, insulin 951 ± 476 μIU/mL, c-
peptide 173 ± 92 ng/ml and glucagon 173 ± 92 pmol/L, with a total response (AUC120) of 564 ± 
120 mmol/L, 4452 ± 2068 μIU/mL, 874 ± 354 ng/ml and 2219 ± 632pmol/L respectively. 
B. Cystic	Fibrosis	
The initial response (AUC30) for glucose was 185 ± 25 mmol/L, insulin 487 ± 195 μIU/mL, c-
peptide 110 ± 54 ng/ml and glucagon 394 ± 121 pmol/L, with a total response (AUC120) of 787 ± 
119 mmol/L, 3067 ± 1427 μIU/mL, 686 ± 333 ng/ml and 1741 ± 660 pmol/L respectively. 
C. Controls	v	Cystic	Fibrosis	
Compared to controls, the CF group had higher initial (AUC30 p= 0.006) and total (AUC120 p= 
0.0003) glucose levels. 
Both initial response insulin and c-peptide responses were greater in the control group 
(p=0.01 and p=0.048 respectively), but there was no difference in the total response.  
There was no difference in glucagon levels at any stage throughout the study. 
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Table 4-12: Incremental and total responses to the MMT 
  
Glucose 
(mmol/L) 
Insulin 
(μIU/mL) 
C-peptide 
(ng/mL) 
Glucagon 
(pmol/L) 
AUC30 
Controls 151 ± 29 951 ± 476 173 ± 92 448 ± 166 
CF 185 ± 25 487 ± 195 110 ± 54 394 ± 121 
p 0.006 0.01 0.048 0.42 
      
AUC120 
Controls 564 ± 120 4452 ± 2068 874 ± 354 2219 ± 632 
CF 787 ± 119 3067 ± 1427 686 ± 333 1741 ± 660 
p 0.0003 0.08 0.2 0.15 
Comparison of the initial (AUC30) and total (AUC120) glucose (mmol/L), insulin (μIU/mL), c-
peptide (ng/mL) and glucagon (pmol/L) levels following a mixed meal (MMT) between control 
(n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between groups were 
carried out using the independent t-test.  
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4.3.3 Comparison between OGTT and MMT 
 
4.3.3.1 Glucose 
See Table 4-13 on page 105 and Figure 4-11, Figure 4-12 on page 107  
I then evaluated the responses between the OGTT and the MMT in controls and CF subjects. 
A. Controls	
The OGTT glucose value at 60-minutes was higher (p=0.0009) compared to MMT, and 
although there was no difference in the initial (AUC30) response, the total (AUC120) response 
was higher following the OGTT (p=0.02) compared to the MMT. 
B. Cystic	Fibrosis	
The OGTT glucose 30-minute (p=0.02) and 60-minute (p=0.01) levels were higher compared 
to the MMT. Although the AUC30 after the OGTT was higher, this difference was not 
statistically significant (p=0.07), but the total response (AUC120) was higher after the OGTT 
(p=0.02).  
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Table 4-13:  Glucose differences between OGTT and MMT 
  
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 
OGTT 4.52 ± 0.44 6.64 ± 1.54 6.31 ± 2.45 4.54 ± 1.52 4.59 ± 1.48 
MMT 4.61 ± 0.42 5.43 ±1.68 4.17 ± 1.65 4.60 ± 0.89 4.58 ±1.17 
p 0.41 0.05 0.0009 0.88 0.98 
       
CF 
OGTT 4.61 ± 0.46 8.56 ± 1.68 8.90 ± 2.75 7.09 ± 2.37 5.06 ± 1.13 
MMT 4.78 ± 0.13 7.53 ± 0.39 7.57 ± 0.46 6.02 ± 0.39 5.43 ±0.24 
p 0.26 0.02 0.01 0.11 0.38 
Comparison of glucose (mmol/L) levels following a liquid (OGTT) and mixed meal (MMT) over 
120 minutes in control (n=10) and CF (n=12) subjects (mean ± SD). Statistical comparisons 
between tests were carried out using the paired t-test. 
Table 4-14: Glucose – Differences between the OGTT and MMT – incremental 
and total responses 
  
AUC30 AUC120 
Controls 
OGTT 166 ± 28 661 ± 170 
MMT 151 ± 29 564 ± 120 
p 0.1 0.02 
CF 
OGTT 198 ± 29 882 ± 179 
MMT 185 ± 25 787 ± 119 
p 0.07 0.02 
Comparison of the initial (AUC30) and total (AUC120) glucose (mmol/L) levels following a liquid 
meal (OGTT) and mixed meal (MMT) in control (n=10) and CF (n=13) subjects (mean ± SD). 
Statistical comparisons between groups were carried out using the paired t-test.  
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Comparison of glucose (mol/L) levels following a liquid meal (OGTT) and mixed meal (MMT) 
over 120 minutes in control (n=10, top panel) and CF (n=13) subjects (bottom panel). [mean ± 
CI]. 
Figure 4-11: Glucose differences between OGTT and MMT 
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Comparison of the initial (AUC30) and total (AUC120) glucose (mmol/L) levels following a liquid 
meal (OGTT) and mixed meal (MMT) in control (n=10) and CF (n=13) subjects (mean ± CI).  
Figure 4-12: Glucose differences between the OGTT and MMT – incremental 
and total responses 
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4.3.3.2 Insulin 
See Table 4-15 below, Table 4-16 on page 109 and Figure 4-13 on page 110 
 
Controls 
Insulin value was higher on the OGTT (p=0.005) at 60-minutes, but there was no difference 
in the initial (AUC30) or the total (AUC120) response between the OGTT and MMT. 
A. Cystic	Fibrosis	
The AUC30 in CF subjects was higher (p=0.0001) after the OGTT compared to the MMT.  
Table 4-15: Insulin differences between OGTT and MMT 
  
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 
OGTT 9.2 ± 6.5 55.8 ± 26.8 55.3 ± 29.6 43.2 ± 29.2 35.7 ± 27.2 
MMT 8.5 ± 4.7 54.9 ± 29.6 35.3 ± 21.4 39.1 ± 21.0 29.7 ± 23.2 
p 0.76 0.9 0.005 0.65 0.39 
       
CF 
OGTT 7.6 ± 2.3 30.5 ± 21.9 42.0 ± 24.9 36.5 ± 20.9 19.4 ± 9.9 
MMT 7.7 ± 2.9 24.7 ± 13.6 32.4 ± 19.1 31.2 ± 29.2 19.8 ± 8.5 
p 0.8 0.19 0.15 0.4 0.89 
 
Comparison of insulin (μIU/mL) levels following a liquid (OGTT) and mixed meal (MMT) over 
120 minutes in control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons 
between tests were carried out using the Wilcoxon signed-rank test. 
. 
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Table 4-16: Insulin - Differences between the OGTT and MMT – incremental 
and total responses 
  
AUC30 AUC120 
Controls 
OGTT 975 ± 465 4945 ± 1699 
MMT 951 ± 476 4452 ± 2068 
p 0.82 0.37 
CF 
OGTT 606 ± 356 3743 ± 1610 
MMT 487 ± 195 3067 ± 1427 
p 0.0001 0.13 
Comparison of the initial (AUC30) and total (AUC120) insulin (μIU/mL) levels following a liquid 
meal (OGTT) and mixed meal (MMT) in control (n=10) and CF (n=13) subjects (mean ± SD). 
Statistical comparisons between groups were carried out using the Wilcoxon signed-rank test.  
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Comparison of insulin (μIU/mL) levels following a liquid meal (OGTT) and mixed meal (MMT) 
over 120 minutes in control (n=10, top panel) and CF (n=13) subjects (bottom panel). [mean ± 
CI]. 
Figure 4-13: Insulin differences between OGTT and MMT 
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4.3.3.3 C-peptide 
 See Table 4-17, Table 4-18 on page 112 and Figure 4-14, Figure 4-15 on page 114 
A. Controls	
C-peptide at 60-minutes was higher for the OGTT (p=0.02), but there was no difference at 
baseline, 30, 90 and 120-minutes.  
Although there was no difference in the initial (AUC30) response, the total (AUC120) response 
was higher (p=0.03) after the OGTT. 
B. Cystic	Fibrosis	
There were no statistically significant differences up to 90-minutes or the AUC30 but there 
were higher levels after the OGTT at 120-minutes (p=0.04). Although the total response 
(AUC120) after the OGTT was higher, this did not reach statistical significance (p=0.07).  
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Table 4-17:  C-peptide - differences between OGTT and MMT 
  
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 
OGTT 4.4 ± 2.2 8.9 ± 3.0 11.4 ± 2.8 7.9 ± 2.8 8.4 ± 2.3 
MMT 3.89 ± 2.38 7.61 ± 4.42 7.24 ± 3.72 7.95 ± 2.36 7.14 ± 2.44 
 
p 0.23 0.31 0.02 0.76 0.11 
       
CF 
OGTT 2.6 ± 2.0 5.2 ± 3.5 8.0 ± 4.7 11.7 ± 8.5 7.6 ± 2.7 
MMT 2.45 ± 1.71 4.88 ± 1.97 6.63 ± 3.43 7.35 ± 4.45 5.58 ± 3.56 
 
p 0.62 0.72 0.21 0.06 0.04 
 
Comparison of c-peptide (ng/ml) levels following a liquid (OGTT) and mixed meal (MMT) over 
120 minutes in control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons 
between tests were carried out using the paired t-test. 
 
Table 4-18: C-peptide- Differences between the OGTT and MMT – incremental 
and total responses 
  
AUC30 AUC120 
Controls 
OGTT 193.7 ± 74.9 1044.4 ± 242.1 
MMT 172.7 ± 91.8 874.5 ± 353.6 
p 0.19 0.03 
CF 
OGTT 116.4 ± 76.1 899.8 ± 432.5 
MMT 110.0 ± 54.0 686.3 ± 333.1 
p 0.64 0.07 
Comparison of the initial (AUC30) and total (AUC120) c-peptide (ng/ml) level following a liquid 
meal (OGTT) and mixed meal (MMT) in control (n=10) and CF (n=13) subjects (mean ± SD). 
Statistical comparisons between groups were carried out using the paired t-test.  
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Comparison of c-peptide (ng/mL) levels following a liquid meal (OGTT) and mixed meal (MMT) 
over 120 minutes in control (n=10, top panel) and CF (n=13) subjects (bottom panel). [mean ± 
CI]. 
Figure 4-14: C-peptide - Differences between OGTT and MMT 
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Comparison of the initial (AUC30) and total (AUC120) c-peptide (ng/ml) levels following a liquid 
meal (OGTT) and mixed meal (MMT) in control (n=10) and CF (n=13) subjects (mean ± CI).  
Figure 4-15: C-peptide - Differences between the OGTT and MMT – incremental 
and total responses 
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4.3.3.4 Glucagon 
See Table 4-19, Table 4-20  on page 116 and Figure 4-16 and Figure 4-17 on page 118  
A. Controls	
The glucagon value at 60-minutes (p=0.05) and 120-minutes (p=0.03) was higher for the 
MMT, but there was no difference at baseline, 30 and 90-minutes.  
There was no difference in the initial (AUC30) or total (AUC120) response. 
B. Cystic	Fibrosis	
CF subjects had higher glucagon levels after the MMT at 90 (p=0.002) and 120 (p=0.02) 
minutes, and the total glucagon response (AUC120) was higher for the MMT compared to the 
OGTT.  
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Table 4-19: Glucagon differences between OGTT and MMT 
  
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 
OGTT 20.1 ± 7.9 16.3 ± 5.5 15.4 ± 6.3 19.1 ± 8.3 15.3 ± 5.1 
MMT 15.2 ± 4.8 17.2 ± 9.7 21.0 ± 7.6 18.1 ± 7.6 21.2 ± 3.8 
p 0.21 0.94 0.05 0.87 0.03 
       
CF 
OGTT 11.0 ± 3.4 10.6 ± 3.8 9.5 ± 2.5 8.9 ± 4.0 8.8 ± 4.3 
MMT 11.4 ± 5.1 13.8 ± 4.0 12.6 ± 5.8 14.4 ± 6.6 15.5 ± 9.3 
p 0.86 0.17 0.18 0.002 0.02 
 
Comparison of glucagon (pmol/L) levels following a liquid (OGTT) and mixed meal (MMT) over 
120 minutes in control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons 
between tests were carried out using the Wilcoxon signed-rank test. 
 
Table 4-20: Glucagon - Differences between the OGTT and MMT – incremental 
and total responses 
  
AUC30 AUC120 
Controls 
OGTT 556 ± 51 2004 ± 597 
MMT 448 ± 59 2219 ± 223 
p 0.23 0.45 
    
CF 
OGTT 332 ± 23 1201 ± 62 
MMT 394 ± 37 1741 ± 220 
p 0.19 0.04 
Comparison of the initial (AUC30) and total (AUC120) glucagon (pmol/L) level following a liquid 
meal (OGTT) and mixed meal (MMT) in control (n=10) and CF (n=13) subjects (mean ± SD). 
Statistical comparisons between groups were carried out using the Wilcoxon signed ranks test.  
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Comparison of glucagon (pmol/L) levels following a liquid meal (OGTT) and mixed meal 
(MMT) over 120 minutes in control (n=10) (top panel) and CF (n=13) subjects (bottom panel). 
[mean ± CI]. 
Figure 4-16: Glucagon - Differences between OGTT and MMT 
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Comparison of the initial (AUC30) and total (AUC120) glucagon (pmol/L) levels following a liquid 
meal (OGTT) and mixed meal (MMT) in control (n=10) and CF (n=13) subjects (mean ± CI).  
Figure 4-17: Glucagon - Differences between the OGTT and MMT – incremental 
and total responses 
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4.3.4 Diurnal Studies (MMT2 and MMT3)  
As with gastric motility, I then compared changes in blood glucose, insulin, c-peptide and 
glucagon through the day and evaluated the early response [30-minutes (AUC30)] and the 
total response [120-minutes (AUC120)], to evaluate the concept of pancreatic fatigue. 
 
4.3.4.1 Glucose 
See Table 4-21, Table 4-22 on page 121 and Figure 4-18 and Figure 4-19 Error! Reference 
source not found.on pages 122 and 123 
A. Controls:		
In the afternoon (MMT2), all had normal baseline (4.6 ± 0.3 mmol/L) and 120-minute values 
(5.0 ± 0.4 mmol/L). In the evening (MMT3), all subjects again had normal baseline (4.6 ± 0.3 
mmol/L) and 120-minute values (5.03 ± 0.4 mmol/L). 
In the healthy control subjects, there was no difference between times of the day with the 
corresponding time during the test. 
When the incremental initial (AUC30) and total (AUC120) responses were evaluated, there was 
no difference within the control group between the various tests.  
B. Cystic	Fibrosis	
In the afternoon (MMT2), CF subjects had a normal baseline (mean 4.3 ± 0.7 mmol/L) and 
120-minute values (5.3 ± 0.5 mmol/L). 
However, at the evening study (MMT3), two subjects had impaired baseline levels (6.8, 5.7 
mmol/L) and at 120-minutes 6 had impaired glucose values (mean 6.11 ± 1.07 mmol/L) and 
two had glucose levels within the diabetic range (7.3 and 8.6 mmol/L). 
A diurnal variation existed for the 60-minute glucose value (p=0.03) within the CF group 
with the afternoon level less than the (morning (p=0.01) and the evening (p=0.01). Although 
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the 120-minute did show diurnal variation (p=0.04) with the evening level the highest, on the 
post-hoc analysis this did not achieve statistical significance. 
There was a diurnal variation in the AUC30 (p=0.04) and AUC120 (p=0.02). The AUC30 was 
lower in the afternoon (166 ± 20 mmol/L) compared to the morning (185 ± 25 mmol/L; 
p=0.004) and evening (180 ± 16 mmol/L, p=0.001). The AUC120 was lower in the afternoon (692 
± 81 mmol/L) compared to the morning [787 ± 119 mmol/L; p=0.002] and the evening (792 ± 
124 mmol/L, p=0.012). This was not seen in control subjects. 
C. Controls	v	Cystic	Fibrosis	
When the 2 groups were compared, after the MMT2, CF subjects had higher blood glucose 
levels at 30 (p=0.04) and 60-minutes (p=0.009). For the MMT3, CF subjects had higher 30 
(p=0.03), 60 (p=0.008), 90 (p=0.009) and 120-minute (p=0.01) values compared to control 
subjects.  
Furthermore, CF subjects had higher glucose levels (AUC30) in the morning (p=0.006) and 
evening (p=0.01) and the AUC120 was higher throughout the day compared to controls.  
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Table 4-21: Glucose levels through the day 
 
Morning Afternoon Evening 
 
Controls CF p Controls CF  Controls CF  
0 
mins 
4.61± 
0.42 
4.78 ± 
0.47 
0.37 
4.64 ± 
0.30 
4.33 ± 
0.71 
0.20 
4.65 ± 
0.31 
4.82 ± 
0.75 
0.46 
30 
mins 
5.43 ± 
1.68 
7.53 ± 1.41 0.004 
5.69 ± 
1.06 
6.59 ± 
0.94 
0.04 
5.88 ± 
1.50 
7.21 ± 
1.21 
0.03 
60 
mins 
4.17 ± 
1.65 
7.57 ± 
1.65 
<0.0001 
4.74 ± 
0.85 
6.03 ± 
1.22*^ 
0.009 5.40 ± 1.17 7.12 ±1.55  0.008 
90 
mins 
4.60 ± 
0.89 
6.02 ± 1.41 0.01 
4.90 ± 
0.74 
5.39 ± 
0.85 
0.15 
5.13 ± 
0.74 
6.61 
±1.64 
0.009 
120 
mins 
4.58 ±1.17 
5.43 ± 
0.86 
0.06 
5.03 ± 
0.37 
5.32 ± 
0.50 
0.13 
5.09 ± 
0.56 
6.11 ± 
1.07  
0.01 
Comparison between glucose (mmol/L) levels over 120 minutes, following the mixed meal in the 
morning, afternoon and evening (Mean ± SD). Statistical comparisons between control (n=10) 
and CF (n=13) subjects at each time point were carried out using independent t-tests and a 
repeated measures ANOVA was performed to study differences within the group through the 
day [*p=0.01 (compared to morning); ^p=0.02 (compared to evening)]. 
Table 4-22: Glucose - Incremental and total responses through the day 
AUC30 
 
Morning Afternoon Evening 
Controls 151 ± 29 155 ±17 160 ± 21 
CF 185 ± 25* 166 ± 20 180 ±16 Ω 
p 0.006 0.2 0.01 
AUC30: Within Group: vs afternoon: *p=0.004; Ω p=0.001 
AUC120 
 
Morning Afternoon Evening 
Controls 564 ± 120 605 ± 69 638 ±101 
CF 787 ± 119 Ω 692 ± 81  792 ± 124 ˄ 
p 0.0003 0.02 0.004 
AUC120: Within Group: vs afternoon: Ωp=0.002; ˄p=0.01 
Comparison between the initial (AUC30) and total (AUC120) glucose (mmol/L) levels, following 
the mixed meal in the morning, afternoon and evening (Mean ± SD). Statistical comparisons 
between control (n=10) and CF (n=13) subjects at each time point were carried out using 
independent t-test and a repeated measures ANOVA was performed to study differences within 
the group through the day.  
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Comparison of glucose (mmol/L) levels in response to the mixed meal (mean ± CI) over 120 
minutes between control (n=10) and CF (n=13) subjects in the morning, afternoon and evening. 
[For p-values see Table 4-21] 
Figure 4-18: Glucose handling through the day 
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Comparison of initial (AUC30) and total (AUC120) glucose (mmol/L) levels following the mixed 
meal (mean ± CI) between control (n=10) and CF (n=13) subjects in the morning, afternoon and 
evening. 
Figure 4-19: Glucose - Incremental and Total responses through the day 
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4.3.4.2 Insulin 
See Table 4-23, Table 4-24 on pages 126 and Figure 4-20, Figure 4-21 on page 128 
A. Controls		
In the afternoon (MMT2), all but one subject (41.9 μIU/mL) had normal (< 25 μIU/mL) 
baseline (12.1 ± 11.4 μIU/mL) levels and all but 3 subjects (<16 μIU/mL) had normal (16-166 
μIU/mL) 120-minute values (26.5 ± 18.5 μIU/mL). 
In the evening (MMT3), all subjects had normal baseline levels (mean 9.1 ± 6.0 μIU/mL) but 3 
subjects had low insulin levels at 120-minutes (group mean 28.7 ± 20.6 μIU/mL). 
Analysis of insulin release throughout the day, showed no differences in control subjects at 
any time point. 
There was no difference within the group for MMT1, MMT2 and MMT3 in incremental initial 
(AUC30) and total (AUC120) responses.  
B. Cystic	Fibrosis	
At the afternoon study (MMT2), two baseline samples and one 120-minute sample were 
unable to be analysed due to haemolysis.  
In the remaining samples, there was a normal baseline (mean 8.5 ± 3.1 μIU/mL) but at 120-
minutes, 7 subjects had low 120-minute levels.  
In the evening (MMT3), there was a normal baseline (mean 9.7 ± 6.2 μIU/mL) but at 120-
minutes, (mean 21.9 ± 12.3 μIU/mL), five had low insulin levels (<16 μIU/mL).  
Analysis of insulin release throughout the day showed no difference in control subjects at any 
time point.  
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Total (AUC120) insulin responses were, were lower (p=0.003) in the afternoon (2393 ± 919 
μIU/mL) compared to the morning (3067 ± 1427 μIU/mL), but there was no difference in the 
AUC30 between the 3 tests.  
C. Controls	v	Cystic	Fibrosis	
Following MMT2 and MMT3, CF subjects had lower insulin levels at 30-minutes (p=0.01), 
with diminished AUC30 MMT2 (p=0.03) and MMT3 (p=0.02). There was no difference at other 
time points.  
The total insulin response (AUC120) was less in CF subjects (p=0.05) in the afternoon 
(p=0.04).  In the evening, although   the CF group had lower levels, this was not statistically 
significant (p=0.08). 
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Table 4-23: Insulin levels through the day  
 
Morning Afternoon Evening 
 
Controls CF p Controls CF p Controls CF p 
0 
mins 
8.5 ± 4.7 7.7 ± 2.9 0.66 12.1 ± 11.4 8.5 ± 3.1 0.36 9.1 ± 6.0 9.7 ± 6.2 0.8 
30 
mins 
54.9 ± 29.6 
24.7 ± 
13.6 
0.01 53.2 ± 28.3 24.8 ± 10.9 0.01 46.4 ± 24.7 23.3 ± 11.1 0.02 
60 
mins 
35.3 ± 21.4 32.4 ± 19.1 0.73 34.9 ± 20.9 23.9 ± 11.0 0.16 37.2 ± 26.5 23.7 ± 8.7 0.15 
90 
mins 
39.1 ± 21.0 
31.2 ± 
29.2 
0.48 32.0 ± 23.2 18.3 ± 9.7 0.1 35.8 ± 24.9 27.6 ± 19.9 0.41 
120 
mins 
29.7 ± 23.2 19.8 ± 8.5 0.11 26.5 ± 18.5 15.4 ± 8.4 0.11 28.7 ± 20.6 21.9 ± 12.3 0.37 
Comparison between insulin (μIU/mL) levels over 120 minutes, following the mixed meal in the 
morning, afternoon and evening (Mean ± SD). Statistical comparisons between control (n=10) 
and CF (n=13) subjects at each time point were carried out using the Mann-Whitney U test and 
a repeated measures ANOVA was performed to study differences within the group through the 
day [No significant differences]. 
Table 4-24: Insulin - Incremental and total responses through the day 
AUC30 
 
Morning Afternoon Evening 
Controls 951 ± 476 949 ± 536 860 ± 420 
CF 487 ± 195 504 ± 205 486 ± 193 
p 0.01 0.03 0.02 
 
AUC120 
 
Morning Afternoon Evening 
Controls 4452 ± 2068 4054 ± 2256 4048 ± 2236 
CF 3067 ± 142 2393 ± 919* 2703 ±1213 
p 0.08 0.04 0.08 
Comparison between the initial (AUC30) and total (AUC120) insulin (μIU/mL) levels, following 
the mixed meal in the morning, afternoon and evening (Mean ± SD). Statistical comparisons 
between control (n=10) and CF (n=13) subjects at each time point were carried out using the 
Mann-Whitney U test and a repeated measures ANOVA was performed to study differences 
within the group through the day [Within CF group: comparison with morning: * p=0.003]. 
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Comparison of insulin (μIU/mL) levels in response to the mixed meal (mean ± CI) over 120 
minutes between control (n=10) and CF (n=13) subjects in the morning, afternoon and evening. 
[For p-values see Table 4-23] 
Figure 4-20: Diurnal variation in insulin levels 
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Comparison of initial (AUC30) and total (AUC120) insulin (μIU/mL) levels following the mixed 
meal (mean ± CI) between control (n=10) and CF (n=13) subjects in the morning, afternoon and 
evening. 
Figure 4-21: Insulin - Incremental and Total responses through the day 
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4.3.4.3 C-peptide 
See Table 4-25, Table 4-26 on page 130 and Figure 4-22 Figure 4-23 on pages 131 and 132  
A. Controls		
In the afternoon (MMT2), c-peptide levels in healthy controls at baseline were 5.2 ± 2.1 and at 
120-minutes were 6.5 ± 1.9 ng/mL. 3 subjects had high baseline levels (normal 0.8-5.1 ng/mL). 
In the evening (MMT3), c-peptide levels in healthy controls at baseline were 5.2 ± 1.7 and at 
120-minutes were 8.2 ± 2.4 ng/mL. 5 subjects had high baseline levels (normal 0.8-5.1 ng/mL). 
Analysis of c-peptide release through the day, showed no difference in healthy control 
subjects during the day at any time point with the corresponding time point between MMT1, 
MMT2 and MMT3. 
There was no difference the incremental initial (AUC30) and total (AUC120) responses within 
the control group throughout the day (MMT1, MMT2 and MMT3).  
B. Cystic	Fibrosis	
Two baseline and one 120-minute c-peptide samples were not analysed (haemolysis and 
insufficient sample).  
In the afternoon (MMT2), one subject had a high baseline level (group mean 3.5 ± 1.8 ng/mL) 
but all had normal 120-minute level (group mean 5.7 ± 2.6 ng/mL). 
In the evening (MMT3), 3 subjects had high baseline levels (group mean 3.5 ± 2.4 ng/mL) and 
all had normal 120-minutes levels (group mean 7.9 ± 3.8 ng/mL). 
There was no difference the incremental initial (AUC30) and total (AUC120) responses within 
the CF group throughout the day (MMT1, MMT2 and MMT3).  
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C. Controls	v	Cystic	Fibrosis	
CF subjects had lower c-peptide levels at 30-minutes during the MMT2 (p=0.02) and MMT3 
(p=0.04). Although they had lower baseline levels in the afternoon and evening, the 
difference was not statistically significant (p=0.06) 
There was a lower initial (AUC30) response in the CF group in the morning (p=0.048) and 
evening (p=0.04), but no difference in the total (AUC120) c-peptide levels between the 2 
groups throughout the day. 
Table 4-25: C-peptide levels through the day 
 
Morning Afternoon Evening 
 
Control
s 
CF p Controls CF p Controls CF p 
0 mins 3.9 ± 2.4 2.5 ± 1.7 0.1 5.2 ± 2.1 3.5 ± 1.8 0.06 5.2 ± 1.7 3.5 ± 2.4 0.06 
30 
mins 
7.6 ± 4.4 4.9 ± 2.0 0.07 8.2 ± 2.9 5.2 ± 2.9 0.02 7.8 ± 2.6 5.3 ± 3.3 0.04 
60 
mins 
7.2 ± 3.7 6.6 ± 3.4 0.48 7.9 ± 2.4 5.9 ± 3.0 0.06 8.2 ± 2.1 6.8 ± 3.8 0.24 
90 
mins 
8.0 ± 2.4 7.3 ± 4.5 0.62 6.8 ± 2.5 5.7 ± 2.6 0.19 8.7 ± 2.0 7.3 ± 3.6 0.19 
120 
mins 
7.1 ± 2.4 5.6 ± 3.6 0.19 6.5 ± 1.9 5.7 ± 2.6 0.23 8.2 ± 2.4 7.9 ± 3.8 0.82 
Comparison between c-peptide (ng/mL) levels over 120 minutes, following the mixed meal in the 
morning, afternoon and evening (Mean ± SD). Statistical comparisons between control (n=10) 
and CF (n=13) subjects at each time point were carried out using the independent test and a 
repeated measures ANOVA was performed to study differences within the group through the 
day [No significant differences]. 
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Table 4-26: C-peptide - Incremental and Total responses through the day 
AUC30 
 
Morning Afternoon Evening 
Controls 173 ± 92 202 ± 70 198 ± 60 
CF 110 ± 54 142 ± 62 132 ± 79 
p 0.048 0.06 0.04 
AUC120 
 
Morning Afternoon Evening 
Controls 874 ± 354 896 ± 302 963 ± 242 
CF 686 ± 333 698 ± 288 754 ± 374 
p 0.2 0.15 0.11 
Comparison between the initial (AUC30) and total (AUC120) c-peptide (ng/mL) levels, following 
the mixed meal in the morning, afternoon and evening (Mean ± SD). Statistical comparisons 
between control (n=10) and CF (n=13) subjects at each time point were carried out using the 
independent test and a repeated measures ANOVA was performed to study differences within 
the group through the day [No significant differences]. 
 
 
Comparison of c-peptide (ng/mL) levels in response to the mixed meal (mean ± CI) over 120 
minutes between control (n=10) and CF (n=13) subjects in the morning, afternoon and evening. 
[For p-values see Table 4-25] 
Figure 4-22: Diurnal variation in C-peptide 
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Comparison of initial (AUC30) and total (AUC120) c-peptide (ng/mL) levels following the mixed 
meal (mean ± CI) between control (n=10) and CF (n=13) subjects in the morning, afternoon and 
evening. 
Figure 4-23: C-peptide - Incremental and Total responses through the day 
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4.3.4.4 Glucagon 
See Table 4-27, Comparison between glucagon (pmol/L) levels over 120 minutes, following the 
mixed meal in the morning, afternoon and evening (Mean ± SD). Statistical comparisons 
between control (n=10) and CF (n=13) subjects at each time point were carried out using the 
independent test and a repeated measures ANOVA was performed to study differences within 
the group through the day [No significant differences]. 
Table 4-28 on page 135 and Figure 4-24 and Figure 4-25 on pages 136 and 137 
 
A. Controls		
In the afternoon (MMT2), 3 subjects had high baseline levels (normal < 17.2 pmol/L), 1 had a 
level below the assay detection range at baseline, 60, 90 and 120-minutes, and another at 30, 
60 and 90-minutes. Glucagon levels in the remainder were 18.6 ± 9.3 at baseline and 23.6 ± 
12.4 pmol/L at 120-minutes.  
In the evening (MMT3), 1 subject had glucagon levels below the lower level of assay detection 
at baseline, 60 and 90-minutes, and levels could not be analysed in a further subject at 90 
and 120-minutes due to insufficient sampling. In the remainder, 3 subjects had high baseline 
levels (group mean 16.7 ± 4.6) and the group mean at 120-minutes was 19.2 ± 6.3 pmol/L.  
There was no difference the incremental initial (AUC30) and total (AUC120) responses within 
the control group throughout the day (MMT1, MMT2 and MMT3).  
B. Cystic	Fibrosis	
In the afternoon (MMT2) insufficient samples were taken for baseline analysis in 2 subjects. 
In the remainder, 2 had high baseline levels (group mean 12.2 ± 4.3) and at 120-minutes (17.4 
± 6.6 pmol/L).  
In the evening (MMT3) insufficient sampling prevented analysis in one subject at 60-
minutes, but 5 subjects had high baseline levels (group mean 16.4 ± 4.2) with a group mean of 
13.1 ± 4.5 pmol/L at 120-minutes. 
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There was no difference in the incremental initial (AUC30) and total (AUC120) responses 
within the CF group throughout the day (MMT1, MMT2 and MMT3).  
 
C. Controls	v	Cystic	Fibrosis	
 There was no difference between control and CF subjects at any time point during the 
MMT2, but CF subjects had lower glucagon levels at 120-minutes (p=0.01) at MMT3.  
There was no difference in the initial (AUC30) response between the groups in the morning 
and evening, but in the afternoon, CF subjects had a lower incremental response (p=0.03). 
There was no difference in the total (AUC120) glucagon levels between the 2 groups 
throughout the day. 
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Table 4-27: Glucagon levels through the day 
 
Morning Afternoon Evening 
 
Controls CF p Controls CF p Controls CF 
 
0 
mins 
15.2 ± 4.8 11.4 ± 5.1 0.1 18.6 ± 9.3 12.2 ± 4.3 0.08 16.7 ± 4.6 16.4 ± 4.2 0.85 
30 
mins 
17.2 ± 9.7 13.8 ± 4.0 0.35 14.8 ± 4.8 12.3 ± 3.7 0.2 15.5 ± 3.9 13.1 ± 5.0 0.23 
60 
mins 
21.0 ± 7.6 12.6 ± 5.8 0.01 17.2 ± 9.1 14.4 ± 6.0 0.42 21.0 ± 12.2 13.4 ± 4.7 0.11 
90 
mins 
18.1 ± 7.6 14.4 ± 6.6 0.23 19.9 ± 11.9 15.6 ± 5.1 0.33 19.1 ± 7.4 15.7 ± 3.5 0.25 
120 
mins 
21.2 ± 3.8 15.5 ± 9.3 0.06 23.6 ± 12.4 17.4 ± 6.6 0.2 19.2 ± 6.3 13.1 ± 4.5 0.01 
Comparison between glucagon (pmol/L) levels over 120 minutes, following the mixed meal in 
the morning, afternoon and evening (Mean ± SD). Statistical comparisons between control 
(n=10) and CF (n=13) subjects at each time point were carried out using the independent test 
and a repeated measures ANOVA was performed to study differences within the group through 
the day [No significant differences]. 
Table 4-28: Glucagon - Incremental and Total responses through the day 
AUC30 
 
Morning Afternoon Evening 
Controls 448 ± 166 498 ± 171 483 ± 96 
CF 394 ± 121 355 ± 94 442 ± 110 
p 0.42 0.03 0.38 
AUC120 
    
Controls 2219 ± 632 2205 ± 804 2159 ± 683 
CF 1741 ± 660 1691 ± 454 1728 ± 408 
p 0.14 0.1 0.1 
Comparison between the initial (AUC30) and total (AUC120) glucagon (pmol/L) levels, following 
the mixed meal in the morning, afternoon and evening (Mean ± SD). Statistical comparisons 
between control (n=10) and CF (n=13) subjects at each time point were carried out using the 
independent test and a repeated measures ANOVA was performed to study differences within 
the group through the day [No significant differences]. 
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Comparison of glucagon (pmol/L) levels in response to the mixed meal (mean ± CI) over 120 
minutes between control (n=10) and CF (n=13) subjects in the morning, afternoon and evening. 
[For p-values see Table 4-27] 
Figure 4-24: Glucagon responses through the day 
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Comparison of initial (AUC30) and total (AUC120) glucagon (pmol/L) levels following the mixed 
meal (mean ± CI) between control (n=10) and CF (n=13) subjects in the morning, afternoon and 
evening. 
Figure 4-25: Glucagon - Incremental and Total responses through the day 
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4.3.4.5 Time to peak response 
See Table 4-29 on page 139 
I also evaluated the time taken to reach a peak level for insulin, c-peptide and glucagon at the 
different times of the day. 
A. Insulin	
There was no difference within the control group or the CF group in the time taken to reach 
a peak level of insulin.  Comparing the two groups, the time taken to reach a peak insulin 
level was longest in CF subjects in the evening compared to control subjects (78 ± 31 vs 51 ± 5-
minutes, p=0.03). 
B. C-peptide	
There was no difference within the control group or the CF group in the time taken to reach 
a peak level of insulin.  Comparing the two groups, the time taken to reach a peak c-peptide 
level was greater in CF subjects in the afternoon and evening compared to control subjects 
(afternoon 65 ± 36 vs 83 ± 27-minutes, p=0.04; evening 72 ± 35 vs 90 ± 35 p=0.04). 
C. Glucagon	
There were no differences within the control group or the CF group in the time taken to 
reach a peak level of glucagon. Comparing the two groups, there was no difference in the 
time taken to reach a peak level through the day.  
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Table 4-29: Time to reach a peak level through the day 
  
Insulin C-peptide Glucagon 
Morning 
Controls 52.5 ± 26.6 60.00 ± 32.28 63 ± 51.87 
CF 67.50 ± 28.96 83.08 ± 27.24 85.71 ± 43.80 
p 0.11 0.18 0.35 
Afternoon 
Controls 45.0 ± 22.7 64.5 ± 35.5 84.0 ± 44.3 
CF 55.4 ± 24.0 83.1 ± 27.2 68.6 ± 44.7 
p 0.17 0.04 > 0.99 
Evening 
Controls 48.8 ± 22.3 72.0 ± 35.2 72.0 ± 42.9 
CF 78.5 ± 31.3 90.0 ± 34.6 81.4 ± 43.1 
p 0.03 0.04 0.06 
Mean ± SD (minutes) 
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4.3.5 Insulin Sensitivity 
See Table 4-30 below 
As glucose handling appeared better in the afternoon compared to the other times of the day 
in CF subjects, I went on to evaluate b cell indices looking at insulin sensitivity and 
disposition. 
Within CF subjects, the Matsuda Index (MI) was highest in the afternoon compared to 
control subjects (p=0.04) suggesting greater insulin sensitivity in the afternoon in the CF 
group. The Disposition Index (DI) was consistently lower throughout the day compared to 
control subjects. There were no statistical differences between the DI at various times of the 
day in both groups.  
Table 4-30: Indices of Insulin sensitivity 
  
Morning Afternoon Evening 
Matsuda Index 
(MI) 
Controls 9.6 ± 6.6 8.4 ± 5.3 9.6 ± 6.6 
CF 8.1 ± 2.8 10.5 ± 5.3^ 8.5 ± 4.1 
Disposition 
Index (DI) 
Controls 11.3 ± 5.7 21.6 ± 21.9 16.9 ± 16.3 
CF 2.1 ± 1.6 * 4.5 ± 2.9 ^ 3 ± 3.2 * 
Mean ± SD; Comparison with controls: * p=0.02; ^ p=0.04 
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4.4 Discussion 
In this chapter I have shown that in CF subjects without frank diabetes, there is deficient 
glucose handling throughout the OGTT and early morning MMT. This confirms the results of 
other workers [256] and therefore validates my methodology.  
Clinical decline in CF precedes the detection of diabetes by current OGTT criteria and its 
early treatment confers a clinical advantage, with improvement in lung function and body 
mass index (BMI) within 3 to 6 months of introducing  insulin replacement therapy [40, 46, 
257]. This “CFRD” is characterised by post-prandial hyperglycaemia rather than fasting 
hyperglycaemia and is frequently evident in CF patients with a normal OGTT. 
The factors contributing to this early decline in CF are not fully understood. The patho-
physiology of diabetes has been studied using a variety of oral glucose tolerance tests, but the 
OGTT is un-physiological, unpalatable, time consuming and poorly reproducible [258, 259]. 
Furthermore, in CF it has poor sensitivity and specificity [23, 75] and might give misleading 
results. 
Hence, the administration of a standard mixed meal, considered a more physiological test, 
both at the time of diagnosis and during follow-up has been proposed for clinical practice. 
I have also shown that fasting and total insulin secreted are similar in CF and healthy 
subjects, again in keeping with previous studies [260, 261]. However, healthy subjects 
achieved an earlier peak level (30-minutes). A number of studies have shown this ‘insulin lag’ 
in CF and a decreased first-phase insulin secretion in CFRD. Data from our unit showed that 
the time taken to achieve peak insulin was delayed in individuals with impaired glucose 
tolerance (IGT) and CFRD patients [101]. This first phase insulin secretion and consequent 
increase in plasma insulin after a glucose load is crucial in limiting post-prandial 
hyperglycaemia [262] and CFRD is best thought of as an insulinopaenic condition, as a result 
of β cell failure [36, 52, 263] resulting in impaired and delayed insulin release. It is plausible 
that the well described rapid hepatic uptake of glucose, contributed to no difference 
observed in insulin secretion at 90-minutes between the 2 groups, in this study. 
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To evaluate pancreatic β cell function further I studied C-peptide, a 31 amino acid peptide, a 
good marker of pancreatic β cell function as it is released from the β cells during cleavage of 
insulin from proinsulin, is mainly excreted by the kidney and has a half-life 3-4 times longer 
than that of insulin. I have shown by this study, lower 30 and 60-minute c-peptide levels and 
a longer time to reach a peak level in CF subjects. This reflects a similar response to insulin 
release and reiterates a β cell defect.  
This suggests that altered glucose handling is related to decreased insulin and c-peptide 
levels, a reflection of decreased β cell activity. This is in keeping with the previous study by 
Battezzati et al [264] who showed that β cell function is impaired in CF patients with NGT, 
specifically with regard to insulin secretion increments for a given glucose concentration 
increment. This group also described the impairment of the early insulin secretion index with 
the reduced ability to increase insulin secretion, in response to the speed of glucose 
increment after glucose ingestion. In addition, CF patients with NGT may compensate for a 
decreased β cell function with an intact or increased insulin sensitivity [264]. 
What my study adds to the existing literature is the contribution of glucagon, an α cell 
hormone, to glucose handling. Glucagon is the most important of the counter-regulatory 
hormones. In those with type 2 diabetes, defects in insulin secretion and loss of β cells, 
contribute in part to glucose imbalance. Another major pathway is the counter-regulation by 
glucagon to decreased insulin levels. Raised glucagon levels have been shown to contribute to 
T2DM. Lanng et al [36] demonstrated that following an oral glucose load, glucagon 
suppression is increasingly impaired. Lippe [138] and Moran [52] demonstrated that CF 
patients are not able to appropriately increase glucagon secretion in response to arginine or 
hypoglycaemia using clamp studies, consistent with a reduced α cell mass. By evaluating α 
cell activity, I have shown that glucagon does not contribute to the increased glucose levels 
in CF patients with NGT. This lack of glucagon may explain why the occurrence of abnormal 
fasting plasma glucose is a late occurrence in CF and why the OGTT is a poor test in CF. 
In humans, the diurnal variation in glucose tolerance is well established, yet the current 
diagnostic criteria for diabetes are based on plasma glucose levels recorded in the morning 
after an overnight fast of at least 8 hours. However, many in the CF population have an 
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uncertain duration of fasting and usually have their largest meal later in the day - thereby 
making an early morning assessment of blood glucose un-physiological.  
Despite this, the diurnal variation of glucose handling in CF has not been previously studied. 
This experiment has evaluated glucose tolerance through the day and sets out to describe 
insulin, c-peptide, glucagon responses. 
I chose a standard mixed meal in this study, as it provides a more physiological alternative to 
the OGTT, as dietary constituents other than glucose affect insulin secretion. The addition of 
protein, amino acids or fat to carbohydrate is known to enhance insulin secretion, via the 
incretin system [265]. The main incretins - GIP and GLP1 are secreted from the intestinal L 
and K cells respectively, with the primary physiological stimulus being fat [266] and the 
insulin secretory response of incretins, called the incretin effect, accounting for two-thirds of 
the insulin response to an oral glucose load.  
I have shown that glucose handling in CF patients is variable through the day. Although the 
120-minute glucose value failed to differentiate between healthy and CF subjects with 
abnormal glucose handling based on the standard early morning OGTT, its value in the 
evening deserves further attention and this may be a better indication of glucose intolerance 
later in the day.  
Early morning rises in fasting glucose levels and insulin requirements known as the ‘dawn 
phenomenon’ have been seen in patients with diabetes [218] and in some patients with non-
diabetes [219, 220]. Nocturnal elevations in growth hormone and early morning increases in 
cortisol secretion have been explored as contributors to this phenomenon [221-223]. 
However, a number of studies have shown that blood glucose levels in response to a mixed 
meal are markedly higher in the late afternoon or evening compared to the morning and 
both the size of responses and diurnal variation are more pronounced when the meal has a 
high carbohydrate content [224, 225] and could be partially mediated by circadian variations 
in circulating concentrations of cortisol, a counter-regulatory hormone [226].  
Interestingly, I found that in the CF group glucose handling improved in the afternoon. This 
has not been evaluated or described in the CF population before and is unexpected. The main 
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difference between studies in the healthy population showing glucose intolerance increasing 
throughout the day [209-215] and my subjects (both healthy controls and CF patients) was 
the younger group that I studied and this might possibly account for the differences in 
responses compared to other studies.  
This study also shows CF subjects are insulinopaenic at different times of the day, with the 
lowest insulin level in the afternoon. The initial insulin response, a reflection of the first-
phase insulin response, was lower than control subjects through the day. Importantly the 
time taken to reach a peak insulin level in the evening was the longest. This would suggest 
the b cells take longer to produce insulin at this time of the day – a concept I refer to as ‘CF 
pancreatic fatigue’. 
It is possible to attribute the loss of glucose tolerance to a diminished pancreatic response to 
a glycaemic stimulus. Freinkel et al [228] observed a diurnal variation in plasma insulin levels 
during periods of total fasting, with mean levels in the morning exceeding those in the 
afternoon. Lambert and Hoet [229] also noted a diurnal pattern in insulin levels. They found 
high levels during the night, even though daytime meals were presumably stimulating insulin 
release from the pancreas. It is also plausible that these observations in our CF group may be 
explained by the existence of a periodicity that would regulate insulin secretion. It is also 
possible that insulin liberated post-prandially in the morning conserves a certain activity at 
the moment of the next meal, and still intervenes in maintaining glucose homeostasis. Later 
in the day, however, glucose homeostasis would necessitate a new synthesis of insulin, which 
would explain the plasma insulin response to the evening meal. 
Importantly with a lower blood glucose level in the afternoon and a decreased insulin level, 
other factors might be contributing to this response in the CF group.  In healthy subjects, 
~80% of endogenous insulin secretion is extracted during the first liver passage, insulin 
clearance is pulsatile, wherein the rate of pre-hepatic insulin secretion primarily dictates 
time-varying clearance of endogenously secreted insulin. Moreover, the pattern of insulin 
delivery by the pancreas is the predominant determinant of momentary hepatic insulin 
clearance [267].  It is possible that hepatic extraction of insulin was highest in the afternoon 
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in the CF group in this study. In addition, this might be partly explained by the similar 
diurnal variation in the sensitivity to endogenous insulin.  
Changes in glucose handling can also be explained by circadian rhythms in insulin sensitivity 
which is higher in the afternoon (1200-1800) compared to the night [268]. Moreover, insulin 
sensitivity is impacted by diet and fat, healthy people are more insulin-sensitive, suggesting 
that  changes would be exaggerated in a more insulin-resistant population [269].  
I have shown that insulin sensitivity as measured by the "Matsuda Index" (MI) was highest in 
the afternoon in the CF group possibly explaining the improved level of glucose control at 
this time.  
b cell indices determined by insulin secretion and insulin sensitivity have been validated in 
CF [270]. The MI has been designed to indicate values which are comparable to the rate of 
disappearance of plasma glucose and is a surrogate measure of insulin secretion and insulin 
sensitivity. Such indices have been developed and validated for the OGTT [117] and the MMT 
[271, 272]. The product of insulin secretion and sensitivity derived from OGTT also termed 
disposition index (DI) is a useful marker of integrated islet β cell function. β cell function as 
measured by the DI is reduced in CF patients compared to non-CF controls [121] - even in CF 
patients with normal glucose tolerance and is further decreased in CF patients with diabetes. 
The low DI in our sample of CF patients is due primarily to an insulin secretory defect 
despite stable pulmonary disease and adequate nutritional status. Our findings indicate that 
in CF patients with normal glucose tolerance, the underlying insulin secretory defect might 
be unmasked during times of pancreatic stress such as a response to a meal, possibly 
resulting in hyperglycaemia. 
The DI has the potential to be used as a screening tool and predictor of the development of 
pre-diabetes and CFRD in larger studies and allows for the identification of CF patients who 
are at particularly high risk. This would allow early intervention aimed to preserve their β 
cells and help prevent or delay the development of CFRD and its associated morbidity and 
mortality. 
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In summary, these data from a representative sample of non-diabetic CF adults demonstrate 
that there are clinically significant differences in subjects examined in the afternoon 
compared to the morning and evening. The 120-minute result on a test of glucose handling is 
of no-significance when done in the morning in CF patients and the 120-minute value on an 
evening test and the concept of ‘pancreatic fatigue’ deserves further attention. This study re-
emphasises the need for tests of serial glucose handling with tests that provide ‘glucose 
profiles’ and Continuous Glucose Monitoring (CGM) provides this and I encourage its use. 
Moreover, dietary constituents other than glucose affect insulin secretion. The addition of 
protein, amino acids or fat to carbohydrate is known to enhance insulin secretion, via the 
incretin system [265] The main incretins – GIP and GLP1 are secreted from the intestinal L 
and K cells respectively, with the primary physiological stimulus being fat [266] and the 
insulin secretory response of incretins, called the incretin effect, accounts for two-thirds of 
the insulin response to an oral glucose load. The incretin effect is severely impaired or absent 
in patients with Type 2 Diabetes and has fuelled the interest in the development of therapies 
that target the incretin system. 
To explain the changes I observed in this experiment, I set out to evaluate the GLP1 and GIP 
and pancreatic polypeptide and determine their impact on glucose handling through the day. 
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5 Experiment 3: Pancreatic endocrine and incretin 
responses to mixed versus liquid meal tests in 
non-diabetic CF subjects 
The experiment was carried out as in the study protocol described in the previous chapter. 
5.1 GLP1 analysis (RIA) 
Analysis was carried out at the Clinical Biochemistry Laboratory, Department of Genomics of 
Common Disease, Hammersmith Hospital, Imperial College London, Burlington-Danes 
Building, Du Cane Road, London, W12 0NN, UK. [Dr Paul Bech] 
Total GLP1 was measured using established in-house RIAs [253, 254]. All samples were 
assayed in duplicate. GLP1 was purchased from Bachem Ltd (Switzerland). All other reagents 
and materials were supplied by Sigma (Poole, Dorset, UK). The GLP1 labels were prepared by 
Professor M. Ghatei (Professor of Regulatory Peptides, Metabolic Medicine, Faculty of 
Medicine, Imperial College) who iodinated the peptide using the iodogen method [255] and 
this was purified by reverse-phase HPLC.  
Assays were performed in veronal buffer (1 litre distilled water containing 10.3g sodium 
barbitone, 0.3g sodium azide), at pH 8.0 with 0.02% tween for the GLP1 assay (VWR 
International, UK). Standard curves were prepared in assay buffer at 0.25, added in duplicate 
at volumes of 1, 2, 3, 5, 10, 15, 20, 30, 50 and 100 μl.  
The GLP1 antibody was 149, raised in rabbits against the N terminal of GLP1 (7-36) and binds 
to all amidated forms of GLP1 (1-36, 7-36, 9-36). Experimental samples of 50 μl, 100 μl GLP1 
antibody solution and 100 μl of GLP1 label solution were used and all tubes were buffered to a 
total volume of 700 μl with assay buffer. The assays were incubated for 96 hours at 4oC. Free 
peptide was separated from bound using charcoal adsorption. To each tube, 4 mg of charcoal, 
suspended in 0.06 M phosphate buffer with gelatine was added immediately prior to 
 148 
 
centrifugation. The samples were then centrifuged at 1500 rpm at 4o C, for 20 minutes. Bound 
and free label were separated and both the pellet and supernatant counted for 180 seconds in 
a γ-counter (model NE1600, Thermo Electron Corporation). GLP1 concentrations in the 
samples were calculated using a non-linear plot (RIA Software, Thermo Electron 
Corporation) and results calculated in terms of the standard. 
5.2 GIP analysis (RIA) 
Analysis was carried out at the Clinical Biochemistry Laboratory, Department of Genomics of 
Common Disease, Hammersmith Hospital, Imperial College London, Burlington-Danes 
Building, Du Cane Road, London, W12 0NN, UK. [Dr Paul Bech] 
Plasma GIP concentration was measured by gel-permeation chromatography  
radioimmunoassay [273]. This method is summarised below: 
125I-Labelled GIP was prepared using a modification of an enzymatic iodination method [274] 
carried out at room temperature. Two nmol GIP were dissolved in 50 μL 0.05 mol sodium 
acetate/L, pH 5.0 followed by rapid serial additions of approximately 0.5 nmol Na125I (37 MBq; 
IMS 30,555 MBq/ μgL; The Radiochemical Centre, Amersham), 22 pmol lacto-peroxidase 
derived from milk (Sigma Chemical Co) and 1.8 nmol H2O2/L, the latter two in 10 μL acetate 
buffer. The reagents were mixed by bubbling and then allowed to incubate for 15 minutes. 
The reaction was stopped by dilution with 250 μL of a solution of 100 μL 0.1 mol formic 
acid/L, 200 μL human serum albumin (HAS; Lister Blood Products Laboratory, Elstree, 
Herts), 100 μL 2000 Kallikrein inhibitor units (KIU) aprotinin/ml (Trasylol; Bayer Co West 
Germany), 30 mmol cysteine hydrochloride and 0.05 mol potassium iodide/L. The reaction 
mixture was immediately loaded onto a 60 x 0.9 cm column containing Sephadex G-50 
superfine gel (Pharmacia Co, Uppsala, Sweden) and eluted overnight at 4 °C with 0.1 mol 
formic acid/L containing 10 μmol HSA/L, 1000 KIU aprotinin/ml and 0.02 mol potassium 
iodide/L. Flow rate was maintained at 4 ml/h. Fractions containing radioactivity were tested 
under normal assay conditions for adsorption to charcoal and for binding to antiserum at the 
normal assay concentrations and also in excess. Fractions demonstrating the highest 
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antibody binding and the lowest charcoal blank were pooled, diluted in a special solution for 
freeze-drying, lyophilized to 1.33 Pa, sealed in vacuo and stored at -20 oC in portions each 
sufficient for one assay of 500 tubes. 
Vials of standard hormone were prepared by weighing desiccated pure porcine GIP directly 
on a Cahn electrostatic balance. This was then dissolved in a solution designed to inhibit 
losses by surface adsorption or oxidation and which was easily solubilized after 
lyophilization. The constituents of this solution were 0-14 mol lactose/L, 0.04 mol BSA/L, 11 
nmol citric acid/1.6 nmol cysteine hydrochloride/L and 1600 KIU aprotinin/ml in 0.1 mol 
formic acid/L. Vials containing 1.5 pmol GIP were freeze-dried to 1.33 Pa, sealed in vacuo and 
stored at -20 °C. The stability of this preparation was regularly assessed by assaying 
againststandard. 
Samples were assayed in duplicate in 2ml polystyrene tubes. The plasma sample (200 μL) was 
added to 600 μL 0.05 mol sodium barbitone/L buffer, pH 8.0, containing 1% HSA and 1.5 fmol 
125I-labelled GIP (approx. 100counts/s). Antiserum was added to make a final dilution of 1:96 
000. Tubes for calculating the standard curve and other control tubes contained 200 μL 
subject plasma. The GIP was extracted to constant value by specific immunoadsorption, 
using a high avidity GIP antiserum covalently bound to Sepharose beads [275] . 
To demonstrate that the process completely and specifically removed GIP, samples of plasma 
were taken and exogenous GIP was added. These samples were incubated with GIP antibody-
linked beads, with vasoactive intestinal polypeptide antibody-linked beads and with beads, 
which were in the unlinked state. Beads linked to GIP antibody, which were incubated with 
all the other available gut peptides showed negligible cross-reactivity. Standard curves were 
derived by the addition to this plasma of pure porcine GIP in the range 0-50 fmol/tube. The 
assay constituents were incubated for 96 h at 4 °C before separation. The effect of pre-
incubation with antibody at 4 °C was also assessed by delaying the addition of label for 24 h 
and by incubation after the addition of label for a further 96 h. Separation of antibody-bound 
from free 125I-labelled GIP was achieved using dextran-coated (clinical grade; approximate 
average mol. wt 60-90 000; Sigma Chemical Co.) activated charcoal (Norit GSX, Hopkin and 
Williams, Chadwell Heath, Essex). This was added as a 500 μL slurry in 0.05 M-barbitone 
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buffer, pH 8.0, to each assay tube. The assay tubes were then mixed, incubated for 10 min and 
centrifuged at 2000 g for 15 min at 4 °C. 
The supernatant fraction (containing antibody bound fraction) was aspirated and both this 
and the charcoal precipitate were counted sequentially in the same well of a multi-detector 
counter (NE 1600, Nuclear Enterprises, Edinburgh). The dose-response meta-meter used was 
percentage antibody bound. 
5.3 Pancreatic polypeptide (PYY) analysis 
Analysis was carried out at the Clinical Biochemistry Laboratory, Department of Genomics of 
Common Disease, Hammersmith Hospital, Imperial College London, Burlington-Danes 
Building, Du Cane Road, London, W12 0NN, UK. [Dr Paul Bech] [276] 
Preparation of 125-I-PYY Tracer 
Peptides were iodinated using the iodogen method [277] and purified by HPLC using a C18 
column (Waters, Milford, CT, USA). In brief, the iodogen method adds a 125I molecule onto a 
tyrosine residue in an oxidative reaction. Iodogen reagent (1,3,4,6,-tetrachloro-3α,6α-
diphenylglycoluril; Pierce Chemical Co., Rockford, IL, USA) is reacted with Na125I to oxidise 
the 125I to the reactive iodine state, which subsequently incorporates into available tyrosine 
residues. The iodogen method requires the reaction (peptide in 0.2 M phosphate buffer, 37 
MBq Na125I, 23 nmol iodogen reagent) to be incubated at 22 °C before the reaction products 
are purified by reverse-phase HPLC using a NovaPak C18 column (Millipore, Milford, MA, 
USA). The column was equilibrated for 10 minutes with 15% (v/v) acetonitrile (AcN) solution 
in water containing 0.05% (v/v) trifluoroacetic acid (TFA), at a flow rate of 1 ml/min. The 
concentration of AcN was then gradually increased to 20-45% over the following 80 minutes 
and maintained at the final concentration of 45% for the next 10 minutes. Fractions were 
collected every 1.5 minutes into tubes containing 1 ml 20 mM HEPES at pH 11.0 (to neutralise 
the acidity of the collected fractions) and 0.3% (v/v) bovine serum albumin (BSA) (ICN 
Biochemicals Inc, Costa Mesa, CA, USA). The fractions were tested in an RIA and used at 
1500 cpm/tube. 
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PYY3-36 antibody 
Plasma PYY3-36 was measured using a specific and sensitive RIA.  The assay was performed 
using 0.06 M phosphate buffer with 0.3% BSA at a total volume of 700μl per tube and a 
sample volume of 1–100μl. The antiserum (Y21) was raised in rabbits against synthetic porcine 
PYY1-36 (Bachem Ltd. U.K), coupled to BSA, and used at a final dilution of 1:50,000. The Y21 
antibody is specific for the C-terminal of PYY and reacts fully with human PYY1-36 and PYY3-
36 and does not cross-react with PP, NPY or other known gut hormones.  
The assays were incubated for 3 days at 4ºC before separation of free and antibody-bound 
label by secondary antibody (sheep anti-rabbit antibody). The intra- and inter-assay 
coefficients of variation were 6% and 10% respectively. 
PYY3-36 assays were performed using 0.06M phosphate buffer and a standard curve was 
made for each assay using a solution of unlabelled antigen at a known concentration and 
made up to varying concentrations in the assay by adding in duplicate at volumes of 1, 2, 3, 5, 
10, 20, 30, 50 and 100 µl to the assay buffer. All samples were assayed in duplicate. To measure 
for assay drift in antibody-antigen equilibrium, tubes with no sample (‘zero’ tubes) were 
placed at regular intervals throughout the assay and standard curves were performed at the 
beginning and end of each assay. Similar binding should be observed in the zero tubes and in 
both standard curves. 
After incubation of RIAs for 72 hours at 4°C, free and bound peptides were separated using 
secondary antibody. For secondary antibody separation, 100µl sheep anti-rabbit solid phase 
secondary antibody (Pharmacia Diagnostics, Uppsala, Sweden) was added to the samples and 
allowed to incubate for at least one hour. Immediately prior to centrifugation, 500μl 0.01% 
Triton-X-100 solution was added to each tube. The samples were then immediately 
centrifuged at 1500g, 4°C for 20 minutes. Bound and free label were separated and both the 
pellet and the supernatant counted for 180 seconds in a γ counter (model NE1600, Thermo 
Electro Corporation, Reading, Berks, UK). Peptide concentrations in the samples were 
calculated using a non-linear plot (RIA Software, Thermo Electron Corporation) and results 
calculated in terms of the standard.  
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5.4 Results 
As outlined in the subject demographics and selection, subjects with a 120-minute value >11.1 
mmol/L were excluded from analysis. Data are reported on 10 controls and 13 CF subjects.  
5.4.1 Oral Glucose Tolerance Test (liquid meal) 
5.4.1.1 GLP1 
See Table 5-1 on page 153 and Figure 5-1 on page 154. 
A. Controls	
In response to the OGTT, control subjects had a mean baseline of 6.0 ± 2.2 pmol/L and 120-
minute value of 5.9 ± 2.5 pmol/L. 
Seven control subjects had low GLP1 levels at baseline and 8 had low 120-minute levels 
[Normal levels 7-36 pmol/L] [254] .  
B. Cystic	Fibrosis	
CF subjects had a baseline of 4.9 ± 1.5 pmol/L and 120-minute value of 4.8 ± 1.5 pmol/L. 12 CF  
subjects had low GLP1 levels at baseline and all had low 120-minute levels [Normal levels 7 - 
36 pmol/L] [254].  
C. Controls	v	Cystic	Fibrosis	
Compared to healthy controls, in response to the OGTT there was no difference in CF 
subjects at any time points. 
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Table 5-1: GLP1 levels following the OGTT 
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 6.0 ± 2.2 7.5 ± 2.0 7.9 ± 4.1 6.3 ± 2.9 5.9 ± 2.5 
CF 4.9 ± 1.5 7.4 ± 2.4 5.9 ± 1.9 5.4 ± 1.7 4.8 ± 1.5 
p 0.2 0.95 0.19 0.4 0.21 
Comparison of GLP1 (pmol/L) levels following a liquid meal (OGTT) over 120 minutes between 
control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between groups 
were carried out using independent t-tests.  
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(Top panel): Comparison of GLP1 (pmol/L) levels following a liquid meal (OGTT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual GLP1 levels over 120 minutes, following the liquid meal (OGTT). [ 
Controls  x  CF] 
Figure 5-1: Plasma GLP1 response to the OGTT 
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5.4.1.2 GIP 
See Table 5-2 on page 156 and Figure 5-2 on page 157 
The assay limit of detection (LOD) for GIP was 32 pmol/L. Some subjects had concentrations 
< LOD and have been indicated below. These data were censored for analysis and substituted 
with a constant value(LOD/√2) as described by Helsel [278] and Boeckel [279].  
A. Controls	
Eight subjects had concentrations <LOD at baseline. Two subjects had concentrations < LOD 
at 30, 60, 90 and 120-minutes. 
In response to the OGTT, these subjects had mean baseline of 36.9 ± 36.1 pmol/L and 120-
minute value of 59.0 ± 31.6 pmol/L. 
B. Cystic	Fibrosis	
Six CF subjects had concentrations <LOD (32 pmol/L) at baseline.  One subject had 
concentrations < the LOD at 30, 60, 90 and 120-minutes and one had concentration < the 
LOD at 90 minutes. 
CF subjects had a baseline of 41.8 ± 25.7 pmol/L and 120-minute value of 73.7 ± 39.9 pmol/L.  
C. Controls	v	Cystic	Fibrosis	
Compared to healthy controls, in response to the OGTT there was no difference in CF 
subjects at baseline (p=0.71), 60 (p=0.57), 90 (p=0.26) and 120 (p=0.34) minutes. At 30 
minutes, CF subjects had higher GIP [Controls: 61.0 ± 30.6, CF: 101.2 ± 55.4 (p=0.04)].   
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Table 5-2: GIP levels following the OGTT 
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 36.9 ± 36.1 61.0 ± 30.6 83.9 ± 60.8 75.0 ± 35.6 59.0 ± 31.6 
CF 41.8 ± 25.7 101.2 ± 55.4 97.5 ± 51.0 100.6 ± 62.8 73.7 ± 39.9 
p 0.71 0.04 0.57 0.26 0.34 
Comparison of GIP (pmol/L) levels following a liquid meal (OGTT) over 120 minutes between 
control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between groups 
were carried out using independent t-tests.  
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(Top panel): Comparison of GIP (pmol/L) levels following a liquid meal (OGTT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual GIP levels over 120 minutes, following the liquid meal (OGTT).     
[ Controls  x  CF] 
Figure 5-2: Plasma GIP response to the OGTT 
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5.4.1.3 PYY 
See Table 5-3 on page 159 and Figure 5-3 on page 160 
The assay detection limit (LOD) for PYY was 10 pmol/L. Some subjects had concentrations 
<LOD and have been indicated below. These data were censored for analysis and substituted 
with a constant value (LOD/√2). 
A. 	Controls	
No control subjects had levels below the assay detection limit. 
In response to the OGTT, subjects had a mean baseline level of 29.6 ± 11.1 pmol/L and 120-
minute value of 35.9 ± 17.3 pmol/L.  
B. Cystic	Fibrosis	
Seven CF subjects had concentrations <LOD, at baseline.  Two subjects had concentrations < 
LOD at baseline, 30, 60 and 120-minutes, one at 60 and 90 minutes, two at all time points 
during the test, two at 90 and 120-minutes, one at 30 and 90 minutes and for one subject 
there was insufficient sample available at 60 minutes to assay.  
CF subjects had a baseline of 10.3 ± 4.0 pmol/L and 120-minute value of 10.9 ± 4.6 pmol/L.  
C. Controls	v	Cystic	Fibrosis	
Compared to healthy controls (Table 5-3) in response to the OGTT, CF subjects had lower 
PYY levels at baseline (p=0.0003), 30 (p=0.0001), 60 (p<0.0001), 90 (p=0.0004) and 120 
(p=0.001) minutes.  
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Table 5-3: PYY levels following the OGTT 
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 29.6 ± 11.1 39.1 ± 14.5 31.3 ± 9.6 36.4 ± 16.1 35.9 ± 17.3 
CF 10.3 ± 4.0 11.2 ± 4.5 10.6 ± 4.3 9.5 ± 3.4 10.9 ± 4.6 
p 0.0003 0.0001 <0.0001 0.0004 0.001 
Comparison of PYY (pmol/L) levels following a liquid meal (OGTT) over 120 minutes between 
control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between groups 
were carried out using the Mann-Whitney U test.  
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(Top panel): Comparison of PYY (pmol/L) levels following a liquid meal (OGTT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual PYY levels over 120 minutes, following the liquid meal (OGTT).    
[ Controls  x  CF] 
Figure 5-3: PYY responses to the OGTT 
  
0
5
10
15
20
25
30
35
40
45
50
0	mins 30	mins 60	mins 90	mins 120	mins
pm
ol
/L
PYY	responses	to	OGTT
Controls CF
0
10
20
30
40
50
60
70
0 30 60 90 120
pm
ol
/L
Minutes
PYY	responses	to	the	OGTT
 161 
 
5.4.1.4 Incremental changes in response to the OGTT 
See Table 5-4 below 
I studied the incremental and total response to the OGTT by evaluating the initial response 
at 30 minutes (AUC30) and the total response at 120-minutes (AUC120). 
A. GLP1:	
CF subjects had comparable AUC30 [controls: 202 ± 51, CF: 174 ± 45 pmol/L p=0.43] and 
AUC120 [controls: 828 ± 259, CF: 712 ± 244 pmol/L, p= 0.20]. 
B. GIP	
Again, CF subjects had comparable AUC30 [controls: 1611 ± 845, CF: 1837 ± 869 pmol/L p=0.54] 
and AUC120 [controls: 10680 ± 4699, CF: 10638 ± 6074 pmol/L, p= 0.98]. 
C. PYY	
CF subjects had lower AUC30 [controls: 1031 ± 326, CF: 322 ± 122; p<0.0001] and AUC120 
[controls: 4187 ± 141, CF: 1213 ± 364; p<0.0001]. 
Table 5-4: Incremental and Total responses to the OGTT 
 
AUC30 AUC120 
 
GLP1 GIP PYY GLP1 GIP PYY 
Controls 202 ± 51 1611± 845 1031 ± 326 828 ± 259 8035 ± 4628 4187 ± 1417 
CF 174 ± 45 1837 ± 869 322 ± 122 712 ± 244 10713 ± 5413 1256 ± 382 
p 0.43 0.11 <0.0001 0.2 0.26 <0.0001 
Comparison of the initial (AUC30) and total (AUC120) responses to the liquid meal (OGTT) for 
GLP1 (pmol/L), GIP (pmol/L) and PYY (pmol/L) over 120 minutes between control (n=10) and CF 
(n=13) subjects (mean ± SD). Statistical comparisons between groups were carried out using 
independent t- tests.  
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5.4.2 Mixed meal test (MMT1) 
5.4.2.1 GLP1 
See Table 5-5 below and Figure 5-4 on page 163 
A. Controls	
In response to the MMT, subjects had a mean baseline level of 5.2 ± 1.6 pmol/L and 120-
minute value of 7.7 ± 4.7 pmol/L. 
Eight control subjects had low levels at baseline and 5 had low 120-minute levels [Normal 
levels 7-36 pmol/L] [254] . No subjects had high GLP1 levels. 
B. Cystic	Fibrosis	
CF subjects had a baseline of 4.7 ± 0.9 pmol/L and 120-minute value of 6.1 ± 1.7 pmol/L. 
All CF  subjects had low levels at baseline and only three had normal 120-minute levels 
[Normal levels 7-36 pmol/L] [254].  
C. Controls	v	Cystic	Fibrosis	
Compared to healthy controls (Table 5-5), in response to the MMT there was no difference in 
CF subjects at any time points. 
Table 5-5: GLP1 levels following the MMT 
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 5.2 ± 1.6 6.3 ± 1.8 6.8 ± 2.3 8.1 ± 3.3 7.7 ± 4.7 
CF 4.7 ± 0.9 6.6 ± 2.5 6.7 ± 3.0 6.3 ± 1.7 6.1 ± 1.7 
p 0.38 0.73 0.93 0.14 0.33 
Comparison of GLP1 (pmol/L) levels following a mixed meal (MMT) over 120 minutes between 
control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between groups 
were carried out using independent t-tests.   
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(Top panel): Comparison of GLP1 (pmol/L) levels following a mixed meal (MMT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual GLP1 levels over 120 minutes, following the mixed meal (MMT). [ 
Controls  x  CF] 
Figure 5-4: Plasma GLP1 response to the MMT 
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5.4.2.2 GIP 
See Table 5-6 on page 165 and Figure 5-5 on page 166  
The number of subjects with concentrations < LOD (32 pmol/L) have been indicated below. 
Data at these points were censored for analysis and substituted with a constant value 
(LOD/√2). 
A. Controls	
Six control subjects had concentrations <LOD. Of these, one subject had concentrations < 
LOD at 30 minutes, one at 30 and 60 minutes and one at 30, 60 and 120-minutes.  
In response to the MMT, control subjects had mean baseline levels of 35.6 ± 20.9 pmol/L and 
120- value of 108.2 ± 50.1 pmol/L.  
B. Cystic	Fibrosis	
Five CF subjects had concentrations <LOD at baseline.  One subject had concentrations < 
LOD at all time points during the test, one at baseline, 30, 90 and 120-minutes, one at 90 and 
120-minutes and one at 120-minutes.  
CF subjects had a baseline of 47.2 ± 24.4 pmol/L and 120-minute value of 87.1 ± 52.1 pmol/L.  
C. Controls	v	Cystic	Fibrosis	
In response to the MMT, compared to healthy controls, CF subjects had no difference in the 
GIP levels at any time points. 
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Table 5-6: GIP levels following the MMT 
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 35.6 ± 20.9 71.9 ± 43.2 93.9 ± 53.0 118.4 ± 44.3 108.2 ± 50.1 
CF 47.2 ± 24.4 74.3 ± 38.1 109.2 ± 82.8 95.3 ± 64.4 87.1 ± 52.1 
p 0.24 0.9 0.61 0.34 0.34 
Comparison of GIP (pmol/L) levels following a mixed meal (MMT) over 120 minutes between 
control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between groups 
were carried out using  independent t-tests.   
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(Top panel): Comparison of GIP (pmol/L) levels following a mixed meal (MMT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual GIP levels over 120 minutes, following the mixed meal (MMT).     
[ Controls  x  CF] 
Figure 5-5: Plasma GIP response to the MMT 
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5.4.2.3 PYY 
See Table 5-7 on page 168 and Figure 5-6 on page 169 
The assay detection limit (LOD) for PYY was 10 pmol/L. Some subjects had concentrations < 
LOD and have been indicated below. These data were censored for analysis and substituted 
with a constant value (LOD/√2). 
A. Controls	
One control subject had levels < LOD at all time points.  
In response to the OGTT, the control subjects had mean baseline of 25.5 ± 9.5 pmol/L and 
120-minute value of 43.4 ± 21.7 pmol/L.  
B. Cystic	Fibrosis	
Four CF subjects had concentrations below the assay detection limit (10 pmol/L), at baseline. 
Two subjects had concentrations <LOD at baseline, 60 and 90-minutes, one at 30, 60, 90 and 
120-minutes, one at 30-minutes, one had no detectable levels at any time point during the 
test, two at 90 and 120-minutes, one at baseline and 90-minutes, one at 90, one at 120-
minutes and one at baseline, 30 and 90-minutes. There was insufficient sample for assay for 
one subject at baseline and for another at 120-minutes.  
CF subjects had a baseline of 12.1 ± 7.1 pmol/L and 120-minute value of 16.8 ± 15.7 pmol/L. 
C. Controls	v	Cystic	Fibrosis	
Compared to healthy controls in response to the MMT, CF subjects had lower PYY levels at 
baseline (p=0.001), 30 (p=0.001), 60 (p=0.01), 90 (p=0.005) and 120 (p=0.006) minutes.  
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Table 5-7: PYY levels following the MMT  
 
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 25.5 ± 9.5 42.5 ± 17.5 48.0 ± 28.3 52.7 ± 28.7 43.4 ± 21.7 
CF 12.1 ± 7.1 16.3 ± 16.3 18.0 ± 18.4 18.0 ± 19.2 16.8 ± 15.7 
p 0.001 0.001 0.01 0.005 0.006 
Comparison of PYY (pmol/L) levels following a mixed meal (MMT) over 120 minutes between 
control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between groups 
were carried out using independent t- tests.  
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(Top panel): Comparison of PYY (pmol/L) levels following a mixed meal (MMT) over 120 
minutes between control (n=10) and CF (n=13) subjects (mean ± CI). (Bottom panel): 
Comparison of the individual PYY levels over 120 minutes, following the mixed meal (MMT).     
[ Controls  x  CF] 
Figure 5-6: Plasma PYY response to the MMT 
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5.4.2.4 Incremental changes in response to the MMT 
See Table 5-8 below 
As with the other hormones, I studied the incremental and total response to the MMT by 
evaluating the initial response at 30 minutes (AUC30) and the total response at 120-minutes 
(AUC120). 
A. GLP1	
CF subjects had comparable AUC30 [controls: 172 ± 45, CF: 139 ± 17 pmol/L, p=0.98] and 
AUC120 [controls: 829 ± 280, CF: 649 ± 100 pmol/L, p= 0.52]. 
B. GIP	
CF subjects had comparable AUC30 [controls: 1611 ± 845, CF: 1837 ± 869 pmol/L, p=0.54] and 
AUC120 [controls: 10680 ± 4699, CF: 10638 ± 6074 pmol/L, p= 0.99]. 
C. PYY	
CF subjects had lower AUC30 [controls: 1019 ± 374, CF: 411 ± 267 pmol/L, p=0.0002] and 
AUC120 [controls: 5325 ± 2435, CF: 2037 ± 1720 pmol/L, p=0.0002]. 
Table 5-8: Incremental responses to the MMT  
 
AUC30 AUC120 
 
GLP1 GIP PYY GLP1 GIP PYY 
Controls 172 ± 45 1611 ± 845 1019 ± 374 829 ± 280 10680 ± 4699 5325 ± 2435 
CF 139 ± 17 1837 ± 869 411 ± 267 649 ± 100 10638 ± 6074 2037 ± 1720 
p 0.98 0.54 0.0002 0.52 0. 99 0.0002 
Comparison of the initial (AUC30) and total (AUC120) responses to the mixed meal (MMT) for 
GLP1 (pmol/L), GIP (pmol/L) and PYY (pmol/L) over 120 minutes between control (n=10) and CF 
(n=13) subjects (mean ± SD). Statistical comparisons between groups were carried out using 
independent t- tests.  
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5.4.3 Comparison between the OGTT and MMT 
5.4.3.1 GLP1 
See Table 5-9, Table 5-10 on page 172 and Figure 5-7, Figure 5-8 on 174.  
I then evaluated the responses between the OGTT and the MMT in both healthy controls and 
in CF subjects. 
A. Controls	
With the control group, when the OGTT and MMT were compared, there were no statistical 
differences between the two tests at any time point. This was also the case for the AUC30 and 
AUC120.  
B. Cystic	Fibrosis	
The responses were similar in the CF group, where there were no statistical differences 
between the two tests at any time point when the OGTT and MMT were compared. This was 
also the case for the AUC30 and AUC120.  
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Table 5-9: GLP1 differences between OGTT and MMT 
  
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 
OGTT 6.0 ± 2.2 7.5 ± 2.0 7.9 ± 4.1 6.3 ± 2.9 5.9 ± 2.5 
MMT 5.2 ± 1.6 6.3 ± 1.8 6.8 ± 2.3 8.1 ± 3.3 7.7 ± 4.7 
p 0.13 0.1 0.51 0.06 0.29 
CF 
OGTT 4.9 ± 1.5 7.4 ± 2.4 5.9 ± 1.9 5.4 ± 1.7 4.8 ± 1.5 
MMT 4.7 ± 0.9 6.6 ± 2.5 6.7 ± 3.0 6.3 ± 1.7 6.1 ± 1.7 
p 0.54 0.27 0.48 0.27 0.08 
Comparison of GLP1 (pmol/L) responses to a liquid and mixed meal over 120 minutes in control 
(n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between tests were carried 
out using the paired t-test. 
 
Table 5-10: GLP1 – Incremental and total responses 
  AUC30 AUC120 
Controls 
OGTT 202 ± 51 828 ± 259 
MMT 172 ± 45 829 ± 280 
p 0.06 0.99 
CF 
OGTT 174 ± 45 712 ± 244 
MMT 139 ± 17 649 ± 100 
p 0.28 0.42 
Comparison of the initial (AUC30) and total (AUC120) responses in GLP1 (pmol/L) of a liquid and 
mixed meal over 120 minutes in control (n=10) and CF (n=13) subjects (mean ± SD). Statistical 
comparisons between tests were carried out using the paired t-test. 
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Comparison of GLP1 (pmol/L) responses to a liquid meal (OGTT) and mixed meal (MMT) over 
120 minutes in control (n=10) (top panel) and CF (n=13) subjects (bottom panel). [mean ± CI]. 
Figure 5-7: GLP1 differences between OGTT and MMT 
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Comparison of the initial (AUC30) and total (AUC120) responses in GLP1 (pmol/L) to a liquid and 
mixed meal over 120 minutes in control (n=10) and CF (n=13) subjects (mean ± CI).  
Figure 5-8: GLP1 – Incremental and total responses 
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5.4.3.2 GIP 
 See Table 5-11, Table 5-12 on page 176 and Figure 5-9, Figure 5-10 on pages 177 and 178  
A. Controls	
With the control group, when the OGTT and MMT were compared, there were higher GIP 
levels after the MMT at 90 minutes [OGTT: 75.0 ± 35.6; MMT: 118.4 ± 44.3 pmol/L; p=0.02)] 
and 120-minutes [OGTT: 59.0 ± 31.6; MMT: 108.2 ± 50.1 pmol/L; p=0.005)]. There was no 
difference observed at the other time points. 
When the incremental and total responses were compared, within the control group, there 
were no difference between the 2 tests for the AUC30 (p=0.52) and AUC120 (p=0.10). 
B. Cystic	Fibrosis	
With the CF group, when the two tests were compared, there was lower GIP at 30 minutes 
after the MMT [OGTT: 101.2 ± 55.4; MMT 74.3 ± 38.1 pmol/L; p=0.04]. There were no 
differences observed at the other time points.  
When the incremental and total responses were compared, within the CF group, there were 
no differences between the OGTT and MMT for both AUC30 (p=0.18) and AUC120 (p=0.96).  
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Table 5-11: GIP differences between OGTT and MMT 
  
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 
OGTT 36.9 ± 36.1 61.0 ± 30.6 83.9 ± 60.8 75.0 ± 35.6 59.0 ± 31.6 
MMT 35.6 ± 20.9 71.9 ± 43.2 93.9 ± 53.0 118.4 ± 44.3 108.2 ± 50.1 
 
p 0.82 0.37 0.61 0.02 0.005 
       
CF 
OGTT 41.8 ± 25.7 101.2 ± 55.4 97.5 ± 51.0 100.6 ± 62.8 73.7 ± 39.9 
MMT 47.2 ± 24.4 74.3 ± 38.1 109.2 ± 82.8 95.3 ± 64.4 87.1 ± 52.1 
 
p 0.38 0.04 0.55 0.78 0.31 
Comparison of GIP (pmol/L) responses to a liquid and mixed meal over 120 minutes in control 
(n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between tests were carried 
out using the paired t-test. 
 
Table 5-12: GIP – Incremental and Total responses 
  AUC30 AUC120 
Controls 
OGTT 1469 ± 942 8035 ± 4628 
MMT 1611 ± 845 10680 ± 4699 
p 0.52 0.1 
CF 
OGTT 2145 ± 1095 10713 ± 5413 
MMT 1837 ± 869 110638 ± 6074 
p 0.18 0.96 
Comparison of the initial (AUC30) and total (AUC120) GIP response to a liquid and mixed meal 
over 120 minutes in control (n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons 
between tests were carried out using the paired t-test. 
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Comparison of GIP (pmol/L) responses to a liquid meal (OGTT) and mixed meal (MMT) over 
120 minutes in control (n=10) (top panel) and CF (n=13) subjects (bottom panel). [mean ± CI]. 
Figure 5-9: GIP differences between OGTT and MMT 
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Comparison of the initial (AUC30) and total (AUC120) responses in GIP (pmol/L) to a liquid and 
mixed meal over 120 minutes in control (n=10) and CF (n=13) subjects (mean ± CI). For p-values 
see Table 5-12. 
 
Figure 5-10: GIP – Incremental and total responses 
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5.4.3.3 PYY 
See summary Table 5-13, Table 5-14  on page 180  and Figure 5-11, Figure 5-12 on pages 181 and 
182 
A. Controls	
With the control group, when the OGTT and MMT were compared, there were no 
differences observed at all time points. 
When the incremental and total responses were compared, within the control group, there 
were no difference between the 2 tests for the AUC30 (p=0.59) and AUC120 (p=0.19). 
B. Cystic	Fibrosis	
As with the control group, in the CF group, when the OGTT and MMT were compared, there 
were no differences observed at all time points. 
When the incremental and total responses were compared, within the CF group, there were 
no differences between the OGTT and MMT for both AUC30 (p=0.23) and AUC120 (p=0.13).  
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Table 5-13: PYY differences between OGTT and MMT 
  
0 mins 30 mins 60 mins 90 mins 120 mins 
Controls 
OGTT 29.6 ± 11.1 39.1 ± 14.5 31.3 ± 9.6 36.4 ± 16.1 35.9 ± 17.3 
MMT 25.5 ± 9.5 42.5 ± 17.5 48.0 ± 28.3 52.7 ± 28.7 43.4 ± 21.7 
p 0.28 0.56 0.1 0.14 0.35 
       
CF 
OGTT 10.3 ± 4.0 11.2 ± 4.5 10.6 ± 4.3 9.5 ± 3.4 10.9 ± 4.6 
MMT 12.1 ± 7.1 16.3 ± 16.3 18.0 ± 18.4 18.0 ± 19.2 16.8 ± 15.7 
p 0.36 0.26 0.15 0.11 0.2 
Comparison of PYY (pmol/L) responses to a liquid and mixed meal over 120 minutes in control 
(n=10) and CF (n=13) subjects (mean ± SD). Statistical comparisons between tests were carried 
out using paired t-tests. 
Table 5-14: PYY – Incremental and Total responses 
  
AUC30 AUC120 
Controls 
OGTT 1031 ± 326 4187 ± 1417 
MMT 1019 ± 374 5325 ± 2435 
p 0.59 0.19 
CF 
OGTT 322 ± 122 5325 ± 2435 
MMT 411 ± 267 2037 ± 1720 
p 0.23 0.13 
Comparison of the initial (AUC30) and total (AUC120) responses in PYY (pmol/L) to a liquid and 
mixed meal over 120 minutes in control (n=10) and CF (n=13) subjects (mean ± SD). Statistical 
comparisons between tests were carried out using paired t-tests. 
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Comparison of PYY (pmol/L) responses to a liquid meal (OGTT) and mixed meal (MMT) over 
120 minutes in control (n=10) (top panel) and CF (n=13) subjects (bottom panel). [mean ± CI]. 
Figure 5-11: PYY - Differences between OGTT and MMT 
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Figure 5-12: PYY - Incremental and total responses 
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5.4.4 Diurnal variation of GLP1, GIP and PYY (MMT2 and MMT3) 
As with gastric motility, glucose, insulin, c-peptide and glucagon, I compared changes in 
GLP1, GIP and PYY through the day and evaluated the early response [30 minutes (AUC30)] 
and the total response [120-minutes (AUC120)]. 
5.4.4.1 GLP1 
See Table 5-15 , Table 5-16 on page 185 and Figure 5-13, Figure 5-14 on pages 186 and 187 
A. Controls:		
In the afternoon (MMT2), control subjects had a baseline level of 6.1 ± 1.4 pmol/L and a 120-
minute level of 6.0 ± 1.1 pmol/L. 7 control subjects had a baseline below normal [Normal 
levels 7-36 pmol/L] and 8 subjects had 120-minute values lower than normal. 
In the evening (MMT3), control subjects had a baseline level of 6.1 ± 2.0 pmol/L and a 120-
minute level of 5.9 ± 1.8 pmol/L. Again, 7 control subjects had a baseline level below normal 
[Normal levels 7-36 pmol/L] and 7 subjects had 120-minute levels lower than normal.  
In this group, there was no difference between times of the day with the corresponding time 
during the test. [Baseline: p=0.41, 30 minutes: p=0.17, 60 minutes: p=0.50, 90 minutes: p=0.49, 
120-minutes: p=0.27). 
When the incremental initial (AUC30) and total (AUC120) responses were evaluated, there 
were no differences within the group between the various tests [AUC30: p=0.28; AUC120: 
p=0.82]. 
 
B. Cystic	Fibrosis	
In the afternoon (MMT2), CF subjects had a baseline level of 5.2 ± 1.5 pmol/L and a 120-
minute level of 6.6 ± 1.8 pmol/L. 7 CF subjects had a baseline level below normal [Normal 
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levels 7-36 pmol/L] and 8 subjects had low 120-minute levels. In 2 subjects, there was 
insufficient sample to carry out GLP1 analysis at baseline. 
In the evening (MMT3), CF subjects had a baseline level of 5.3 ± 1.3 pmol/L and a 120-minute 
level of 5.7 ± 1.7 pmol/L. 7 subjects had low baseline levels and 7 subjects had low 120-minute 
levels.  
In CF subjects, there was no difference between times of the day with the corresponding time 
during the test. [Baseline: p=0.47, 30 minutes: p=0.62, 60 minutes: p=0.79, 90 minutes: 
p=0.97, 120-minutes: p=0.41). 
When the incremental initial (AUC30) and total (AUC120) responses were evaluated, there was 
no difference within the control group between the various test [AUC30: p=0.98; AUC120: 
p=0.91]  
C. Controls	v	Cystic	Fibrosis	
When the 2 groups were compared, there was no difference at the corresponding time during 
the test. [Afternoon: Baseline: p=0.17, 30 minutes: p=0.33, 60 minutes: p=0.83, 90 minutes: 
p=0.46, 120-minutes: p=0.34. Evening: Baseline: p=0.29, 30 minutes: p=0.28, 60 minutes: 
p=0.62, 90 minutes: p=0.91, 120-minutes: p=0.75). 
Comparing the incremental responses between the groups, there was no difference in the 
AUC30 in the morning (p=0.98), afternoon (p=0.13) and evening (p=0.18). Similarly, there was 
no difference in the AUC120 between the 2 groups [Morning: p=0.55; Afternoon: p=044; 
Evening: p=0.68]. 
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Table 5-15: GLP1 levels through the day 
 Morning Afternoon Evening 
 Controls CF 
p Controls CF p Controls CF p 
0 
mins 
5.2 ± 1.6 4.7 ± 0.9 
0.38 
6.1 ± 1.4 5.2 ± 1.5 
0.17 
6.1 ± 2.0 5.3 ± 1.3 
0.29 
30 
mins 
6.3 ± 1.8 6.6 ± 2.5 
0.73 
8.1 ± 3.7 
6.8 ± 
2.0 
0.33 
7.2 ± 3.1 6.0 ± 1.6 
0.28 
60 
mins 
6.8 ± 2.3 6.7 ± 3.0 
0.93 
7.7 ± 3.4 7.5 ± 2.3 
0.83 
6.6 ± 2.2 7.2 ± 2.8 
0.62 
90 
mins 
8.1 ± 3.3 6.3 ± 1.7 
0.14 
7.1 ± 2.5 6.4 ± 1.4 
0.46 
6.5 ± 3.0 6.4 ± 1.8 
0.91 
120 
mins 
7.7 ± 4.7 6.1 ± 1.7 
0.33 
6.0 ± 1.1 6.6 ± 1.8 
0.34 
5.9 ± 1.8 5.7 ± 1.7 
0.75 
Comparison between GLP1 (pmol/L) responses over 120 minutes, following the mixed meal in 
the morning, afternoon and evening (Mean ± SD). Statistical comparisons between control 
(n=10) and CF (n=13) subjects at each time point were carried out using independent t-tests and 
a repeated measures ANOVA was performed to study differences within the group through the 
day. [There were no significant differences through the day in both groups]. 
Table 5-16: Incremental and total responses through the day 
  
Morning Afternoon Evening 
AUC30 
Controls 172 ± 45 212 ± 65 200 ± 58 
CF 139 ± 17 162 ± 35 163 ± 36 
p 0.98 0.13 0.18 
     
AUC120 
Controls 829 ± 280 869 ± 280 793 ± 245 
CF 649 ± 100 670 ± 91 658 ± 166 
p 0.55 0.44 0.68 
Comparison between the initial (AUC30) and total (AUC120) GLP1 (pmol/L) responses, following 
the mixed meal in the morning, afternoon and evening (Mean ± SD). Statistical comparisons 
between control (n=10) and CF (n=13) subjects at each time point were carried out using 
independent t-tests and a repeated measures ANOVA was performed to study differences within 
the group through the day. [There were no significant differences through the day in both 
groups] 
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Comparison of GLP1 (pmol/L) levels in response to a mixed meal (MMT) over 120 minutes 
between control (n=10) and CF (n=13) subjects in the morning, afternoon and evening (mean ± 
CI). [For p-values see Table 5-15].  
Figure 5-13: GLP1 response through the day 
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Comparison of initial (AUC30; top panel) and total (AUC120; bottom panel) GLP1 (pmol/L) 
response following a mixed meal (MMT) in the morning, afternoon and evening in control 
(n=10) and CF (n=13) subjects [mean ± CI]. 
Figure 5-14: GLP1 – Incremental and total responses through the day 
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5.4.4.2 GIP 
See Table 5-17, Table 5-18 on page 190 and Figure 5-15, Figure 5-16 on pages 191 and 192 
A. Controls		
In the afternoon (MMT2), 3 control subjects had concentrations < LOD at baseline. These 
data were censored for analysis and substituted with a constant value (LOD/√2). 
At this time, subjects had a baseline GIP level of 74.2 ± 44.2 pmol/L and a 120-minute value of 
99.9 ± 41.3 pmol/L. 
In the evening (MMT3), only one subject had levels <LOD, at baseline. This data point was 
censored for analysis and substituted with a constant value (LOD/√2). 
Subjects had a baseline level of 76.0 ± 50.5 pmol/L and a 120-minute value of 99.1 ± 40.6 
pmol/L.  
In this group, there was a diurnal variation observed at baseline (p=0.05) with the afternoon 
(p=0.01) and evening (p=0.01) values higher compared to the morning. At 30-minutes a 
diurnal variation was again observed (p=0.04) with the afternoon (p=0.01) and evening 
(p=0.001) values higher compared to the morning. There was no difference at 60 (p=0.38), 90 
(p=0.98) and 120-minutes (p=0.88). 
When the incremental initial (AUC30) and total (AUC120) responses were compared, there was 
a diurnal variation observed (p=0.02) in the AUC30 with the afternoon (p=0.002) and evening 
(p=0.0004) being higher than the morning. There was no difference with the AUC120 (p=0.85) 
between times of the day. 
B. Cystic	Fibrosis	
In the afternoon (MMT2), 3 subjects had concentrations <LOD at baseline, one at 30 minutes 
and 90 minutes, one at 30 minutes, one at 90 and 120-minutes and one at 120-minutes. These 
data were censored for analysis and substituted with a constant value (LOD/√2). 
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At this time of the day, these subjects had a baseline level of 70.6 ± 38.8 pmol/L and a 120-
minute value of 115.3 ± 85.4 pmol/L.  
In the evening (MMT3), subjects had a baseline level of 74.2 ± 47.3 pmol/L and a 120-minute 
value of 113.7 ± 73.2 pmol/L. Four subjects had concentrations <LOD at baseline. Of these, 
one had concentrations <LOD at 30 minutes and 90 minutes and two at 120-minutes. These 
data were censored for analysis and substituted with a constant value (LOD/√2). 
In CF subjects, there was no difference between times of the day with the corresponding time 
during the test [Baseline: p=0.16, 30 minutes: p=0.35, 60 minutes: p=0.63, 90 minutes: p=0.31, 
120-minutes: p=0.53). 
When the incremental initial (AUC30) and total (AUC120) responses were evaluated, there was 
no difference within the CF group between the various test [AUC30: p=0.22; AUC120: p=0.40].  
C. Controls	v	Cystic	Fibrosis	
When the 2 groups were compared, there was no difference between the groups at the 
corresponding time during the test. (Afternoon: Baseline: p=0.84, 30 minutes: p=0.66, 60 
minutes: p=0.59, 90 minutes: p=0.85, 120-minutes: p=0.39. Evening: Baseline: p=0.94, 30 
minutes: p=0.17, 60 minutes: p=0.76, 90 minutes: p=0.47, 120-minutes: p=0.57). 
Comparing the incremental responses between the groups, there was no difference in the 
AUC30 in the morning (p=0.54), afternoon (p=0.72) and evening (p=0.38). Similarly, there was 
no difference in the AUC120 between the 2 groups [Morning: p=0.98; Afternoon: p=0.72; 
Evening: p=0.38]. 
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Table 5-17: GIP levels through the day 
 
Morning Afternoon  Evening 
 
Controls CF p Controls CF p  Controls CF p 
0 
mins 
35.6 ± 
20.9 
47.2 ± 
24.4 
0.24 
74.2 ± 
44.2 * 
70.6 ± 
38.8 
0.84  
76.0 ± 
50.5 * 
74.2 ± 
47.3 
0.94 
30 
mins 
71.9 ± 
43.2 
74.3 ± 
38.1 
0.90 
108.8 ± 
43.4^ 
99.7 ± 
52.0 
0.66  
131.6 ± 
60.6 
95.7 ± 
54.5£ 
0.17 
60 
mins 
93.9 ± 
53.0 
109.2 
± 82.8 
0.61 
120.4 ± 
52.1 
133.3 ± 
58.1 
0.59  
124.0 ± 
50.1 
132.0 ± 
69.3 
0.76 
90 
mins 
118.4 ± 
44.3 
95.3 ± 
64.4 
0.34 
121.3 ± 
41.4 
126.3 ± 
74.4 
0.85  
117.5 ± 
38.3 
136.1 ± 
70.5 
0.47 
120 
mins 
108.2 ± 
50.1 
87.1 ± 
52.1 
0.34 
99.9 ± 
41.3 
115.3 ± 
85.4 
0.39  
99.1 ± 
40.6 
113.7 ± 
73.2 
0.57 
Comparison between GIP (pmol/L) responses over 120 minutes, following the mixed meal in the 
morning, afternoon and evening (Mean ± SD). Statistical comparisons between control (n=10) 
and CF (n=13) subjects at each time point were carried out using independent t-tests and a 
repeated measures ANOVA was performed to study differences within the group through the 
day [Compared to morning: *p=0.01, ^p=0.01, £ p=0.001] 
Table 5-18: GIP - Incremental and Total responses through the day 
  
Morning Afternoon Evening 
AUC30 
Controls 1611 ± 845 2744 ± 1219* 3113 ± 1410^ 
CF 1837 ±869 2554 ± 1309 2576 ± 1405 
p 0.54 0.72 0.38 
  
   
AUC120 
Controls 10680 ± 4699 13126 ± 4683 13817 ± 4843 
CF 10638 ± 6074 13566 ± 6750 13790 ± 6823 
p 0.98 0.86 0.99 
Comparison between the initial (AUC30) and total (AUC120) GIP (pmol/L) response, following 
the mixed meal in the morning, afternoon and evening (Mean ± SD). Statistical comparisons 
between control (n=10) and CF (n=13) subjects at each time point were carried out using 
independent t-tests and a repeated measures ANOVA was performed to study differences within 
the group through the day. [Compared to morning: * p=0.002, ^ p=0.0004] 
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Comparison of GIP (pmol/L) responses to a mixed meal (MMT) over 120 minutes between 
control (n=10) and CF (n=13) subjects in the morning, afternoon and evening (mean ± CI). [For 
p-values see Table 5-17) 
Figure 5-15: GIP responses through the day 
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Comparison of initial (AUC30; top panel) and total (AUC120; bottom panel) GIP (pmol/L) 
responses following a mixed meal (MMT) in the morning, afternoon and evening in control 
(n=10) subjects and CF (n=13) subjects [mean ± CI]. 
Figure 5-16: GIP – Incremental and Total responses through the day 
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5.4.4.3 PYY 
See Table 5-19 and Table 5-20 on page 195 and Figure 5-17, Figure 5-18 on pages 196 and 197  
A. Controls		
In the afternoon (MMT2), one control subject had concentrations <LOD (10 pmol/L) at all-
time points. These data points were censored for analysis and substituted with a constant 
value (LOD/√2). 
At this time, subjects had a baseline level of 43.7 ± 23.2 pmol/L and a 120-minute value of 56.1 
± 24.0 pmol/L. 
In the evening (MMT3), the same subject had levels <LOD, at baseline. This data point was 
censored for analysis and substituted with a constant value (LOD/√2). 
Subjects had a baseline level of 43.3 ± 22.3 pmol/L and a 120-minute value of 61.8 ± 37.3 
pmol/L.  
In this group, although the afternoon and evening baseline levels were higher than the 
morning, this variation was not statistically significant (p=0.06).There was no differences at 
30 (p=0.31) 60 (p=0.382), 90 (p=0.84) and 120-minutes (p=0.34). 
When the incremental initial (AUC30) and total (AUC120) responses were compared, there was 
no diurnal variation observed (p=0.14) in the AUC30 or the AUC120 (p=0.40). 
B. Cystic	Fibrosis	
In the afternoon (MMT2), 4 subjects had concentrations <LOD at baseline. Of these one had 
levels <LOD at all time points, two at 60 minutes, one at 60 and 120-minutes. One subject 
had detectable levels at baseline but levels <LOD at 30, 60 and 90 minutes. 
These data were censored for analysis and substituted with a constant value (LOD/√2). 
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At this time of the day, these subjects had a baseline level of 18.6 ± 17.6 pmol/L and a 120-
minute value of 21.2 ± 20 pmol/L.   
In the evening (MMT3), subjects had a baseline PYY level of 17.2 ± 13.9 pmol/L and a 120-
minute value of 26.1 ± 30.6 pmol/L. Five subjects had concentrations <LOD at baseline. Of 
these, two had concentrations <LOD at all time points and one at 30 and 120-minutes. One 
subject had levels <LOD at 30, 60, 90 and 120-minutes and one at 60, 90 and 120-minutes. 
These data were censored for analysis and substituted with a constant value (LOD/√2). 
In CF subjects, there was no difference between times of the day with the corresponding time 
during the test. [Baseline: p=0.46, 30 minutes: p=0.47, 60 minutes: p=0.94, 90 minutes: 
p=0.76, 120-minutes: p=0.62). 
When the incremental initial (AUC30) and total (AUC120) responses were evaluated, there was 
no difference within the CF group between the various test [AUC30: p=0.39; AUC120: p=0.50].  
C. Controls	v	Cystic	Fibrosis	
When the 2 groups were compared, CF subjects had lower PYY levels at all time points 
during the test. (Afternoon: Baseline: p=0.01, 30 minutes: p=0.02, 60 minutes: p=0.006, 90 
minutes: p=0.01, 120-minutes: p=0.002. Evening: Baseline: p=0.006, 30 minutes: p=0.02, 60 
minutes: p=0.003, 90 minutes: p=0.007, 120-minutes: p=0.02). 
Comparing the incremental responses between the groups, CF subjects had lower AUC30 in 
the morning (p=0.0002), afternoon (p=0.01) and evening (p=0.007). Similarly, they had lower 
AUC120 in the morning: p=0.002, afternoon: p=0.02 and evening: p=0.007. 	
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Table 5-19: PYY (pmol/L) levels through the day 
 
Morning Afternoon Evening 
 
Controls CF p Controls CF p Controls CF p 
0 mins 25.5 ± 9.5 12.1 ± 7.1 0.001 
43.7 ± 
23.2 
18.6 ± 
17.6 
0.01 
43.3 ± 
22.3 
17.2 ± 
13.9 
0.006 
30 
mins 
42.5 ± 17.5 
16.3 ± 
16.3 
0.001 
58.3 ± 
27.6 
26.9 ± 
29.5 
0.02 
64.7 ± 
46.4 
23.4 ± 
19.5 
0.02 
60 
mins 
48.0 ± 
28.3 
18.0 ± 
18.4 
0.01 51.1 ± 25.2 
19.7 ± 
22.1 
0.006 
66.4 ± 
35.9 
20.8 ± 
18.9 
0.003 
90 
mins 
52.7 ± 
28.7 
18.0 ± 
19.2 
0.005 
59.7 ± 
30.1 
24.9 ± 
29.7 
0.01 
60.0 ± 
32.9 
22.3 ± 
21.9 
0.007 
120 
mins 
43.4 ± 
21.7 
16.8 ± 
15.7 
0.006 
56.1 ± 
24.0 
21.2 ± 
20.0 
0.002 61.8 ± 37.3 
26.1 ± 
30.6 
0.02 
Comparison between PYY (pmol/L) responses over 120 minutes, following the mixed meal in the 
morning, afternoon and evening (Mean ± SD). Statistical comparisons between control (n=10) 
and CF (n=13) subjects at each time point were carried out using independent t-tests and a 
repeated measures ANOVA was performed to study differences within the group through the 
day. [There were no significant differences in the groups] 
Table 5-20: Incremental and Total responses through the day 
  
Morning Afternoon Evening 
AUC30 
Controls 1019 ± 374 1530 ± 723 1620 ± 908 
CF 411 ± 267 691 ± 691 610 ± 487 
p 0.002 0.01 0.007 
  
   
AUC120 
Controls 5325 ± 2435 6570 ± 2997 7308 ± 4137 
CF 2037 ± 1720 3232 ± 3079 2647 ± 2199 
p 0.002 0.02 0.007 
Comparison between the initial (AUC30) and total (AUC120) PYY (pmol/L) response, following 
the mixed meal in the morning, afternoon and evening (Mean ± SD). Statistical comparisons 
between control (n=10) and CF (n=13) subjects at each time point were carried out using 
independent t-test and a repeated measures ANOVA was performed to study differences within 
the group through the day. [There were no significant differences in the groups]  
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Comparison of GIP (pmol/L) levels in response to a mixed meal (MMT) over 120 minutes 
between control (n=10) and CF (n=13) subjects in the morning, afternoon and evening (mean ± 
CI). [For p-values see Table 5-19) 
 
Figure 5-17: PYY release through the day 
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Comparison of initial (AUC30; top panel) and total (AUC120; bottom panel) PYY (pmol/L) 
responses following a mixed meal (MMT) in the morning, afternoon and evening in control 
(n=10) and CF (n=13) subjects [mean ± CI]. 
Figure 5-18: PYY – Incremental and total responses through the day 
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5.4.5 Experiment 3 summary 
5.4.5.1 OGTT: 
A. GLP1	
Ø There	were	low	baseline	and	120-minute	values	seen	in	both	groups.	
Ø There	was	 no	 difference	 between	 the	 two	 groups	 at	 any	 time	 or	with	 the	 initial	(AUC30)	and	total	(AUC120)	responses.	
B. GIP	
Ø At	30-minutes,	CF	subjects	had	higher	GIP	levels	than	control	subjects	
Ø There	was	 no	 difference	 between	 the	 two	 groups	 at	 any	 time	 or	with	 the	 initial	(AUC30)	and	total	(AUC120)	responses.	
C. PYY	
Ø CF	subjects	had	lower	levels	at	all	time	points.	
Ø CF	subjects	had	lower	initial	(AUC30)	and	total	(AUC120)	responses	when	compared.		
5.4.5.2 MMT: 
A. GLP1	
Ø All	CF	subjects	had	low	baseline	levels.	
Ø Only	3	CF	subjects	had	normal	120-minute	levels	
Ø There	was	 no	 difference	 between	 the	 two	 groups	 at	 any	 time	 or	with	 the	 initial	(AUC30)	and	total	(AUC120)	responses.	
B. GIP	
Ø There	was	 no	 difference	 between	 the	 two	 groups	 at	 any	 time	 or	with	 the	 initial	(AUC30)	and	total	(AUC120)	responses.	
C. PYY	
Ø CF	subjects	had	lower	levels	at	all	time	points,	
Ø CF	subjects	had	lower	initial	(AUC30)	and	total	(AUC120)	responses	when	compared	to	control	subjects.	
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5.4.5.3 Difference between OGTT and MMT: 
A. GLP1	
Ø There	were	no	statistically	significant	differences	between	the	two	tests.	
B. GIP	
Ø In	 control	 subjects,	 there	 were	 higher	 GIP	 levels	 after	 the	MMT	 at	 90	 and	 120-minutes.	
Ø In	CF	subjects,	there	were	lower	levels	at	30-minutes	following	the	MMT.	
Ø There	were	no	differences	between	the	two	tests	with	the	initial	(AUC30)	and	total	(AUC120)	responses.	
C. PYY	
Ø There	were	no	differences	between	the	two	tests	at	the	various	times	and	with	the	initial	(AUC30)	and	total	(AUC120)	responses.	
5.4.5.4 Diurnal variation: 
A. GLP1	
Ø There	was	no	diurnal	variation	observed	in	both	control	and	CF	subjects.	
Ø There	was	no	difference	between	the	controls	and	CF	subjects	at	the	different	times	of	the	day.		
B. GIP	
Ø In	control	subjects,	there	were	higher	GIP	levels	at	baseline	and	30	minutes	in	the	afternoon	and	evening	compared	to	the	morning.		
Ø In	the	control	group,	the	initial	(AUC30)	response	in	the	afternoon	and	evening	was	higher	than	the	morning.		
Ø In	CF	 subjects,	 there	was	no	diurnal	 variation	and	 there	was	no	difference	when	compared	to	control	subjects	at	various	time	points	during	the	day.		
C. PYY	
Ø In	control	subjects,	there	was	no	statistically	significant	diurnal	variation.	
Ø In	CF	subjects,	 there	was	no	diurnal	variation	observed,	but	 there	were	 lower	PYY	levels	at	all	times	of	the	day,	compared	with	controls.	
  
 200 
 
5.5 Discussion 
In experiment 2, I have shown that in CF subjects without frank diabetes, there is deficient 
glucose handling throughout the OGTT and early morning MMT.  I have also shown that 
fasting and total insulin secretion is similar in CF and healthy subjects, although healthy 
subjects achieve an earlier peak level. The experiment reiterated a β cell defect, as CF subjects 
had lower 30 and 60-minute c-peptide levels and took a longer time to reach a peak level. By 
evaluating α cell activity, I have shown that glucagon does not contribute to the increased 
glucose levels in CF patients with NGT, possibly explaining why abnormal fasting plasma 
glucose is a late occurrence in CF and why the OGTT is a poor test in CF. 
By studying diurnal variation, I have shown that glucose handling in CF patients is variable 
throughout the day, with the 120-minute value in the evening deserving further attention 
since it may be a better indicator of glucose intolerance later in the day. Interestingly, I found 
that in the CF group glucose handling improved in the afternoon, with these subjects 
insulinopaenic at different times of the day, with the lowest insulin level in the afternoon and 
the longest time taken to reach a peak insulin level in the evening, suggesting b cells working 
harder at this time of the day. 
It is also possible to attribute the loss of glucose tolerance to a diminished pancreatic 
response to a glycaemic stimulus. Dietary stimuli other than glucose affect insulin secretion 
via the incretin system.   
To explain the changes I observed in experiment 2, I set out to evaluate the impact of the 
incretins GLP1 and GIP and also PYY on glucose handling throughout the day. 
In this chapter (experiment 3), I have shown that in fasting CF subjects without frank 
diabetes, there was no difference in GLP1 secretion when compared to healthy control 
subjects following a liquid or a mixed meal.  Although CF subjects had low baseline levels, 
this was similar to the control group and has been demonstrated before [280, 281]. Hillman et 
al [281] have previously shown that total GLP1 did not differ between healthy controls and CF 
subjects with and without diabetes. However, in their study active GLP1 was lower in CF 
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individuals, indicating that the inactive form of GLP1 was more pronounced in the CF group. 
It is thought that individuals with CF, irrespective of glycaemic status, hypersecrete total 
GLP1 to achieve similar levels of the active hormone seen in matched controls suggesting that 
the CF condition is associated with higher levels of incretin degradation even in stable non-
diabetic individuals [280]. 
When the OGTT and MMT were compared, control subjects tended to have higher GLP1 
levels at 90-minutes after the MMT and a higher initial response to the MMT. In contrast, CF 
subjects tended to have higher levels at 120-minutes after the MMT, suggesting a later peak 
in the CF group. Although the total amount secreted was no different between the groups, it 
is possible that those with CF have this delayed response due to decreased gastric motility (as 
I demonstrated in experiment 1) and the delayed presentation of food substrate to the 
duodenum where GLP1 is secreted. 
Traditionally, is it thought that GLP1 secretion rises early, starting 10-15 minutes after 
ingestion of food, peaking during the second hour, then slowly declining to baseline over the 
next two hours [164, 282]. However, this mono-phasic response is disputed, with some 
studies suggesting a “biphasic” pattern, where an early peak takes place within a few minutes 
after nutrient ingestion and lasts for approximately 30-60 min, followed by a nadir and then a 
second rise in GLP1 which continues for up to 3 hours [283-285]. 
In my experiment, a monophasic pattern was observed, with levels back to baseline at 120-
minutes. One reason for this response could be explained by the meal size and meal 
composition that I used in this study, since the levels of GLP1 secretion are known to change 
with the intake of different nutrients [286].  
Only two studies have previously looked at diurnal rhythms of plasma GLP1 levels, and these 
were in non-CF individuals. Munoz et al [287] did not demonstrate a diurnal variation in 
healthy subjects but demonstrated a disruption in GLP1 secretion in overweight and obese 
subjects. Brubaker et al [288] evaluated the secretory patterns of GLP1 following short-term 
sleep deprivation with nocturnal light exposure. They demonstrated a diurnal variation in 
GLP1 responses to identical meals (850 kcal), served 12-hours apart in normal dark and light 
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periods and suggested the existence of a daily pattern of activity GLP1 secretion. I did not 
demonstrate a diurnal variation in GLP1 secretion in normal subjects: however, these two 
studies are not comparable to my experiment, since meal sizes and constituents were 
different, my subjects were not over-weight or obese and were well rested prior to the 
experiment. GLP1 secretory patterns throughout the day have not been evaluated in CF 
subjects before and my experiment addressed this: I was unable to find any diurnal variation. 
Thus, it is unlikely that GLP1 contributes to the changes in glucose handing through the day 
seen in my study population.  
With regards to GIP, I have shown that although there are no differences in the total GIP 
secreted following the OGTT, CF subjects had higher levels at 30-minutes compared to 
controls. Hypersecretion of GIP in non-diabetic children with CF was shown in 1981 by Ross 
and colleagues [205]. Despite apparently normal glucose handling, in that study, CF children 
demonstrated significant insulinopenia compared to the normal control subjects supporting 
the hypothesis that insulin exerts feedback control on GIP secretion. Subsequent to my 
study, Jones et al [280] showed using an isoglycaemic clamp the incretin effect is lost in those 
with CFRD and although incretin hormones are produced appropriately there is a failure of b 
cells to respond. My study evaluated non-diabetic CF individuals and the hypersecretion of 
GIP demonstrated can be explained by the effect of the gut that would not occur with 
isoglycaemic clamping.  
As regards the MMT, my study showed no difference between the control and CF groups, 
suggesting an intact and appropriate GIP response. This differs from the study by Kuo et al 
[206] where CF subjects were found to have abnormally low postprandial stimulation of GIP, 
but in that work the level was normalised with pancreatic supplementation. In my study, 
subjects had their usual pancreatic supplements (Creon®) with the mixed meal correcting for 
the lack of pancreatic enzyme. Although my study differs in methodology from the study of 
Kuo, my results concur that GIP secretion is normal in those with CF without diabetes.  
More recently, Sheikh and colleagues [256] showed that in a group of CF pancreatic 
insufficient subjects there was less GIP produced over a 4-hour period when compared to 
pancreatic sufficient CF subjects. However, they found no difference in GIP secretion 
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between healthy control subjects and those CF subjects with pancreatic insufficiency, similar 
to my results.  
In my study, towards the latter part of the test, control subjects had higher GIP levels after 
the MMT compared to the OGTT. A number of studies have compared postprandial 
metabolic responses between OGTTs and MMTs in healthy subjects. 
GIP may be higher after the MMT due to a number of reasons. The incretin effect itself is a 
major contributor [164] to gastric emptying that is more rapid after the OGTT than after a 
solid meal, and the proteins and fats present in a mixed meal delay gastrointestinal glucose 
absorption, leading to an attenuated postprandial glucose gradient [289, 290]. While my 
study responses are similar to those in other studies, once again comparisons between 
studies of metabolic responses to meal tests are limited by the differences in contents and 
sizes of meals [290-293].  
No study has previously looked at the differences in response to a liquid and a mixed meal in 
the CF population. The initial (30-minute) lower GIP response in CF subjects after the MMT 
compared to the OGTT was unexpected and has not been described before. One explanation 
is that the gut-sensing or GIP-release patterns to a mixed meal and other nutritional 
constituents are defective in CF.  Also, the glycaemic index of the mixed meal is less than that 
of the OGTT, resulting in lower GIP stimulation. Furthermore, individuals with CF are 
advised to consume at least 3000 calories/day, most of which will have a high glycaemic 
index, and this may condition the GIP response. 
As regards the diurnal variation in secretion, the only study [294] previously evaluating GIP 
responses through the day looked at 12 healthy male subjects who consumed a standard 
breakfast at 0800 hrs and 1700 hrs on the same day. The authors found that the early release 
of GIP was more pronounced in the morning: in my study control subjects had higher 
baseline and 30-minute levels in the afternoon and evening - i.e. - the early response. These 
two studies, however, are not directly comparable: Lindgren fasted subjects for 11 hours 
between tests, which is not a normal meal ingestion pattern, whereas in my study meals were 
provided at more physiological intervals (5 hours). 
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It is also possible that a period of prolonged fasting between the two tests alters the cephalic 
phase of digestion [282], impacting on insulin release and its interaction with GIP. This is yet 
to be studied.  
For the first time my study has looked at the diurnal variation of GIP in CF. I have shown that 
there is no diurnal variation in GIP secretion in CF and there were no differences in 
comparison to control subjects. I did not find higher responses in the afternoon and evening 
in this group similar to the control group suggesting an intact and appropriate GIP response. 
This was similar to my findings comparing the 2 groups during MMT1 (the morning MMT). 
Despite my findings, there are a number of possible reasons why diurnal variation might be 
expected – variation in autonomic nervous activity, changes in gastric motility (as shown in 
experiment 1) or changes in growth hormone and cortisol levels through the day, all known 
to be present in CF subjects. There is also the possibility of a diurnal variation in K and L cell 
activity and an alteration in DPP-4 activity due to neural effect (which does not occur in 
healthy subjects).  
Finally, I studied pancreatic polypeptide (PYY) a hormone that is known to be decreased 
secondary to pancreatic exocrine damage [52, 150, 151], but has received little attention in CF 
where its response to stimuli has not been previously studied. 
PYY release is stimulated via the vagus, GIP, gastric distension, gastrin and vasoactive 
intestinal peptide.  It is localised almost entirely to the pancreas where it is produced by 
discrete, small, granular endocrine cells, scattered throughout the exocrine parenchyma. PYY 
levels rise rapidly after food, especially protein or fat and remain raised for several hours. PYY 
inhibits gastric emptying of solid food and delays the postprandial rise in plasma glucose and 
insulin.  
The pancreas is the only significant source of PYY and intravenous infusions of amino acids, 
glucose or lipids do not alter PYY levels, suggesting an entero-insular axis, an area I wished to 
evaluate in this experiment.   
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In response to the OGTT and MMT, CF subjects had lower levels at all time points when 
compared to control subjects.  This would be in keeping with literature [52, 150, 151] where 
low circulating levels of PYY have been reported. In my study, I have shown for the first time 
a lack of PYY response to an appropriate stimulus – sugar, protein and fat. This might be 
related to existing pancreatic insufficiency in my study group.  
As PYY release is mediated via the vagus, one future consideration would be to study the 
effect of vagal stimulation and the possibility of autonomic dysfunction secondary to 
dysglycaemia in the CF population. 
In control subjects, although the afternoon and evening baseline levels were higher than the 
morning, this variation did not achieve significance. A diurnal variation in PYY  has been 
described, where concentrations are lowest in the morning and peak during the evening 
[295]. This might be secondary to the diurnal variation in vagal tone, with parasympathetic 
vagal activity increasing through the day [296]. I did not see a significant change through the 
day in my study group. This could be due to the inability to analyse some samples (< LOD) in 
my study population, the younger age range of my study group or related to the small sample 
size in my study. 
I did not see a diurnal variation in the CF subjects although there were lower PYY levels at all 
times of the day, compared with controls. This diurnal variation has not been studied before. 
One explanation for this lack of diurnal variation might be an underlying autonomic 
neuropathy [297] in those with CF, who are known to be sympathetically overactive. 
Whether there is a lack of diurnal variation in autonomic activity in this patient group 
remains to be studied. 
I acknowledge my study has limitations. 
Firstly, the small sample size that may have reduced its ability to detect a statistical 
difference through the day. 
Secondly, GLP1 is quickly deactivated by the serine DPP-4 as an important regulatory 
mechanism. I did not use DPP-4 inhibitors while collecting blood samples as I wanted to 
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evaluate the total GLP1 response. However, active GLP1 (using DPP-4 inhibitor) needs to be 
looked at in CF individuals with NGT using insulin clamp studies through the day and this 
was beyond the scope of my study but should be considered in future studies. 
Thirdly, due to limitations of the analytical procedures a number of samples analysed from 
my study (GIP and PYY) were below the LOD and couldn’t be precisely measured. I needed 
to censor and substitute these values with a constant value (LOD/√2)	 value – a factor that 
might have influenced my results and the ability to show significant changes. 
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6 Summary discussion, Limitations, Future 
considerations and Conclusions 
6.1 Discussion 
With increasing survival, CFRD is now the most common comorbidity in individuals with CF. 
The additional diagnosis of CFRD to an already complex clinical condition has a negative 
impact on pulmonary function and survival in CF.  
The pathophysiology of diabetes in CF has not been fully understood and there is a long-held 
view that CFRD stems from physical damage to the pancreas. While it shares features of type 
1 and type 2 diabetes, CFRD is a unique clinical entity and is unlike other types of diabetes for 
several pertinent reasons as I have described in my literature review at the beginning of this 
thesis. 
Firstly, gastric emptying and motility are likely to be altered in the condition, changing the 
way in which nutrients are presented to the gut compared to normal individuals. Secondly, 
relative progressive insulinopaenia occurring over time may result in diurnal changes in 
glucose and other nutrient handling that has not previously been explained. Thirdly, 
abnormalities in the small intestine due to the CF condition may alter the secretion of 
incretins and the associated pancreatic enzymes compared to non-CF individuals. 
With this background, this study was set up to look at factors that could possibly contribute 
to the development of CFRD and I studied individuals who were not known to be diabetic or 
had previously developed diabetes. Being aware that these individuals had not developed 
diabetes and their chances of doing so were high as their condition and age advances, 
allowed me to evaluate the early changes that occur in insulin regulation and whether CF 
causes a second problem which underlies diabetes, separate from pancreatic structural 
damage. 
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The main purpose of this study was to look at possible additional factors that might be 
related to the development of CFRD. The aims of this thesis were to determine some of the 
hormonal and gastric influences on glucose handling. The results of the studies presented in 
this thesis centre around three main themes, which address my hypothesis at the beginning 
of this study that are discussed below.  
6.1.1 Gastric emptying in CF  
Gastric motility within CF has received little attention and previous investigations comparing 
the gastric emptying rate (GER) in CF have shown inconsistent results [206, 237-241]. An 
altered GER in patients with CF can have important clinical consequences. 
A number of factors affect GER in CF - pancreatic enzyme supplementation, glycaemia and 
the high fat/high energy diets prescribed for these individuals.  Gastric emptying is itself 
influenced by acute changes in blood glucose concentrations, with hyperglycaemia delaying 
gastric emptying, which in turn slows the absorption of ingested carbohydrate and reduces 
the propensity for further hyperglycaemia [236]. 
Circadian changes in glucose handling are well described in the normal population [209, 212, 
213, 217] and gastric emptying, which is in turn slowed by hyperglycaemia [242] may influence 
these changes. However there have been no studies of circadian changes in gastric emptying 
in CF subjects, a group with poor glucose handling and there was a need to explore gastric 
motility in CF and the effects this might have on glucose handling and CFRD.  
The study presented in experiment 1 of this thesis was designed to investigate GER in healthy 
control subjects and individuals with CF. Several different methods have been used to 
evaluate gastric emptying in adults. The gold standard test to assess gastric emptying is 
scintigraphy which is not practicable for daily use and not practicable for the nature of my 
study as scintigraphy requires subjects fasted for at least 12 hours, which would not have been 
possible to do in a study assessing diurnal changes. Moreover, scintigraphy requires 
expensive equipment not readily available and has an associated radiation burden. I chose 
ultrasound measurements, a validated and comparable method [298] with advantages over 
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other techniques in that it is non-invasive, does not entail radiation and makes use of 
standard ward based ultrasound equipment, which is easily accessed.  
I assessed GER using an ultrasound method that is safe, easy to use,  requires a standard 
ultrasound transducer and gives real time results. This method has previously been 
standardized [243] and validated [244-246] with good intra- and inter-observer agreement 
[243]. I was able to reliably measure GER in 96% of my subjects. 
My study is the first to use ultrasound to assess gastric emptying in the adult CF population. 
Using this method, I have shown that healthy control subjects have normal gastric emptying 
for both liquid and mixed meals after an overnight fast, in keeping with existing literature 
[248]. 
For the first time, I have shown that although adult CF subjects without known CFRD have a 
normal antral size, following an overnight fast, they have delayed gastric emptying for both 
liquid and mixed meals.  
In my study cohort, although the mean gastric emptying rate in response to a liquid meal was 
normal, 42% of CF subjects had decreased gastric emptying at 60-minutes. These subjects 
also had reduced emptying of a mixed meal. 
I have also shown that more CF subjects have decreased gastric emptying in response to a 
mixed meal compared to a liquid meal, demonstrating that the mixed meal test is the more 
physiological test in CF individuals.  
My study is the first to explore gastric emptying in adult CF patients throughout the day. I 
have shown that not only do CF individuals without known CFRD have delayed gastric 
emptying in the morning, but this delay continues throughout the day.  
A number of studies have demonstrated that pre-existing hyperglycaemia slows gastric 
emptying in healthy humans [232], Type 1 [250-252] and Type 2 diabetics [231]: I chose CF 
individuals without known CFRD to minimise this and also prevent the possibility of occult 
gastroparesis due to diabetic-related autonomic neuropathy. Similarly, by using the same 
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carefully measured constituents in each experiment I sought to control for differences in food 
composition and volume. Nevertheless, these CF subjects still had a delay in gastric emptying 
and the subsequent experiments in my thesis explored dynamic glucose handling and the 
influence of incretins and other hormones that might influence gastric emptying. 
In experiment 2, I had shown CF subjects had higher glucose responses at 30 to 90 minutes 
after the OGTT and 30 to 120-minutes after the MMT. Coinciding with this hyperglycaemia 
the GER was delayed at 90 and 120-minutes after the OGTT and 60 to 120-minutes after the 
MMT and it is likely that this lag is due to the preceding hyperglycaemia delaying GER. 
Among the other factors that may determine postprandial glucose excursions is glucose 
influx from the gut [299] which appears to be determined to a certain extent by the rate of 
gastric emptying: since as much as 40–50% of variation in postprandial glucose excursions 
may be explained by differences in the rate of gastric emptying [233]. In Type 1 diabetes, 
gastroparesis is a late diabetic complication resulting from irreversible intestinal nerve 
damage [299] and is different from the physiological inhibitory effects of acute 
hyperglycemia on gastric motility [300, 301]. The latter has been proposed as a defence 
mechanism to minimize postprandial hyperglycemia by reducing the rate of efflux of glucose 
into the circulation from the gut [232]. Whether this mechanism exists in CF remains to be 
determined and it is possible that this mechanism is responsible for the delayed initial 
emptying seen in the evening in this study. 
It is also possible that an increased GIP early on following the OGTT, that I found in 
experiment 3, contributed to some delayed emptying. However, I was unable to demonstrate 
significant changes during the MMT or during the day, making a significant contribution of 
GIP to a delayed emptying unlikely.  
Finally, in a real world and practical setting, gastric ultrasound may also be useful in the 
clinical setting, by providing a simple cheap non-invasive way of assessing gastric emptying.  
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6.1.2 Glucose handling in CF and its diurnal variation 
Clinical decline in CF precedes the detection of diabetes by current OGTT criteria and its 
early treatment confers a clinical advantage. CFRD is characterised by post-prandial 
hyperglycaemia rather than fasting hyperglycaemia and is frequently evident in CF patients 
with a normal OGTT. 
In experiment 2, I showed that in CF subjects without frank diabetes, there is deficient 
glucose handling throughout the OGTT and early morning MMT and was able to 
demonstrate significant differences in subjects examined in the afternoon compared to the 
morning and evening. Whether this might be clinically significant remains to be determined. 
Importantly, the 120-minute result on a test of glucose handling is of no significance when 
done in the morning in CF subjects and the 120-minute value on an evening test deserves 
more attention. 
This emphasises the need for tests of serial glucose handling with tests that provide ‘glucose 
profiles’. The standard mixed meal test considered a more physiological test, both at the time 
of diagnosis and during follow-up has been proposed for clinical practice. Carrying out 
routine evening MMTs would not be practicable on a larger scale in clinical practice. Hence, 
there is a role for ambulatory Continuous Glucose Monitoring (CGM) systems that have been 
validated for use in those with CF [88-90].  
In experiment 2, I sought to evaluate the impact of pancreatic β cell function on glucose 
handling. I showed that fasting and total insulin secreted are similar in CF and healthy 
subjects with an insulin lag in CF subjects. This has been shown before [101, 260, 261] and it is 
likely to be this insulin lag that contributed to the initial glucose excursions I saw in this 
study. Moreover, in addition to lower c-peptide levels, CF subjects took a longer time to 
reach a peak level reiterating a β cell defect and suggests that altered glucose handling is 
related to decreased insulin and c-peptide levels, a reflection of decreased β cell activity. This 
reduced β cell activity appears to go together with decreased α cell activity and the counter-
regulation by glucagon to decreased insulin levels. In my study, it appears that glucagon does 
not contribute to the increased glucose levels in CF patients with NGT. This is in keeping 
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with the studies of Lanng [36], Lippe [138] and Moran [52] who demonstrated that CF 
patients are not able to appropriately increase glucagon secretion in response to arginine or 
hypoglycaemia using clamp studies, consistent with a reduced α cell mass.  
The main focus of my study was to evaluate pancreatic function through the day. 
Surprisingly, I found CF subjects had better glucose handing in the afternoon and at the same 
time had the lowest insulin levels. As discussed in experiment 2, it is possible that insulin 
liberated post-prandially in the morning conserves a certain activity at the moment of the 
next meal, and still intervenes in maintaining glucose homeostasis. In addition, when I 
studied insulin sensitivity, this was highest in the afternoon and appears to play a significant 
part in improving glucose handling in the afternoon. Importantly the time taken to reach a 
peak insulin level in the evening was the longest, suggesting the b cells take longer to 
produce insulin at this time of the day – a concept I referred to as ‘CF pancreatic fatigue’. 
6.1.3 The contribution of the entero-insular axis to altered glucose 
handling 
Gastric emptying and glucose handling is regulated by a complex interaction of neuronal and 
hormonal input. Many of these hormones produced and secreted by the gastrointestinal tract 
have simultaneous effects on glucose handling via the release of insulin. Dietary constituents 
other than glucose affect insulin secretion. The addition of protein, amino acids or fat to 
carbohydrate is known to enhance insulin secretion, via the incretin system [265] The main 
incretins - GIP and GLP1 are stimulated by fat [266]. I also sought to measure PYY, which is 
secreted solely by the pancreas but is under autonomic vagal control and has received little 
attention in CF. 
I have shown that in fasting CF subjects without frank diabetes, there was no difference in 
GLP1 secretion when compared to healthy control subjects following a liquid or a mixed meal 
or through the day. However, CF subjects in contrast to controls tended to have higher levels 
later during the MMT.  It is possible that those with CF have this delayed response due to 
decreased gastric motility and the delayed presentation of food substrate to the duodenum 
where GLP1 is secreted. It is unlikely that GLP1 contributed to the changes in glucose handing 
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seen through the day seen in my study population. I did not measure active GLP1, by using 
DPP-4 inhibitors and this is a limitation of the study that I have addressed in the subsequent 
section.  
When measuring GIP, CF subjects had early hypersecretion of GIP following the OGTT. 
Hypersecretion of GIP in non-diabetic children with CF was shown in 1981 by Ross and 
colleagues [205] and my study is the first to show this in adults. I did not find any significant 
differences after the MMT or on evaluation of GIP through the day suggesting an intact and 
appropriate GIP response to food substances. 
When I set out at the beginning of this study, I had hoped to show differences in the incretin 
responses and a significant contribution of the entero-insular axis to glucose handing and the 
diurnal variation in glucose handling. This did not occur and there are several possible 
explanations for it. The CF patients I studied were comparatively well: CFRD tends to 
manifest in the sicker population and it might be that those I studied had yet to develop 
significant limitations of the entero-insular axis. Another factor that might have contributed 
is the calorific size of the meal I administered. Although I used a standard mixed meal, this 
may not have been sufficient to stimulate the incretin system in a population with a high 
metabolic rate who are used to consuming meals with high calorific values.  
In my PYY experiment I showed, for the first time a lack of response in CF subjects to oral 
stimuli with no diurnal variation. This is likely to be secondary to the known existing 
pancreatic exocrine insufficiency in my CF study group. PYY inhibits gastric emptying of 
solid food and delays the postprandial rise in plasma glucose and insulin. The lack of PYY in 
my CF study group would not have contributed to the delayed gastric emptying I showed in 
experiment 1. It is also unlikely to contribute to the delayed insulin response that has been 
well described in the CF population.  
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6.2 Limitations 
This study does have its limitations. I have discussed some of these in previous chapters. 
Firstly, a limitation of the experiments in this thesis is the small sample size. However, 
although the number of subjects was relatively small, it was still adequate to demonstrate 
significant differences among groups in several independently measured variables. 
Secondly, there were more male subjects in the CF study group. However, females with CF 
develop CFRD earlier than males (on average 5–7 years) [302] and tend to be sicker than their 
male counterparts [86], limiting the period of clinical stability required for recruitment. Why 
this occurs is not clear, but female hormones, lack of anabolic male hormones, and oral 
contraceptives are all possible explanations [29]. 
Thirdly, the screening OGTT (or the liquid meal) carried out was a ‘single’ test. Given the up 
to 50% variability in OGTT results in CF patients [23], some may have shown a different 
response to a second OGTT on another day. 
The small sample size might have limited the ability to detect statistical differences in insulin 
and c-peptide at some time points or later in the day. It could very well be that secretion of 
insulin and c-peptide change, albeit at a later time, but continuous monitoring of insulin 
secretion to measure its pulsatility is not practicable. 
One criticism of my study could be the non-measurement of active GLP1. GLP1 is quickly 
deactivated by the serine protease dipeptidyl peptidase IV (DPP-4) as an important 
regulatory mechanism. I did not use DPP-4 inhibitors as I wanted to evaluate the total GLP1 
response. However, active GLP1 (using DPP-4 inhibitor) needs to be looked at in CF 
individuals with NGT using insulin clamp studies through the day and this was beyond the 
scope of my study. On reflection, at the end of this work, it would have been prudent to 
collect an additional blood sample with DPP-4 inhibitor, as the results might have 
strengthened my work and thesis.  
As discussed in experiment 1, with the assessment of gastric motility, I was not blinded to 
subjects’ responses due to the nature of the study. I was trained and had a competency 
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assessment by an experienced radiologist, but I did not evaluate reproducibility and 
repeatability. However, four complete studies for each subject were carried out on two 
different days, three of which were performed on the second day and the analysis indicated 
an acceptable level of repeatability. With regards to reproducibility, I had initially set out to 
compare the GER30 in the morning on separate days. However, since the volumes of 
substance used to make up the OGTT and MMT were different, stomach distension was 
dissimilar such that comparison was not possible. 
A number of samples analysed from my study (GIP and PYY) were below the LOD and 
therefore could not be precisely measured. I censored and substituted these values with a 
constant (LOD/√2), in keeping with accepted statistical practice, but nevertheless this might 
have influenced the ability to show significant changes.  
Finally, some tests of diurnal variation (Repeated ANOVA) were significant, but the post-hoc 
tests (Bonferroni tests) were not. This might have been due to small sample size and low 
power. The Bonferroni correction might have been too conservative a test and a larger 
sample size and Bonferroni correction might have confirmed results.  
Some of the limitations of this study need to be addressed in future studies discussed in the 
next section. 
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6.3 Future considerations 
The studies presented in this thesis provide insights into glucose handling in CF patients 
without known diabetes.  
Future work in this area should consider the following: 
Following completion of data collection in my study, Hillman et al [281] showed that active 
GLP1 was significantly decreased in patients with CF and CFRD compared to healthy controls. 
GLP1 analogues are now used as anti-diabetic drugs in patients with T2DM, but it is not 
known whether these drugs are clinically effective in CF patients. Further work needs to be 
done looking at active GLP1, in particular in response to a mixed meal. 
I have also shown the predominant defect in CFRD is poor β cell function. In my study, it 
appeared the incretin system functions normally in those with CF. However, further work 
needs to be done in this area to confirm this. Using matching isoglycaemic and 
hyperglycaemic clamps would enable measurement of the dependency of insulin secretion on 
incretin hormones. By comparing levels following OGTT, MMT and then an intravenous 
glucose infusion, the incretin effect could be evaluated. Measuring active GLP1, at the same 
time and throughout the day would improve our understanding of the pathogenesis of CFRD.  
My study did not evaluate the effect of individual components of the mixed-meal. This is 
important to consider for future research, as the responses to various concentrations of fat, 
carbohydrate or protein might vary through the day and the meals I administered had fixed 
amounts of nutrients. It is possible that the raised sugars seen commonly at the end of the 
day might be related to abnormal handing of nutrients later in the day. As discussed earlier, a 
limitation of my study is the calorific size of the meal I administered which might not be high 
enough to stimulate the CF pancreas and altering meal constituents at different times of the 
day might address this. 
Elder et al [303] showed that patients with CF have reduced insulin secretion during an 
OGTT regardless of exocrine pancreatic status. This would suggest abnormal insulin 
secretion in all CF patients and may predispose them to developing glucose intolerance, 
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particularly when challenged by inflammation, infection, or nutritional deficiencies.  I chose 
pancreatic insufficient subjects for my study. Future work should evaluate the same aims of 
my study, but in pancreatic sufficient individuals with CF.  At the time of writing this thesis, 
Sheikh et al [256] published data demonstrating reduced β cell secretory capacity in 
pancreatic-insufficient, but not pancreatic-sufficient CF patients with normal glucose 
tolerance. The study by Sheikh did not evaluate changes through the day and this needs 
further attention in the pancreatic sufficient group.  
Following the availability of CFTR modulators such as Ivacaftor (Kalydeco®) which corrects 
the gating defect of the CFTR channel associated with the G551D genetic mutation, there 
have been reports of resolution [304] or the delay in the onset [305] of CFRD. A direct role for 
CFTR in islet function has been demonstrated in the ferret and pig models of CF [306, 307] 
and there is a possible regulatory mechanism of CFTR on insulin production [308]. 
Treatments such as these might affect CFTR function, but the impact of CFTR on β cells in 
humans is not known. Studying pancreatic sufficient individuals with CF, might give further 
insight into the effect of glucose handing and incretin responses. 
Insulin secretion is regulated through a complex of different signals stimulated by nutrients, 
incretins, and important autonomic stimuli.  The cephalic phase insulin response, which lasts 
for about 10 minutes, is initiated by meal ingestion and has been demonstrated before [309]. I 
did not measure this in my study. Whether this has an impact on glucose handling in CF is 
not known and has not been evaluated before and deserves further attention.   
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6.4 Conclusions 
The experimental studies described within this thesis have extended knowledge on the 
gastric emptying rate, glucose handling and gut hormone responses in CF subjects without 
known CFRD.  The main conclusions that can be drawn from this work are:  
This is the first study to use ultrasound to assess gastric motility in the adult CF population 
and demonstrates delayed gastric emptying throughout the day in CF subjects, compared to 
matched controls, for both liquid and mixed meals. Moreover, this study shows that this 
novel inexpensive bedside technique provides a simple method of assessing GER in CF and 
will have a role in the clinical setting. 
This is the first study to show that although adult CF subjects without known CFRD have a 
normal antral size, following an overnight fast they have delayed gastric emptying for both 
liquid and mixed meals.  
CF subjects have decreased gastric emptying in response to a mixed meal compared to a 
liquid meal, demonstrating that the mixed meal test is more physiological in CF individuals. 
In CF subjects without frank diabetes, there is deficient glucose handling throughout the 
OGTT and early morning MMT. 
There are significant differences in glucose handling in the afternoon compared to the 
morning and evening, with the 120-minute value at an evening test deserving more attention. 
Fasting and total insulin secreted are similar in CF and healthy subjects with an insulin lag in 
CF subjects and glucagon does not appear to contribute to elevated blood sugars. 
Insulin sensitivity is highest in the afternoon and appears to play a significant part in 
improving glucose handling in the afternoon. 
The time taken to reach a peak insulin level in the evening is the longest, suggesting that b 
cells work harder at this time of the day. 
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In fasting CF subjects without frank diabetes, there is no difference in GLP1 secretion when 
compared to healthy control subjects following a liquid or a mixed meal.   
In fasting CF subjects without frank diabetes, there is no difference in GIP secretion when 
compared to healthy control subjects following a mixed meal, but hypersecretion exists early 
in the response to the OGTT.   
CF subjects have lower PYY levels in response to the OGTT and MMT with no diurnal 
variation, likely to be secondary to the existing pancreatic insufficiency. 
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National Research Ethics Service 
NRES Committee North West - Greater Manchester East 
3rd Floor, Barlow House 
4 Minshull Street 
Manchester 
M1 3DZ 
 
Tel: 0161 625 7830 
Fax: 0161 625 7299 
 
18 June 2012 
 
Dr Dilip S Nazareth 
Clinical Research Fellow 
Liverpool Heart and Chest Hospital NHS Trust 
Adult CF Unit 
Thomas Drive 
Liverpool 
L14 3PE 
 
 
Dear Dr Nazareth 
 
Study title: Factors responsible for the development of diabetes in 
adults with Cystic Fibrosis 
REC reference: 11/NW/0552 
Amendment number: Substantial amendment 1 
Amendment date: 20 May 2012 
 
The above amendment was reviewed June 2012 by the Sub-Committee in correspondence.  
 
Ethical opinion 
 
The sub- committee reviewed the amendment and have no ethical concerns.  
 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
 Document  Version  Date  
Participant Consent Form  1.1  19 May 2012  
Participant Information Sheet  1.5  19 May 2012  
Protocol  3.5  18 May 2012  
Notice of Substantial Amendment (non-CTIMPs)  Substantial 
amendment 
1  
20 May 2012  
  
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
11/NW/0552:     Please quote this number on all correspondence 
 
Yours sincerely 
 
 
 
Mr Francis Chan 
Chair 
 
E-mail: nicola.burgess@northwest.nhs.uk 
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Copy to:  Dr Margarita Perez-Casal 
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Mr Francis Chan  Consultant Orthopaedic Surgeon  Expert  
Dr  Michael  Hollingsworth  Retired Senior Lecturer in Pharmacology  Lay  
Professor Janet Marsden  Professor of Ophthalmology and 
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28#September#2011# # Version#1.4#
#
When%complete,%1%copy%for%participant:%1%copy%for%researcher%site%file:%1%(original)%to%be%kept%in%medical%notes#
Consent'Form'
Study#Number'
Participant#Identification#Number#for#this#Study:#
Title'of'Project:'Factors(responsible(for(the(development(of(diabetes(in(adults(with(Cystic(
Fibrosis(
Name of Researcher: Dr. Dilip Nazareth 
                  Please Initial Box 
1. I# confirm# that# I# have# read# the# information# sheet# dated# 28@September@2011#
(version#1.5)#of#the#above#study.# # I#have#had#the#opportunity#to#consider#the#
information,#ask#questions#and#have#had#these#answered#satisfactorily. 
 
   
2. I#understand#that#my#participation#is#voluntary#and#that#I#am#free#to#withdraw#
at#any#time#without#giving#any#reason,#without#my#medical#care#or#legal#rights#
being#affected.# 
 
   
3. I# understand# that# relevant# sections# of#my#medical# notes# and# data# collected#
during#the#study#may#be#looked#at#by#responsible#individuals#from#regulatory#
authorities,#the#research#team,#or#from#the#NHS#Trust,#were#it#is#relevant#to#my#
taking# part# in# this# research.# I# give# permission# for# these# individuals# to# have#
access#to#my#records.# 
 
   
4.  I#agree#to#my#GP#being#informed#of#my#participation#in#the#study.#  
   
5.  I#understand#that#blood#samples#collected#will#be#frozen#and#analysis#may#take#
place#at#a#later#date#and#may#occur#in#an#external#laboratory.###
 
6. I#agree#to#gift#the#samples#collected#for#use#in#future#research#projects#which#
have#been#reviewed#by#a#Research#Ethics#Committee. 
 
 # #
7. I#agree#to#participate#in#this#study.## #
#
Name#of#Participant###__________________________##################Date########__________##
Researcher###__________________________##
#
#
#
#
#
#
#
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Participant)Information)Sheet)(CF))Summary)
Factors)responsible)for)the)development)of)diabetes)in)adults)with)Cystic)Fibrosis)
)
Cystic"Fibrosis"(CF)"affects"over"8,500"people"and"affects"multiple"parts"of"the"body."One"organ"that"
is"affected"is"the"pancreas"that"is"responsible"for"the"release"of"insulin"and"those"with"CF"are"prone"
to"develop"diabetes."The"type"of"diabetes"in"CF"is"different"from"the"other"types"of"diabetes"and"is"
‘unique’." The" exact" nature" of" why" diabetes" develops" is" not" known" but" is" thought" that" both" the"
release"and"action""of"insulin"may"be"responsible"and"it"has"been"found"that"insulin"enhances"muscle"
mass"and"improves"lung"function."
The"purpose"of"this"study"is"to"look"at"possible"factors"that"might"be"related"to"the"development"of"
diabetes"and"to"develop"a"new"test"for"diabetes"that"may"be"suited"for"use"in"someone"with"CF"as"
the"current"tests"are"derived"from"information"available"from"people"with"diabetes"who"do"not"have"
cystic"fibrosis."""
You"have"been"invited"to"take"part"in"this"study"as"our"records"indicate"that"you"have"cystic"fibrosis"
but"currently"do)not"have"a"diagnosis"of"cystic" fibrosis" related"diabetes." "We"want" to"assess"some"
factors" (stomach"movements,"hormones"and" insulin"release)"that"will"allow"us"to"determine,"more"
precisely,"the"risk"of" individuals" like"you"developing"diabetes." "We"intend"to"recruit"30"participants"
with"CF"to"take"part"in"this"study.""
The"participant" information" sheet"attached"gives"details"of" the" study"and"how" it"would"be"carried"
out."""
Your"participation" is" entirely" voluntary" and"you"would"be"able" to"withdraw" from" the" study"at" any"
time."
"
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Participant)Information)Sheet)(CF))
Factors)responsible)for)the)development)of)diabetes)in)adults)with)Cystic)Fibrosis)
)
We"would"like"to"invite"you"to"take"part"in"our"research"study."However,"before"you"decide,"we"need"
you"to"understand"the"reason"for"the"research"and"what"it"involves.))))"You"may"talk"to"others"about"
the"study" if"you"so"wish." "Part"1"tells"you"the"purpose"of"the"study"and"what"to"expect" if"you"take"
part.""Part"2"gives"you"more"detailed"information"about"the"conduct"of"the"study.""Please"ask"if"there"
is"anything"you"do"not"understand."Take"time"to"decide"whether"or"not"you"wish"to"take"part"in"this"
research"study.""
If" you" are" willing" to" participate" please" telephone" Mrs.) Patricia) Stanley" (Pulmonary" Function"
Administrator)"on"01516001780"to" indicate" that"you"are" interested" in" taking"part" in" the"study"and"
your" contact" information" will" then" be" passed" on" to" the" Investigator" of" the" study" who" will" then"
contact"you."A"member"of" the"Research"Team"will"go"through"the" information"sheet"with"you"and"
answer"any"questions"you"may"raise."
PART)1)
)
Background)
Cystic"Fibrosis"(CF)"is"the"UK's"most"common"lifeVthreatening"inherited"disease"and"according"to"the"
CF"Trust"(UK)"the"disease"affects"over"8,500"people."The"genetic"defect"is"responsible"for"abnormal"
salt" and"water"movements"across" cells" causing" thickened" secretions."One"organ" that" is" affected" is"
the" pancreas" that" is" responsible" for" the" release" of" insulin." Diabetes" mellitus" is" a" wellVrecognised"
complication"of"cystic"fibrosis,"is"unique"and"distinct,"sharing"features"of"other"types"of"diabetes."The"
current" recommendation" is" that" a" test" called" the" oral" glucose" tolerance" test" be" carried" out" to"
diagnose"diabetes" in"CF." "However,"the"test"and" its"normal"and"abnormal"values"are"drawn"from"a"
diabetic"population"who"do"not"have"CF."The"exact"nature"of"why"diabetes"develops" in" individuals"
with"CF" is" not" known,"but" is" thought" that" both" a"defect" in" the" release"of" insulin" and" a" sensing"of"
insulin"by"tissues"may"be"responsible.""
It"is"known"that"falls"in"weight"and"lung"function"occur"prior"to"the"development"of"diabetes"and"that"
diabetes"in"CF"is"associated"with"early"death."It"is"also"known"that"insulin"enhances"muscle"mass"and"
improves"lung"function,"thereby"improving"quality"of"life."
What)is)the)purpose)of)the)study?))
The"purpose"of"this"study"is"to"look"at"possible"factors"that"might"be"related"to"the"development"of"
diabetes"and"to"develop"a"new"test"that"may"be"suited"for"use"in"someone"with"CF.""
The"main"purposes"of"this"research"is"to"study"the"following:"
1. Does" the"pancreas" tire"as" the"day"progresses"and"does" this" contribute" to" the"altered" insulin"
release"that"is"seen"in"people"with"CF.""
2. "Should"a"glucose"tolerance"test"be"done"at"a"later"time"in"the"day,"as"against"first"thing"in"the"
morning"as"is"currently"done?"
3. To"determine"if"stomach"movements"affect"the"release"of"insulin?"
4. "To"study"the" "changes" in"hormones"that"affect" insulin" in"response"to"a" liquid"and"solid"meal"
and""patterns"of"change"through"the"day."
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)
Why)have)I)been)invited?)"
You"have"been"invited"to"take"part"in"this"study"as"our"records"indicate"that"you"have"cystic"fibrosis"
but"currently"do)not"have"a"diagnosis"of"cystic" fibrosis" related"diabetes." "We"want" to"assess"some"
factors" (stomach"movements,"hormones"and" insulin"release)"that"will"allow"us"to"determine,"more"
precisely," the" risk"of" individuals" like" you"developing"diabetes." "We" intend" to" recruit" 30" individuals"
with"CF"take"part"in"the"project.""
)
Do)I)have)to)take)part?))
Your"participation"is"completely"voluntary,"and"you"can"withdraw"your"consent"at"any"time"without"
penalty."This"will"not"affect"your"medical"care"in"any"way.""
If" you" choose" to" participate" in" this" study" you"must" sign" the" Informed" Consent" Form" before" your"
participation"in"the"study"is"initiated."Read"this"information"carefully"before"you"decide"if"you"want"
to"participate."You"have"the"right"to"have"time"for"reflection"before"you"give"your"informed"consent.""
In" addition" to" this" information" document" you"will" receive" a" copy" of" the" signed" Informed"Consent"
Form."If"you"need"further"information"you"can"contact"the"study"doctor."
What)will)happen)to)me)if)I)take)part?))
• Reasonable" expenses" including" travel" costs" incurred" to" participate" in" this" study" would" be"
reimbursed"for"the"duration"you"are"in"the"study."Taking"part"in"this"study"will"involve"3"visits"to"
the"hospital."If"you"agree"to"take"part"in"this"study"you"will"be"asked"to"visit"the"clinic"(visit"1)"to"
discuss" the"study"with" the" investigator," sign" the"consent" form," talk"about"your"medical"history"
(including" " smoking," exercise," alcohol" habits)," your" Cystic" Fibrosis" history" (including" date" of"
diagnosis," previous" and" current" CF" medications)," undergo" a" routine" physical" examination"
(including"body"weight" ,"height"blood"pressure,"heart"rate"and"oxygen" levels)."You"will"need"to"
undergo" lung"function"testing"(simple"spirometry)."At"this"visit"you"will"be"required"to"undergo"
one"blood"test"to"ensure"your"blood"levels"are"not"too" low"and"you"are"not"anaemic."This"visit"
will"last"approximately"45"minutes.""
"
If"following"completion"of"the"screening"test"you"are"still"eligible"to"take"part"and"wish"to"continue"in"
the"study,"your"participation"may"last"up"to"a"week.""
We"will" be" performing" a" number" of" tests" which" will" require" two" further" visits" (visits" 2" and" 3)" to"
hospital.""These"visits"should"occur"within"a"week"of"each"other,"following"your"consent"to"take"part"
in"the"project."Visit"2"will"last"approximately"3"hours"and"visit"3"will"last"approximately"12.5"hours."
With"your"permission," information"will"be"gathered"by"the"research"team"from"your"medical"notes"
(medical"history,"medications,"and"investigation"results)"and"your"GP"will"be" informed"that"you"are"
taking"part"in"this"study.""
The"only"people"who"will"have"access"to"your"medical"notes"as"part"of"this"study"are"a"few"members"
of" the" research" team"who"are"qualified"doctors"or"nurses"working" in" the"NHS," and" the" regulatory"
bodies"overseeing"the"research.""
This"study"has"2"distinct"parts"involving"meals,"blood"tests"and"ultrasound"scanning"of"the"stomach"
to"evaluate"movements."""These"tests"are"described"below:"
• Oral"and"mixed"meals:"For"both"parts"of"the"study"you"would"need"to"come"to"the"hospital"
after"having" fasted"overnight" (12"hours)."For" the" first"part"of" the"study"you"will"be"given"a"
glucose"drink"(75"grams"of"glucose"in"water)"called"Procal"®"and"blood"tests"and"ultrasound"
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scanning" (see"below)"will"be"performed"over"2"hours."This" then"completes" this"part"of" the"
study.""
Within" a"week" you"will" be" required" to" come" back" to" have" a" similar" test" done" and" having"
fasted"overnight" (12"hours)." This" time" instead"of" being" asked" to" drink" a" liquid" you"will" be"
given"what" is" called" a" ‘mixed"meal’" to" complete" within" 10"minutes." This"meal" contains" a"
certain"amount"of"solid"and"liquid"foods"(37%"carbohydrate,"18%"protein,"44%"fat)"and"blood"
samples"will"be"collected"over"2"hours."This"test"will"be"carried"out"twice"more"at"1300"and"
1800" hrs" to" coincide" with" usual"meal" times." The" usual"meal" would" consist" of" a" ham" and"
cheese" sandwich" with" butter," orange" juice" and" digestive" biscuits." " You" will" need" to" fast"
between"each"meal."
"
• Blood"tests:""As"part"of"this"study"20"blood"samples"(each"of"9"mls,"overall"180"mls"of"blood)"
will"be"collected"for"analysis."For"each"part"of"the"study"(2"hour"duration),"one"sample"at"the"
beginning" followed" by" 4" samples" at" 30," 60," 90" and" 120"minutes" will" be" collected" from" a"
cannula"(see"below).""These"blood"samples"will"be"stored"in"the"Biochemistry"Laboratory"at"
Liverpool" Heart" and" Chest" Hospital." "Most" of" these" tests" will" be" performed" at" the" above"
laboratory"at"Liverpool"Heart"and"Chest"Hospital,"but"with"your"permission,"we"may"have"to"
send"some"of"these"samples,"to"an"outside"laboratory"for"analysis."""
"
• Ultrasound" test:"Ultrasound" is" a" safe"procedure." " You"will" be" asked" to" lie"on" your"back"or"
slightly"towards"your"leftVhand"side"during"this"scan,"which"may"be"uncomfortable."The"scan"
will"be"carried"out" for"2V3"minutes" following"a"blood"sample"collection"to"study"the"size"of"
the"stomach.""This"test"will"be"done"in"both"parts"of"the"study."
"
• Inserting"a"cannula"(Cannulation)"(described"below)"in"the"arm"or"forearm"would"avoid"the"
need"for"repetitive"blood"collection"using"needles."Usually"1"cannula"is"required"for"each"part"
of" the" study" (visit"2"and"3)"but"occasionally" the"cannula"does"not"work"any"more"and"you"
might" need" another" one" inserted." To" ensure" that" the" cannula" remains" patent" 3V5mLs" of"
Normal"Saline"would"be"used"as"a"flush"after"insertion"and"after"each"blood"collection"point."
At"the"end"of"each"visit"the"cannula"would"be"removed.""
"
• A"summary"of"investigations"and"time"points"is"represented"in"the"table"below:"
" Time)Points) Baseline) 30)mins) 60)mins) 90)mins) 120)mins)
Visit)1) 1)blood)sample) )
Visit)2) Blood)collection) x" x" x" x" x"
) Ultrasound)study) x" x" x" x" x"
Visit)3) Time)Points) Baseline) 30)mins) 60)mins) 90)mins) 120)mins)
Blood)collection) x" x" x" x" x"
0800"–"1000"hrs"
Ultrasound)study) x" x" x" x" x"
Blood)collection) x" x" x" x" x"
1300"–"1500"hrs"
Ultrasound)study) x" x" x" x" x"
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Blood)collection) x" x" x" x" x"
1800"–"2000"hrs"
Ultrasound)study) x" x" x" x" x"
)
• All"your"usual"medication"and"supplements"(including"Creon/Pancreozymin)"will"continue"as"
usual"and"you"will"be"asked"to"take"any"routine"medication"at"least"one"hour"before"the"start"
of" tests" at" the" second" and" third" visits." You" will" not" be" required" to" stop" or" withhold" any"
medication.""
What)will)I)have)to)do?)"
If,"after"reading"this"leaflet,"you"wish"to"take"part,"one"of"our"research"team"will"speak"with"you"to"
make"sure"that"you"understand"what"is"involved.""You"will"then"be"asked"to"sign"a"consent"form."
We"will"arrange"a"mutually"convenient"time"in"order"for"us"to"carry"out"the"study."
"
What)are)the)possible)disadvantages)or)risks)of)taking)part?)
• Inconvenience"of"having"to"come"into"hospital"thrice"
• Inconvenience"of"having"investigations""
• Inconvenience"of"being"contacted"by"the"research"team""
"
The"possible"disadvantages"and"risks"of"the"additional"investigations"are:"
• Blood"tests:""There"may"be"discomfort,"bleeding"and"bruising"as"a"result"of"having"additional"
blood" tests." " Blood" tests"will" only" be" taken" by" a"member" of" staff" qualified" to" do" so" using"
appropriate"hospital"equipment."""
"""
• Cannulation:"A" cannula" is" inserted"using" a"needle" similar" to" those"used" in" taking" standard"
blood" tests." " This" may" cause" pain," bleeding" or" bruising." " This" is" usually" slightly" more"
uncomfortable"than"a"blood"test"but"once"the"cannula"is"in"place"should"not"cause"you"any"
real"discomfort.""This"will"be"placed"by"a"member"of"staff"trained"to"do"so.""This"cannula"will"
be"removed"once"the"test"is"complete"unless"you"become"unwell"during"the"test"and"require"
this"cannula"for"medical"reasons." "An"additional"risk"of"cannulation"is" infection." "A"previous"
study"of"hospital"patients"reported"the"risk"of"serious"infection"of"2/10,000.""The"risk"should"
be"less"as"part"of"this"study"as"the"cannula"will"only"be"in"place"for"a"short"time."
"
What)are)the)side)effects)of)any)treatment)received)when)taking)part?"
You" will" only" be" asked" to" drink" a" glucose" drink" called" Procal" ®" that" is" routinely" used" in" tests" to"
diagnose"diabetes."No"side"effects"have"been"reported.""The"components"of"the"meal"are"a"part"of"a"
usual"Western"diet.""
)
What)are)the)possible)benefits)of)taking)part?)"
We"cannot"promise"that"the"study"will"have"a"direct"benefit"to"you,"but"the"information"we"gather"
may"help"improve"the"management"of"people"with"cystic"fibrosis"who"develop"diabetes"and"identify"
those"who"are"at"an"increased"risk"of"developing"diabetes"in"order"to"optimise"lung"function"to"the"
maximum"possible."""
As"a"result"of"the"investigations"we"may"discover"that"you"have"diabetes"or"are"prone"to"developing"
diabetes,"which"may"require"further"evaluation"or"treatment.""Any"abnormal"results"will"be"discussed"
with"you"and"arrangements"made"for"further"management."Your"GP"may"need"to"be"informed"or"you"
may"require"referral"to"another"clinic."
"
"
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What)happens)when)the)research)study)stops?)"
If"there"is"an"important"finding"that"has"an"implication"in"the"way"you"should"be"managed,"we"may"
invite" you" to" attend" for" further" discussions/tests," if" we" think" you" are" at" increased" risk" of" having"
diabetes.""
Once"the"initial" investigations"are"collected,"you"will"as"part"of"your"routine"Cystic"Fibrosis"care,"be"
followed"up"on"a"regular"basis"in"clinic"(usually"2"monthly)."If"during"these"routine"clinic"visits"it"might"
be"suspected"that"you"may"be"diabetic"then"these"tests"described"above"may"help"to"clarify"this."If"
needed,"at"that"point,"with"your"permission,"these"results"will"be"entered"into"your"clinical"record.""
"
What)if)there)is)a)problem?))
Any"complaint"about"the"way"you"have"been"treated"during"the"study"or"any"possible"harm"you"may"
suffer"will"be"addressed."Detailed"information"regarding"this"option"is"given"in"Part"2.""
"
Will)my)taking)part)in)the)study)be)kept)confidential?))
Yes." We" will" follow" ethical" and" legal" practices" and" all" information" about" you" will" be" handled" in"
confidence."The"details"are"included"in"Part"2."If"the"information"in"Part"1"has"interested"you"and"you"
are" considering" participating," please" read" the" additional" information" in" Part" 2" before" making" a"
decision.")
)
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PART)2)
)
What)if)relevant)new)information)becomes)available?)"
On"receiving"new"information,"your"doctor"may"consider"it"to"be"in"your"best"interests"to"withdraw"
from"further"investigations"in"the"study." "For" instance," if"your"blood"tests"suggest"there"is"a"reason"
why"it"may"be"unsafe"to"put"you"through"the"study.""If"anything"untoward"does"arise"your"research"
doctor"will"explain"the"reasons"and"inform"your"GP.""
Once" the"study" is" completed"and"you"wish" to"know"the" results,"we"will"be"happy" to"discuss" these"
with"you"at"a"routine"clinic"visit." " If"during"these"routine"clinic"visits" it"might"be"suspected"that"you"
may"be"diabetic"then"these"tests"described"above"may"help"to"clarify"this." If"needed,"at"that"point,"
with"your"permission,"these"results"will"be"entered"into"your"clinical"record.""
"
What)will)happen)if)I)don’t)want)to)carry)on)with)the)study?))
If"you"wish"to"withdraw"from"the"study,"you"can"contact"the"Research"Team"to"notify"them"whether"
you"want"to"withdraw"from"the"study"entirely,"or"just"from"part"of"it.""
• We"will"remove"you"from"our"followVup"database"if"you"do"not"want"to"be"contacted"again."
• Identifiable"data"or"tissue"already"collected"with"consent"would"be"retained"and"used"in"the"
study."No"further"data"or"tissue"would"be"collected"or"any"other"research"procedures"carried"
out"on"you."
• We"would"be"unable" to"destroy" the" results"of" investigations" already"performed"as"part"of"
this"study"which"may"assist"standard"medical"care."
• We"would"be"unable"to"destroy"any"information"from"your"general"medical"notes."
If"you"lose"capacity"or"are"unable"to"consent"at"any"part"of"the"study"then"we"will"not"carry"out"
any" further" part" of" the" study."We"would" analyse" samples" that" have" been" collected"while" you"
consented"and"had"capacity"to"make"that"decision."
"
What)if)there)is)a)problem?)"
If"you"have"a"concern"about"any"aspect"of"this"study,"you"should"ask"to"speak"with"the"researchers"
who"will" do" their" best" to" answer" your" questions" and" can" be" contacted" via" The" Regional" Adult" CF"
Centre,"Liverpool"Heart"and"Chest"Hospital""on"0151"228"1616.""If"you"remain"unhappy"and"wish"to"
complain"formally,"you"can"do"this"via"the"NHS"Complaints"Procedure."Details"can"be"obtained"from"
the"Research"Team"or"through"the"Patient"Advice"and"Liaison"Services"on"0151"228"1616.""
This"study"is"covered"by"The"NHS"Indemnity"Scheme."The"normal"National"Health"Service"complaints"
mechanisms"will"still"be"available"to"you.""
"
Will)my)taking)part)in)this)study)be)kept)confidential?))
With"your"consent,"we"would"normally"inform"your"general"practitioner"that"you"are"participating"in"
the" study." Reports" of" these" investigations" will" be" placed" in" your" medical" notes." All" patient"
information" collected" in" the" study" will" be" stored" on" password" protected" computers" or" in" locked"
rooms"at"Liverpool"Heart"and"Chest"Hospital.""When"the"results"of"the"study"are"reported,"individuals"
who"have"taken"part"will"not"be"identified"in"any"way."
All"data"will"remain"confidential"and"no"personal"details"will"be"made"available"to"any"third"parties"or"
transferred" outside" of" the" hospital." " Details" about" you" will" be" stored" on" computer" during" the"
research"project"but"your"data"will"only"be"reviewed"by"members"of"the"research"team.""Blood"will"
be"stored"in"a"secure"storage"facility"at"the"Liverpool"Heart"and"Chest"Hospital"NHS"Trust."The"data"
will"only"be"used"for"research"purposes"in"this"project.""No"other"use"of"the"data"will"be"undertaken"
without"seeking"your"prior"consent."""
"
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Involvement)of)the)General)Practitioner/Family)doctor)(GP))"
With" your" consent," your" GP"will" be" notified" of" your" participation" in" the" study." " If" any" tests" show"
results"which"may"affect"the"way"you"should"be"treated"medically,"your"GP"will"be"made"aware"of"
these"changes."""
"
What)will)happen)to)any)samples)I)give?)"
Blood" samples"will" be" frozen" and" stored"onVsite" in" the"biochemistry" laboratory" at" Liverpool"Heart"
and"Chest"Hospital"NHS"Trust."All"blood"samples"will"be"handled"as"any"other"blood"samples"are"at"
the"Hospital,"will"be"kept"securely"and"only"accessed"by" research"and" laboratory"staff."All" samples"
taken"as"part" of" this" study"will" be" taken"and" labelled" in" accordance"with" standard" trust" policy." " A"
code"will" link"your"data"and"samples"through"a"name"list."This"list"that"links"your"name"to"the"code"
will"be"kept"by"the"chief"investigator."This"is"to"ensure"that"if"the"results"are"needed"in"the"future"for"
your"routine"clinical"care"then"they"can"be"referred"back"to"and"that"we"can"be"sure"the"results"apply"
to"the"correct"participant."Some"blood"tests"may"need"to"be"sent"to"different"laboratories"and"if"this"
is"needed"then"your"name"and"date"of"birth"will"be"included"on"the"sample."
"Only"the"investigator"for"the"study"will"have"access"to"the"results"and"if"the"tests"show"information"
of" clinical" significance," a"member"of" the" research" team"will" inform"you"of" the" results" in"person" in"
clinic"and"explain"any"action"needed.""
We"will"not"routinely"inform"you"of"the"results"of"tests."If"you"agree"to"take"part"in"the"study,"we"will"
ask" you" to" gift" any" samples" we" take" so" that" we" may" use" them" for" any" future" research." " Serum"
samples"obtained"from"blood"tests"will"be"stored"for"up"to"10"years"in"a"tissue"bank"approved"under"
the"Human"Tissue"Act"2004.""At"the"end"of"this"time"the"samples"will"be"destroyed."
When"all" the"participants"have"been"recruited"we"may"analyse"stored"blood"samples" taken"during"
the"study"for"additional"biomarkers;"these"again"would"be"biomarkers"related"to"diabetes"or"cystic"
fibrosis." The" storage" of" blood" and" tissue" samples" are" guided" by" strict" regulations" and" would" be"
stored"in"accordance"with"this.""
"
Will)any)genetic)tests)be)done?))
No"
"
What)will)happen)to)the)results)of)the)research)study?))
You"will"not"be"personally" identified" in"any" report"or"publication." " The" results"of" the" study"will"be"
disseminated" via" electronic" and" paper"medical" journals" as" well" as" presentations" in" various"major"
medical"societies"throughout"the"world."
"
Who)is)organising)and)funding)the)research?))
The"study"is"being"funded"by"inVhouse"funds"from"Liverpool"Heart"and"Chest"Hospital"NHS"Trust.""The"
research" group" performing" this" research" study" has" no" conflict" of" interests." " Your" research"
nurse/doctor"will"not"receive"any"additional"money"for"including"you"in"this"study."
"
Who)has)reviewed)the)study?))
All" research" in" the"NHS" is" looked" at" by" an" independent" group" of" people," called" a" Research" Ethics"
Committee,"to"protect"your"interests."This"study"has"been"reviewed"and"given"a"favourable"opinion"
by"the"National"Research"Ethics"Service"(NRES)"Committee"North"West"–"Greater"Manchester"East.""
"
"
28#September#2011#####Factors#responsible#for#the#development#of#diabetes#in#adults#with#Cystic#Fibrosis#(CF)#########Version#1.5#
 
9"
Further)information)and)contact)details))
Further" information" regarding" this" project" can"be"obtained" from"The"Research" Team,"who" can"be"
contacted"by"calling"the"Regional"Adult"CF"Unit"on"0151"228"1616."
"
Dr)Dilip)Nazareth,"Clinical"Research"Fellow,"Principal"Investigator"
"
Dr)Kamlesh)Mohan,"Consultant"Chest"Physician"
"
Dr)Martin)Walshaw,"Consultant"Chest"Physician"and"Clinical"Director"
"
Further" information" about" research" in" general" can" be" found" at" the" National" Institute" for" Health"
Research,"at"the"following"web"address:""www.nihr.ac.uk/research"
"
If" you" develop" any" concerns" about" the" study," you" can" contact" any"member" of" the" research" team"
above."""
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Participant)(Control))Information)Sheet)Summary)
)
Factors)responsible)for)the)development)of)diabetes)in)adults)with)Cystic)Fibrosis)
)
Cystic#Fibrosis#(CF)#affects#over#8,500#people#and#affects#multiple#parts#of#the#body.#One#organ#that#
is#affected#is#the#pancreas#that#is#responsible#for#the#release#of#insulin#and#those#with#CF#are#prone#
to#develop#diabetes.#The#type#of#diabetes#in#CF#is#different#from#the#other#types#of#diabetes#and#is#
‘unique’.# The# exact# nature# of# why# diabetes# develops# is# not# known# but# is# thought# that# both# the#
release#and#action##of#insulin#may#be#responsible#and#it#has#been#found#that#insulin#enhances#muscle#
mass#and#improves#lung#function.#
The#purpose#of#this#study#is#to#look#at#possible#factors#that#might#be#related#to#the#development#of#
diabetes#and#to#develop#a#new#test#for#diabetes#that#may#be#suited#for#use#in#someone#with#CF#as#
the#current#tests#are#derived#from#information#available#from#people#with#diabetes#who#do#not#have#
cystic#fibrosis.##In#order#to#do#so,#we#need#to#compare#2#groups#of#people#–#those#with#CF#and#those#
without.##
You#have#been# invited#to#take#part# in# this#study#as#you#currently#do)not#have#a#diagnosis#of#cystic#
fibrosis#or#diabetes.# #We#want#to#assess#some#factors# (stomach#movements,#hormones#and# insulin#
release)# that#will# allow#us# to#determine,#more#precisely,# the# risk#of# individuals#with#CF#developing#
diabetes.##We#intend#to#recruit#6#volunteers#to#take#part#in#this#study.##
The#Participant# information# sheet#attached#gives#details#of# the# study#and#how# it#would#be#carried#
out.###
Your#participation# is# entirely# voluntary# and#you#would#be#able# to#withdraw# from# the# study#at# any#
time.#
#
Appendix 6
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Participant)Information)Sheet)
Factors)responsible)for)the)development)of)diabetes)in)adults)with)Cystic)Fibrosis)
)
We#would#like#to#invite#you#to#take#part#in#our#research#study.#However,#before#you#decide,#we#need#
you#to#understand#the#reason#for#the#research#and#what#it#involves.))))#You#may#talk#to#others#about#
the#study# if#you#so#wish.# #Part#1#tells#you#the#purpose#of#the#study#and#what#to#expect# if#you#take#
part.##Part#2#gives#you#more#detailed#information#about#the#conduct#of#the#study.##Please#ask#if#there#
is#anything#you#do#not#understand.#Take#time#to#decide#whether#or#not#you#wish#to#take#part#in#this#
research#study.##
If# you# are# willing# to# participate# please# telephone# Mrs.) Patricia) Stanley# (Pulmonary# Function#
Administrator)#on#01516001780#to# indicate# that#you#are# interested# in# taking#part# in# the#study#and#
this#information#will#then#be#passed#on#to#the#Investigator#of#the#study#who#will#then#contact#you.#A#
member# of# the# Research# Team# will# go# through# the# information# sheet# with# you# and# answer# any#
questions#you#may#raise#
PART)1)
Background)
Cystic#Fibrosis#(CF)#is#the#UK's#most#common#lifeYthreatening#inherited#disease#and#according#to#the#
CF#Trust#(UK)#the#disease#affects#over#8,500#people.#The#genetic#defect#is#responsible#for#abnormal#
salt# and#water#movements#across# cells# causing# thickened# secretions.#One#organ# that# is# affected# is#
the# pancreas# that# is# responsible# for# the# release# of# insulin.# Diabetes# mellitus# is# a# wellYrecognised#
complication#of#cystic#fibrosis,#is#unique#and#distinct,#sharing#features#of#other#types#of#diabetes.#The#
current# recommendation# is# that# a# test# called# the# oral# glucose# tolerance# test# be# carried# out# to#
diagnose#diabetes# in#CF.# #However,#the#test#and# its#normal#and#abnormal#values#are#drawn#from#a#
diabetic#population#who#do#not#have#CF.#The#exact#nature#of#why#diabetes#develops# in# individuals#
with#CF# is# not# known,#but# is# thought# that# both# a#defect# in# the# release#of# insulin# and# a# sensing#of#
insulin#by#tissues#may#be#responsible.##
It#is#known#that#falls#in#weight#and#lung#function#occur#prior#to#the#development#of#diabetes#and#that#
diabetes#in#CF#is#associated#with#early#death.#It#is#also#known#that#insulin#enhances#muscle#mass#and#
improves#lung#function,#thereby#improving#quality#of#life.#
What)is)the)purpose)of)the)study?))
The#main#purposes#of#this#research#is#to#study#the#following:#
1. Does# the#pancreas# tire#as# the#day#progresses#and#does# this# contribute# to# the#altered# insulin#
release#that#is#seen#in#people#with#CF.##
2. #Should#a#glucose#tolerance#test#be#done#at#a#later#time#in#the#day,#as#against#first#thing#in#the#
morning#as#is#currently#done?#
3. To#determine#if#stomach#movements#affect#the#release#of#insulin?#
4. #To#study#the# #changes# in#hormones#that#affect# insulin# in#response#to#a# liquid#and#solid#meal#
and##patterns#of#change#through#the#day#
)
)
)
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Why)have)I)been)invited?)#
You#have#been#invited#to#take#part#in#this#study#as#you#do)not#have#cystic#fibrosis#or#diabetes.##We#
want#to#assess#some#factors#(stomach#movements,#hormones#and#insulin#release)#that#will#allow#us#
to# determine,# more# precisely,# the# risk# of# individuals# with# CF# developing# diabetes.# #We# intend# to#
recruit#6#healthy#Participants#(controls)#for#this#study,#in#order#to#compare#the#differences#between#
individuals#like#yourself#and#those#with#CF.##
)
Do)I)have)to)take)part?)#
Your#participation#is#completely#voluntary,#and#you#can#withdraw#your#consent#at#any#time#without#
penalty.##
If# you# choose# to# participate# in# this# study# you#must# sign# the# Informed# Consent# Form# before# your#
participation#in#the#study#is#initiated.#Read#this#information#carefully#before#you#decide#if#you#want#
to#participate.#You#have#the#right#to#have#time#for#reflection#before#you#give#your#informed#consent.#
In# addition# to# this# information# document# you#will# receive# a# copy# of# the# signed# Informed#Consent#
Form.#If#you#need#further#information#you#can#contact#the#study#doctor.#
#
What)will)happen)to)me)if)I)take)part?))
• Reasonable# expenses# including# travel# costs# incurred# to# participate# in# this# study# would# be#
reimbursed#for#the#duration#you#are#in#the#study.#Taking#part#in#this#study#will#involve#3#visits#to#
the#hospital.#If#you#agree#to#take#part#in#this#study#you#will#be#asked#to#visit#the#clinic#(visit#1)#to#
discuss# the#study#with# the# investigator,# sign# the#consent# form,# talk#about#your#medical#history#
(including# # smoking,# exercise,# alcohol# habits),# your# Cystic# Fibrosis# history# (including# date# of#
diagnosis,# previous# and# current# CF# medications),# undergo# a# routine# physical# examination#
(including#body#weight# ,#height#blood#pressure,#heart#rate#and#oxygen# levels).#You#will#need#to#
undergo# lung#function#testing#(simple#spirometry).#At#this#visit#you#will#be#required#to#undergo#
one#blood#test#to#ensure#your#blood#levels#are#not#too# low#and#you#are#not#anaemic.#This#visit#
will#last#approximately#45#minutes.##
If#following#completion#of#the#screening#test,#you#are#still#eligible#to#take#part#and#wish#to#continue#in#
the#study,#your#participation#may#last#up#to#a#week.##
We#will# be# performing# a# number# of# tests# which# will# require# two# further# visits# (visits# 2# and# 3)# to#
hospital.##These#visits#should#occur#within#a#week#of#each#other,#following#your#consent#to#take#part#
in#the#project.#Visit#2#will#last#approximately#3#hours#and#visit#3#will#last#approximately#12.5#hours.#
With#your#permission,# information#will#be#gathered#by#the#research#team#from#your#medical#notes#
(medical#history,#medications,#and#investigation#results)#and#your#GP#will#be# informed#that#you#are#
taking#part#in#this#study.##
The#only#people#who#will#have#access#to#your#medical#notes#as#part#of#this#study#are#a#few#members#
of# the# research# team#who#are#qualified#doctors#or#nurses#working# in# the#NHS,# and# the# regulatory#
bodies#overseeing#the#research.##
This#study#has#2#distinct#parts#involving#meals,#blood#tests#and#ultrasound#scanning#of#the#stomach#
to#evaluate#movements.###These#tests#are#described#below:#
• Oral#and#mixed#meals:#For#both#parts#of#the#study#you#would#need#to#come#to#the#hospital#
after#having# fasted#overnight# (12#hours).#For# the# first#part#of# the#study#you#will#be#given#a#
glucose#drink#(75#grams#of#glucose#in#water)#called#Procal#®#and#blood#tests#and#ultrasound#
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scanning# (see#below)#will#be#performed#over#2#hours.#This# then#completes# this#part#of# the#
study.##
Within# a#week# you#will# be# required# to# come# back# to# have# a# similar# test# done# and# having#
fasted#overnight# (12#hours).# This# time# instead#of# being# asked# to# drink# a# liquid# you#will# be#
given#what# is# called# a# ‘mixed#meal’# to# complete# within# 10#minutes.# This#meal# contains# a#
certain#amount#of#solid#and#liquid#foods#(37%#carbohydrate,#18%#protein,#44%#fat)#and#blood#
samples#will#be#collected#over#2#hours.#This#test#will#be#carried#out#twice#more#at#1300#and#
1800# hrs# to# coincide# with# usual#meal# times.# The# usual#meal# would# consist# of# a# ham# and#
cheese# sandwich# with# butter,# orange# juice# and# digestive# biscuits.# You# will# need# to# fast#
between#each#meal.#
• Blood#tests:##As#part#of#this#study#20#blood#samples#(each#of#9#mls,#overall#180#mls#of#blood)#
will#be#collected#for#analysis.#For#each#part#of#the#study#(2#hour#duration),#one#sample#at#the#
beginning# followed# by# 4# samples# at# 30,# 60,# 90# and# 120#minutes# will# be# collected# from# a#
cannula#(see#below).##These#blood#samples#will#be#stored#in#the#Biochemistry#Laboratory#at#
Liverpool# Heart# and# Chest# Hospital.# #Most# of# these# tests# will# be# performed# at# the# above#
laboratory#at#Liverpool#Heart#and#Chest#Hospital,#but#with#your#permission,#we#may#have#to#
send#some#of#these#samples,#to#an#outside#laboratory#for#analysis.###
• Ultrasound# test:#Ultrasound# is# a# safe#procedure.# # You#will# be# asked# to# lie#on# your#back#or#
slightly#towards#your#leftYhand#side#during#this#scan,#which#may#be#uncomfortable.#The#scan#
will#be#carried#out# for#2Y3#minutes# following#a#blood#sample#collection#to#study#the#size#of#
the#stomach.##This#test#will#be#done#in#both#parts#of#the#study.#
• Inserting#a#cannula#(Cannulation)#(described#below)#in#the#arm#or#forearm#would#avoid#the#
need# for# repetitive# blood# collection# using# needles.# Usually# 1# cannula# is# required# for# each#
study#but#occasionally#the#cannula#does#not#work#any#more#and#you#might#need#another#one#
inserted.#To#ensure#that#the#cannula#remains#patent#3Y5mLs#of#Normal#Saline#would#be#used#
as#a#flush#after# insertion#and#after#each#blood#collection#point.#At#the#end#of#each#visit#the#
cannula#would#be#removed.##
#
• A#summary#of#investigations#and#time#points#is#represented#in#the#table#below:#
# Time)Points) Baseline) 30)mins) 60)mins) 90)mins) 120)mins)
Visit)1) 1)blood)sample) )
Visit)2) Blood)collection) x# x# x# x# x#
) Ultrasound)study) x# x# x# x# x#
Visit)3) Time)Points) Baseline) 30)mins) 60)mins) 90)mins) 120)mins)
Blood)collection) x# x# x# x# x#
0800#–#1000#hrs#
Ultrasound)study) x# x# x# x# x#
Blood)collection) x# x# x# x# x#
1300#–#1500#hrs#
Ultrasound)study) x# x# x# x# x#
Blood)collection) x# x# x# x# x#
1800#–#2000#hrs#
Ultrasound)study) x# x# x# x# x#
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• All#your#usual#medications#(if#any)#will#continue#as#usual#and#you#will#be#asked#to#take#any#
routine#medication#at#least#one#hour#before#the#start#of#tests#at#the#second#and#third#visits.#
You#will#not#be#required#to#stop#or#withhold#any#medication.##
#
What)will)I)have)to)do?)#
If,#after#reading#this#leaflet,#you#wish#to#take#part,#one#of#our#research#team#will#speak#with#you#to#
make#sure#that#you#understand#what#is#involved.##You#will#then#be#asked#to#sign#a#consent#form.#
We#will#arrange#a#mutually#convenient#time#in#order#for#us#to#carry#out#the#study.#
#
What)are)the)possible)disadvantages)or)risks)of)taking)part?)
• Inconvenience#of#having#to#come#into#hospital#twice#
• Inconvenience#of#having#investigations##
• Inconvenience#of#being#contacted#by#the#research#team##
#
The#possible#disadvantages#and#risks#of#the#additional#investigations#are:#
#
• Blood#tests:##There#may#be#discomfort,#bleeding#and#bruising#as#a#result#of#having#additional#
blood# tests.# # Blood# tests#will# only# be# taken# by# a#member# of# staff# qualified# to# do# so# using#
appropriate#hospital#equipment.###
###
• Cannulation:# a# cannula# is# inserted#using# a# needle# similar# to# those#used# in# taking# standard#
blood# tests.# # This# may# cause# pain,# bleeding# or# bruising.# # This# is# usually# slightly# more#
uncomfortable#than#a#blood#test#but#once#the#cannula#is#in#place#should#not#cause#you#any#
real#discomfort.##This#will#be#placed#by#a#member#of#staff#trained#to#do#so.##This#cannula#will#
be#removed#once#the#test#is#complete#unless#you#become#unwell#during#the#test#and#require#
this#cannula#for#medical#reasons.# #An#additional#risk#of#cannulation#is# infection.# #A#previous#
study#of#hospital#patients#reported#the#risk#of#serious#infection#of#2/10,000.##The#risk#should#
be#less#as#part#of#this#study#as#the#cannula#will#only#be#in#place#for#a#short#time.#
#
#
What)are)the)side)effects)of)any)treatment)received)when)taking)part?#
You# will# only# be# asked# to# drink# a# glucose# drink# called# Procal# ®# that# is# routinely# used# in# tests# to#
diagnose#diabetes.#No#side#effects#have#been#reported.##The#components#of#the#meal#are#a#part#of#a#
usual#Western#diet.##
)
What)are)the)possible)benefits)of)taking)part?)#
The# information#we#gather#may#help# improve# the#management#of#people#with# cystic# fibrosis#who#
develop#diabetes#and#identify#those#who#are#at#an#increased#risk#of#developing#diabetes#in#order#to#
optimise#lung#function#to#the#maximum#possible.###
As#a#result#of#the#investigations#we#may#discover#that#you#have#diabetes#or#are#prone#to#developing#
diabetes,#which#may#require#further#evaluation#or#treatment.##Any#abnormal#results#will#be#discussed#
with#you#and#arrangements#made#for#further#management.#Your#GP#may#need#to#be#informed#or#you#
may#require#referral#to#another#clinic.#
#
#
#
#
What)happens)when)the)research)study)stops?)#
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If#there#is#an#important#finding#that#has#an#implication#in#the#way#you#should#be#managed,#we#may#
invite# you# to# attend# for# further# discussions/tests,# if# we# think# you# are# at# increased# risk# of# having#
diabetes.##
#
What)if)there)is)a)problem?))
Any#complaint#about#the#way#you#have#been#treated#during#the#study#or#any#possible#harm#you#may#
suffer#will#be#addressed.#Detailed#information#regarding#this#option#is#given#in#Part#2.##
)
Will)my)taking)part)in)the)study)be)kept)confidential?))
Yes.# We# will# follow# ethical# and# legal# practices# and# all# information# about# you# will# be# handled# in#
confidence.#The#details#are#included#in#Part#2.#If#the#information#in#Part#1#has#interested#you#and#you#
are# considering# participating,# please# read# the# additional# information# in# Part# 2# before# making# a#
decision.##
#
#
PART)2)
What)if)relevant)new)information)becomes)available?)#
On#receiving#new#information,#your#doctor#may#consider#it#to#be#in#your#best#interests#to#withdraw#
from#further#investigations#in#the#study.# #For# instance,# if#your#blood#tests#suggest#there#is#a#reason#
why#it#may#be#unsafe#to#put#you#through#the#study.##If#anything#untoward#does#arise#your#research#
doctor#will#explain#the#reasons#and#inform#your#GP.##
Once# the#study# is# completed#and#you#wish# to#know#the# results,#we#will#be#happy# to#discuss# these#
with#you#once#all#the#results#have#been#analysed.##You#can#contact#a#member#of#the#research#team#
to#discuss#these#results#if#you#wish.##
#
What)will)happen)if)I)don’t)want)to)carry)on)with)the)study?))
If#you#wish#to#withdraw#from#the#study,#you#can#contact#the#Research#Team#to#notify#them#whether#
you#want#to#withdraw#from#the#study#entirely,#or#just#from#part#of#it.##
• We#will#remove#you#from#our#followYup#database#if#you#do#not#want#to#be#contacted#again.#
• Identifiable#data#or#tissue#already#collected#with#consent#would#be#retained#and#used#in#the#
study.#No#further#data#or#tissue#would#be#collected#or#any#other#research#procedures#carried#
out#on#you.#
• We#would#be#unable# to#destroy# the# results#of# investigations# already#performed#as#part#of#
this#study#which#may#assist#standard#medical#care.#
• We#would#be#unable#to#destroy#any#information#from#your#general#medical#notes.#
If#you#lose#capacity#or#are#unable#to#consent#at#any#part#of#the#study#then#we#will#not#carry#out#
any# further# part# of# the# study.#We#would# analyse# samples# that# have# been# collected#while# you#
consented#and#had#capacity#to#make#that#decision.#
#
What)if)there)is)a)problem?)#
If#you#have#a#concern#about#any#aspect#of#this#study,#you#should#ask#to#speak#with#the#researchers#
who#will# do# their# best# to# answer# your# questions# and# can# be# contacted# via# The# Regional# Adult# CF#
Centre,# Liverpool#Heart# and#Chest#Hospital# # on# 0151# 228# 1616.# This# study# is# covered# by# The#NHS#
Indemnity# Scheme# and# the# normal# National# Health# Service# complaints# mechanisms# will# still# be#
available#to#you.##
#
#
Will)my)taking)part)in)this)study)be)kept)confidential?))
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With#your#consent,#we#would#normally#inform#your#general#practitioner#that#you#are#participating#in#
the# study.# Reports# of# these# investigations# will# be# placed# in# your# medical# notes.# All# patient#
information# collected# in# the# study# will# be# stored# on# password# protected# computers# or# in# locked#
rooms#at#Liverpool#Heart#and#Chest#Hospital.##When#the#results#of#the#study#are#reported,#individuals#
who#have#taken#part#will#not#be#identified#in#any#way.#
All#data#will#remain#confidential#and#no#personal#details#will#be#made#available#to#any#third#parties#or#
transferred# outside# of# the# hospital.# # Details# about# you# will# be# stored# on# computer# during# the#
research#project#but#your#data#will#only#be#reviewed#by#members#of#the#research#team.##Blood#will#
be#stored#in#a#secure#storage#facility#at#the#Liverpool#Heart#and#Chest#Hospital#NHS#Trust.##The#data#
will#only#be#used#for#research#purposes#in#this#project.##No#other#use#of#the#data#will#be#undertaken#
without#seeking#your#prior#consent.###
#
Involvement)of)the)General)Practitioner/Family)doctor)(GP))#
Your#GP#will#be#informed#only#if#any#study#investigations#reveal#information#of#which#the#GP#should#
be#made#aware#of.##
#
What)will)happen)to)any)samples)I)give?))
Blood# samples#will# be# frozen# and# stored#onYsite# in# the#biochemistry# laboratory# at# Liverpool#Heart#
and#Chest#Hospital#NHS#Trust.#All#blood#samples#will#be#handled#as#any#other#blood#samples#are#at#
the#Hospital,#will#be#kept#securely#and#only#accessed#by# research#and# laboratory#staff.#All# samples#
taken#as#part#of# this# study#will# be# taken#and# labelled# in#accordance#with# standard#Trust#policy.# #A#
code#will# link#your#data#and#samples#through#a#name#list.#This#list#that#links#your#name#to#the#code#
will#be#kept#by#the#chief#investigator.#This#is#to#ensure#that#if#the#results#are#needed#in#the#future#for#
your#routine#clinical#care#then#they#can#be#referred#back#to#and#that#we#can#be#sure#the#results#apply#
to#the#correct#participant.#Some#blood#tests#may#need#to#be#sent#to#different#laboratories#and#if#this#
is#needed#then#your#name#and#date#of#birth#will#be#included#on#the#sample.#
#Only#the#investigator#for#the#study#will#have#access#to#the#results#and#if#the#tests#show#information#
of# clinical# significance,# a#member#of# the# research# team#will# inform#you#of# the# results# in#person# in#
clinic#and#explain#any#action#needed.##
We#will#not#routinely#inform#you#of#the#results#of#tests.#If#you#agree#to#take#part#in#the#study,#we#will#
ask#you#to#gift#any#samples#we#take#so#that#we#may#use#them#for#future#research.# #Serum#samples#
obtained# from# blood# tests#will# be# stored# for# up# to# 10# years# in# a# tissue# bank# approved# under# the#
Human#Tissue#Act#2004.##At#the#end#of#this#time#the#samples#will#be#destroyed.#
When#all# the#participants#have#been#recruited#we#may#analyse#stored#blood#samples# taken#during#
the#study#for#additional#biomarkers;#these#again#would#be#biomarkers#related#to#diabetes#or#cystic#
fibrosis.# The# storage# of# blood# and# tissue# samples# are# guided# by# strict# regulations# and# would# be#
stored#in#accordance#with#this.##
#
Will)any)genetic)tests)be)done?))
No#
#
What)will)happen)to)the)results)of)the)research)study?))
You#will#not#be#personally# identified# in#any# report#or#publication.# # The# results#of# the# study#will#be#
disseminated# via# electronic# and# paper#medical# journals# as# well# as# presentations# in# various#major#
medical#societies#throughout#the#world.#
#
Who)is)organising)and)funding)the)research?))
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The#study#is#being#funded#by#inYhouse#funds#from#Liverpool#Heart#and#Chest#Hospital#NHS#Trust.##The#
research# group# performing# this# research# study# has# no# conflict# of# interests.# # Your# research#
nurse/doctor#will#not#receive#any#additional#money#for#including#you#in#this#study.#
#
Who)has)reviewed)the)study?))
All# research# in# the#NHS# is# looked# at# by# an# independent# group# of# people,# called# a# Research# Ethics#
Committee,#to#protect#your#interests.#This#study#has#been#reviewed#and#given#a#favourable#opinion#
by#the#National#Research#Ethics#Service#(NRES)#Committee#North#West#–#Greater#Manchester#East.##
Further)information)and)contact)details))
Further# information# regarding# this# project# can#be#obtained# from#The#Research# Team,#who# can#be#
contacted#by#calling#the#Regional#Adult#CF#Unit#on#0151#228#1616.#
#
Dr)Dilip)Nazareth,#Clinical#Research#Fellow,#Principal#Investigator#
#
Dr)Kamlesh)Mohan,#Consultant#Chest#Physician#
#
Dr)Martin)Walshaw,#Consultant#Chest#Physician#and#Clinical#Director#
#
Further# information# about# research# in# general# can# be# found# at# the# National# Institute# for# Health#
Research,#at#the#following#web#address:##www.nihr.ac.uk/research#
#
If# you# develop# any# concerns# about# the# study,# you# can# contact# any#member# of# the# research# team#
above.###
#
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1 INTRODUCTION 
1.1 Intended Use 
The DRG Insulin ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of Insulin in 
serum and plasma  
1.2 Summary and Explanation 
Insulin is the principal hormone responsible for the control of glucose metabolism. It is synthesized in the β-cells of the 
islets of Langerhans as the precursor, proinsulin, which is processed to form C-peptide and insulin. Both are secreted in 
equimolar amounts into the portal circulation. The mature insulin molecule comprises two polypeptide chains, the A chain 
and B chain (21 and 30 amino acids respectively). The two chains are linked together by two inter-chain disulphide 
bridges. There is also an intra-chain disulphide bridge in the A chain. 
Secretion of insulin is mainly controlled by plasma glucose concentration, and the hormone has a number of important 
metabolic actions. Its principal function is to control the uptake and utilisation of glucose in peripheral tissues via the 
glucose transporter. This and other hypoglycaemic activities, such as the inhibition of hepatic gluconeogenesis and 
glycogenolysis are counteracted by the hyperglycaemic hormones including glucagon, epinephrine (adrenaline), growth 
hormone and cortisol. 
Insulin concentrations are severely reduced in insulin-dependent diabetes mellitus (IDDM) and some other conditions 
such as hypopituitarism. Insulin levels are raised in non-insulin-dependent diabetes mellitus (NIDDM), obesity, 
insulinoma and some endocrine dysfunctions such as Cushing’s syndrome and acromegaly. 
2 PRINCIPLE OF THE TEST 
The DRG Insulin ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich 
principle.  
The microtiter wells are coated with a monoclonal antibody directed towards a unique antigenic site on the Insulin 
molecule.  
An aliquot of patient sample containing endogenous Insulin is incubated in the coated well with enzyme conjugate, which 
is an anti-Insulin antibody conjugated with Biotin. After incubation the unbound conjugate is washed off.  
During the second incubation step Streptavidin Peroxidase Enzyme Complex binds to the biotin-anti-Insulin antibody.  
The amount of bound HRP complex is proportional to the concentration of Insulin in the sample.  
Having added the substrate solution, the intensity of colour developed is proportional to the concentration of Insulin in the 
patient sample. 
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3 WARNINGS AND PRECAUTIONS 
1. This kit is for in vitro diagnostic use only. For professional use only. 
2. All reagents of this test kit which contain human serum or plasma have been tested and confirmed negative for HIV 
I/II, HBsAg and HCV by FDA approved procedures. All reagents, however, should be treated as potential biohazards 
in use and for disposal. 
3. Before starting the assay, read the instructions completely and carefully. Use the valid version of instructions for use 
provided with the kit. Be sure that everything is understood. 
4. The microplate contains snap-off strips.  Unused wells must be stored at 2 °C to 8 °C in the sealed foil pouch and 
used in the frame provided. 
5. Pipetting of samples and reagents must be done as quickly as possible and in the same sequence for each step. 
6. Use reservoirs only for single reagents.  This especially applies to the substrate reservoirs.  Using a reservoir for 
dispensing a substrate solution that had previously been used for the conjugate solution may turn solution coloured. 
Do not pour reagents back into vials as reagent contamination may occur. 
7. Mix the contents of the microplate wells thoroughly to ensure good test results. Do not reuse microwells. 
8. Do not let wells dry during assay; add reagents immediately after completing the rinsing steps. 
9. Allow the reagents to reach room temperature (21 °C - 26 °C) before starting the test.  Temperature will affect the 
absorbance readings of the assay.  However, values for the patient samples will not be affected. 
10. Never pipet by mouth and avoid contact of reagents and specimens with skin and mucous membranes. 
11. Do not smoke, eat, drink or apply cosmetics in areas where specimens or kit reagents are handled. 
12. Wear disposable latex gloves when handling specimens and reagents. Microbial contamination of reagents or 
specimens may give false results. 
13. Handling should be done in accordance with the procedures defined by an appropriate national biohazard safety 
guideline or regulation. 
14. Do not use reagents beyond expiry date as shown on the kit labels. 
15. All indicated volumes have to be performed according to the protocol. Optimal test results are only obtained when 
using calibrated pipettes and microtiter plate readers. 
16. Do not mix or use components from kits with different lot numbers. It is advised not to exchange wells of different 
plates even of the same lot. The kits may have been shipped or stored under different conditions and the binding 
characteristics of the plates may result slightly different. 
17. Avoid contact with Stop Solution containing 0.5 M H2SO4. It may cause skin irritation and burns. 
18. Some reagents contain Proclin 300, BND and/or MIT as preservatives. In case of contact with eyes or skin, flush 
immediately with water. 
19. TMB substrate has an irritant effect on skin and mucosa.  In case of possible contact, wash eyes with an abundant 
volume of water and skin with soap and abundant water.  Wash contaminated objects before reusing them.  If inhaled, 
take the person to open air. 
20. Chemicals and prepared or used reagents have to be treated as hazardous waste according to the national biohazard 
safety guideline or regulation. 
21. For information on hazardous substances included in the kit please refer to Material Safety Data Sheets. 
Material Safety Data Sheets for this product are available upon request directly from DRG. 
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4 REAGENTS  
4.1 Reagents provided 
1. Microtiterwells, 12 x 8 (break apart) strips, 96 wells; 
Wells coated with anti-Insulin antibody (monoclonal). 
2. Zero Standard, 1 vial, 3 mL, ready to use 
0 µIU/mL 
Contains non-mercury preservative. 
3. Standard (Standard 1-5), 5 vials, 1 mL, ready to use; 
Concentrations:  6.25 - 12.5 – 25 - 50 and 100 µIU/mL, 
Conversion:  µIU/mL  x  0.0433  =  ng/mL, 
  ng/mL  x  23.09  =  µIU/mL 
The standards are calibrated against international WHO approved Reference material NIBSC 66/304.; 
Contain non-mercury preservative. 
4. Enzyme Conjugate, 1 vial, 5 mL, ready to use, 
mouse monoclonal anti-Insulin conjugated to biotin; 
Contains non-mercury preservative. 
5. Enzyme Complex, 1 vial, 7 mL, ready to use, 
Streptavidin-HRP Complex 
Contains non-mercury preservative. 
6. Substrate Solution, 1 vial, 14 mL, ready to use, 
Tetramethylbenzidine (TMB). 
7. Stop Solution, 1 vial, 14 mL, ready to use, 
contains 0.5 M H2SO4, 
Avoid contact with the stop solution. It may cause skin irritations and burns. 
8. Wash Solution, 1 vial, 30 mL (40X concentrated), 
see „Preparation of Reagents“. 
 
Note: Additional Zero Standard for sample dilution is available upon request. 
4.2 Materials required but not provided 
 A microtiter plate calibrated reader (450 ± 10 nm) (e.g. the DRG Instruments Microtiter Plate Reader).  
 Calibrated variable precision micropipettes. 
 Absorbent paper. 
 Distilled or deionised water 
 Timer  
 Graph paper or software for data reduction 
4.3 Storage Conditions 
When stored at 2 °C to 8 °C unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this 
date. 
Opened reagents must be stored at 2 °C to 8 °C.  Microtiter wells must be stored at 2 °C to 8 °C. Once the foil bag has 
been opened, care should be taken to close it tightly again.  
Opened kits retain activity for 8 weeks if stored as described above.  
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4.4 Reagent Preparation 
Bring all reagents and required number of strips to room temperature prior to use. 
 
Wash Solution 
Add deionized water to the 40X concentrated Wash Solution. 
Dilute 30 mL of concentrated Wash Solution with 1170 mL deionized water to a final volume of 1200 mL.  
The diluted Wash Solution is stable for 2 weeks at room temperature. 
4.5 Disposal of the Kit 
The disposal of the kit must be made according to the national regulations. Special information for this product is given in 
the Material Safety Data Sheet. 
4.6 Damaged Test Kits 
In case of any severe damage to the test kit or components, DRG has to be informed in writing, at the latest, one week 
after receiving the kit. Severely damaged single components should not be used for a test run. They have to be stored until 
a final solution has been found. After this, they should be disposed according to the official regulations. 
5 SPECIMEN COLLECTION AND PREPARATION 
Serum or plasma (only heparin- or citrate plasma) can be used in this assay.  
Do not use haemolytic, icteric or lipaemic specimens. 
Please note: Samples containing sodium azide should not be used in the assay. 
5.1 Specimen Collection 
Serum: 
Collect blood by venipuncture (e.g. Sarstedt Monovette for serum), allow to clot, and separate serum by centrifugation at 
room temperature. Do not centrifuge before complete clotting has occurred. Patients receiving anticoagulant therapy may 
require increased clotting time. 
 
Plasma: 
Whole blood should be collected into centrifuge tubes containing anti-coagulant (e.g. Sarstedt Monovette with the 
appropriate plasma preparation) and centrifuged immediately after collection.  
5.2 Specimen Storage and Preparation 
Specimens should be capped and may be stored for up to 5 days at 2 °C to 8 °C prior to assaying.  
Specimens held for a longer time (at least one year) should be frozen only once at -20 °C prior to assay. Thawed samples 
should be inverted several times prior to testing.  
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5.3 Specimen Dilution 
If in an initial assay, a specimen is found to contain more than the highest standard, the specimens can be diluted with 
Zero Standard and re-assayed as described in Assay Procedure. 
For the calculation of the concentrations this dilution factor has to be taken into account.  
 
Example: 
a) dilution 1:10:   10 µL sample + 90 µL Zero Standard (mix thoroughly) 
b) dilution 1:100: 10 µL dilution a) 1:10 + 90 µL Zero Standard (mix thoroughly).  
6 ASSAY PROCEDURE 
6.1 General Remarks 
 All reagents and specimens must be allowed to come to room temperature before use. All reagents must be mixed 
without foaming. 
 Once the test has been started, all steps should be completed without interruption. 
 Use new disposal plastic pipette tips for each standard, control or sample in order to avoid cross contamination. 
 Absorbance is a function of the incubation time and temperature. Before starting the assay, it is recommended that all 
reagents are ready, caps removed, all needed wells secured in holder, etc. This will ensure equal elapsed time for each 
pipetting step without interruption. 
 As a general rule the enzymatic reaction is linearly proportional to time and temperature.  
            
  DRG® Insulin ELISA    (EIA-2935) 
 
Revised 13 Dec. 2013 rm (Vers. 8.1)             IVD  
 
DRG International, Inc.  USA  Fax:  (973) 564-7556  e-mail:  corp@drg-international.com                 6 
6.2 Test Procedure 
Each run must include a standard curve. 
 
1. Secure the desired number of Microtiter wells in the frame holder. 
2. Dispense 25 µL of each Standard, control and samples with new disposable tips into appropriate wells.  
3. Dispense 25 µL Enzyme Conjugate into each well. 
Thoroughly mix for 10 seconds. It is important to have a complete mixing in this step. 
4. Incubate for 30 minutes at room temperature. 
5. Briskly shake out the contents of the wells. 
Rinse the wells 3 times with diluted Wash Solution (400 µL per well). Strike the wells sharply on absorbent paper to 
remove residual droplets. 
Important note: 
The sensitivity and precision of this assay is markedly influenced by the correct performance of the washing 
procedure! 
6. Add 50 µL of Enzyme Complex to each well. 
7. Incubate for 30 minutes at room temperature. 
8. Briskly shake out the contents of the wells. 
Rinse the wells 3 times with diluted Wash Solution (400 µL per well). Strike the wells sharply on absorbent paper to 
remove residual droplets. 
9. Add 50 µL of Substrate Solution to each well. 
10. Incubate for 15 minutes at room temperature. 
11. Stop the enzymatic reaction by adding 50 µL of Stop Solution to each well. 
12. Determine the absorbance (OD) of each well at 450 ± 10 nm with a microtiter plate reader. 
It is recommended that the wells be read within 10 minutes after adding the Stop Solution. 
 
6.3 Calculation of Results 
1. Calculate the average absorbance values for each set of standards, controls and patient samples. 
2. Using linear graph paper, construct a standard curve by plotting the mean absorbance obtained from each standard 
against its concentration with absorbance value on the vertical (Y) axis and concentration on the horizontal (X) axis. 
3. Using the mean absorbance value for each sample determine the corresponding concentration from the standard 
curve.  
4. Automated method: The results in the Instructions for Use have been calculated automatically using a 4-Parameter 
curve fit. (4 Parameter Rodbard or 4 Parameter Marquardt are  the preferred methods.) 
Other data reduction functions may give slightly different results.  
5. The concentration of the samples can be read directly from this standard curve. Samples with concentrations higher 
than that of the highest standard have to be further diluted or reported as > 100 µIU/mL. For the calculation of the 
concentrations this dilution factor has to be taken into account. 
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6.3.1 Example of Typical Standard Curve 
The following data is for demonstration only and cannot be used in place of data generations at the time of assay. 
Standard Optical Units (450 nm) 
Standard 0  (0 µIU/mL) 0.03 
Standard 1  (6.25 µIU/mL) 0.07 
Standard 2  (12.5 µIU/mL) 0.14 
Standard 3  (25 µIU/mL) 0.35 
Standard 4  (50 µIU/mL) 0.88 
Standard 5  (100 µIU/mL) 2.05 
7 EXPECTED  NORMAL VALUES 
It is strongly recommended that each laboratory should determine its own normal and abnormal values. 
 
In a study conducted with apparently normal healthy adults, using the DRG Insulin ELISA the following values are 
observed: 
 
2 µIU/mL to 25 µIU/mL 
 
The results alone should not be the only reason for any therapeutic consequences.  The results should be correlated to 
other clinical observations and diagnostic tests.   
8 QUALITY CONTROL 
Good laboratory practice requires that controls be run with each calibration curve. A statistically significant number of 
controls should be assayed to establish mean values and acceptable ranges to assure proper performance.  
It is recommended to use control samples according to state and federal regulations. The use of control samples is advised 
to assure the day to day validity of results. Use controls at both normal and pathological levels. 
The controls and the corresponding results of the QC-Laboratory are stated in the QC certificate added to the kit. The 
values and ranges stated on the QC sheet always refer to the current kit lot and should be used for direct comparison of the 
results. 
It is also recommended to make use of national or international Quality Assessment programs in order to ensure the 
accuracy of the results. 
Employ appropriate statistical methods for analysing control values and trends. If the results of the assay do not fit to the 
established acceptable ranges of control materials patient results should be considered invalid. 
In this case, please check the following technical areas: Pipetting and timing devices; photometer, expiration dates of 
reagents, storage and incubation conditions, aspiration and washing methods. 
After checking the above mentioned items without finding any error contact your distributor or DRG directly. 
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9 PERFORMANCE CHARACTERISTICS 
9.1 Assay Dynamic Range 
The range of the assay is between 1.76 – 100 µIU/mL.  
9.2 Specificity of Antibodies (Cross Reactivity) 
The cross reactivities were determinated by addition of different analytes to serum containing 4 ng/mL ( 100 µIU/mL) 
Insulin and measuring the apparent Insulin concentration.  
Added analyte to a high value serum  
(4 ng/mL) 
Observed Insulin value  
(ng/mL) 
Cross reaction  
(%) 
Porcine Insulin    8 ng/mL 
Bovine Insulin    8 ng/mL 
Dog Insulin    16 ng/mL 
Rabbit Insulin    16 ng/mL 
Rat Insulin     16 ng/mL 
Human Proinsulin    32 ng/mL 
Porcine Proinsulin    16 ng/mL 
Bovine Proinsulin    16 ng/mL 
17 
17.8 
17.2 
14.1 
4.0 
4.1 
4.0 
4.1 
> 100 
> 100 
82 
63 
0 
0 
0 
0 
9.3 Sensitivity 
The analytical sensitivity of the DRG ELISA was calculated by adding 2 standard deviations to the mean of 20 replicate 
analyses of the Zero Standard and was found to be 1.76 µIU/mL. 
 
9.4 Reproducibility 
9.4.1 Intra-Assay  
The within assay variability is shown below: 
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Sample n Mean  (µIU/mL) CV (%) 
1 20 17.5 2.6 
2 20 66.4 1.8 
9.4.2 Inter-Assay  
The between assay variability is shown below: 
Sample n Mean  (µIU/mL) CV (%) 
1 12 17.4 2.9 
2 12 66.9 6.0 
9.5 Recovery 
Samples have been spiked by adding Insulin solutions with known concentrations in a 1:1 ratio. 
The expected values were calculated by addition of half of the values determined for the undiluted samples and half of the 
values of the known solutions. The % Recovery has been calculated by multiplication of the ratio of the measurements 
and the expected values with 100. 
Sample Added Concentration 1:1 (v/v) (µIU/mL) 
Measured Conc. 
(µIU/mL) 
Expected Conc. 
(µIU/mL) 
Recovery  
(%) 
1 
 21.2     
100 66.4 60.6 109.6 
50 38.8 35.6 108.9 
25 23.4 23.1 101.1 
12.5 17.37 16.9 102.9 
2 
 69.0     
100 84.6 84.5 100.1 
50 58.4 59.5 98.1 
25 43.2 47.0 91.8 
12.5 37.5 40.8 91.9 
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9.6   Linearity 
Sample Dilution Measured Conc.  (µIU/mL) 
Expected Conc.  
(µIU/mL) 
Recovery  
(%) 
1 
None 21.2 21.2   
1:2 9.4 10.6 88.5 
1:4 5.2 5.3 98.5 
1:8 2.8 2.7 105.9 
1:16 1.5 1.3 110.3 
2 
None 69.0 69.0   
1:2 30.5 34.5 88.4 
1:4 17.6 17.3 102.0 
1:8 8.7 8.6 101.2 
1:16 4.8 4.3 110.4 
10 LIMITATIONS OF USE 
Reliable and reproducible results will be obtained when the assay procedure is performed with a complete understanding 
of the package insert instruction and with adherence to good laboratory practice. 
Any improper handling of samples or modification of this test might influence the results. 
10.1 Interfering Substances 
Haemoglobin (up to 4 mg/mL), bilirubin (up to 0.5 mg/mL) and triglyceride (up to 30 mg/mL) have no influence on the 
assay results. 
10.2 Drug Interferences 
Until today no substances (drugs) are known to us, which have an influence to the measurement of Insulin in a sample. 
10.3 High-Dose-Hook Effect 
No hook effect was observed in this test up to 1600 µIU/mL of Insulin. 
11 LEGAL ASPECTS 
11.1 Reliability of Results 
The test must be performed exactly as per the manufacturer’s instructions for use. Moreover the user must strictly adhere 
to the rules of GLP (Good Laboratory Practice) or other applicable national standards and/or laws. This is especially 
relevant for the use of control reagents. It is important to always include, within the test procedure, a sufficient number of 
controls for validating the accuracy and precision of the test. 
The test results are valid only if all controls are within the specified ranges and if all other test parameters are also within 
the given assay specifications. In case of any doubt or concern please contact DRG. 
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11.2 Therapeutic Consequences 
Therapeutic consequences should never be based on laboratory results alone even if all test results are in agreement with 
the items as stated under point 11.1. Any laboratory result is only a part of the total clinical picture of a patient. 
Only in cases where the laboratory results are in acceptable agreement with the overall clinical picture of the patient 
should therapeutic consequences be derived. 
The test result itself should never be the sole determinant for deriving any therapeutic consequences. 
11.3 Liability 
Any modification of the test kit and/or exchange or mixture of any components of different lots from one test kit to 
another could negatively affect the intended results and validity of the overall test. Such modification and/or exchanges 
invalidate any claim for replacement. 
Claims submitted due to customer misinterpretation of laboratory results subject to point 11.2. are also invalid. 
Regardless, in the event of any claim, the manufacturer’s liability is not to exceed the value of the test kit. Any damage 
caused to the test kit during transportation is not subject to the liability of the manufacturer. 
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1 INTRODUCTION 
1.1 Intended Use 
The DRG C-Peptide ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of C-
Peptide in serum, plasma and urine 
1.2 Summary and Explanation 
Insulin is synthesized in the pancreatic beta cells as a 6000 MW component of an 86 amino acid polypeptide called 
proinsulin (1, 2, 3). Proinsulin is subsequently cleaved enzymatically, releasing insulin into the circulation along with a 
residual 3000 MW fragment called connection ("C") peptide, so-named because it connects A and B chains of insulin 
within the proinsulin molecule (1, 2, 3, 4). Human C-Peptide, a 31 amino acid residue peptide, has a molecular mass of 
approximately 3000 daltons. C-Peptide has no metabolic function. However, since C-Peptide and insulin are secreted in 
equimolar amounts, the immunoassay of C-Peptide permits the quantitation of insulin secretion (4, 5, 6). This is the 
reason for the clinical interest of serum and urinary determinations of C-Peptide. Moreover, C-Peptide measurement has 
several advantages over immunoassays of insulin. 
The half-life of C-Peptide in the circulation is between two and five times longer than that of insulin (7). Therefore, C-
Peptide levels are a more stable indicator of insulin secretion than the more rapidly changing levels of insulin. A very 
clear practical advantage of C-Peptide measurement arising from its relative metabolic inertness as compared to insulin is 
that C-Peptide levels in peripheral venous blood are about 5-6 times greater than insulin levels (3). Also, relative to an 
insulin assay, the C-Peptide assay's advantage is its ability to distinguish endogenous from injected insulin. 
Thus, low C-Peptide levels are to be expected when insulin is diminished (as in insulin-dependent diabetes) or suppressed 
(as a normal response to exogenous insulin), whereas elevated C-Peptide levels may result from the increased β-cell 
activity observed in insulinomas (3, 6, 9). 
C-Peptide has also been measured as an additional means for evaluating glucose tolerance and glibenclamide glucose tests 
(2, 3, 9, 10). 
C-Peptide levels are in many ways a better measurement of endogenous insulin secretion than peripheral insulin levels. C-
Peptide may be measured in either blood or urine (9). With improved sensitive C-Peptide immunoassays, it is now 
possible to measure C-Peptide values at extremely low levels. The clinical indications for C-Peptide measurement include 
diagnosis of insulinoma and differentation from factitious hypoglycemia, follow-up of pancreatectomy, and evaluation of 
viability of islet cell transplants (11, 12, 13). Recently, these indications have been dramatically expanded to permit 
evaluation of insulin dependence in maturity onset diabetes mellitus. 
1.3 Clinical Indications for the DRG C-Peptide ELISA 
 Assessment of residual β-cell function in diabetics under insulin therapy 
 Detection and monitoring of the remission phase of type I diabetes 
 Adjunct in the differential diagnosis between type I (insulin dependent) and type II (non-insulin-dependent) diabetes 
 Diagnosis of insulin-induced factitious hypoglycemia. 
 Contribution to the diagnosis of insulinoma (insulin suppression test) 
 Prognostic index of fetal outcome in pregnant diabetic women 
 Evaluation of insulin secretion in liver disease 
 Monitoring of pancreasectomy 
Appendix 8
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2 PRINCIPLE OF THE TEST 
The DRG C-Peptide ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA), based on the principle of 
competitive binding.  
The microtiter wells are coated with anti-mouse antibody, which binds a monoclonal antibody directed towards a unique 
antigenic site on the C-Peptide molecule.  Endogenous C-Peptide of a patient sample competes with a C-Peptide-
horseradish peroxidase conjugate for binding to the coated antibody. After incubation the unbound conjugate is washed 
off.  
The amount of bound peroxidase conjugate is inversely proportional to the concentration of C-Peptide in the sample. 
After addition of the substrate solution, the intensity of colour developed is inversely proportional to the concentration of 
C-Peptide in the patient sample. 
3 WARNINGS AND PRECAUTIONS 
1. This kit is for in vitro diagnostic use only. For professional use only. 
2. All reagents of this test kit which contain human serum or plasma have been tested and confirmed negative for HIV 
I/II, HBsAg and HCV by FDA approved procedures. All reagents, however, should be treated as potential biohazards 
in use and for disposal. 
3. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert 
provided with the kit. Be sure that everything is understood. 
4. The microplate contains snap-off strips.  Unused wells must be stored at 2 °C to 8 °C in the sealed foil pouch and 
used in the frame provided. 
5. Pipetting of samples and reagents must be done as quickly as possible and in the same sequence for each step. 
6. Use reservoirs only for single reagents.  This especially applies to the substrate reservoirs.  Using a reservoir for 
dispensing a substrate solution that had previously been used for the conjugate solution may turn solution colored. Do 
not pour reagents back into vials as reagent contamination may occur. 
7. Mix the contents of the microplate wells thoroughly to ensure good test results. Do not reuse microwells. 
8. Do not let wells dry during assay; add reagents immediately after completing the rinsing steps. 
9. Allow the reagents to reach room temperature (21 °C – 26 °C) before starting the test.  Temperature will affect the 
absorbance readings of the assay.  However, values for the patient samples will not be affected. 
10. Never pipet by mouth and avoid contact of reagents and specimens with skin and mucous membranes. 
11. Do not smoke, eat, drink or apply cosmetics in areas where specimens or kit reagents are handled. 
12. Wear disposable latex gloves when handling specimens and reagents. Microbial contamination of reagents or 
specimens may give false results. 
13. Handling should be done in accordance with the procedures defined by an appropriate national biohazard safety 
guideline or regulation. 
14. Do not use reagents beyond expiry date as shown on the kit labels. 
15. All indicated volumes have to be performed according to the protocol. Optimal test results are only obtained when 
using calibrated pipettes and microtiterplate readers. 
16. Do not mix or use components from kits with different lot numbers. It is advised not to exchange wells of different 
plates even of the same lot. The kits may have been shipped or stored under different conditions and the binding 
characteristics of the plates may result slightly different. 
17. Avoid contact with Stop Solution containing 0.5 M H2SO4. It may cause skin irritation and burns. 
18. Some reagents contain Proclin 300, BND and/or MIT as preservatives. In case of contact with eyes or skin, flush 
immediately with water. 
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19. TMB substrate has an irritant effect on skin and mucosa.  In case of possible contact, wash eyes with an abundant 
volume of water and skin with soap and abundant water.  Wash contaminated objects before reusing them.  If inhaled, 
take the person to open air. 
20. Chemicals and prepared or used reagents have to be treated as hazardous waste according to the national biohazard 
safety guideline or regulation. 
21. For information on hazardous substances included in the kit please refer to Material Safety Data Sheets. 
Material Safety Data Sheets for this product are available upon request directly from DRG. 
 
4 REAGENTS  
4.1 Reagents provided 
1. Microtiterwells, 12 x 8 (break apart) strips, 96 wells; 
Wells coated with anti-mouse-antibody   
2. Standard (Standard 0-5), 6 vials, lyophilized, 0.75 mL 
Concentrations:  0 – 16 ng/mL (see exact value on the vial label or on the QC-Datasheet).  
The standards are calibrated against WHO approved Reference material IRR C-Peptide, code 84/510. 
see „Preparation of Reagents“ 
Contain non-mercury preservative. 
3. Sample Diluent, 1 vial, 3 mL, ready to use, 
Contains non-mercury preservative. 
4. Antiserum, 1 vial, 7 mL, ready to use 
monoclonal mouse anti C-Peptide antibody 
Contains non-mercury preservative. 
5. Enzyme Conjugate, 1 vial, 14 mL, ready to use 
biotinylated C-Peptide  
Contains non-mercury preservative. 
6. Enzyme Complex, 1 vial, 14ml, ready to use 
contains horseradish Peroxidase 
Contains non-mercury preservative. 
7. Substrate Solution, 1 vial, 14 mL, ready to use 
TMB 
8. Stop Solution, 1 vial, 14 mL, ready to use 
contains 0.5 M H2SO4 
Avoid contact with the stop solution. It may cause skin irritations and burns. 
9. Wash Solution, 1 vial, 30 mL (40X concentrated) 
see „Preparation of Reagents“ 
 
Note: Additional Sample Diluent for sample dilution is available upon request. 
4.2 Materials required but not provided 
 A microtiter plate calibrated reader (450 ± 10 nm) (e.g. the DRG Instruments Microtiter Plate Reader).  
 Calibrated variable precision micropipettes. 
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 Absorbent paper. 
 Distilled or deionized water 
 Timer  
 Semi logarithmic graph paper or software for data reduction 
4.3 Storage Conditions 
When stored at 2 °C to 8 °C unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this 
date. 
Opened reagents must be stored at 2 °C to 8 °C.  Microtiter wells must be stored at 2 °C to 8 °C. Once the foil bag has 
been opened, care should be taken to close it tightly again.  
Reagent Preparation 
Bring all reagents and required number of strips to room temperature prior to use. 
4.4 Reagent Preparation 
Standards 
Reconstitute the lyophilized contents of the standard vial with 0.75 mL Aqua dest. 
Note:  The reconstituted standards are stable for 3 days at 2 °C to 8 °C. 
For longer storage the reconstituted standards should be aliquoted and stored at -20 °C. 
 
Wash Solution 
Add deionized water to the 40X concentrated Wash Solution. 
Dilute 30 mL of concentrated Wash Solution with 1170 mL deionized water to a final volume of 1200 mL.  
The diluted Wash Solution is stable for 2 weeks at room temperature. 
 
4.5 Disposal of the Kit 
The disposal of the kit must be made according to the national regulations. Special information for this product is given in 
the Material Safety Data Sheet. 
4.6 Damaged Test Kits 
In case of any severe damage to the test kit or components, DRG has to be informed in writing, at the latest, one week 
after receiving the kit. Severely damaged single components should not be used for a test run. They have to be stored until 
a final solution has been found. After this, they should be disposed according to the official regulations. 
            
 
DRG® C-Peptide ELISA    (EIA-1293) 
              
 
Revised 5 Sept. 2012 rm (Vers. 11.1)        IVD  
 
DRG International, Inc., USA 
Fax:  (973) 564-7556  e-mail:  corp@drg-international.com                   5 
5 SPECIMEN COLLECTION AND PREPARATION 
Serum, plasma (EDTA-, heparin- or citrate plasma) or urine can be used in this assay.  
Do not use haemolytic, icteric or lipaemic specimens. 
Please note: Samples containing sodium azide should not be used in the assay. 
5.1 Specimen Collection 
Serum: 
Collect blood by venipuncture (e.g. Sarstedt Monovette for serum), allow to clot, and separate serum by centrifugation at 
room temperature. Do not centrifuge before complete clotting has occurred. Patients receiving anticoagulant therapy may 
require increased clotting time. 
 
Plasma: 
Whole blood should be collected into centrifuge tubes containing anti-coagulant (e.g. Sarstedt Monovette with the 
appropriate plasma preparation) and centrifuged immediately after collection.   
 
Urine: 
The total volume of urine excreted during a 24 hour period should be collected and mixed in a single container. 
Note: Specimens should be stored at 2 °C - 8 °C during collection period and total volume collected should be recorded. 
5.2 Specimen Storage and Preparation 
Serum / Plasma: 
Specimens should be capped and may be stored for up to 24 hours at 2 °C to 8 °C prior to assaying.  
Specimens held for a longer time should be frozen only once at -20 °C prior to assay. Thawed samples should be inverted 
several times prior to testing. 
 
Urine: 
Aliquot a well-mixed sample to be used in the assay. Centrifuge sample to clear. Urine samples may be stored for up to 36 
hours at 2 °C - 8 °C prior to assaying.  
Specimens held for a longer time should be frozen only once at -20 °C prior to assay. 
5.3 Specimen Dilution 
If in an initial assay, a specimen is found to contain more than the highest standard, the specimens can be diluted with 
Sample Diluent and reassayed as described in Assay Procedure. 
For the calculation of the concentrations this dilution factor has to be taken into account.  
Example: 
a) dilution 1:10:   10 µL Serum + 90 µL Sample Diluent (mix thoroughly) 
b) dilution 1:100: 10 µL dilution a) 1:10 + 90 µL Sample Diluent (mix thoroughly).  
 
Urine Samples 
Prior to use dilute urine samples 1:20 with Sample Diluent. 
 
If the Sample Diluent included in the kit is insufficient, you can order additional Sample Diluent (40 mL vial) with REF.: 
EIA-1293DIL 
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6 ASSAY PROCEDURE 
6.1 General Remarks 
 All reagents and specimens must be allowed to come to room temperature before use. All reagents must be mixed 
without foaming. 
 Once the test has been started, all steps should be completed without interruption. 
 Use new disposal plastic pipette tips for each standard, control or sample in order to avoid cross contamination. 
 Absorbance is a function of the incubation time and temperature. Before starting the assay, it is recommended that all 
reagents are ready, caps removed, all needed wells secured in holder, etc. This will ensure equal elapsed time for each 
pipetting step without interruption. 
 As a general rule the enzymatic reaction is linearly proportional to time and temperature.  
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6.2 Test Procedure 
Each run must include a standard curve. 
 
1. Secure the desired number of Microtiter wells in the frame holder. 
2. Dispense 100 µL of each Standard, controls and samples with new disposable tips into appropriate wells.  
3. Dispense 50 µL Antiserum into each well 
4. Dispense 100 µL Enzyme Conjugate into each well. 
Thoroughly mix for 10 seconds. It is important to have a complete mixing in this step. 
5. Incubate for 60 minutes at room temperature with shaking (400 - 500 rpm). 
6. Briskly shake out the contents of the wells. 
Rinse the wells 3 times with diluted Wash Solution (400 µL per well). Strike the wells sharply on absorbent paper to 
remove residual droplets. 
Important note: 
The sensitivity and precision of this assay is markedly influenced by the correct performance of the washing 
procedure! 
7. Add 100 µL of Enzyme Complex to each well. 
8. Incubate for 30 minutes at room temperature with shaking (400 - 500 rpm). 
9. Briskly shake out the contents of the wells. 
Rinse the wells 3 times with diluted Wash Solution (400 µL per well). Strike the wells sharply on absorbent paper to 
remove residual droplets. 
10. Add 100 µL of Substrate Solution to each well. 
11. Incubate for 20 minutes at room temperature. 
12. Stop the enzymatic reaction by adding 100 µL of Stop Solution to each well. 
13. Determine the absorbance (OD) of each well at 450 ± 10 nm with a microtiter plate reader. 
It is recommended that the wells be read within 10 minutes after adding the Stop Solution. 
6.3 Calculation of Results 
1. Calculate the average absorbance values for each set of standards, controls and patient samples. 
2. Using semi-logarithmic graph paper, construct a standard curve by plotting the mean absorbance obtained from each 
standard against its concentration with absorbance value on the vertical (Y) axis and concentration on the horizontal 
(X) axis. 
3. Using the mean absorbance value for each sample determine the corresponding concentration from the standard 
curve.  
4. Automated method: The results in the IFU have been calculated automatically using a 4 PL (4 Parameter Logistics) 
curve fit. 4 Parameter Logistics is the preferred method. Other data reduction functions may give slightly different 
results.  
5. The concentration of the samples can be read directly from this standard curve. Samples with concentrations higher 
than that of the highest standard have to be further diluted or reported as > 16 ng/mL. For the calculation of the 
concentrations this dilution factor has to be taken into account. 
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6.3.1 Example of Typical Standard Curve 
The following data is for demonstration only and cannot be used in place of data generations at the time of assay. 
Standard Optical Units (450 nm) 
Standard 0  (0 ng/mL) 1.82 
Standard 1  (0.2 ng/mL) 1.64 
Standard 2  (0.7 ng/mL) 1.46 
Standard 3  (2.0 ng/mL) 1.02 
Standard 4  (6.0 ng/mL) 0.47 
Standard 5  (16 ng/mL) 0.21 
7 EXPECTED  NORMAL VALUES 
It is strongly recommended that each laboratory should determine its own normal and abnormal values. 
 
In a study conducted with apparently normal healthy adults, using the DRG C-Peptide ELISA the following values are 
observed: 
 
 n Mean ± 2SD    
Serum (Post 12-hour Fasting) 60 0.5 – 3.2 ng/mL 
Urine  1 - 200 µg/day 
 
he results alone should not be the only reason for any therapeutic consequences.  The results should be correlated to other 
clinical observations and diagnostic tests.   
8 QUALITY CONTROL 
Good laboratory practice requires that controls be run with each calibration curve. A statistically significant number of 
controls should be assayed to establish mean values and acceptable ranges to assure proper performance.  
It is recommended to use control samples according to state and federal regulations. The use of control samples is advised 
to assure the day to day validity of results. Use controls at both normal and pathological levels. 
The controls and the corresponding results of the QC-Laboratory are stated in the QC certificate added to the kit. The 
values and ranges stated on the QC sheet always refer to the current kit lot and should be used for direct comparison of the 
results. 
It is also recommended to make use of national or international Quality Assessment programs in order to ensure the 
accuracy of the results. 
Employ appropriate statistical methods for analysing control values and trends. If the results of the assay do not fit to the 
established acceptable ranges of control materials patient results should be considered invalid. 
In this case, please check the following technical areas: Pipetting and timing devices; photometer, expiration dates of 
reagents, storage and incubation conditions, aspiration and washing methods. 
After checking the above mentioned items without finding any error contact your distributor or DRG directly. 
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9 PERFORMANCE CHARACTERISTICS 
9.1 Assay Dynamic Range 
The range of the assay is between 0.06 – 16 ng/mL.  
9.2 Specificity of Antibodies (Cross Reactivity) 
The cross-reactivity of intact or split-Proinsulin is clinically not significant. 
9.3 Sensitivity 
The analytical sensitivity of the DRG ELISA was calculated by subtracting 2 standard deviations from the mean of 20 
replicate analyses of the Zero Standard (S0) and was found to be be 0.064 ng/mL. 
9.4 Reproducibility 
9.4.1 Intra Assay  
The within assay variability is shown below: 
Sample n Mean  (ng/mL) CV (%) 
1 20 0.48 6.54 
2 20 2.30 6.70 
3 20 3.86 5.13 
 
9.4.2 Inter Assay  
The between assay variability is shown below: 
Sample n Mean  (ng/mL) CV (%) 
1 12 0.42 9.33 
2 12 2.05 9.92 
3 12 4.23 8.38 
 
9.5 Recovery 
Samples have been spiked by adding C-Peptide solutions with known concentrations in a 1:1 ratio. 
The % Recovery has been calculated by multiplication of the ratio of the measurements and the expected values with 100. 
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Serum 
Sample 
 
Endogenus 
C-Peptide 
ng/mL 
Added 
C-Peptide 
ng/mL 
Measured Conc. 
ng/mL 
Expected Conc 
ng/mL 
Recovery 
( % ) 
1 5.36 0.00 5.36   
  8.00 10.31 10.68 96.6 
  3.00 5.57 5.68 98.0 
  1.00 3.63 3.68 98.7 
  0.35 3.08 3.03 101.8 
2 9.70 0.00 9.70   
  8.00 12.49 12.85 97.2 
  3.00 8.23 7.85 104.8 
  1.00 5.15 5.85 87.9 
  0.35 4.54 5.20 87.2 
3 12.12 0.00 12.12   
  8.00 15.52 14.06 110.4 
  3.00 9.72 9.06 107.3 
  1.00 7.30 7.06 103.4 
  0.35 5.65 6.41 88.1 
 
 
Urine 
Sample 
 
Endogenous  
C-Peptide 
(ng/mL) 
Added Conc. 
1:1 (v/v) 
(ng/mL) 
Measured Conc. 
(ng/mL) 
Expected Conc. 
(ng/mL) 
Recovery  
(%) 
1 
 
 
 
2.1     
 8.0 10.9 10.1 107.9 
 3.0 5.57 5.1 109.2 
 1.0 2.6 2.62 99.2 
2 
 
 
 
1.01     
 8.0 9.2 9.01 102.1 
 3.0 4.03 4.01 100.5 
 1.0 2.2 2.01 109.5 
3 
 
 
 
2.5     
 8.0 10.1 10.5 96.2 
 3.0 5.3 5.5 96.4 
 1.0 3.8 3.5 108.6 
 
            
 
DRG® C-Peptide ELISA    (EIA-1293) 
              
 
Revised 5 Sept. 2012 rm (Vers. 11.1)        IVD  
 
DRG International, Inc., USA 
Fax:  (973) 564-7556  e-mail:  corp@drg-international.com                   11 
 
9.6 Linearity 
Sample Dilution Measured Conc. ng/mL 
Expected Conc. 
ng/mL 
Recovery 
( % ) 
1 undil 6.10 6.10   
Serum 1 : 2 3.25 3.05 106.7 
 1 : 4 1.61 1.52 105.3 
 1 : 8 0.84 0.76 110.6 
 1:16 0.41 0.38 107.6 
2 undil 9.90 9.90   
Serum 1 : 2 5.59 4.95 112.8 
 1 : 4 2.48 2.48 100.3 
 1 : 8 1.29 1.24 104.0 
 1:16 0.69 0.62 111.8 
3 undil 13.25 13.25   
Serum 1 : 2 6.97 6.62 105.1 
 1 : 4 3.22 3.31 97.1 
 1 : 8 1.70 1.66 102.8 
 1:16 0.85 0.83 103.1 
 
 
Urine 
Sample Dilution 
Measured Conc. 
ng/mL 
Expected Conc. 
ng/mL 
Recovery 
( % ) 
1 
 
 
 
undil 8.7 8.7  
1 : 2 4.29 4.35 98.6 
1 : 4 2.01 2.18 92.4 
1 : 8 1.09 1.09 100.2 
2 
 
 
 
undil 9.2 9.2  
1 : 2 4.7 4.6 102.2 
1 : 4 2.25 2.3 97.8 
1 : 8 1.12 1.15 97.5 
3 
 
 
 
undil 13.9 13.9  
1 : 2 6.6 6.95 95.0 
1 : 4 3.3 3.48 95.0 
1 : 8 1.8 1.74 103.6 
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10 LIMITATIONS OF USE 
Reliable and reproducible results will be obtained when the assay procedure is performed with a complete understanding 
of the package insert instruction and with adherence to good laboratory practice. 
Any improper handling of samples or modification of this test might influence the results. 
10.1 Interfering Substances 
Haemoglobin (up to 4 mg/mL), Bilirubin (up to 0.5 mg/mL) and Triglyceride (up to 30 mg/mL) have no influence on the 
assay results. 
10.2 Drug Interferences 
Until today no substances (drugs) are known to us, which have an influence to the measurement of C-Peptide in a sample. 
10.3 High-Dose-Hook Effect 
No hook effect was observed in this test. 
11 LEGAL ASPECTS 
11.1 Reliability of Results 
The test must be performed exactly as per the manufacturer’s instructions for use. Moreover the user must strictly adhere 
to the rules of GLP (Good Laboratory Practice) or other applicable national standards and/or laws. This is especially 
relevant for the use of control reagents. It is important to always include, within the test procedure, a sufficient number of 
controls for validating the accuracy and precision of the test. 
The test results are valid only if all controls are within the specified ranges and if all other test parameters are also within 
the given assay specifications. In case of any doubt or concern please contact DRG. 
11.2 Therapeutic Consequences 
Therapeutic consequences should never be based on laboratory results alone even if all test results are in agreement with 
the items as stated under point 11.1. Any laboratory result is only a part of the total clinical picture of a patient. 
Only in cases where the laboratory results are in acceptable agreement with the overall clinical picture of the patient 
should therapeutic consequences be derived. 
The test result itself should never be the sole determinant for deriving any therapeutic consequences. 
11.3 Liability 
Any modification of the test kit and/or exchange or mixture of any components of different lots from one test kit to 
another could negatively affect the intended results and validity of the overall test. Such modification and/or exchanges 
invalidate any claim for replacement. 
Claims submitted due to customer misinterpretation of laboratory results subject to point 11.2. are also invalid. 
Regardless, in the event of any claim, the manufacturer’s liability is not to exceed the value of the test kit. Any damage 
caused to the test kit during transportation is not subject to the liability of the manufacturer. 
            
 
DRG® C-Peptide ELISA    (EIA-1293) 
              
 
Revised 5 Sept. 2012 rm (Vers. 11.1)        IVD  
 
DRG International, Inc., USA 
Fax:  (973) 564-7556  e-mail:  corp@drg-international.com                   13 
12 REFERENCES / LITERATURE 
1. Ashby, J. and Frier, B.: Circulating C-Peptide: Measurement and Clinical Applications.  
Annals of Clinical Biochemistry. 18:125, 1981 
2. Beischer, W.: Proinsulin and C-Peptide in Humans. Hormones in Normal and Abnormal Human Tissues. Volume 3K, 
Fotherby and Pal, S., ed. (Berlin: Walter DeGruyter). pp. 1-43, 1983 
3. Beyer, J., Krause V., Cordes V.: C-Peptide: Its Biogenesis, Structure, Determination and Clinical Significance. 
Giornale Italiano di Chimica Clinica 4 Supp. 9:22, 1979 
4. Bonger, A. and Garcia-Webb, P.: C-Peptide Measurement: Methods and Clinical Utility.  
CRC Critical Reviews in Clinical Laboratory Sciences. 19:297, 1984. 
5. Blix, P. Boddie-Wills, C., Landau, R., Rochman, H. Rubenstein, A.: Urinary C-Peptide: An Indicator of Beta-Cell 
Secretion under Different Metabolic Conditions.  
Journal of Clinical Endocrinology and Metabolism. 54:574, 1982. 
6. Rendell, M.: C-Peptide Levels as a Criterion in Treatment of Maturity-Onset Diabetes.  
Journal of Clinical Endocrinology and Metabolism. 57 (6): 1198, 1983 
7. Horwitz, D., et al.: Proinsulin, Insulin and C-Peptide concentrations in Human Portal and Peripheral Blood. Journal of 
Clinical Investigation. 55:1278, 1975 
8. Horwitz, D., Kurzuya, H., Rubenstein, A.: Circulating Serum C-Peptide.  
The New England Journal of Medicine. 295:207,1976 
9. Rendell, M.: The Expanding Clinical Use of C-Peptide, Radioimmunoassay.  
Acta Diabetologica Latina. 20:105, 1983 
10. Heding, L. and Rasmussen, S.: Human C-Peptide in Normal and Diabetic Subjects.  
Diabetologica. 11:201, 1975 
11. Canivet, B., Harter, M., Viot, G., Balgrac, N., Krebs, B.: Residual ß-Cell Function in Insulin-Dependent Diabetes: 
Evaluation by Circadian Determination of C-Peptide Immuno reactivity.  
Journal of Endocrinological Investigation. 3:107, 1980. 
12. Starr, J., Horwitz, D., Rubenstein, A., Mako, M.: Insulin, Proinsulin and C-Peptide. Methods of Hormone 
Radioimmunoassay 2nd Ed., Academic Press Inc., 1979 
13. Rubenstein, A., Kuruya, H., Horwitz, D.: Clinical Significance of Circulating C-Peptide in Diabetes Mellitus and 
Hypoglycemic Disorders. Archives of Internal Medicine. Vol. 137:625, May 1977. 
14. Yalow, R., Berson, S.: Introduction and General Considerations. Principles of Competitive Protein Binding Assays. 
Ch. 2, Eds. Odell, W. and Daugheday, W., J.B. Lippincott Co., Philadelphia, 1971 
 
  
 
 
Vers. 2012-09-05_RM 
  
8 Bibliography 
[1] Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic Extracts 
in the Treatment of Diabetes Mellitus. Canadian Medical Association journal. 
1922;12:141-6. 
[2] Brown H, Sanger F, Kitai R. The structure of pig and sheep insulins. Biochem J. 
1955;60:556-65. 
[3] Diabetes mellitus. Report of a WHO expert committee. World Health 
Organization technical report series. 1965;310:1-44. 
[4] Classification and diagnosis of diabetes mellitus and other categories of glucose 
intolerance. National Diabetes Data Group. Diabetes. 1979;28:1039-57. 
[5] Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, et al. 
The 1997 American Diabetes Association and 1999 World Health Organization 
criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes 
Care. 2000;23:1108-12. 
[6] Report of the expert committee on the diagnosis and classification of diabetes 
mellitus. Diabetes Care. 2003;26 Suppl 1:S5-20. 
[7] Will new diagnostic criteria for diabetes mellitus change phenotype of patients 
with diabetes? Reanalysis of European epidemiological data. DECODE Study 
Group on behalf of the European Diabetes Epidemiology Study Group. BMJ. 
1998;317:371-5. 
[8] de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, et al. 
Hyperglycaemia is associated with all-cause and cardiovascular mortality in the 
Hoorn population: the Hoorn Study. Diabetologia. 1999;42:926-31. 
[9] Ito C, Maeda R, Ishida S, Harada H, Inoue N, Sasaki H. Importance of OGTT for 
diagnosing diabetes mellitus based on prevalence and incidence of retinopathy. 
Diabetes Res Clin Pract. 2000;49:181-6. 
[10] Definition, Diagnosis and Classification of Diabetes Mellitus and its 
Complications: Report of a WHO consultation. Part 1: Diagnosis and Classification 
of Diabetes Mellitus. Geneva: World Health Organization; 1999. 
[11] Report of the Expert Committee on the Diagnosis and Classification of 
Diabetes Mellitus. Diabetes Care. 1997;20:1183-97. 
[12] Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in 
patients with diabetes mellitus. Biochem Biophys Res Commun. 1969;36:838-43. 
  
[13] Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin 
levels and mean glucose levels over time. Diabetologia. 2007;50:2239-44. 
[14] Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes 
mellitus. American family physician. 2009;79:29-36. 
[15] Rother KI. Diabetes treatment--bridging the divide. The New England journal 
of medicine. 2007;356:1499-501. 
[16] Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type 
II diabetes. Diabetes. 1994;43:1066-84. 
[17] Robertson RP. Antagonist: diabetes and insulin resistance--philosophy, 
science, and the multiplier hypothesis. The Journal of laboratory and clinical 
medicine. 1995;125:560-4; discussion 5. 
[18] Fujioka K. Pathophysiology of type 2 diabetes and the role of incretin 
hormones and beta-cell dysfunction. JAAPA : official journal of the American 
Academy of Physician Assistants. 2007;Suppl:3-8. 
[19] Krentz A. Acute metabolic complications of diabetes. 3rd ed: Wiley-Blackwell; 
2003. 
[20] Brownlee M. The pathobiology of diabetic complications: a unifying 
mechanism. Diabetes. 2005;54:1615-25. 
[21] Gerich JE. Normal Glucose Homeostasis. In: Poretsky L, editor. Principles of 
Diabetes Mellitus: Springer; 2010. 
[22] Shwachman H, Leubner H, Catzel P. Mucoviscidosis. Advances in pediatrics. 
1955;7:249-323. 
[23] Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in 
patients with cystic fibrosis: five year prospective study. BMJ. 1995;311:655-9. 
[24] Yung B, Kemp M, Hooper J, Hodson ME. Diagnosis of cystic fibrosis related 
diabetes: a selective approach in performing the oral glucose tolerance test based 
on a combination of clinical and biochemical criteria. Thorax. 1999;54:40-3. 
[25] Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC, et al. 
Diabetes mellitus associated with cystic fibrosis. J Pediatr. 1988;112:373-7. 
[26] Rosenecker J, Eichler I, Kuhn L, Harms HK, von der Hardt H. Genetic 
determination of diabetes mellitus in patients with cystic fibrosis. Multicenter 
Cystic Fibrosis Study Group. J Pediatr. 1995;127:441-3. 
[27] Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-
related diabetes: current trends in prevalence, incidence, and mortality. Diabetes 
Care. 2009;32:1626-31. 
  
[28] Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, et al. 
Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung 
function in patients with cystic fibrosis: data from the European Epidemiologic 
Registry of Cystic Fibrosis. Pediatric pulmonology. 2001;32:343-50. 
[29] Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. 
Epidemiology of cystic fibrosis-related diabetes. J Pediatr. 2005;146:681-7. 
[30] Stutchfield PR, O'Halloran SM, Smith CS, Woodrow JC, Bottazzo GF, Heaf D. 
HLA type, islet cell antibodies, and glucose intolerance in cystic fibrosis. Arch Dis 
Child. 1988;63:1234-9. 
[31] Rodman HM, Doershuk CF, Roland JM. The interaction of 2 diseases: diabetes 
mellitus and cystic fibrosis. Medicine (Baltimore). 1986;65:389-97. 
[32] Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of 
diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr. 
1992;151:684-7. 
[33] Mohan K, Israel KL, Miller H, Grainger R, Ledson MJ, Walshaw MJ. Long-term 
effect of insulin treatment in cystic fibrosis-related diabetes. Respiration. 
2008;76:181-6. 
[34] Couce M, O'Brien TD, Moran A, Roche PC, Butler PC. Diabetes mellitus in 
cystic fibrosis is characterized by islet amyloidosis. J Clin Endocrinol Metab. 
1996;81:1267-72. 
[35] Dobson L, Sheldon CD, Hattersley AT. Understanding cystic-fibrosis-related 
diabetes: best thought of as insulin deficiency? J R Soc Med. 2004;97 Suppl 44:26-
35. 
[36] Lanng S, Thorsteinsson B, Roder ME, Orskov C, Holst JJ, Nerup J, et al. 
Pancreas and gut hormone responses to oral glucose and intravenous glucagon in 
cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta 
Endocrinol (Copenh). 1993;128:207-14. 
[37] Holl RW, Heinze E, Wolf A, Rank M, Teller WM. Reduced pancreatic insulin 
release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in 
cystic fibrosis. Eur J Pediatr. 1995;154:356-61. 
[38] Moran A. Cystic fibrosis-related diabetes: an approach to diagnosis and 
management. Pediatr Diabetes. 2000;1:41-8. 
[39] Strong TV, Boehm K, Collins FS. Localization of cystic fibrosis transmembrane 
conductance regulator mRNA in the human gastrointestinal tract by in situ 
hybridization. J Clin Invest. 1994;93:347-54. 
  
[40] Rolon MA, Benali K, Munck A, Navarro J, Clement A, Tubiana-Rufi N, et al. 
Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects 
of insulin therapy. Acta Paediatr. 2001;90:860-7. 
[41] Polychronakos C. Early onset diabetes mellitus. Tip or iceberg? Pediatr 
Diabetes. 2004;5:171-3. 
[42] Blackman SM, Hsu S, Vanscoy LL, Collaco JM, Ritter SE, Naughton K, et al. 
Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J 
Clin Endocrinol Metab. 2009;94:1302-9. 
[43] Adler AI, Shine BS, Chamnan P, Haworth CS, Bilton D. Genetic determinants 
and epidemiology of cystic fibrosis-related diabetes: results from a British cohort 
of children and adults. Diabetes Care. 2008;31:1789-94. 
[44] Hardin DS, Moran A. Diabetes mellitus in cystic fibrosis. Endocrinol Metab 
Clin North Am. 1999;28:787-800, ix. 
[45] Moran A, Pyzdrowski KL, Weinreb J, Kahn BB, Smith SA, Adams KS, et al. 
Insulin sensitivity in cystic fibrosis. Diabetes. 1994;43:1020-6. 
[46] Lanng S, Thorsteinsson B, Lund-Andersen C, Nerup J, Schiotz PO, Koch C. 
Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic 
complications. Acta Paediatr. 1994;83:72-7. 
[47] Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell 
deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 
2003;52:102-10. 
[48] Seaquist ER, Robertson RP. Effects of hemipancreatectomy on pancreatic 
alpha and beta cell function in healthy human donors. J Clin Invest. 1992;89:1761-6. 
[49] Cucinotta D, De Luca F, Scoglio R, Lombardo F, Sferlazzas C, Di Benedetto A, 
et al. Factors affecting diabetes mellitus onset in cystic fibrosis: evidence from a 10-
year follow-up study. Acta Paediatr. 1999;88:389-93. 
[50] Battezzati A, Battezzati PM, Costantini D, Seia M, Zazzeron L, Russo MC, et 
al. Spontaneous hypoglycemia in patients with cystic fibrosis. European journal of 
endocrinology / European Federation of Endocrine Societies. 2007;156:369-76. 
[51] Tierney S, Webb K, Jones A, Dodd M, McKenna D, Rowe R, et al. Living with 
cystic fibrosis-related diabetes or type 1 diabetes mellitus: a comparative study 
exploring health-related quality of life and patients' reported experiences of 
hypoglycaemia. Chronic Illn. 2008;4:278-88. 
[52] Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP. Pancreatic endocrine 
function in cystic fibrosis. J Pediatr. 1991;118:715-23. 
  
[53] Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla C, et al. 
Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care. 
2007;30:1056-61. 
[54] Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic 
fibrosis-related diabetes: the presence of microvascular diabetes complications. 
Diabetes Care. 2006;29:2660-3. 
[55] van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG. 
Microvascular complications in patients with cystic fibrosis-related diabetes 
(CFRD). J Cyst Fibros. 2008;7:515-9. 
[56] Waugh N, Royle P, Craigie I, Ho V, Pandit L, Ewings P, et al. Screening for 
cystic fibrosis-related diabetes: a systematic review. Health technology assessment. 
2012;16:iii-iv, 1-179. 
[57] Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. 
Pneumonia. Infectious disease clinics of North America. 1995;9:65-96. 
[58] Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen 
HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a 
population-based case-control study. Diabetes care. 2008;31:1541-5. 
[59] Ardigo D, Valtuena S, Zavaroni I, Baroni MC, Delsignore R. Pulmonary 
complications in diabetes mellitus: the role of glycemic control. Current drug 
targets Inflammation and allergy. 2004;3:455-8. 
[60] Black C, Cummins E, Royle P, Philip S, Waugh N. The clinical effectiveness 
and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review 
and economic evaluation. Health technology assessment. 2007;11:1-126. 
[61] Baker EH, Wood DM, Brennan AL, Clark N, Baines DL, Philips BJ. 
Hyperglycaemia and pulmonary infection. The Proceedings of the Nutrition 
Society. 2006;65:227-35. 
[62] Philips BJ, Meguer JX, Redman J, Baker EH. Factors determining the 
appearance of glucose in upper and lower respiratory tract secretions. Intensive 
care medicine. 2003;29:2204-10. 
[63] Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients 
with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am 
J Respir Crit Care Med. 2000;162:891-5. 
[64] Rosenecker J, Eichler I, Barmeier H, von der Hardt H. Diabetes mellitus and 
cystic fibrosis: comparison of clinical parameters in patients treated with insulin 
versus oral glucose-lowering agents. Pediatr Pulmonol. 2001;32:351-5. 
[65] Adler AI, Gunn E, Haworth CS, Bilton D. Characteristics of adults with and 
without cystic fibrosis-related diabetes. Diabet Med. 2007;24:1143-8.
  
[66] Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfalt R, Lindblad A, 
et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatric 
pulmonology. 2002;33:483-91. 
[67] Brennan ALG, K.M.; Clark, N.; Fisher, D.A.; Wood, D.M.; Baines, D.L.; Philips, 
B.J.; Geddes, D.M.; Hodson, M.E.; Baker, E.H. . Detection of increased glucose 
concentrations in lower airway secretions from people with cystic fibrosis. Thorax. 
2005;60:93. 
[68] Van Sambeek L, Cowley ES, Newman DK, Kato R. Sputum glucose and 
glycemic control in cystic fibrosis-related diabetes: a cross-sectional study. PLoS 
One. 2015;10:e0119938. 
[69] Hameed S, Morton JR, Jaffe A, Field PI, Belessis Y, Yoong T, et al. Early glucose 
abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care. 
2010;33:221-6. 
[70] Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in 
cystic fibrosis. J Pediatr. 1998;133:10-7. 
[71] Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical 
care guidelines for cystic fibrosis-related diabetes: a position statement of the 
American Diabetes Association and a clinical practice guideline of the Cystic 
Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 
2010;33:2697-708. 
[72] International Expert Committee report on the role of the A1C assay in the 
diagnosis of diabetes. Diabetes Care. 2009;32:1327-34. 
[73] O'Riordan SM, Robinson PD, Donaghue KC, Moran A. Management of cystic 
fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2009;10 
Suppl 12:43-50. 
[74] Godbout A, Hammana I, Potvin S, Mainville D, Rakel A, Berthiaume Y, et al. 
No relationship between mean plasma glucose and glycated haemoglobin in 
patients with cystic fibrosis-related diabetes. Diabetes Metab. 2008;34:568-73. 
[75] Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate 
glycaemia in cystic fibrosis patients. Diabetic medicine : a journal of the British 
Diabetic Association. 2004;21:691-6. 
[76] Management of Cystic Fibrosis Related Diabetes. UK Cystic Fibrosis Trust; 
2004. 
[77] Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical 
care guidelines for cystic fibrosis-related diabetes: a position statement of the 
American Diabetes Association and a clinical practice guideline of the Cystic 
Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes 
Care.33:2697-708. 
  
[78] Alberti KG. The World Health Organisation and diabetes. Diabetologia. 
1980;19:169-73. 
[79] Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, et al. 
Elevated 1-hour postload plasma glucose levels identify subjects with normal 
glucose tolerance but impaired beta-cell function, insulin resistance, and worse 
cardiovascular risk profile: the GENFIEV study. J Clin Endocrinol Metab. 
2013;98:2100-5. 
[80] Brodsky J, Dougherty S, Makani R, Rubenstein RC, Kelly A. Elevation of 1-hour 
plasma glucose during oral glucose tolerance testing is associated with worse 
pulmonary function in cystic fibrosis. Diabetes Care. 2011;34:292-5. 
[81] Coriati A, Ziai S, Lavoie A, Berthiaume Y, Rabasa-Lhoret R. The 1-h oral 
glucose tolerance test glucose and insulin values are associated with markers of 
clinical deterioration in cystic fibrosis. Acta Diabetol. 2016;53:359-66. 
[82] Schmid K, Fink K, Holl RW, Hebestreit H, Ballmann M. Predictors for future 
cystic fibrosis-related diabetes by oral glucose tolerance test. J Cyst Fibros. 
2014;13:80-5. 
[83] Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, et al. Insulin therapy 
to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: 
results of the cystic fibrosis related diabetes therapy trial. Diabetes Care. 
2009;32:1783-8. 
[84] Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane F, et al. Glucose 
tolerance and insulin secretion, morbidity, and death in patients with cystic 
fibrosis. J Pediatr. 2008;152:540-5, 5 e1. 
[85] Tofe S, Moreno JC, Maiz L, Alonso M, Escobar H, Barrio R. Insulin-secretion 
abnormalities and clinical deterioration related to impaired glucose tolerance in 
cystic fibrosis. Eur J Endocrinol. 2005;152:241-7. 
[86] Milla CE, Billings J, Moran A. Diabetes is associated with dramatically 
decreased survival in female but not male subjects with cystic fibrosis. Diabetes 
Care. 2005;28:2141-4. 
[87] Walshaw M. Routine OGTT screening for CFRD - no thanks. J R Soc Med. 
2009;102 Suppl 1:40-4. 
[88] O'Riordan SM, Hindmarsh P, Hill NR, Matthews DR, George S, Greally P, et 
al. Validation of continuous glucose monitoring in children and adolescents with 
cystic fibrosis: a prospective cohort study. Diabetes Care. 2009;32:1020-2. 
[89] Moreau F, Weiller MA, Rosner V, Weiss L, Hasselmann M, Pinget M, et al. 
Continuous glucose monitoring in cystic fibrosis patients according to the glucose 
tolerance. Horm Metab Res. 2008;40:502-6. 
  
[90] Jefferies C, Solomon M, Perlman K, Sweezey N, Daneman D. Continuous 
glucose monitoring in adolescents with cystic fibrosis. J Pediatr. 2005;147:396-8. 
[91] Schiaffini R, Brufani C, Russo B, Fintini D, Migliaccio A, Pecorelli L, et al. 
Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of 
continuous glucose monitoring system. Eur J Endocrinol. 2010;162:705-10. 
[92] Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric 
patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35:246-59. 
[93] Sheppard DN, Welsh MJ. Effect of ATP-sensitive K+ channel regulators on 
cystic fibrosis transmembrane conductance regulator chloride currents. J Gen 
Physiol. 1992;100:573-91. 
[94] Grover P, Thomas W, Moran A. Glargine versus NPH insulin in cystic fibrosis 
related diabetes. J Cyst Fibros. 2008;7:134-6. 
[95] Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: 
effect of insulin therapy on lung function and infections. Acta Paediatr. 
1994;83:849-53. 
[96] Hutton JC. Insulin secretory granule biogenesis and the proinsulin-processing 
endopeptidases. Diabetologia. 1994;37 Suppl 2:S48-56. 
[97] Hutton JC. The insulin secretory granule. Diabetologia. 1989;32:271-81. 
[98] Barg S, Eliasson L, Renstrom E, Rorsman P. A subset of 50 secretory granules 
in close contact with L-type Ca2+ channels accounts for first-phase insulin 
secretion in mouse beta-cells. Diabetes. 2002;51 Suppl 1:S74-82. 
[99] Reaven GM, Bernstein R, Davis B, Olefsky JM. Nonketotic diabetes mellitus: 
insulin deficiency or insulin resistance? Am J Med. 1976;60:80-8. 
[100] Pfeifer MA, Halter JB, Porte D, Jr. Insulin secretion in diabetes mellitus. Am J 
Med. 1981;70:579-88. 
[101] Mohan K, Miller H, Dyce P, Grainger R, Hughes R, Vora J, et al. Mechanisms 
of glucose intolerance in cystic fibrosis. Diabet Med. 2009;26:582-8. 
[102] Cucinotta D, De Luca F, Arrigo T, Di Benedetto A, Sferlazzas C, Gigante A, et 
al. First-phase insulin response to intravenous glucose in cystic fibrosis patients 
with different degrees of glucose tolerance. J Pediatr Endocrinol. 1994;7:13-7. 
[103] Ahmad T, Nelson R, Taylor R. Insulin sensitivity and metabolic clearance rate 
of insulin in cystic fibrosis. Metabolism. 1994;43:163-7. 
[104] Bergman RN. Lilly lecture 1989. Toward physiological understanding of 
glucose tolerance. Minimal-model approach. Diabetes. 1989;38:1512-27. 
  
[105] Lanng S, Thorsteinsson B, Roder ME, Nerup J, Koch C. Insulin sensitivity and 
insulin clearance in cystic fibrosis patients with normal and diabetic glucose 
tolerance. Clin Endocrinol (Oxf). 1994;41:217-23. 
[106] Lombardo F, De Luca F, Rosano M, Sferlazzas C, Lucanto C, Arrigo T, et al. 
Natural history of glucose tolerance, beta-cell function and peripheral insulin 
sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol. 
2003;149:53-9. 
[107] Austin A, Kalhan SC, Orenstein D, Nixon P, Arslanian S. Roles of insulin 
resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in 
cystic fibrosis. J Clin Endocrinol Metab. 1994;79:80-5. 
[108] Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. Cystic 
fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell 
dysfunction. Diabet Med. 2002;19:221-6. 
[109] McAuley KA, Mann JI, Chase JG, Lotz TF, Shaw GM. Point: HOMA--
satisfactory for the time being: HOMA: the best bet for the simple determination 
of insulin sensitivity, until something better comes along. Diabetes Care. 
2007;30:2411-3. 
[110] Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell 
dysfunction and insulin resistance to the pathogenesis of impaired glucose 
tolerance and impaired fasting glucose. Diabetes Care. 2006;29:1130-9. 
[111] Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral 
glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes 
Care. 1999;22:1462-70. 
[112] Monzillo LU, Hamdy O. Evaluation of insulin sensitivity in clinical practice 
and in research settings. Nutrition reviews. 2003;61:397-412. 
[113] Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing 
insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate 
usage. Am J Physiol Endocrinol Metab. 2008;294:E15-26. 
[114] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and beta-cell function from 
fasting plasma glucose and insulin concentrations in man. Diabetologia. 
1985;28:412-9. 
[115] Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. 
Diabetes Care. 2004;27:1487-95. 
[116] Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment 
(HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191-2. 
  
[117] Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften 
T, et al. Use of the oral glucose tolerance test to assess insulin release and insulin 
sensitivity. Diabetes Care. 2000;23:295-301. 
[118] Stumvoll M, Van Haeften T, Fritsche A, Gerich J. Oral glucose tolerance test 
indexes for insulin sensitivity and secretion based on various availabilities of 
sampling times. Diabetes Care. 2001;24:796-7. 
[119] Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B. 
Hyperbolic relationship between insulin secretion and sensitivity on oral glucose 
tolerance test. Obesity. 2008;16:1901-7. 
[120] Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ, et 
al. Oral disposition index predicts the development of future diabetes above and 
beyond fasting and 2-h glucose levels. Diabetes Care. 2009;32:335-41. 
[121] Merjaneh L, He Q, Long Q, Phillips LS, Stecenko AA. Disposition index 
identifies defective beta-cell function in cystic fibrosis subjects with normal 
glucose tolerance. J Cyst Fibros. 2015;14:135-41. 
[122] Marena S, Montegrosso G, De Michieli F, Pisu E, Pagano G. Comparison of 
the metabolic effects of mixed meal and standard oral glucose tolerance test on 
glucose, insulin and C-peptide response in healthy, impaired glucose tolerance, 
mild and severe non-insulin-dependent diabetic subjects. Acta Diabetol. 
1992;29:29-33. 
[123] Turner RC, Mann JI, Simpson RD, Harris E, Maxwell R. Fasting 
hyperglycaemia and relatively unimpaired meal responses in mild diabetes. Clin 
Endocrinol (Oxf). 1977;6:253-64. 
[124] Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, 
Ludvigsson J, et al. Mixed-meal tolerance test versus glucagon stimulation test for 
the assessment of beta-cell function in therapeutic trials in type 1 diabetes. 
Diabetes Care. 2008;31:1966-71. 
[125] Hovorka R, Chassin L, Luzio SD, Playle R, Owens DR. Pancreatic beta-cell 
responsiveness during meal tolerance test: model assessment in normal subjects 
and subjects with newly diagnosed noninsulin-dependent diabetes mellitus. J Clin 
Endocrinol Metab. 1998;83:744-50. 
[126] Henquin JC, Accili D, Ahren B, Boitard C, Seino S, Cerasi E. Long in the 
shade, glucagon re-occupies centre court. Diabetes Obes Metab. 2011;13 Suppl 1:v-
viii. 
[127] Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human 
diabetic pancreas. Diabetologia. 1983;24:366-71. 
[128] Unger RH, Orci L. The essential role of glucagon in the pathogenesis of 
diabetes mellitus. Lancet. 1975;1:14-6. 
  
[129] Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and 
postprandial hyperglycemia in type 2 diabetes and therapeutic implications. 
Endocrine reviews. 2007;28:253-83. 
[130] Henquin JC, Rahier J. Pancreatic alpha cell mass in European subjects with 
type 2 diabetes. Diabetologia. 2011;54:1720-5. 
[131] Sherwin RS, Fisher M, Hendler R, Felig P. Hyperglucagonemia and blood 
glucose regulation in normal, obese and diabetic subjects. N Engl J Med. 
1976;294:455-61. 
[132] Raskin P, Unger RH. Hyperglucagonemia and its suppression. Importance in 
the metabolic control of diabetes. N Engl J Med. 1978;299:433-6. 
[133] Lefebvre PJ. Glucagon and its family revisited. Diabetes Care. 1995;18:715-30. 
[134] Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, et al. Role 
of reduced suppression of glucose production and diminished early insulin release 
in impaired glucose tolerance. N Engl J Med. 1992;326:22-9. 
[135] Ahren B, Larsson H. Impaired glucose tolerance (IGT) is associated with 
reduced insulin-induced suppression of glucagon concentrations. Diabetologia. 
2001;44:1998-2003. 
[136] Larsson H, Ahren B. Islet dysfunction in insulin resistance involves impaired 
insulin secretion and increased glucagon secretion in postmenopausal women with 
impaired glucose tolerance. Diabetes Care. 2000;23:650-7. 
[137] Redmond AO, Buchanan KD, Trimble ER. Insulin and glucagon response to 
arginine infusion in cystic fibrosis. Acta paediatrica Scandinavica. 1977;66:199-204. 
[138] Lippe BM, Sperling MA, Dooley RR. Pancreatic alpha and beta cell functions 
in cystic fibrosis. J Pediatr. 1977;90:751-5. 
[139] Chen MH, Joffe SN, Magee DF, Murphy RF, Naruse S. Cyclic changes of 
plasma pancreatic polypeptide and pancreatic secretion in fasting dogs. J Physiol. 
1983;341:453-61. 
[140] Lonovics J, Devitt P, Watson LC, Rayford PL, Thompson JC. Pancreatic 
polypeptide. A review. Arch Surg. 1981;116:1256-64. 
[141] Floyd JC, Jr., Fajans SS, Pek S, Chance RE. A newly recognized pancreatic 
polypeptide; plasma levels in health and disease. Recent progress in hormone 
research. 1976;33:519-70. 
[142] Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz PH, Barnes AJ. 
Distribution and release of human pancreatic polypeptide. Gut. 1976;17:940-44. 
[143] Hazelwood RL. The pancreatic polypeptide (PP-fold) family: gastrointestinal, 
vascular, and feeding behavioral implications. Proceedings of the Society for 
  
Experimental Biology and Medicine Society for Experimental Biology and 
Medicine. 1993;202:44-63. 
[144] Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, Kasuga M. Mouse 
pancreatic polypeptide modulates food intake, while not influencing anxiety in 
mice. Peptides. 1999;20:1445-8. 
[145] Lieverse RJ, Masclee AA, Jansen JB, Lamers CB. Plasma cholecystokinin and 
pancreatic polypeptide secretion in response to bombesin, meal ingestion and 
modified sham feeding in lean and obese persons. International journal of obesity 
and related metabolic disorders : journal of the International Association for the 
Study of Obesity. 1994;18:123-7. 
[146] Alderdice JT, Dinsmore WW, Buchanan KD, Adams C. Gastrointestinal 
hormones in anorexia nervosa. Journal of psychiatric research. 1985;19:207-13. 
[147] Uhe AM, Szmukler GI, Collier GR, Hansky J, O'Dea K, Young GP. Potential 
regulators of feeding behavior in anorexia nervosa. Am J Clin Nutr. 1992;55:28-32. 
[148] Schmidt PT, Naslund E, Gryback P, Jacobsson H, Holst JJ, Hilsted L, et al. A 
role for pancreatic polypeptide in the regulation of gastric emptying and short-
term metabolic control. J Clin Endocrinol Metab. 2005;90:5241-6. 
[149] Orci L, Baetens D, Ravazzola M, Stefan Y, Malaisse-Lagae F. [Pancreatic 
polypeptide islets and glucagon islets : distinct topographic distribution in rat 
pancreas]. Comptes rendus hebdomadaires des seances de l'Academie des sciences 
Serie D: Sciences naturelles. 1976;283:1213-6. 
[150] Nousia-Arvanitakis S, Tomita T, Desai N, Kimmel JR. Pancreatic polypeptide 
in cystic fibrosis. Arch Pathol Lab Med. 1985;109:722-6. 
[151] Stern A, Davidson GP, Kirubakaran CP, Deutsch J, Smith A, Hansky J. 
Pancreatic polypeptide secretion. A marker for disturbed pancreatic function in 
cystic fibrosis. Dig Dis Sci. 1983;28:870-3. 
[152] Brown JC, Dryburgh JR. A gastric inhibitory polypeptide. II. The complete 
amino acid sequence. Can J Biochem. 1971;49:867-72. 
[153] Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by 
gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973;37:826-8. 
[154] Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin 
secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 
2004;287:E199-206. 
[155] Meier JJ, Nauck MA. The potential role of glucagon-like peptide 1 in diabetes. 
Curr Opin Investig Drugs. 2004;5:402-10. 
  
[156] Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: 
Similarities and differences. Journal of diabetes investigation. 2010;1:8-23. 
[157] Pederson RA, Schubert HE, Brown JC. Gastric inhibitory polypeptide. Its 
physiologic release and insulinotropic action in the dog. Diabetes. 1975;24:1050-6. 
[158] Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci. 2000;66:91-103. 
[159] Newgard CB. Cellular engineering and gene therapy strategies for insulin 
replacement in diabetes. Diabetes. 1994;43:341-50. 
[160] Matschinsky FM. Evolution of the glucokinase glucose sensor paradigm for 
pancreatic beta cells. Diabetologia. 1993;36:1215-7. 
[161] Ehses JA, Casilla VR, Doty T, Pospisilik JA, Winter KD, Demuth HU, et al. 
Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival 
via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation 
of p38 mitogen-activated protein kinase. Endocrinology. 2003;144:4433-45. 
[162] Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, McIntosh CH. Glucose-
dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell 
survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B 
(PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-
regulation of bax expression. J Biol Chem. 2005;280:22297-307. 
[163] Ross SA, Dupre J. Effects of ingestion of triglyceride or galactose on secretion 
of gastric inhibitory polypeptide and on responses to intravenous glucose in 
normal and diabetic subjects. Diabetes. 1978;27:327-33. 
[164] Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, et al. 
Predictors of incretin concentrations in subjects with normal, impaired, and 
diabetic glucose tolerance. Diabetes. 2008;57:678-87. 
[165] Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial 
concentrations of intact biologically active glucagon-like peptide 1 in type 2 
diabetic patients. Diabetes. 2001;50:609-13. 
[166] Vilsboll T, Agerso H, Lauritsen T, Deacon CF, Aaboe K, Madsbad S, et al. The 
elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are 
similar in type 2 diabetic patients and healthy subjects. Regul Pept. 2006;137:168-
72. 
[167] Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in 
type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52. 
[168] Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA. Defective 
glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty 
Zucker rats. Diabetes. 2001;50:1004-11. 
  
[169] Zhou J, Livak MF, Bernier M, Muller DC, Carlson OD, Elahi D, et al. 
Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in 
islets. Am J Physiol Endocrinol Metab. 2007;293:E538-47. 
[170] Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor 
agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 
2006;368:1696-705. 
[171] Theodorakis MJ, Carlson O, Muller DC, Egan JM. Elevated plasma glucose-
dependent insulinotropic polypeptide associates with hyperinsulinemia in 
impaired glucose tolerance. Diabetes Care. 2004;27:1692-8. 
[172] Ross SA, Brown JC, Dupre J. Hypersecretion of gastric inhibitory polypeptide 
following oral glucose in diabetes mellitus. Diabetes. 1977;26:525-9. 
[173] Crockett SE, Cataland S, Falko JM, Mazzaferri EL. The insulinotropic effect of 
endogenous gastric inhibitory polypeptide in normal subjects. J Clin Endocrinol 
Metab. 1976;42:1098-103. 
[174] Creutzfeldt W, Talaulicar M, Ebert R, Willms B. Inhibition of gastric 
inhibitory polypeptide (GIP) release by insulin and glucose in juvenile diabetes. 
Diabetes. 1980;29:140-5. 
[175] Jones IR, Owens DR, Luzio S, Hayes TM. Glucose dependent insulinotropic 
polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in 
type 2 (non-insulin dependent) diabetes mellitus. Horm Metab Res. 1989;21:23-6. 
[176] Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the 
pancreas. Pharmacol Ther. 2007;113:546-93. 
[177] Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J, et al. 
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like 
peptide-1. Proc Natl Acad Sci U S A. 2007;104:15069-74. 
[178] Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion 
by intestinal regulatory peptides. Endocrinology. 1991;128:3175-82. 
[179] Roberge JN, Brubaker PL. Regulation of intestinal proglucagon-derived 
peptide secretion by glucose-dependent insulinotropic peptide in a novel 
enteroendocrine loop. Endocrinology. 1993;133:233-40. 
[180] Roberge JN, Gronau KA, Brubaker PL. Gastrin-releasing peptide is a novel 
mediator of proximal nutrient-induced proglucagon-derived peptide secretion 
from the distal gut. Endocrinology. 1996;137:2383-8. 
[181] Balks HJ, Holst JJ, von zur Muhlen A, Brabant G. Rapid oscillations in plasma 
glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion 
via muscarinic receptors. J Clin Endocrinol Metab. 1997;82:786-90. 
  
[182] Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, et 
al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients 
with NIDDM. Diabetologia. 1996;39:1546-53. 
[183] Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, et al. 
Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. 
Diabetes. 1989;38:902-5. 
[184] Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of glucose 
production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. 
Am J Physiol Endocrinol Metab. 2003;285:E701-7. 
[185] Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al. Glucagon-
like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic 
rats. Endocrinology. 2002;143:4397-408. 
[186] Holz GGt, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered 
glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). 
Nature. 1993;361:362-5. 
[187] Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of 
glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell 
function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-30. 
[188] Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-
like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide 
secretion in response to nutrient ingestion in man: acute post-prandial and 24-h 
secretion patterns. J Endocrinol. 1993;138:159-66. 
[189] Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, 
Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like 
peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-23. 
[190] Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-
like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 
2011;54:10-8. 
[191] Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB. Gut incretin hormones in 
identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--
evidence for decreased glucagon-like peptide 1 secretion during oral glucose 
ingestion in NIDDM twins. Eur J Endocrinol. 1996;135:425-32. 
[192] Meier JJ, Gallwitz B, Askenas M, Vollmer K, Deacon CF, Holst JJ, et al. 
Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory 
polypeptide in women with a history of gestational diabetes. Diabetologia. 
2005;48:1872-81. 
  
[193] Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, Volund A, et al. 
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic 
state? Diabetes. 2007;56:1951-9. 
[194] Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive 
insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide 
and glucagon-like peptide-1-(7-36) amide infused at near-physiological 
insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 
1993;76:912-7. 
[195] Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. 
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of 
synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes 
mellitus. J Clin Invest. 1993;91:301-7. 
[196] Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahren B. GLP-1 
tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care. 
1997;20:1874-9. 
[197] Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal 
glucose concentrations by continuous administration of glucagon-like peptide-1 
(GLP-1) in subjects with NIDDM. Diabetologia. 1997;40:205-11. 
[198] Meier JJ, Gallwitz B, Nauck MA. Glucagon-like peptide 1 and gastric 
inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs 
: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2003;17:93-
102. 
[199] Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of 
glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes 
mellitus. N Engl J Med. 1992;326:1316-22. 
[200] Holst JJ, Gromada J, Nauck MA. The pathogenesis of NIDDM involves a 
defective expression of the GIP receptor. Diabetologia. 1997;40:984-6. 
[201] Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. Insulinotropic 
action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. 
Diabetes Care. 1992;15:270-6. 
[202] Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker 
KL, et al. The insulinotropic actions of glucose-dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic 
subjects. Regul Pept. 1994;51:63-74. 
[203] Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D. Effects of 3 
months of continuous subcutaneous administration of glucagon-like peptide 1 in 
elderly patients with type 2 diabetes. Diabetes Care. 2003;26:2835-41. 
  
[204] Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (GLP-1) 
as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes. 
1997;105:187-95. 
[205] Ross SA, Morrison D, McArthur RG. Hypersecretion of gastric inhibitory 
polypeptide in nondiabetic children with cystic fibrosis. Pediatrics. 1981;67:252-4. 
[206] Kuo P, Stevens JE, Russo A, Maddox A, Wishart JM, Jones KL, et al. Gastric 
emptying, incretin hormone secretion, and postprandial glycemia in cystic 
fibrosis--effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab. 
2011;96:E851-5. 
[207] Anzeneder L, Kircher F, Feghelm N, Fischer R, Seissler J. Kinetics of insulin 
secretion and glucose intolerance in adult patients with cystic fibrosis. Horm 
Metab Res. 2011;43:355-60. 
[208] Perano SJ, Couper JJ, Horowitz M, Martin AJ, Kritas S, Sullivan T, et al. 
Pancreatic enzyme supplementation improves the incretin hormone response and 
attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized 
crossover trial. J Clin Endocrinol Metab. 2014;99:2486-93. 
[209] Jarrett RJ, Baker IA, Keen H, Oakley NW. Diurnal variation in oral glucose 
tolerance: blood sugar and plasma insulin levels morning, afternoon, and evening. 
Br Med J. 1972;1:199-201. 
[210] Jarrett RJ. [Circadian variation in blood glucose levels, in glucose tolerance 
and in plasma immunoreactive insulin levels]. Acta Diabetol Lat. 1972;9:263-75. 
[211] Bowen AJ, Reeves RL, Nielsen RL. Afternoon diabetes. Journal of the 
American Medical Women's Association. 1968;23:261-4. 
[212] Jarrett RJ, Keen H. Diurnal variation of oral glucose tolerance: a possible 
pointer to the evolution of diabetes mellitus. Br Med J. 1969;2:341-4. 
[213] Jarrett RJ, Keen H. Further observations on the diurnal variation in oral 
glucose tolerance. Br Med J. 1970;4:334-7. 
[214] Carroll KF, Nestel PJ. Diurnal variation in glucose tolerance and in insulin 
secretion in man. Diabetes. 1973;22:333-48. 
[215] Oakley NW, Monier D, Wynn V. Diurnal variation on oral glucose tolerance: 
insulin and growth hormone changes with special reference to women taking oral 
contraceptives. Diabetologia. 1973;9:235-8. 
[216] Jarrett RJ, Viberti GC, Sayegh HA. Does "afternoon diabetes" predict diabetes? 
Br Med J. 1978;1:548-9. 
  
[217] Lee A, Ader M, Bray GA, Bergman RN. Diurnal variation in glucose tolerance. 
Cyclic suppression of insulin action and insulin secretion in normal-weight, but 
not obese, subjects. Diabetes. 1992;41:750-9. 
[218] Bolli GB, De Feo P, De Cosmo S, Perriello G, Ventura MM, Calcinaro F, et al. 
Demonstration of a dawn phenomenon in normal human volunteers. Diabetes. 
1984;33:1150-3. 
[219] Schmidt MI, Lin QX, Gwynne JT, Jacobs S. Fasting early morning rise in 
peripheral insulin: evidence of the dawn phenomenon in nondiabetes. Diabetes 
Care. 1984;7:32-5. 
[220] Arslanian S, Ohki Y, Becker DJ, Drash AL. Demonstration of a dawn 
phenomenon in normal adolescents. Horm Res. 1990;34:27-32. 
[221] Campbell PJ, Bolli GB, Cryer PE, Gerich JE. Pathogenesis of the dawn 
phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated 
glucose production and impaired glucose utilization due to nocturnal surges in 
growth hormone secretion. N Engl J Med. 1985;312:1473-9. 
[222] Trumper BG, Reschke K, Molling J. Circadian variation of insulin 
requirement in insulin dependent diabetes mellitus the relationship between 
circadian change in insulin demand and diurnal patterns of growth hormone, 
cortisol and glucagon during euglycemia. Horm Metab Res. 1995;27:141-7. 
[223] Scheen AJ, Van Cauter E. The roles of time of day and sleep quality in 
modulating glucose regulation: clinical implications. Horm Res. 1998;49:191-201. 
[224] Service FJ, Hall LD, Westland RE, O'Brien PC, Go VL, Haymond MW, et al. 
Effects of size, time of day and sequence of meal ingestion on carbohydrate 
tolerance in normal subjects. Diabetologia. 1983;25:316-21. 
[225] Van Cauter E, Shapiro ET, Tillil H, Polonsky KS. Circadian modulation of 
glucose and insulin responses to meals: relationship to cortisol rhythm. Am J 
Physiol. 1992;262:E467-75. 
[226] Plat L, Byrne MM, Sturis J, Polonsky KS, Mockel J, Fery F, et al. Effects of 
morning cortisol elevation on insulin secretion and glucose regulation in humans. 
Am J Physiol. 1996;270:E36-42. 
[227] Troisi RJ, Cowie CC, Harris MI. Diurnal variation in fasting plasma glucose: 
implications for diagnosis of diabetes in patients examined in the afternoon. 
JAMA. 2000;284:3157-9. 
[228] Freinkel N, Mager M, Vinnick L. Cyclicity in the interrelationships between 
plasma insulin and glucose during starvation in normal young men. The Journal of 
laboratory and clinical medicine. 1968;71:171-8. 
  
[229] Lambert AE, Hoet JJ. Diurnal pattern of plasma insulin concentration in the 
human. Diabetologia. 1966;2:69-72. 
[230] Abbott J, Conway S, Etherington C, Fitzjohn J, Gee L, Morton A, et al. 
Perceived body image and eating behavior in young adults with cystic fibrosis and 
their healthy peers. J Behav Med. 2000;23:501-17. 
[231] Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships between gastric 
emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 
2013;36:1396-405. 
[232] Woerle HJ, Albrecht M, Linke R, Zschau S, Neumann C, Nicolaus M, et al. 
Importance of changes in gastric emptying for postprandial plasma glucose fluxes 
in healthy humans. Am J Physiol Endocrinol Metab. 2008;294:E103-9. 
[233] Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between 
oral glucose tolerance and gastric emptying in normal healthy subjects. 
Diabetologia. 1993;36:857-62. 
[234] Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper 
gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 
2001;24:371-81. 
[235] Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BE, Shearman 
DJ. Relationships between oesophageal transit and solid and liquid gastric 
emptying in diabetes mellitus. Eur J Nucl Med. 1991;18:229-34. 
[236] Barnett JL, Owyang C. Serum glucose concentration as a modulator of 
interdigestive gastric motility. Gastroenterology. 1988;94:739-44. 
[237] Collins CE, Francis JL, Thomas P, Henry RL, O'Loughlin EV. Gastric emptying 
time is faster in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1997;25:492-8. 
[238] Pauwels A, Blondeau K, Mertens V, Farre R, Verbeke K, Dupont LJ, et al. 
Gastric emptying and different types of reflux in adult patients with cystic fibrosis. 
Aliment Pharmacol Ther. 2011;34:799-807. 
[239] Perano S, Rayner CK, Couper J, Martin J, Horowitz M. Cystic fibrosis related 
diabetes--a new perspective on the optimal management of postprandial glycemia. 
Journal of diabetes and its complications. 2014;28:904-11. 
[240] Roulet M, Weber AM, Paradis Y, Roy CC, Chartrand L, Lasalle R, et al. 
Gastric emptying and lingual lipase activity in cystic fibrosis. Pediatr Res. 
1980;14:1360-2. 
[241] Symonds EL, Omari TI, Webster JM, Davidson GP, Butler RN. Relation 
between pancreatic lipase activity and gastric emptying rate in children with cystic 
fibrosis. J Pediatr. 2003;143:772-5. 
  
[242] Samsom M, Smout AJ. Abnormal gastric and small intestinal motor function 
in diabetes mellitus. Digestive diseases. 1997;15:263-74. 
[243] Darwiche G, Almer LO, Bjorgell O, Cederholm C, Nilsson P. Measurement of 
gastric emptying by standardized real-time ultrasonography in healthy subjects 
and diabetic patients. J Ultrasound Med. 1999;18:673-82. 
[244] Bolondi L, Bortolotti M, Santi V, Calletti T, Gaiani S, Labo G. Measurement of 
gastric emptying time by real-time ultrasonography. Gastroenterology. 
1985;89:752-9. 
[245] Darwiche G, Bjorgell O, Thorsson O, Almer LO. Correlation between 
simultaneous scintigraphic and ultrasonographic measurement of gastric emptying 
in patients with type 1 diabetes mellitus. J Ultrasound Med. 2003;22:459-66. 
[246] Benini L, Sembenini C, Heading RC, Giorgetti PG, Montemezzi S, Zamboni 
M, et al. Simultaneous measurement of gastric emptying of a solid meal by 
ultrasound and by scintigraphy. Am J Gastroenterol. 1999;94:2861-5. 
[247] Cucchiara S, Raia V, Minella R, Frezza T, De Vizia B, De Ritis G. Ultrasound 
measurement of gastric emptying time in patients with cystic fibrosis and effect of 
ranitidine on delayed gastric emptying. J Pediatr. 1996;128:485-8. 
[248] Muresan C, Surdea Blaga T, Muresan L, Dumitrascu DL. Abdominal 
Ultrasound for the Evaluation of Gastric Emptying Revisited. J Gastrointestin Liver 
Dis. 2015;24:329-38. 
[249] Goo RH, Moore JG, Greenberg E, Alazraki NP. Circadian variation in gastric 
emptying of meals in humans. Gastroenterology. 1987;93:515-8. 
[250] Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. 
Physiological hyperglycemia slows gastric emptying in normal subjects and 
patients with insulin-dependent diabetes mellitus. Gastroenterology. 1997;113:60-6. 
[251] Woerle HJ, Albrecht M, Linke R, Zschau S, Neumann C, Nicolaus M, et al. 
Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 
diabetes deficient for islet amyloid polypeptide. Diabetes Care. 2008;31:2325-31. 
[252] Samsom M, Akkermans LM, Jebbink RJ, van Isselt H, vanBerge-Henegouwen 
GP, Smout AJ. Gastrointestinal motor mechanisms in hyperglycaemia induced 
delayed gastric emptying in type I diabetes mellitus. Gut. 1997;40:641-6. 
[253] Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR. Molecular 
forms of human enteroglucagon in tissue and plasma: plasma responses to 
nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin 
Endocrinol Metab. 1983;57:488-95. 
[254] Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-
36: a physiological incretin in man. Lancet. 1987;2:1300-4. 
  
[255] Preparation of Derivatives. In: Conn M, editor. Neuroendocrine Peptide 
Methodology. London: Academic Press; 1989. p. 396. 
[256] Sheikh S, Gudipaty L, De Leon DD, Hadjiliadis D, Kubrak C, Rosenfeld NK, et 
al. Reduced beta-Cell Secretory Capacity in Pancreatic-Insufficient, but Not 
Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance. Diabetes. 
2017;66:134-44. 
[257] Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves 
clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta 
Paediatr. 2001;90:515-9. 
[258] McDonald GW, Fisher GF, Burnham C. Reproducibility of the Oral Glucose 
Tolerance Test. Diabetes. 1965;14:473-80. 
[259] Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter 
LM, et al. Intra-individual variation of glucose, specific insulin and proinsulin 
concentrations measured by two oral glucose tolerance tests in a general 
Caucasian population: the Hoorn Study. Diabetologia. 1996;39:298-305. 
[260] Costa M, Potvin S, Hammana I, Malet A, Berthiaume Y, Jeanneret A, et al. 
Increased glucose excursion in cystic fibrosis and its association with a worse 
clinical status. J Cyst Fibros. 2007;6:376-83. 
[261] Holl RW, Wolf A, Thon A, Bernhard M, Buck C, Missel M, et al. Insulin 
resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis 
patients. J Pediatr Gastroenterol Nutr. 1997;25:188-93. 
[262] Del Prato S. Loss of early insulin secretion leads to postprandial 
hyperglycaemia. Diabetologia. 2003;46 Suppl 1:M2-8. 
[263] Hamdi I, Green M, Shneerson JM, Palmer CR, Hales CN. Proinsulin, 
proinsulin intermediate and insulin in cystic fibrosis. Clin Endocrinol (Oxf). 
1993;39:21-6. 
[264] Battezzati A, Mari A, Zazzeron L, Alicandro G, Claut L, Battezzati PM, et al. 
Identification of insulin secretory defects and insulin resistance during oral 
glucose tolerance test in a cohort of cystic fibrosis patients. European journal of 
endocrinology / European Federation of Endocrine Societies. 2011;165:69-76. 
[265] Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. 
Gastroenterology. 2007;132:2131-57. 
[266] Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones 
KL, et al. Load-dependent effects of duodenal glucose on glycemia, gastrointestinal 
hormones, antropyloroduodenal motility, and energy intake in healthy men. 
American journal of physiology Endocrinology and metabolism. 2007;293:E743-53. 
  
[267] Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic 
insulin delivery by regulating hepatic insulin extraction in humans. Diabetes. 
2005;54:1649-56. 
[268] Schulz B, Doberne L, Greenfield M, Reaven GM. Insulin receptor binding and 
insulin-mediated glucose uptake in type-II-diabetics. Experimental and clinical 
endocrinology. 1983;81:49-58. 
[269] Daly ME, Vale C, Walker M, Littlefield A, Alberti KG, Mathers JC. Acute 
effects on insulin sensitivity and diurnal metabolic profiles of a high-sucrose 
compared with a high-starch diet. Am J Clin Nutr. 1998;67:1186-96. 
[270] Hammana I, Potvin S, Tardif A, Berthiaume Y, Coderre L, Rabasa-Lhoret R. 
Validation of insulin secretion indices in cystic fibrosis patients. J Cyst Fibros. 
2009;8:378-81. 
[271] Maki KC, McKenney JM, Farmer MV, Reeves MS, Dicklin MR. Indices of 
insulin sensitivity and secretion from a standard liquid meal test in subjects with 
type 2 diabetes, impaired or normal fasting glucose. Nutrition journal. 2009;8:22. 
[272] Selimoglu H, Duran C, Kiyici S, Guclu M, Ersoy C, Ozkaya G, et al. 
Comparison of composite whole body insulin sensitivity index derived from mixed 
meal test and oral glucose tolerance test in insulin resistant obese subjects. 
Endocrine. 2009;36:299-304. 
[273] Sarson DL, Bryant MG, Bloom SR. A radioimmunoassay of gastric inhibitory 
polypeptide in human plasma. The Journal of endocrinology. 1980;85:487-96. 
[274] Holohan KN, Murphy RF, Buchanan KD, Elmore DT. Enzymic iodination of 
polypeptide hormones for radioimmunoassay. Clin Chim Acta. 1973;45:153-7. 
[275] Alford FP, Bloodm SR, Nabarro JD. Glucagon levels in normal and diabetic 
subjects: use of a specific immunoabsorbent for glucagon radioimmunoassay. 
Diabetologia. 1977;13:1-6. 
[276] Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. 
Human distribution and release of a putative new gut hormone, peptide YY. 
Gastroenterology. 1985;89:1070-7. 
[277] Fraker PJ, Speck JC, Jr. Protein and cell membrane iodinations with a 
sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. 
Biochem Biophys Res Commun. 1978;80:849-57. 
[278] Helsel DR. Nondetects and Data Analysis: Statistics for Censored 
Environmental Data. New York: Wiley and Sons; 2005. 
[279] Boeckel JN, Palapies L, Zeller T, Reis SM, von Jeinsen B, Tzikas S, et al. 
Estimation of Values below the Limit of Detection of a Contemporary Sensitive 
  
Troponin I Assay Improves Diagnosis of Acute Myocardial Infarction. Clin Chem. 
2015;61:1197-206. 
[280] Jones GH, Dyce P, Tidbury NM, Greenwood J, Ledson MJ, Walshaw MJ. 181 
Loss of the incretin effect in cystic fibrosis related diabetes (CFRD). Journal of 
Cystic Fibrosis. 2015;14:S104. 
[281] Hillman M, Eriksson L, Mared L, Helgesson K, Landin-Olsson M. Reduced 
levels of active GLP-1 in patients with cystic fibrosis with and without diabetes 
mellitus. J Cyst Fibros. 2012;11:144-9. 
[282] Ahren B, Holst JJ. The cephalic insulin response to meal ingestion in humans 
is dependent on both cholinergic and noncholinergic mechanisms and is 
important for postprandial glycemia. Diabetes. 2001;50:1030-8. 
[283] Reimann F, Gribble FM. Glucose-sensing in glucagon-like peptide-1-secreting 
cells. Diabetes. 2002;51:2757-63. 
[284] Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20:876-
913. 
[285] Rask E, Olsson T, Soderberg S, Johnson O, Seckl J, Holst JJ, et al. Impaired 
incretin response after a mixed meal is associated with insulin resistance in 
nondiabetic men. Diabetes Care. 2001;24:1640-5. 
[286] Wang X, Liu H, Chen J, Li Y, Qu S. Multiple Factors Related to the Secretion 
of Glucagon-Like Peptide-1. Int J Endocrinol. 2015;2015:651757. 
[287] Galindo Munoz JS, Jimenez Rodriguez D, Hernandez Morante JJ. Diurnal 
rhythms of plasma GLP-1 levels in normal and overweight/obese subjects: lack of 
effect of weight loss. J Physiol Biochem. 2015;71:17-28. 
[288] Gil-Lozano M, Hunter PM, Behan LA, Gladanac B, Casper RF, Brubaker PL. 
Short-term sleep deprivation with nocturnal light exposure alters time-dependent 
glucagon-like peptide-1 and insulin secretion in male volunteers. Am J Physiol 
Endocrinol Metab. 2016;310:E41-50. 
[289] Gentilcore D, Chaikomin R, Jones KL, Russo A, Feinle-Bisset C, Wishart JM, 
et al. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin 
responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab. 
2006;91:2062-7. 
[290] Rijkelijkhuizen JM, McQuarrie K, Girman CJ, Stein PP, Mari A, Holst JJ, et al. 
Effects of meal size and composition on incretin, alpha-cell, and beta-cell 
responses. Metabolism. 2010;59:502-11. 
[291] Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, et al. 
Incretin and islet hormonal responses to fat and protein ingestion in healthy men. 
Am J Physiol Endocrinol Metab. 2008;295:E779-84. 
  
[292] Lopez S, Bermudez B, Pacheco YM, Villar J, Abia R, Muriana FJ. Distinctive 
postprandial modulation of beta cell function and insulin sensitivity by dietary 
fats: monounsaturated compared with saturated fatty acids. Am J Clin Nutr. 
2008;88:638-44. 
[293] Ma J, Stevens JE, Cukier K, Maddox AF, Wishart JM, Jones KL, et al. Effects of 
a protein preload on gastric emptying, glycemia, and gut hormones after a 
carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care. 2009;32:1600-
2. 
[294] O. Lindgren MSrW, C. Deacon, B. Ahrén. Diurnal variation in the incretin 
response to a meal challenge in humans.  43rd GENERAL ASSEMBLY OF THE 
EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES. Amsterdam: 
Diabetologia; 2007. p. S1–S588. 
[295] Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol. 
2005;184:291-318. 
[296] Morrison JF, Pearson SB. The effect of the circadian rhythm of vagal activity 
on bronchomotor tone in asthma. Br J Clin Pharmacol. 1989;28:545-9. 
[297] Mirakhur A, Walshaw MJ. Autonomic dysfunction in cystic fibrosis. J R Soc 
Med. 2003;96 Suppl 43:11-7. 
[298] Hveem K, Jones KL, Chatterton BE, Horowitz M. Scintigraphic measurement 
of gastric emptying and ultrasonographic assessment of antral area: relation to 
appetite. Gut. 1996;38:816-21. 
[299] Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. 
Gastric emptying in diabetes: clinical significance and treatment. Diabet Med. 
2002;19:177-94. 
[300] Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. 
Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes 
mellitus. Diabetologia. 1990;33:675-80. 
[301] Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med. 
2007;356:820-9. 
[302] van den Berg JM, Kouwenberg JM, Heijerman HG. Demographics of glucose 
metabolism in cystic fibrosis. J Cyst Fibros. 2009;8:276-9. 
[303] Elder DA, Wooldridge JL, Dolan LM, D'Alessio DA. Glucose tolerance, insulin 
secretion, and insulin sensitivity in children and adolescents with cystic fibrosis 
and no prior history of diabetes. J Pediatr. 2007;151:653-8. 
[304] Hayes D, Jr., McCoy KS, Sheikh SI. Resolution of cystic fibrosis-related 
diabetes with ivacaftor therapy. Am J Respir Crit Care Med. 2014;190:590-1. 
  
[305] Bellin MD, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings J, et al. 
Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: 
a small pilot study. Pediatr Diabetes. 2013;14:417-21. 
[306] Olivier AK, Yi Y, Sun X, Sui H, Liang B, Hu S, et al. Abnormal endocrine 
pancreas function at birth in cystic fibrosis ferrets. J Clin Invest. 2012;122:3755-68. 
[307] Uc A, Olivier AK, Griffin MA, Meyerholz DK, Yao J, Abu-El-Haija M, et al. 
Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs 
despite sparing of islet cell mass. Clin Sci (Lond). 2015;128:131-42. 
[308] Marunaka Y. The Mechanistic Links between Insulin and Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) Cl(-) Channel. Int J Mol Sci. 
2017;18. 
[309] Lucas F, Bellisle F, Di Maio A. Spontaneous insulin fluctuations and the 
preabsorptive insulin response to food ingestion in humans. Physiol Behav. 
1987;40:631-6. 
 
